CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><link href="https://cdn.benzinga.com/files/imagecache/bz2_opengraph_meta_image_400x300/sites/all/themes/bz2/images/bz-icon.png" rel="image_src"/><link href="https://www.benzinga.com/fda-calendar" rel="canonical"/><link color="#1177BA" href="/next-assets/images/safari-pinned-tab.svg" rel="mask-icon"/><link href="/next-assets/images/apple-touch-icon.png" rel="apple-touch-icon" sizes="180x180"/><link href="/next-assets/images/favicon-32x32.png" rel="icon" sizes="32x32" type="image/png"/><link href="/next-assets/images/favicon-16x16.png" rel="icon" sizes="16x16" type="image/png"/><link href="/next-assets/site.webmanifest" rel="manifest"/><link color="#5bbad5" href="/next-assets/images/safari-pinned-tab.svg" rel="mask-icon"/><meta content="159483118580" property="fb:app_id"/><link href="http://feeds.benzinga.com/benzinga" rel="alternate" title="Benzinga" type="application/rss+xml"/><meta content="image/jpeg" property="og:image:type"/><link href="/manifest.json" rel="manifest"/><meta content="648186192" property="fb:admins"/><script id="navigation-header-schema" type="application/ld+json">{"@context":"https://schema.org","@type":"SiteNavigationElement","Name":["Our Services","News","Markets","Options","Ratings","Ideas","Money","Crypto"],"Url":["https://www.benzinga.com/services","https://www.benzinga.com/news","https://www.benzinga.com/markets","https://www.benzinga.com/markets/options","https://www.benzinga.com/analyst-stock-ratings","https://www.benzinga.com/trading-ideas","https://www.benzinga.com/money","https://www.benzinga.com/crypto"]}</script><title>FDA Calendar and Recent FDA News - Benzinga</title><script type="application/ld+json">{ "@context": "http://schema.org", "@type": "WebPage", "publisher": {"@type":"Organization","logo":{"@type":"ImageObject","url":"/next-assets/images/schema-publisher-logo-benzinga.png"},"name":"Benzinga","url":"https://www.benzinga.com"}, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://www.benzinga.com/fda-calendar" }, "mainEntity": "WebPage", "headline": "FDA Calendar and Recent FDA News", "url": "https://www.benzinga.com/fda-calendar", "dateCreated": "2025-02-20T21:27:13.709Z", "datePublished": "2025-02-20T21:27:13.709Z", "dateModified": "2010-01-01T00:00:00Z", "creator": { "@type": "Person", "name": "Benzinga" }, "author": { "@type": "Person", "name": "Benzinga" }, "description": "Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates.", "keywords": ["category: Calendar"], "mentions": [], "image": "https://cdn.benzinga.com/files/imagecache/bz2_opengraph_meta_image_400x300/sites/all/themes/bz2/images/bz-icon.png" }</script><script type="application/ld+json">{ "@context": "http://schema.org", "@type": "NewsMediaOrganization", "name": "Benzinga", "email": "info@benzinga.com", "legalName": "Benzinga", "telephone": "877-440-9464", "url": "https://www.benzinga.com/", "logo": "/next-assets/images/schema-publisher-logo-benzinga.png", "image": "/next-assets/images/schema-image-default.png", "address": { "@type": "PostalAddress", "addressLocality": "Detroit", "addressRegion": "MI", "postalCode": "48226", "streetAddress": "1 Campus Martius Suite 200", "addressCountry": "USA" }, "sameAs": [ "https://www.facebook.com/pages/Benzingacom/159483118580?v=app_7146470109", "https://twitter.com/benzinga", "https://www.linkedin.com/company/benzinga", "https://plus.google.com/108838891574408087738/posts", "https://www.youtube.com/user/BenzingaTV" ], "brand": [ { "@type": "Brand", "name": "PreMarket Playbook", "url": "https://www.benzinga.com/premarket" }, { "@type": "Brand", "name": "Benzinga Markets", "url": "https://www.benzinga.com/markets/" }, { "@type": "Brand", "name": "Benzinga Pro", "url": "https://pro.benzinga.com/" }, { "@type": "Brand", "name": "Benzinga Cloud: Data & APIs", "url": "https://www.benzinga.com/apis" }, { "@type": "Brand", "name": "Benzinga Events", "url": "https://www.benzinga.com/events" }, { "@type": "Brand", "name": "Benzinga Money", "url": "https://www.benzinga.com/money/" } ] }</script><meta content="Copyright Benzinga. All rights reserved." name="copyright"/><link href="https://cdn.benzinga.com/files/imagecache/bz2_opengraph_meta_image_400x300/sites/all/themes/bz2/images/bz-icon.png" rel="image_src"/><meta content="Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates." name="description"/><link href="https://www.benzinga.com/fda-calendar" rel="canonical"/><meta content="Benzinga" name="author"/><link color="#1177BA" href="/next-assets/images/safari-pinned-tab.svg" rel="mask-icon"/><link href="/next-assets/images/apple-touch-icon.png" rel="apple-touch-icon" sizes="180x180"/><link href="/next-assets/images/favicon-32x32.png" rel="icon" sizes="32x32" type="image/png"/><link href="/next-assets/images/favicon-16x16.png" rel="icon" sizes="16x16" type="image/png"/><link href="/next-assets/site.webmanifest" rel="manifest"/><link color="#5bbad5" href="/next-assets/images/safari-pinned-tab.svg" rel="mask-icon"/><meta content="#2d89ef" name="msapplication-TileColor"/><meta content="#ffffff" name="theme-color"/><meta content="159483118580" property="fb:app_id"/><link href="http://feeds.benzinga.com/benzinga" rel="alternate" title="Benzinga" type="application/rss+xml"/><meta content="https://www.benzinga.com/fda-calendar" name="syndication-source"/><meta content="summary" name="twitter:card"/><meta content="@benzinga" name="twitter:site"/><meta content="FDA Calendar and Recent FDA News" name="twitter:title"/><meta content="Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates." name="twitter:description"/><meta content="https://cdn.benzinga.com/files/imagecache/bz2_opengraph_meta_image_400x300/sites/all/themes/bz2/images/bz-icon.png" name="twitter:image:src"/><meta content="Benzinga" property="og:site_name"/><meta content="https://www.benzinga.com/fda-calendar" property="og:url"/><meta content="FDA Calendar and Recent FDA News" property="og:title"/><meta content="website" property="og:type"/><meta content="Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates." property="og:description"/><meta content="/next-assets/images/schema-image-default.png" property="og:image"/><meta content="image/jpeg" property="og:image:type"/><meta content="1200" property="og:image:width"/><meta content="630" property="og:image:height"/><meta content="app-id=688949481, app-argument=https://itunes.apple.com/us/app/id688949481" name="apple-itunes-app" property="Benzinga for iOS"/><meta content="yes" name="mobile-web-app-capable"/><meta content="black" name="apple-mobile-web-app-status-bar-style"/><meta content="max-image-preview:large" name="robots"/><link href="/manifest.json" rel="manifest"/><meta content="648186192" property="fb:admins"/><meta content="B01B3489A33F83DDA4083E88C260097C" name="msvalidate.01"/><meta content="84f3b1552db5dfbe" name="y_key"/><meta content="101a0095-334d-4935-b87e-0e8fc771214e" name="fo-verify"/><meta content="English" name="language"/><script id="voice-search-schema" type="application/ld+json">{"@context":"https://schema.org/","@type":"WebPage","name":"Benzinga","speakable":{"@type":"SpeakableSpecification","xpath":["/html/head/title","/html/head/meta[@name='description']/@content"]},"url":"https://www.benzinga.com/"}</script><script id="sitelink-search-schema" type="application/ld+json">{"@context":"https://schema.org/","@type":"WebSite","name":"Benzinga","potentialAction":{"@type":"SearchAction","query-input":"required name=search_term_string","target":"https://www.benzinga.com/search/fast?cx={search_term_string}"},"url":"https://www.benzinga.com/"}</script><link as="image" href="https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?width=100" rel="preload"/><link as="image" href="https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?width=100" rel="preload"/><link as="image" href="https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=100" rel="preload"/><link as="image" href="https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?width=100" rel="preload"/><script id="faq-schema" type="application/ld+json">{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","acceptedAnswer":{"@type":"Answer","text":"<p><span style="font-weight: 400;">Prescription Drug User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an ‘approved’ decision, or a ‘complete response letter’ or a delay due to reasons specific to the company or extraneous to the company.</span></p>\n<p><span style="font-weight: 400;">PDUFA was passed in the U.S. in 1992, which allows the FDA to collect fees from the sponsor company to fund the review process.</span></p>\n<p><span style="font-weight: 400;">A CRL is issued by the FDA when it deems that the regulatory application is not complete in its current form. The deficiencies usually that lead to rejection could be the need for additional clinical studies to establish the efficacy and/or safety of the treatment option, problems with chemistry, manufacturing and controls, etc.</span></p>\n<p><span style="font-weight: 400;">A delay in the review period may stem from the FDA needs additional time to review any additional data/information that may have been tabled subsequent to the submission of the regulatory application or the FDA’s inability to complete site inspections where the drug ingredients are being made etc.</span></p>\n<p><span style="font-weight: 400;">The FDA may mention a specific date or a period (say Q1, Q2, Q3, Q4, first-half, second-half, the name of the month) as the timeline by which a decision will be given. If the FDA does not mention any timeline, the company may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn’t provide a timeline either, it is left to the investors to do the calculations.</span></p>\n"},"name":"What is an FDA PDUFA date?"},{"@type":"Question","acceptedAnswer":{"@type":"Answer","text":"<p><span style="font-weight: 400;">A regulatory application (NDA, sNDA, BLA, sBLA, etc.) is usually accepted for standard review or priority review. A standard review will mean the FDA has to hand out its verdict within 10 months of filing the application. The review window for a priority review gets shortened to six months.</span></p>\n<p><span style="font-weight: 400;">Once a company files for a regulatory application, the FDA takes up to 60 days to respond with an ‘accepted for review’ or ‘refuse-to-file’ decision.</span></p>\n"},"name":"How long does an FDA approval take? "},{"@type":"Question","acceptedAnswer":{"@type":"Answer","text":"<p><span style="font-weight: 400;">A Catalysts Calendar is one way of tracking all the </span><span style="font-weight: 400;">decisions in a single place. Usually, the FDA puts out a release and/or communicates to the company, which in turn will issue a press release.</span></p>\n"},"name":"How do you find FDA approvals?"}]}</script><meta name="next-head-count" content="66"/><link as="font" crossorigin="anonymous" href="/next-assets/fonts/manrope-v15-latin/manrope-v15-latin-300.woff2" rel="preload" type="font/woff2"/><link as="font" crossorigin="anonymous" href="/next-assets/fonts/manrope-v15-latin/manrope-v15-latin-regular.woff2" rel="preload" type="font/woff2"/><link as="font" crossorigin="anonymous" href="/next-assets/fonts/manrope-v15-latin/manrope-v15-latin-500.woff2" rel="preload" type="font/woff2"/><link as="font" crossorigin="anonymous" href="/next-assets/fonts/manrope-v15-latin/manrope-v15-latin-600.woff2" rel="preload" type="font/woff2"/><link as="font" crossorigin="anonymous" href="/next-assets/fonts/manrope-v15-latin/manrope-v15-latin-700.woff2" rel="preload" type="font/woff2"/><link as="font" crossorigin="anonymous" href="/next-assets/fonts/manrope-v15-latin/manrope-v15-latin-800.woff2" rel="preload" type="font/woff2"/><link href="https://cdn.benzinga.com" rel="dns-prefetch"/><link href="https://cdn.segment.com" rel="preconnect"/><link href="https://www.googletagservices.com" rel="preconnect"/><link as="script" href="https://cdn.parsely.com/keys/benzinga.com/p.js" rel="preload"/><link as="script" href="https://www.google-analytics.com/analytics.js" rel="preload"/><style>:root, :host { --fa-font-solid: normal 900 1em/1 "Font Awesome 6 Solid"; --fa-font-regular: normal 400 1em/1 "Font Awesome 6 Regular"; --fa-font-light: normal 300 1em/1 "Font Awesome 6 Light"; --fa-font-thin: normal 100 1em/1 "Font Awesome 6 Thin"; --fa-font-duotone: normal 900 1em/1 "Font Awesome 6 Duotone"; --fa-font-sharp-solid: normal 900 1em/1 "Font Awesome 6 Sharp"; --fa-font-sharp-regular: normal 400 1em/1 "Font Awesome 6 Sharp"; --fa-font-sharp-light: normal 300 1em/1 "Font Awesome 6 Sharp"; --fa-font-sharp-thin: normal 100 1em/1 "Font Awesome 6 Sharp"; --fa-font-brands: normal 400 1em/1 "Font Awesome 6 Brands"; } svg:not(:root).svg-inline--fa, svg:not(:host).svg-inline--fa { overflow: visible; box-sizing: content-box; } .svg-inline--fa { display: var(--fa-display, inline-block); height: 1em; overflow: visible; vertical-align: -0.125em; } .svg-inline--fa.fa-2xs { vertical-align: 0.1em; } .svg-inline--fa.fa-xs { vertical-align: 0em; } .svg-inline--fa.fa-sm { vertical-align: -0.0714285705em; } .svg-inline--fa.fa-lg { vertical-align: -0.2em; } .svg-inline--fa.fa-xl { vertical-align: -0.25em; } .svg-inline--fa.fa-2xl { vertical-align: -0.3125em; } .svg-inline--fa.fa-pull-left { margin-right: var(--fa-pull-margin, 0.3em); width: auto; } .svg-inline--fa.fa-pull-right { margin-left: var(--fa-pull-margin, 0.3em); width: auto; } .svg-inline--fa.fa-li { width: var(--fa-li-width, 2em); top: 0.25em; } .svg-inline--fa.fa-fw { width: var(--fa-fw-width, 1.25em); } .fa-layers svg.svg-inline--fa { bottom: 0; left: 0; margin: auto; position: absolute; right: 0; top: 0; } .fa-layers-counter, .fa-layers-text { display: inline-block; position: absolute; text-align: center; } .fa-layers { display: inline-block; height: 1em; position: relative; text-align: center; vertical-align: -0.125em; width: 1em; } .fa-layers svg.svg-inline--fa { -webkit-transform-origin: center center; transform-origin: center center; } .fa-layers-text { left: 50%; top: 50%; -webkit-transform: translate(-50%, -50%); transform: translate(-50%, -50%); -webkit-transform-origin: center center; transform-origin: center center; } .fa-layers-counter { background-color: var(--fa-counter-background-color, #ff253a); border-radius: var(--fa-counter-border-radius, 1em); box-sizing: border-box; color: var(--fa-inverse, #fff); line-height: var(--fa-counter-line-height, 1); max-width: var(--fa-counter-max-width, 5em); min-width: var(--fa-counter-min-width, 1.5em); overflow: hidden; padding: var(--fa-counter-padding, 0.25em 0.5em); right: var(--fa-right, 0); text-overflow: ellipsis; top: var(--fa-top, 0); -webkit-transform: scale(var(--fa-counter-scale, 0.25)); transform: scale(var(--fa-counter-scale, 0.25)); -webkit-transform-origin: top right; transform-origin: top right; } .fa-layers-bottom-right { bottom: var(--fa-bottom, 0); right: var(--fa-right, 0); top: auto; -webkit-transform: scale(var(--fa-layers-scale, 0.25)); transform: scale(var(--fa-layers-scale, 0.25)); -webkit-transform-origin: bottom right; transform-origin: bottom right; } .fa-layers-bottom-left { bottom: var(--fa-bottom, 0); left: var(--fa-left, 0); right: auto; top: auto; -webkit-transform: scale(var(--fa-layers-scale, 0.25)); transform: scale(var(--fa-layers-scale, 0.25)); -webkit-transform-origin: bottom left; transform-origin: bottom left; } .fa-layers-top-right { top: var(--fa-top, 0); right: var(--fa-right, 0); -webkit-transform: scale(var(--fa-layers-scale, 0.25)); transform: scale(var(--fa-layers-scale, 0.25)); -webkit-transform-origin: top right; transform-origin: top right; } .fa-layers-top-left { left: var(--fa-left, 0); right: auto; top: var(--fa-top, 0); -webkit-transform: scale(var(--fa-layers-scale, 0.25)); transform: scale(var(--fa-layers-scale, 0.25)); -webkit-transform-origin: top left; transform-origin: top left; } .fa-1x { font-size: 1em; } .fa-2x { font-size: 2em; } .fa-3x { font-size: 3em; } .fa-4x { font-size: 4em; } .fa-5x { font-size: 5em; } .fa-6x { font-size: 6em; } .fa-7x { font-size: 7em; } .fa-8x { font-size: 8em; } .fa-9x { font-size: 9em; } .fa-10x { font-size: 10em; } .fa-2xs { font-size: 0.625em; line-height: 0.1em; vertical-align: 0.225em; } .fa-xs { font-size: 0.75em; line-height: 0.0833333337em; vertical-align: 0.125em; } .fa-sm { font-size: 0.875em; line-height: 0.0714285718em; vertical-align: 0.0535714295em; } .fa-lg { font-size: 1.25em; line-height: 0.05em; vertical-align: -0.075em; } .fa-xl { font-size: 1.5em; line-height: 0.0416666682em; vertical-align: -0.125em; } .fa-2xl { font-size: 2em; line-height: 0.03125em; vertical-align: -0.1875em; } .fa-fw { text-align: center; width: 1.25em; } .fa-ul { list-style-type: none; margin-left: var(--fa-li-margin, 2.5em); padding-left: 0; } .fa-ul > li { position: relative; } .fa-li { left: calc(var(--fa-li-width, 2em) * -1); position: absolute; text-align: center; width: var(--fa-li-width, 2em); line-height: inherit; } .fa-border { border-color: var(--fa-border-color, #eee); border-radius: var(--fa-border-radius, 0.1em); border-style: var(--fa-border-style, solid); border-width: var(--fa-border-width, 0.08em); padding: var(--fa-border-padding, 0.2em 0.25em 0.15em); } .fa-pull-left { float: left; margin-right: var(--fa-pull-margin, 0.3em); } .fa-pull-right { float: right; margin-left: var(--fa-pull-margin, 0.3em); } .fa-beat { -webkit-animation-name: fa-beat; animation-name: fa-beat; -webkit-animation-delay: var(--fa-animation-delay, 0s); animation-delay: var(--fa-animation-delay, 0s); -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 1s); animation-duration: var(--fa-animation-duration, 1s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, ease-in-out); animation-timing-function: var(--fa-animation-timing, ease-in-out); } .fa-bounce { -webkit-animation-name: fa-bounce; animation-name: fa-bounce; -webkit-animation-delay: var(--fa-animation-delay, 0s); animation-delay: var(--fa-animation-delay, 0s); -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 1s); animation-duration: var(--fa-animation-duration, 1s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.28, 0.84, 0.42, 1)); animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.28, 0.84, 0.42, 1)); } .fa-fade { -webkit-animation-name: fa-fade; animation-name: fa-fade; -webkit-animation-delay: var(--fa-animation-delay, 0s); animation-delay: var(--fa-animation-delay, 0s); -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 1s); animation-duration: var(--fa-animation-duration, 1s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1)); animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1)); } .fa-beat-fade { -webkit-animation-name: fa-beat-fade; animation-name: fa-beat-fade; -webkit-animation-delay: var(--fa-animation-delay, 0s); animation-delay: var(--fa-animation-delay, 0s); -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 1s); animation-duration: var(--fa-animation-duration, 1s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1)); animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1)); } .fa-flip { -webkit-animation-name: fa-flip; animation-name: fa-flip; -webkit-animation-delay: var(--fa-animation-delay, 0s); animation-delay: var(--fa-animation-delay, 0s); -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 1s); animation-duration: var(--fa-animation-duration, 1s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, ease-in-out); animation-timing-function: var(--fa-animation-timing, ease-in-out); } .fa-shake { -webkit-animation-name: fa-shake; animation-name: fa-shake; -webkit-animation-delay: var(--fa-animation-delay, 0s); animation-delay: var(--fa-animation-delay, 0s); -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 1s); animation-duration: var(--fa-animation-duration, 1s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, linear); animation-timing-function: var(--fa-animation-timing, linear); } .fa-spin { -webkit-animation-name: fa-spin; animation-name: fa-spin; -webkit-animation-delay: var(--fa-animation-delay, 0s); animation-delay: var(--fa-animation-delay, 0s); -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 2s); animation-duration: var(--fa-animation-duration, 2s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, linear); animation-timing-function: var(--fa-animation-timing, linear); } .fa-spin-reverse { --fa-animation-direction: reverse; } .fa-pulse, .fa-spin-pulse { -webkit-animation-name: fa-spin; animation-name: fa-spin; -webkit-animation-direction: var(--fa-animation-direction, normal); animation-direction: var(--fa-animation-direction, normal); -webkit-animation-duration: var(--fa-animation-duration, 1s); animation-duration: var(--fa-animation-duration, 1s); -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite); animation-iteration-count: var(--fa-animation-iteration-count, infinite); -webkit-animation-timing-function: var(--fa-animation-timing, steps(8)); animation-timing-function: var(--fa-animation-timing, steps(8)); } @media (prefers-reduced-motion: reduce) { .fa-beat, .fa-bounce, .fa-fade, .fa-beat-fade, .fa-flip, .fa-pulse, .fa-shake, .fa-spin, .fa-spin-pulse { -webkit-animation-delay: -1ms; animation-delay: -1ms; -webkit-animation-duration: 1ms; animation-duration: 1ms; -webkit-animation-iteration-count: 1; animation-iteration-count: 1; -webkit-transition-delay: 0s; transition-delay: 0s; -webkit-transition-duration: 0s; transition-duration: 0s; } } @-webkit-keyframes fa-beat { 0%, 90% { -webkit-transform: scale(1); transform: scale(1); } 45% { -webkit-transform: scale(var(--fa-beat-scale, 1.25)); transform: scale(var(--fa-beat-scale, 1.25)); } } @keyframes fa-beat { 0%, 90% { -webkit-transform: scale(1); transform: scale(1); } 45% { -webkit-transform: scale(var(--fa-beat-scale, 1.25)); transform: scale(var(--fa-beat-scale, 1.25)); } } @-webkit-keyframes fa-bounce { 0% { -webkit-transform: scale(1, 1) translateY(0); transform: scale(1, 1) translateY(0); } 10% { -webkit-transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0); transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0); } 30% { -webkit-transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em)); transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em)); } 50% { -webkit-transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0); transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0); } 57% { -webkit-transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em)); transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em)); } 64% { -webkit-transform: scale(1, 1) translateY(0); transform: scale(1, 1) translateY(0); } 100% { -webkit-transform: scale(1, 1) translateY(0); transform: scale(1, 1) translateY(0); } } @keyframes fa-bounce { 0% { -webkit-transform: scale(1, 1) translateY(0); transform: scale(1, 1) translateY(0); } 10% { -webkit-transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0); transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0); } 30% { -webkit-transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em)); transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em)); } 50% { -webkit-transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0); transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0); } 57% { -webkit-transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em)); transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em)); } 64% { -webkit-transform: scale(1, 1) translateY(0); transform: scale(1, 1) translateY(0); } 100% { -webkit-transform: scale(1, 1) translateY(0); transform: scale(1, 1) translateY(0); } } @-webkit-keyframes fa-fade { 50% { opacity: var(--fa-fade-opacity, 0.4); } } @keyframes fa-fade { 50% { opacity: var(--fa-fade-opacity, 0.4); } } @-webkit-keyframes fa-beat-fade { 0%, 100% { opacity: var(--fa-beat-fade-opacity, 0.4); -webkit-transform: scale(1); transform: scale(1); } 50% { opacity: 1; -webkit-transform: scale(var(--fa-beat-fade-scale, 1.125)); transform: scale(var(--fa-beat-fade-scale, 1.125)); } } @keyframes fa-beat-fade { 0%, 100% { opacity: var(--fa-beat-fade-opacity, 0.4); -webkit-transform: scale(1); transform: scale(1); } 50% { opacity: 1; -webkit-transform: scale(var(--fa-beat-fade-scale, 1.125)); transform: scale(var(--fa-beat-fade-scale, 1.125)); } } @-webkit-keyframes fa-flip { 50% { -webkit-transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg)); transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg)); } } @keyframes fa-flip { 50% { -webkit-transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg)); transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg)); } } @-webkit-keyframes fa-shake { 0% { -webkit-transform: rotate(-15deg); transform: rotate(-15deg); } 4% { -webkit-transform: rotate(15deg); transform: rotate(15deg); } 8%, 24% { -webkit-transform: rotate(-18deg); transform: rotate(-18deg); } 12%, 28% { -webkit-transform: rotate(18deg); transform: rotate(18deg); } 16% { -webkit-transform: rotate(-22deg); transform: rotate(-22deg); } 20% { -webkit-transform: rotate(22deg); transform: rotate(22deg); } 32% { -webkit-transform: rotate(-12deg); transform: rotate(-12deg); } 36% { -webkit-transform: rotate(12deg); transform: rotate(12deg); } 40%, 100% { -webkit-transform: rotate(0deg); transform: rotate(0deg); } } @keyframes fa-shake { 0% { -webkit-transform: rotate(-15deg); transform: rotate(-15deg); } 4% { -webkit-transform: rotate(15deg); transform: rotate(15deg); } 8%, 24% { -webkit-transform: rotate(-18deg); transform: rotate(-18deg); } 12%, 28% { -webkit-transform: rotate(18deg); transform: rotate(18deg); } 16% { -webkit-transform: rotate(-22deg); transform: rotate(-22deg); } 20% { -webkit-transform: rotate(22deg); transform: rotate(22deg); } 32% { -webkit-transform: rotate(-12deg); transform: rotate(-12deg); } 36% { -webkit-transform: rotate(12deg); transform: rotate(12deg); } 40%, 100% { -webkit-transform: rotate(0deg); transform: rotate(0deg); } } @-webkit-keyframes fa-spin { 0% { -webkit-transform: rotate(0deg); transform: rotate(0deg); } 100% { -webkit-transform: rotate(360deg); transform: rotate(360deg); } } @keyframes fa-spin { 0% { -webkit-transform: rotate(0deg); transform: rotate(0deg); } 100% { -webkit-transform: rotate(360deg); transform: rotate(360deg); } } .fa-rotate-90 { -webkit-transform: rotate(90deg); transform: rotate(90deg); } .fa-rotate-180 { -webkit-transform: rotate(180deg); transform: rotate(180deg); } .fa-rotate-270 { -webkit-transform: rotate(270deg); transform: rotate(270deg); } .fa-flip-horizontal { -webkit-transform: scale(-1, 1); transform: scale(-1, 1); } .fa-flip-vertical { -webkit-transform: scale(1, -1); transform: scale(1, -1); } .fa-flip-both, .fa-flip-horizontal.fa-flip-vertical { -webkit-transform: scale(-1, -1); transform: scale(-1, -1); } .fa-rotate-by { -webkit-transform: rotate(var(--fa-rotate-angle, none)); transform: rotate(var(--fa-rotate-angle, none)); } .fa-stack { display: inline-block; vertical-align: middle; height: 2em; position: relative; width: 2.5em; } .fa-stack-1x, .fa-stack-2x { bottom: 0; left: 0; margin: auto; position: absolute; right: 0; top: 0; z-index: var(--fa-stack-z-index, auto); } .svg-inline--fa.fa-stack-1x { height: 1em; width: 1.25em; } .svg-inline--fa.fa-stack-2x { height: 2em; width: 2.5em; } .fa-inverse { color: var(--fa-inverse, #fff); } .sr-only, .fa-sr-only { position: absolute; width: 1px; height: 1px; padding: 0; margin: -1px; overflow: hidden; clip: rect(0, 0, 0, 0); white-space: nowrap; border-width: 0; } .sr-only-focusable:not(:focus), .fa-sr-only-focusable:not(:focus) { position: absolute; width: 1px; height: 1px; padding: 0; margin: -1px; overflow: hidden; clip: rect(0, 0, 0, 0); white-space: nowrap; border-width: 0; } .svg-inline--fa .fa-primary { fill: var(--fa-primary-color, currentColor); opacity: var(--fa-primary-opacity, 1); } .svg-inline--fa .fa-secondary { fill: var(--fa-secondary-color, currentColor); opacity: var(--fa-secondary-opacity, 0.4); } .svg-inline--fa.fa-swap-opacity .fa-primary { opacity: var(--fa-secondary-opacity, 0.4); } .svg-inline--fa.fa-swap-opacity .fa-secondary { opacity: var(--fa-primary-opacity, 1); } .svg-inline--fa mask .fa-primary, .svg-inline--fa mask .fa-secondary { fill: black; } .fad.fa-inverse, .fa-duotone.fa-inverse { color: var(--fa-inverse, #fff); }</style><link as="script" href="https://static.chartbeat.com/js/chartbeat.js" rel="preload"/><script data-nscript="beforeInteractive" id="chartbeat"> (function() { var pageDomain = window.location.hostname || ""; // Check if current domain is a test domain if (pageDomain === "" || pageDomain.includes("zingbot") || pageDomain.includes("local.") || pageDomain.includes("bzsbx.") || pageDomain.includes("moneysbx.")) { pageDomain = 'zingbot.bz'; } else if('benzinga.com' === '') { pageDomain = pageDomain.replace('www.', ''); } else { pageDomain = 'benzinga.com'; } var _sf_async_config = window._sf_async_config = (window._sf_async_config || {}); _sf_async_config.uid = '2586'; _sf_async_config.domain = pageDomain; _sf_async_config.useCanonical = true; _sf_async_config.useCanonicalDomain = false; _sf_async_config.sections = ''; _sf_async_config.authors = ''; _sf_async_config.flickerControl = false; function loadChartbeat() { var e = document.createElement('script'); var n = document.getElementsByTagName('script')[0]; e.type = 'text/javascript'; e.async = true; e.src = 'https://static.chartbeat.com/js/chartbeat.js'; n.parentNode.insertBefore(e, n); } window.loadChartbeat = loadChartbeat; })(); </script><script async="" src="//static.chartbeat.com/js/chartbeat_mab.js"></script><script type="text/javascript">window.OneSignal = window.OneSignal || [];</script><script id="parsely" type="text/javascript" data-nscript="beforeInteractive">window.PARSELY = window.PARSELY || {}; window.PARSELY.use_localstorage = true;</script><link rel="preload" href="/_next/static/css/4148f7b1beecd7d8.css" as="style"/><link rel="stylesheet" href="/_next/static/css/4148f7b1beecd7d8.css" data-n-g=""/><link rel="preload" href="/_next/static/css/a32bcad5ec9b0ed7.css" as="style"/><link rel="stylesheet" href="/_next/static/css/a32bcad5ec9b0ed7.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js"></script><script src="/_next/static/chunks/webpack-13371b5e1a9794a9.js" defer=""></script><script src="/_next/static/chunks/framework-e6b7f5edbdf1e600.js" defer=""></script><script src="/_next/static/chunks/main-3787a6b35de580f3.js" defer=""></script><script src="/_next/static/chunks/pages/_app-bf0514513301f76d.js" defer=""></script><script src="/_next/static/chunks/93656207-b34aec0caa119a7d.js" defer=""></script><script src="/_next/static/chunks/ad54e6ef-7c813ab4f14493b0.js" defer=""></script><script src="/_next/static/chunks/4c744e84-475c8634f7d1af26.js" defer=""></script><script src="/_next/static/chunks/8c469d57-278636cb3035cd4d.js" defer=""></script><script src="/_next/static/chunks/aeb74aa0-502d0846ae907fd0.js" defer=""></script><script src="/_next/static/chunks/8eec4907-3b52a9e94580c3e0.js" defer=""></script><script src="/_next/static/chunks/a981ec11-57883dfa93c2b67f.js" defer=""></script><script src="/_next/static/chunks/5adc83ef-393b37d1f739f830.js" defer=""></script><script src="/_next/static/chunks/74927-e6eca17cfd52e04d.js" defer=""></script><script src="/_next/static/chunks/25491-a2c0d84c469150a7.js" defer=""></script><script src="/_next/static/chunks/37149-90d5564dbf56c082.js" defer=""></script><script src="/_next/static/chunks/73737-bc29be1038094f29.js" defer=""></script><script src="/_next/static/chunks/43069-94bdc576dd7d4e78.js" defer=""></script><script src="/_next/static/chunks/80478-55b510ca744c711f.js" defer=""></script><script src="/_next/static/chunks/73268-e15b89d697dd4508.js" defer=""></script><script src="/_next/static/chunks/42568-aa5173511003d9d8.js" defer=""></script><script src="/_next/static/chunks/39097-9e1fd452247607ca.js" defer=""></script><script src="/_next/static/chunks/78283-a0f9e26c29b01da4.js" defer=""></script><script src="/_next/static/chunks/48834-0b3427eb40669fa3.js" defer=""></script><script src="/_next/static/chunks/90162-9baeeb2b96ad8c1c.js" defer=""></script><script src="/_next/static/chunks/62070-6e7150e5f5df9234.js" defer=""></script><script src="/_next/static/chunks/67732-a439f69c1a3ec43f.js" defer=""></script><script src="/_next/static/chunks/26212-66b5594b77072bcf.js" defer=""></script><script src="/_next/static/chunks/24609-e6c6f256225974e7.js" defer=""></script><script src="/_next/static/chunks/20713-7b2b1f9ed4f0be3e.js" defer=""></script><script src="/_next/static/chunks/69769-a05b44105a1671d4.js" defer=""></script><script src="/_next/static/chunks/59392-e5eea99f00426be0.js" defer=""></script><script src="/_next/static/chunks/8732-58847a85e7673f83.js" defer=""></script><script src="/_next/static/chunks/87249-43298e6458be0b59.js" defer=""></script><script src="/_next/static/chunks/4471-2df31ab8f8adb195.js" defer=""></script><script src="/_next/static/chunks/9792-540edc281c26fc6e.js" defer=""></script><script src="/_next/static/chunks/89859-a59102bf3848c087.js" defer=""></script><script src="/_next/static/chunks/62314-f9cbd98c3796e95e.js" defer=""></script><script src="/_next/static/chunks/44084-c479e3ce817c7a66.js" defer=""></script><script src="/_next/static/chunks/49734-4b3bb3d3dcc0b255.js" defer=""></script><script src="/_next/static/chunks/92654-eb9b17cfe8b01f07.js" defer=""></script><script src="/_next/static/chunks/88228-bc9eb3556b4f5a2b.js" defer=""></script><script src="/_next/static/chunks/30807-4a5ebb9f9089cf23.js" defer=""></script><script src="/_next/static/chunks/5677-d5cded249f0ae65a.js" defer=""></script><script src="/_next/static/chunks/77039-23db3ec128afa49a.js" defer=""></script><script src="/_next/static/chunks/13871-ed50c7ffb047749d.js" defer=""></script><script src="/_next/static/chunks/16867-630ddef2b3b6d72c.js" defer=""></script><script src="/_next/static/chunks/14213-e396d0be0c174a4d.js" defer=""></script><script src="/_next/static/chunks/47581-6e5ce703c0178401.js" defer=""></script><script src="/_next/static/chunks/39129-a99af3f6cb3dad5e.js" defer=""></script><script src="/_next/static/chunks/73651-3e1ba4fdf87742a4.js" defer=""></script><script src="/_next/static/chunks/pages/fda-calendar-6fcdfb8d807e7fe0.js" defer=""></script><script src="/_next/static/0BHLnDvbhzltU4ONkiCGh/_buildManifest.js" defer=""></script><script src="/_next/static/0BHLnDvbhzltU4ONkiCGh/_ssgManifest.js" defer=""></script><style data-styled="" data-styled-version="6.1.8">.bz-featured-ad{position:relative;}/*!sc*/ .bz-featured-ad::after{position:absolute;content:'Featured Ad';padding:1px 10px;vertical-align:super;font-size:12px;display:inline-block;background:#f5f5f5;border-radius:16px;margin-left:3px;border:1px solid #cacaca;bottom:5px;left:inherit;}/*!sc*/ data-styled.g37[id="sc-global-jWNYke1"]{content:"sc-global-jWNYke1,"}/*!sc*/ .EuWGp{background:url(https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?width=100);position:absolute;width:100%;height:100%;background-repeat:no-repeat;background-size:cover;filter:blur(20px);}/*!sc*/ .bZSaNx{background:url(https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?width=100);position:absolute;width:100%;height:100%;background-repeat:no-repeat;background-size:cover;filter:blur(20px);}/*!sc*/ .eZzlKy{background:url(https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=100);position:absolute;width:100%;height:100%;background-repeat:no-repeat;background-size:cover;filter:blur(20px);}/*!sc*/ .hnOMtb{background:url(https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?width=100);position:absolute;width:100%;height:100%;background-repeat:no-repeat;background-size:cover;filter:blur(20px);}/*!sc*/ data-styled.g38[id="sc-dffbf6d7-0"]{content:"EuWGp,bZSaNx,eZzlKy,hnOMtb,"}/*!sc*/ .jNoPDg.benzinga-logo{display:inline-block;}/*!sc*/ .jNoPDg.benzinga-logo.desktop{width:192px;min-width:192px;max-width:192px;}/*!sc*/ .jNoPDg.benzinga-logo img,.jNoPDg.benzinga-logo svg{width:100%;height:100%;}/*!sc*/ data-styled.g312[id="sc-hTgaWy"]{content:"jNoPDg,"}/*!sc*/ .jbUZed{color:#000000;font-size:16px;}/*!sc*/ data-styled.g316[id="sc-hidnnO"]{content:"jbUZed,"}/*!sc*/ .bpLYAM{font-size:2.6rem;line-height:3.25rem;font-weight:bold;}/*!sc*/ @media (max-width: 600px){.bpLYAM{font-size:1.5rem;line-height:1.9rem;font-weight:800;}}/*!sc*/ data-styled.g320[id="sc-jmONUi"]{content:"bpLYAM,"}/*!sc*/ .gcWRCu .layout-above .section-description{margin-bottom:1rem;}/*!sc*/ .gcWRCu .related-info-container{display:inline-flex;margin:0.5rem 0;}/*!sc*/ @media (min-width: 800px){.gcWRCu .has-left-sidebar .layout-sidebar{display:none;}}/*!sc*/ @media (min-width: 1100px){.gcWRCu .has-left-sidebar .layout-sidebar{display:block;}}/*!sc*/ @media (min-width: 800px){.gcWRCu .layout-flex{flex-direction:row;}}/*!sc*/ @media (max-width: 799px){.gcWRCu .layout-flex >div{width:100%;}}/*!sc*/ .gcWRCu .layout-header.full-width{padding:0;}/*!sc*/ .gcWRCu .layout-header.full-width .layout-container{max-width:100%;}/*!sc*/ .gcWRCu .layout-main{overflow-x:auto;width:100%;}/*!sc*/ @media (min-width: 1300px){.gcWRCu .layout-container{max-width:1300px;}}/*!sc*/ @media (max-width: 1300px){.gcWRCu .layout-container,.gcWRCu .layout-header{padding-left:0.25rem;padding-right:0.25rem;}.gcWRCu .layout-container.full-width .layout-container,.gcWRCu .layout-header.full-width .layout-container{padding:0;}}/*!sc*/ data-styled.g322[id="sc-fqCdsd"]{content:"gcWRCu,"}/*!sc*/ .kcYnRn{margin-top:1rem;margin-bottom:1.5rem;}/*!sc*/ data-styled.g323[id="sc-fccqSk"]{content:"kcYnRn,"}/*!sc*/ .brajqy{width:300px;}/*!sc*/ @media (min-width: 800px){.brajqy{margin-left:1rem;}}/*!sc*/ data-styled.g324[id="sc-hSWyVn"]{content:"brajqy,"}/*!sc*/ .giQuHe.layout-above{width:100%;overflow:hidden;margin-bottom:1rem;padding-left:unset;}/*!sc*/ @media (max-width: 800px){.giQuHe.layout-above{padding-left:unset;}}/*!sc*/ data-styled.g326[id="sc-eFzpJt"]{content:"giQuHe,"}/*!sc*/ .dUmRRP.qa-container{display:flex;flex-direction:column;width:100%;padding:0.5rem;border-bottom:1px solid #c3ddfd;}/*!sc*/ .dUmRRP.qa-container .question{font-size:16px;}/*!sc*/ @media screen and (min-width: 600px){.dUmRRP.qa-container .question{font-size:18px;}}/*!sc*/ .dUmRRP.qa-container >div{display:flex;align-items:baseline;}/*!sc*/ .dUmRRP.qa-container >div .qa-letter-icon{color:#3f83f8;font-weight:700;background-color:#e1effe;border-radius:0.25rem;display:flex;justify-content:center;align-items:center;width:2rem;height:2rem;min-width:2rem;margin-right:1rem;margin-top:0.25rem;margin-bottom:0.25rem;float:left;}/*!sc*/ .dUmRRP.qa-container >div .answer-container p{margin-bottom:0!important;}/*!sc*/ @media screen and (max-width: 600px){.dUmRRP.qa-container{border:none;border-bottom:1px solid #e1ebfa;max-width:100%;}.dUmRRP.qa-container:nth-of-type(odd){padding-left:0.5rem;}}/*!sc*/ data-styled.g350[id="sc-ldxRAc"]{content:"dUmRRP,"}/*!sc*/ .faGBSq h2{margin-bottom:6px;}/*!sc*/ data-styled.g351[id="sc-cAgXCv"]{content:"faGBSq,"}/*!sc*/ .kEIiVN{border:solid 1px #c3ddfd;border-radius:4px;background:white;}/*!sc*/ .kEIiVN .qa-container:last-of-type{border-bottom:none;}/*!sc*/ .kEIiVN h2{font-weight:700;font-size:18px;line-height:1.75rem;margin-left:0.5rem;margin-top:0.5rem;text-transform:uppercase;}/*!sc*/ data-styled.g352[id="sc-fZcocS"]{content:"kEIiVN,"}/*!sc*/ .jXkXBs{display:flex;position:relative;width:100%;padding-left:unset;}/*!sc*/ .jXkXBs .search-icon{align-items:center;color:#378aff;display:flex;height:44px;justify-content:center;width:44px;}/*!sc*/ .jXkXBs .cancel-button{font-size:1.2rem;padding:0 10px;color:#378aff;}/*!sc*/ .jXkXBs .search-button{border-radius:0;width:50px;}/*!sc*/ .jXkXBs input{background-color:transparent;border-width:0;outline:none;width:100%;font-weight:bold;font-size:16px;}/*!sc*/ data-styled.g412[id="sc-cgyULZ"]{content:"jXkXBs,"}/*!sc*/ .iVgNrI.checkbox-container{display:flex;align-items:center;}/*!sc*/ .iVgNrI.checkbox-container .core-checkbox,.iVgNrI.checkbox-container label{cursor:pointer;}/*!sc*/ .iVgNrI.checkbox-container label{margin-left:0.5rem;font-size:14px;}/*!sc*/ .iVgNrI.checkbox-container input[type='checkbox']{width:16px;height:16px;border:1px solid #B8CBE6;border-radius:4px;outline:none;}/*!sc*/ .iVgNrI.checkbox-container input[type='checkbox']:disabled{background-color:#b9b9b9;border-color:#878787;color:#000000d9;cursor:not-allowed;}/*!sc*/ data-styled.g434[id="sc-bRoQge"]{content:"iVgNrI,"}/*!sc*/ .jRvBse .block{margin:1rem 0;}/*!sc*/ .jRvBse .block:first-of-type{margin-top:0;}/*!sc*/ .jRvBse .block:last-of-type{margin-bottom:0;}/*!sc*/ .jRvBse .right{float:right;margin-left:0.5rem;}/*!sc*/ .jRvBse .left{float:left;margin-right:0.5rem;}/*!sc*/ .jRvBse .center{text-align:center;margin:auto;}/*!sc*/ .jRvBse .center >figure,.jRvBse .center >img,.jRvBse .center >div{margin:auto;}/*!sc*/ .jRvBse h1.core-block,.jRvBse h2.core-block{margin-top:2rem;margin-bottom:1rem;}/*!sc*/ .jRvBse h1.core-block{font-size:36px;}/*!sc*/ .jRvBse h2.core-block{font-size:30px;color:#395173;}/*!sc*/ .jRvBse h3.core-block{font-size:24px;margin:1rem 0px 0.5rem 0px;}/*!sc*/ .jRvBse h4.core-block{margin:1rem 0px 0.5rem 0px;}/*!sc*/ .jRvBse ul.core-block{list-style:disc;margin-left:2rem;margin-bottom:2rem;}/*!sc*/ .jRvBse ul.core-block ul,.jRvBse ul.core-block ol{margin-bottom:0;}/*!sc*/ .jRvBse ol.core-block{list-style:decimal;margin-left:2rem;margin-bottom:2rem;}/*!sc*/ .jRvBse ol.core-block li{margin-bottom:0.2rem;}/*!sc*/ .jRvBse ol.core-block ul,.jRvBse ol.core-block ol{margin-bottom:0;}/*!sc*/ .jRvBse .wp-block-spacer{clear:both;}/*!sc*/ .jRvBse p.core-block{font-size:1.1rem;}/*!sc*/ .jRvBse .core-block a{color:#2ca2d1;}/*!sc*/ .jRvBse .alignright{float:right;margin-left:18px;}/*!sc*/ .jRvBse .image-wrapper{margin-bottom:1rem;}/*!sc*/ .jRvBse .wp-block-table{overflow-x:auto;}/*!sc*/ .jRvBse .wp-element-caption{border-bottom:1px solid #d6d6d6;border-top:1px solid #d6d6d6;background-color:#f4f4f4;font-size:14px;text-align:center;margin-top:-1rem;margin-bottom:1rem;}/*!sc*/ .jRvBse table.core-block,.jRvBse figure.core-block table,.jRvBse figure.wp-block-table table{width:100%;}/*!sc*/ .jRvBse table.core-block th,.jRvBse figure.core-block table th,.jRvBse figure.wp-block-table table th{background-color:#3f83f8;color:#ffffff;padding:4px 8px;font-size:14px;}/*!sc*/ .jRvBse table.core-block tbody thead tr th,.jRvBse figure.core-block table tbody thead tr th,.jRvBse figure.wp-block-table table tbody thead tr th,.jRvBse table.core-block tbody >tr:first-of-type th,.jRvBse figure.core-block table tbody >tr:first-of-type th,.jRvBse figure.wp-block-table table tbody >tr:first-of-type th{padding:4px 8px;font-size:14px;font-weight:600;}/*!sc*/ .jRvBse table.core-block tbody tr:nth-child(even),.jRvBse figure.core-block table tbody tr:nth-child(even),.jRvBse figure.wp-block-table table tbody tr:nth-child(even){background:#f9f9f9;}/*!sc*/ .jRvBse table.core-block tbody td,.jRvBse figure.core-block table tbody td,.jRvBse figure.wp-block-table table tbody td{padding:4px 8px;}/*!sc*/ .jRvBse .blocks-gallery-grid,.jRvBse .wp-block-gallery{display:flex;flex-wrap:wrap;list-style-type:none;padding:0;margin:0;}/*!sc*/ .jRvBse .blocks-gallery-grid .blocks-gallery-item,.jRvBse .wp-block-gallery .blocks-gallery-item{margin:0 1em 1em 0;display:flex;flex-grow:1;flex-direction:column;justify-content:center;position:relative;width:calc(50% - 1em);}/*!sc*/ .jRvBse .blocks-gallery-grid .blocks-gallery-item img,.jRvBse .wp-block-gallery .blocks-gallery-item img{display:block;max-width:100%;}/*!sc*/ .jRvBse .blocks-gallery-grid .blocks-gallery-item figure,.jRvBse .wp-block-gallery .blocks-gallery-item figure{display:flex;align-items:flex-end;justify-content:flex-start;}/*!sc*/ @media (min-width: 600px){.jRvBse .blocks-gallery-grid.columns-3 .blocks-gallery-grid .blocks-gallery-item,.jRvBse .wp-block-gallery.columns-3 .blocks-gallery-grid .blocks-gallery-item{width:calc(32% - 0.66667em);margin-right:1em;}}/*!sc*/ .jRvBse .wp-block-quote{padding:0 1em;margin:0px 0px 2rem;line-height:1.6;color:#2d2d2d;border-left:2px solid #1e429f;font-style:italic;}/*!sc*/ .jRvBse >div >img,.jRvBse >div >figure{max-width:100%;}/*!sc*/ .jRvBse >div >table,.jRvBse >div >figure table,.jRvBse >div .core-block-table-wrapper table{margin:1rem 0;width:100%;max-width:100%;}/*!sc*/ .jRvBse >div >table th,.jRvBse >div >figure table th,.jRvBse >div .core-block-table-wrapper table th{background-color:#3f83f8;color:#ffffff;padding:4px 8px;text-align:left;}/*!sc*/ .jRvBse >div >table tbody thead tr th,.jRvBse >div >figure table tbody thead tr th,.jRvBse >div .core-block-table-wrapper table tbody thead tr th,.jRvBse >div >table tbody >tr:first-of-type th,.jRvBse >div >figure table tbody >tr:first-of-type th,.jRvBse >div .core-block-table-wrapper table tbody >tr:first-of-type th{padding:4px 8px;font-size:14px;}/*!sc*/ .jRvBse >div >table tbody tr:nth-child(even),.jRvBse >div >figure table tbody tr:nth-child(even),.jRvBse >div .core-block-table-wrapper table tbody tr:nth-child(even){background:#f9f9f9;}/*!sc*/ .jRvBse >div >table tbody td,.jRvBse >div >figure table tbody td,.jRvBse >div .core-block-table-wrapper table tbody td{padding:4px 8px;font-size:14px;}/*!sc*/ .jRvBse >div >h1,.jRvBse >div >h2{margin-top:2rem;margin-bottom:1rem;}/*!sc*/ .jRvBse >div >h1{font-size:36px;}/*!sc*/ .jRvBse >div >h2{font-size:30px;color:#395173;}/*!sc*/ .jRvBse >div >h3{font-size:24px;margin:1rem 0px 0.5rem 0px;}/*!sc*/ .jRvBse >div >h4{margin:1rem 0px 0.5rem 0px;}/*!sc*/ .jRvBse >div >ul{list-style:disc;margin-left:2rem;margin-bottom:2rem;}/*!sc*/ .jRvBse >div >ol{list-style:decimal;margin-left:2rem;margin-bottom:2rem;}/*!sc*/ .jRvBse >div >ol li{margin-bottom:0.2rem;}/*!sc*/ .jRvBse >div >p{font-size:1.1rem;}/*!sc*/ .jRvBse >div a{color:#2ca2d1;}/*!sc*/ .jRvBse .bz-campaign hr{background:#5294c1;border:0;height:1px;margin-bottom:26px;padding:0;}/*!sc*/ data-styled.g465[id="sc-dVraiA"]{content:"jRvBse,"}/*!sc*/ .dOEGLi .bz3-search-field{position:relative;max-width:180px;}/*!sc*/ .dOEGLi .bz3-search-field__btn{height:40px;width:40px;border:0;background:#fa8418;color:#fff;font-size:14px;position:absolute;top:2px;right:2px;}/*!sc*/ .dOEGLi .bz3-search-field__tags-wrapper{border:1px solid #e5e5e5;display:flex;flex-wrap:wrap;align-items:center;height:auto;min-height:44px;padding:0 50px 0 15px;border:1px solid #e5e5e5;border-radius:0;box-shadow:none;margin:0;}/*!sc*/ .dOEGLi .bz3-search-field__input{border:none;width:100%;padding:0;font-size:12px;}/*!sc*/ .dOEGLi .bz3-search-field__input::placeholder{color:#7b7b7b;}/*!sc*/ .dOEGLi .bz3-search-field__input:focus{outline:none;box-shadow:none;}/*!sc*/ data-styled.g473[id="sc-MHjuz"]{content:"dOEGLi,"}/*!sc*/ .bzMGnz{flex-grow:1;}/*!sc*/ .bzMGnz .ratings-filters{display:inline-flex;flex-direction:row-reverse;justify-content:space-between;width:100%;margin-bottom:1rem;position:relative;}/*!sc*/ .bzMGnz .ratings-filters .range-date-picker__field-wrapper{font-size:12px;width:200px;font-weight:bold;}/*!sc*/ @media screen and (max-width: 500px){.bzMGnz .ratings-filters .range-date-picker__field-wrapper{width:185px;padding:0;}}/*!sc*/ @media screen and (max-width: 500px){.bzMGnz .ratings-filters .dates-filter{display:inline-flex;align-items:center;}.bzMGnz .ratings-filters .dates-filter .range-date-picker{padding:0;}.bzMGnz .ratings-filters .dates-filter .bz3-search-field{width:160px;}.bzMGnz .ratings-filters .dates-filter .bz3-search-field input.bz3-search-field__input{width:92px;}}/*!sc*/ .bzMGnz .dates-filter{display:flex;align-items:center;justify-content:flex-end;}/*!sc*/ .bzMGnz .dates-filter .range-date-picker{max-width:280px;position:static;}/*!sc*/ .bzMGnz .dates-filter .range-date-picker .DayPicker-NavButton--prev{top:13px;left:41px;}/*!sc*/ .bzMGnz .dates-filter .range-date-picker .DayPicker-NavButton--next{top:13px;right:41px;}/*!sc*/ @media screen and (max-width: 1000px){.bzMGnz .dates-filter .range-date-picker{margin-bottom:15px;}}/*!sc*/ @media screen and (max-width: 1000px){.bzMGnz .dates-filter .bz3-search-field{margin-bottom:15px;}}/*!sc*/ .bzMGnz .dates-filter .bz3-search-field{max-width:180px;margin-left:10px;width:180px;}/*!sc*/ .bzMGnz .dates-filter .bz3-search-field__btn{display:flex;align-items:center;justify-content:center;}/*!sc*/ @media screen and (max-width: 500px){.bzMGnz .dates-filter .bz3-search-field{max-width:100%;margin-left:auto;width:100%;}}/*!sc*/ .bzMGnz .dates-filter__slider{max-width:75%;width:100%;}/*!sc*/ @media screen and (max-width: 1000px){.bzMGnz .dates-filter__slider{margin-bottom:20px;max-width:none;}}/*!sc*/ .bzMGnz .dates-filter .react-datepicker-popper[data-placement^='bottom'] .react-datepicker__triangle:before{border:none!important;border-bottom-color:#fff!important;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker{background-color:#fff;border-radius:2px;box-shadow:0 2px 8px rgba(0, 0, 0, 0.15);border:none;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__header{background-color:#fff;border-bottom-color:#f0f0f0;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__day{border-radius:2px;border:1px solid rgba(0, 0, 0, 0);}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__day:hover{border:1px solid #fa8418;background:none;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__day:focus{outline:none;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__day--in-range,.bzMGnz .dates-filter .react-datepicker__day--in-selecting-range{background-color:rgba(250, 132, 24, 0.5);}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__day--in-range:hover,.bzMGnz .dates-filter .react-datepicker__day--in-selecting-range:hover{color:#000;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__day--selected,.bzMGnz .dates-filter .react-datepicker__day--keyboard-selected{background-color:#fa8418;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__day--selected:hover,.bzMGnz .dates-filter .react-datepicker__day--keyboard-selected:hover{background-color:#fa8418;}/*!sc*/ .bzMGnz .dates-filter .react-datepicker__input-container{position:relative;}/*!sc*/ .bzMGnz .range-date-picker{text-align:right;display:flex;align-items:center;padding-left:15px;position:relative;}/*!sc*/ .bzMGnz .range-date-picker__icon{position:absolute;top:16px;right:10px;color:grey;pointer-events:none;}/*!sc*/ .bzMGnz .range-date-picker .react-datepicker-wrapper{width:100%;}/*!sc*/ .bzMGnz .range-date-picker__label{font-weight:bold;font-size:14px;line-height:22px;margin-right:8px;}/*!sc*/ .bzMGnz .range-date-picker__field-wrapper{width:177px;max-width:223px;position:relative;font-size:12px;font-weight:700;}/*!sc*/ .bzMGnz .range-date-picker__calendar-wrapper{position:absolute;right:0;top:46px;z-index:10;background-color:#fff;border-radius:2px;box-shadow:0 2px 8px rgba(0, 0, 0, 0.15);display:flex;flex-direction:column;justify-content:center;align-items:center;width:100%;max-width:480px;}/*!sc*/ .bzMGnz .range-date-picker__picker-field{padding-left:32px;border-radius:2px;border:1px solid #e5e5e5;line-height:22px;padding:5px 10px;box-shadow:none;width:100%;margin-bottom:0;height:44px;cursor:pointer;padding-right:26px;}/*!sc*/ .bzMGnz .range-date-picker__picker-field:focus{box-shadow:none;border-color:#2ca2d1;}/*!sc*/ .bzMGnz .range-date-picker__presets{display:flex;flex-wrap:wrap;align-items:flex-start;padding:5px 20px;width:100%;justify-content:space-between;}/*!sc*/ .bzMGnz .range-date-picker__preset-btn{padding:5px 5px;font-style:normal;font-weight:normal;font-size:12px;line-height:24px;width:21%;margin-bottom:15px;border-radius:5px;}/*!sc*/ .bzMGnz .range-date-picker__preset-btn:hover{background-color:#fa84188c;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Month{margin:1em 1em 0;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Months{display:flex;justify-content:center;flex-wrap:wrap;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-NavButton--prev{top:20px;left:17px;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-NavButton--next{top:20px;right:10px;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Caption{text-align:center;padding-bottom:10px;border-bottom:1px solid #f0f0f0;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Week,.bzMGnz .range-date-picker .DayPicker-WeekdaysRow{display:flex;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Weekday{text-align:center;font-size:14px;width:24px;height:24px;padding:1px;display:block;margin:1px;cursor:pointer;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Day{border:1px solid rgba(0, 0, 0, 0);border-radius:2px;display:block;width:24px;height:24px;padding:1px;text-align:center;vertical-align:middle;font-size:14px;line-height:20px;margin:1px;cursor:pointer;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Day--selected:not(.DayPicker-Day--disabled):not(.DayPicker-Day--outside){background-color:rgba(250, 132, 24, 0.5);}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Day--start:not(.DayPicker-Day--disabled):not(.DayPicker-Day--outside),.bzMGnz .range-date-picker .DayPicker-Day--end:not(.DayPicker-Day--disabled):not(.DayPicker-Day--outside){background-color:#fa8418;}/*!sc*/ .bzMGnz .range-date-picker .DayPicker-Day:hover:not(.DayPicker-Day--disabled):not(.DayPicker-Day--outside){background-color:rgba(0, 0, 0, 0);border:1px solid #fa8418;color:#000;}/*!sc*/ .bzMGnz .DayPicker-NavButton--prev{margin-right:1.5em;background-image:url(data:image/png;base64,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);}/*!sc*/ .bzMGnz .DayPicker-NavButton--next{background-image:url(data:image/png;base64,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);}/*!sc*/ .bzMGnz .DayPicker-NavButton{position:absolute;top:1em;right:1.5em;left:auto;display:inline-block;margin-top:2px;width:1.25em;height:1.25em;background-position:50%;background-size:50%;background-repeat:no-repeat;color:#8b9898;cursor:pointer;}/*!sc*/ data-styled.g474[id="sc-ijWjlm"]{content:"bzMGnz,"}/*!sc*/ .fFxCoI{position:relative;}/*!sc*/ @media only screen and (max-width: 1000px){.fFxCoI{width:100%;order:1;}}/*!sc*/ @media only screen and (max-width: 800px){.fFxCoI:before{content:'';display:block;width:20px;height:100%;position:absolute;right:0;top:0;background:linear-gradient(90deg, rgba(255, 255, 255, 0) 0, #f2f7ff 67%);z-index:2;}}/*!sc*/ .fFxCoI .top-tabs{display:flex;position:relative;overflow:auto;gap:0 8px;}/*!sc*/ .fFxCoI .top-tabs__tab{background:rgba(26, 121, 255, 0.025);border:2px solid rgba(26, 121, 255, 0.1);box-sizing:border-box;border-radius:4px;color:#3f83f8;padding:8px 16px;font-size:14px;font-weight:600;font-family:Manrope,Manrope-fallback,sans-serif;line-height:20px;cursor:pointer;white-space:nowrap;}/*!sc*/ .fFxCoI .top-tabs__tab:hover,.fFxCoI .top-tabs__tab--active{background:#3f83f8;color:#fff;}/*!sc*/ @media only screen and (max-width: 800px){.fFxCoI .top-tabs:after{content:'';display:block;width:20px;flex-shrink:0;}}/*!sc*/ data-styled.g475[id="sc-kOVexp"]{content:"fFxCoI,"}/*!sc*/ .davtfT{height:24px;width:80px;}/*!sc*/ data-styled.g499[id="sc-cVuPSX"]{content:"davtfT,"}/*!sc*/ .dHGnYo{position:relative;width:100%;}/*!sc*/ data-styled.g504[id="sc-dUVpZY"]{content:"dHGnYo,"}/*!sc*/ .IsyKQ.searchbar-wrapper{box-shadow:0px 0px 2px 0 rgb(0 0 0 / 15%);background:#ffffff;padding:4px 12px;padding-right:10px;flex-grow:1;max-width:290px;position:relative;max-width:none;}/*!sc*/ @media screen and (max-width: 800px){.IsyKQ.searchbar-wrapper{max-width:none;}}/*!sc*/ .IsyKQ.searchbar-wrapper a{text-decoration:none;}/*!sc*/ .IsyKQ.searchbar-wrapper.searchbar-box,.IsyKQ.searchbar-wrapper.searchbar-inline{padding:0;border:solid 1px #E1EBFA;box-shadow:none;}/*!sc*/ .IsyKQ.searchbar-wrapper.searchbar-box .search-results-wrapper,.IsyKQ.searchbar-wrapper.searchbar-inline .search-results-wrapper{padding:0;}/*!sc*/ .IsyKQ.searchbar-wrapper.searchbar-box .search-result-wrapper,.IsyKQ.searchbar-wrapper.searchbar-inline .search-result-wrapper{padding:0;}/*!sc*/ .IsyKQ.searchbar-wrapper.searchbar-box .search-icon,.IsyKQ.searchbar-wrapper.searchbar-inline .search-icon{height:36px;}/*!sc*/ .IsyKQ.searchbar-wrapper.searchbar-box input ::placeholder,.IsyKQ.searchbar-wrapper.searchbar-inline input ::placeholder{color:#99AECC;}/*!sc*/ .IsyKQ.searchbar-wrapper.searchbar-inline{box-shadow:none;}/*!sc*/ .IsyKQ.searchbar-wrapper.searchbar-inline .search-dropdown{position:relative;box-shadow:none;border:none;}/*!sc*/ .IsyKQ.searchbar-wrapper input:focus{box-shadow:none;}/*!sc*/ .IsyKQ.searchbar-wrapper input ::placeholder{color:#395173;}/*!sc*/ data-styled.g516[id="sc-iftxFb"]{content:"IsyKQ,"}/*!sc*/ .dczzGV.stock-movers-table{width:100%;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper{display:block;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper table{width:100%;table-layout:fixed;display:table;text-align:left;font-size:12px;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead{display:table;table-layout:fixed;width:100%;color:#7c7c7c;border-bottom:2px solid #E1EBFA;font-size:10px;background-color:transparent;height:35px;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead tr{text-align:left;border-collapse:collapse;}/*!sc*/ @media screen and (max-width: 800px){.dczzGV.stock-movers-table .stock-movers-table-wrapper thead tr{height:30px;}}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead tr th:last-of-type{text-align:right;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead th{padding:0 0.25rem;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead th:last-of-type{text-align:right;padding-left:unset;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead th button{display:flex;align-items:center;justify-content:space-between;font-weight:600;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead .header-sort-icons{display:flex;flex-direction:column;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead .header-sort-icon{width:8px;height:6px;font-size:6px;margin-left:4px;color:#CEDDF2;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper thead .header-sort-icon__up.active,.dczzGV.stock-movers-table .stock-movers-table-wrapper thead .header-sort-icon__down.active{color:#5B7292;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody{max-height:260px;min-height:80px;overflow-x:hidden;display:block;width:100%;font-size:0.75rem;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody::-webkit-scrollbar{display:none;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody th,.dczzGV.stock-movers-table .stock-movers-table-wrapper tbody td{padding:0.2rem 0.25rem;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr{border-collapse:collapse;box-sizing:inherit;display:table;table-layout:fixed;width:100%;border-bottom:1px solid #f0f0f0;}/*!sc*/ @media screen and (max-width: 950px){.dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr{height:38px;}}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr td{color:#000000;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr td.company{overflow:hidden;text-overflow:ellipsis;white-space:nowrap;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr td.change{font-weight:600;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr td a{color:#2ca2d1;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr td.buy{text-align:right;font-weight:600;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody tr td.ticker{font-weight:600;}/*!sc*/ .dczzGV.stock-movers-table .stock-movers-table-wrapper tbody.no-results tr{border-bottom:unset;}/*!sc*/ .dczzGV.stock-movers-table .benzinga-pro-link{display:flex;justify-content:space-between;padding-bottom:5px;padding-top:5px;font-size:10px;color:#2ca2d1;font-weight:700;width:100%;border-top:1px solid #E1EBFA;}/*!sc*/ @media screen and (max-width: 800px){.dczzGV.stock-movers-table .benzinga-pro-link{line-height:26px;font-size:12px;}}/*!sc*/ data-styled.g549[id="sc-bWtsZH"]{content:"dczzGV,"}/*!sc*/ .fXDUkc.stock-movers-container{width:100%;}/*!sc*/ .fXDUkc.stock-movers-container .header-container{display:flex;align-items:center;margin-bottom:0.5rem;}/*!sc*/ .fXDUkc.stock-movers-container .header-container >h2{font-weight:600;font-size:12px;line-height:1;padding-right:0.5rem;white-space:nowrap;}/*!sc*/ .fXDUkc.stock-movers-container .header-container .styled-line:nth-of-type(1){display:none;}/*!sc*/ .fXDUkc.stock-movers-container .header-container .styled-line:before{background-color:#E1EBFA;}/*!sc*/ @media screen and (min-width: 700px){.fXDUkc.stock-movers-container .header-container >h2{padding:0 0.5rem;}.fXDUkc.stock-movers-container .header-container .styled-line:nth-of-type(1){display:block;}}/*!sc*/ .fXDUkc.stock-movers-container .session-time-container{height:18px;margin-top:0.5rem;}/*!sc*/ .fXDUkc.stock-movers-container .stock-movers-timeframe{font-size:12px;font-style:italic;color:#555;}/*!sc*/ .fXDUkc.stock-movers-container .stock-movers-table-container{border-bottom:1px solid #E1EBFA;}/*!sc*/ .fXDUkc.stock-movers-container .stock-movers-table-container th.volume-table-header,.fXDUkc.stock-movers-container .stock-movers-table-container td.volume{display:none;}/*!sc*/ .fXDUkc.stock-movers-container .stock-movers-table-container.full-width-table >div:first-of-type{margin-right:10px;border-right:1px solid #E1EBFA;padding-right:10px;}/*!sc*/ .fXDUkc.stock-movers-container .stock-movers-table-container.full-width-table .tab{cursor:auto;}/*!sc*/ .fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table th.volume-table-header,.fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table th.buy-stock-table-header,.fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table td.volume,.fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table td.buy{display:table-cell;}/*!sc*/ .fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table.stacked{flex-direction:column;}/*!sc*/ .fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table.stacked.full-width-table >div:first-of-type{margin-right:unset;border-right:unset;padding-right:unset;}/*!sc*/ .fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table.stacked tbody{max-height:100%;}/*!sc*/ .fXDUkc.stock-movers-container.default .stock-movers-table-container.full-width-table.stacked tbody .ticker-box-wrapper{border:none;}/*!sc*/ .fXDUkc.stock-movers-container.nano th.average-volume,.fXDUkc.stock-movers-container.nano th.market-cap,.fXDUkc.stock-movers-container.nano td.average-volume,.fXDUkc.stock-movers-container.nano td.market-cap{display:none;}/*!sc*/ .fXDUkc.stock-movers-container.compact .stock-movers-table-container.full-width-table{display:none!important;}/*!sc*/ .fXDUkc.stock-movers-container.compact .stock-movers-table-container.compact-table{display:block!important;}/*!sc*/ data-styled.g550[id="sc-fvoJAe"]{content:"fXDUkc,"}/*!sc*/ .kvSldG{flex-grow:1;position:relative;width:100%;height:1px;}/*!sc*/ .kvSldG:before{content:'';width:100%;height:1px;display:block;background-color:#5B7292;position:absolute;top:50%;}/*!sc*/ data-styled.g551[id="sc-iiqfCt"]{content:"kvSldG,"}/*!sc*/ .eyWkLM.tab{display:flex;justify-content:center;align-items:center;width:100%;font-weight:700;font-size:12px;line-height:1.25rem;padding-top:0.1rem;padding-bottom:0.1rem;padding-left:0.125rem;padding-right:0.125rem;white-space:nowrap;color:#ffffff;background-color:#0e9f6e;cursor:default;}/*!sc*/ .eyWkLM.tab h3{color:inherit;font-size:inherit;font-weight:inherit;}/*!sc*/ @media screen and (max-width: 800px){.eyWkLM.tab{line-height:1.6rem;}}/*!sc*/ .jQnOJj.tab{display:flex;justify-content:center;align-items:center;width:100%;font-weight:700;font-size:12px;line-height:1.25rem;padding-top:0.1rem;padding-bottom:0.1rem;padding-left:0.125rem;padding-right:0.125rem;white-space:nowrap;color:#ffffff;background-color:#f05252;cursor:default;}/*!sc*/ .jQnOJj.tab h3{color:inherit;font-size:inherit;font-weight:inherit;}/*!sc*/ @media screen and (max-width: 800px){.jQnOJj.tab{line-height:1.6rem;}}/*!sc*/ data-styled.g553[id="sc-eAQwYs"]{content:"eyWkLM,jQnOJj,"}/*!sc*/ .conWOv.post-card-wrapper{display:flex;}/*!sc*/ .conWOv.post-card-wrapper .post-card-article-link{color:#000000;}/*!sc*/ .conWOv.post-card-wrapper .post-card-article-link:hover{color:#76a9fa;}/*!sc*/ .conWOv.post-card-wrapper .post-card-hero,.conWOv.post-card-wrapper .post-card-hero-compact{background:#17253A;}/*!sc*/ @media screen and (max-width: 1024px){.conWOv.post-card-wrapper .post-card-hero,.conWOv.post-card-wrapper .post-card-hero-compact{margin-bottom:12px;}}/*!sc*/ .conWOv.post-card-wrapper .post-card-hero .post-card-text,.conWOv.post-card-wrapper .post-card-hero-compact .post-card-text{background:#17253A;color:white;margin-top:-3em;z-index:0;}/*!sc*/ .conWOv.post-card-wrapper .post-card-hero .post-card-text:before,.conWOv.post-card-wrapper .post-card-hero-compact .post-card-text:before{content:' ';background:linear-gradient(transparent, #17253A);height:3em;margin-top:-3em;position:relative;}/*!sc*/ .conWOv.post-card-wrapper .post-card-hero .post-card-text .post-card-text-wrapper,.conWOv.post-card-wrapper .post-card-hero-compact .post-card-text .post-card-text-wrapper{padding:0.5em 0.75em;min-height:56px;}/*!sc*/ .conWOv.post-card-wrapper .post-card-hero .post-card-text .post-card-text-wrapper:hover,.conWOv.post-card-wrapper .post-card-hero-compact .post-card-text .post-card-text-wrapper:hover{text-decoration:underline;}/*!sc*/ .conWOv.post-card-wrapper .post-card-description{font-size:12px;-webkit-box-orient:vertical;display:-webkit-box;overflow:hidden;text-overflow:ellipsis;-webkit-line-clamp:2;color:#192940;font-weight:400;line-height:1.25rem;}/*!sc*/ .conWOv.post-card-wrapper .news-item-sponsored-tag{display:block;font-size:13px;color:#3f83f8;}/*!sc*/ .conWOv.post-card-wrapper .image-wrapper{position:relative;overflow:hidden;border-radius:2px;display:inline-flex;flex:1;width:100%;height:100%;}/*!sc*/ .conWOv.post-card-wrapper .image-wrapper img{object-fit:cover;}/*!sc*/ .conWOv.post-card-wrapper .image-wrapper-india{position:relative;overflow:hidden;border-radius:8px;display:inline-flex;flex:1;width:100%;height:100%;}/*!sc*/ .conWOv.post-card-wrapper .image-wrapper-india img{object-fit:cover;}/*!sc*/ .conWOv.post-card-wrapper .post-elapsed-india-primary{margin-top:24px;margin-left:24px;height:22px;color:#b8cbe5;}/*!sc*/ .conWOv.post-card-wrapper .post-elapsed-india-secondary{margin-top:16px;margin-left:16px;height:18px;color:#b8cbe5;}/*!sc*/ .conWOv.post-card-wrapper .post-card-default .image-wrapper{height:360px;}/*!sc*/ @media (max-width: 768px){.conWOv.post-card-wrapper .post-card-default .image-wrapper{height:108px;}}/*!sc*/ .conWOv.post-card-wrapper .post-card-card{border-radius:6px;background:#ffffff;border:1px solid #E1EBFA;}/*!sc*/ .conWOv.post-card-wrapper .post-card-card .image-wrapper{height:130px;margin-bottom:0;display:block;}/*!sc*/ .conWOv.post-card-wrapper .post-card-card .post-card-text-wrapper{padding:1rem;}/*!sc*/ .conWOv.post-card-wrapper .post-card-card .post-title{font-size:16px;margin-bottom:0.25rem;display:block;}/*!sc*/ .conWOv.post-card-wrapper .post-card-card .post-teaser{font-size:16px;color:#5B7292;font-weight:300;}/*!sc*/ .conWOv.post-card-wrapper .post-card-feed .post-card-description{font-size:14px;}/*!sc*/ .conWOv.post-card-wrapper .post-card-feed .image-wrapper{max-height:126px;min-width:160px;max-width:160px;min-height:126px;}/*!sc*/ @media (max-width: 768px){.conWOv.post-card-wrapper .post-card-feed .image-wrapper{max-height:108px;min-height:108px;}}/*!sc*/ .conWOv.post-card-wrapper .post-card-size-compact .image-wrapper{max-height:180px;}/*!sc*/ @media (max-width: 768px){.conWOv.post-card-wrapper .post-card-size-compact .image-wrapper{max-height:108px;min-height:108px;}}/*!sc*/ .conWOv.post-card-wrapper .post-card-size-nano .image-wrapper{max-height:108px;}/*!sc*/ @media (max-width: 768px){.conWOv.post-card-wrapper .post-card-size-nano .image-wrapper{max-height:120px;}}/*!sc*/ .conWOv.post-card-wrapper .post-card-feed .post-card-title{font-size:20px;-webkit-line-clamp:3;}/*!sc*/ .conWOv.post-card-wrapper .post-card-feed .post-card-image{margin-right:16px;margin-bottom:0;}/*!sc*/ @media screen and (max-width: 800px){.conWOv.post-card-wrapper .post-card-hero .post-card-title{font-size:18px;}.conWOv.post-card-wrapper .post-card-feed{display:inline-flex;flex-direction:row;}.conWOv.post-card-wrapper .post-card-feed .post-card-title{font-size:18px;}.conWOv.post-card-wrapper .post-card-feed .post-card-image{height:100px;min-height:100px;min-width:100px;max-height:100px;max-width:100px;width:100px;}.conWOv.post-card-wrapper .post-card-feed .post-card-text{margin-left:0;}.conWOv.post-card-wrapper .post-card-feed .post-card-description{font-size:12px;font-weight:normal;line-height:18px;}}/*!sc*/ @media screen and (max-width: 500px){.conWOv.post-card-wrapper .post-card-description{display:none;}}/*!sc*/ data-styled.g581[id="sc-kgTdLl"]{content:"conWOv,"}/*!sc*/ .fjcqMd{border-radius:2px;display:flex;font-size:18px;font-weight:600;overflow:hidden;flex-direction:row;}/*!sc*/ .fjcqMd .post-card-title{font-size:24px;}/*!sc*/ data-styled.g582[id="sc-eTGAKG"]{content:"fjcqMd,"}/*!sc*/ .iZczKq.post-title{line-height:1.4em;font-weight:600;display:-webkit-box;}/*!sc*/ @media screen and (max-width: 600px){.iZczKq.post-title{font-size:0.95rem;line-height:1.4rem;-webkit-box-orient:vertical;-webkit-line-clamp:3;overflow:hidden;text-overflow:ellipsis;display:inherit;}}/*!sc*/ data-styled.g583[id="sc-kQUZUP"]{content:"iZczKq,"}/*!sc*/ .hkniJt.post-thumb{border-radius:2px;width:100%;position:relative;margin-right:16px;}/*!sc*/ data-styled.g587[id="sc-ecjqsm"]{content:"hkniJt,"}/*!sc*/ .hHJzBM.line-wrapper{-webkit-box-orient:vertical;display:-webkit-box;overflow:hidden;text-overflow:ellipsis;}/*!sc*/ data-styled.g588[id="sc-llvwKJ"]{content:"hHJzBM,"}/*!sc*/ .cerdRw.three-line{-webkit-line-clamp:4;}/*!sc*/ data-styled.g589[id="sc-duVdMk"]{content:"cerdRw,"}/*!sc*/ .bZwbEZ{position:relative;}/*!sc*/ .bZwbEZ .status-panel-container{margin-bottom:4px;top:4px;}/*!sc*/ .bZwbEZ .status-panel-container .clear-filters{text-decoration:underline;color:#2ca2d1;cursor:pointer;}/*!sc*/ .bZwbEZ .bz-ag-table{margin-top:0;margin-bottom:10px;}/*!sc*/ .bZwbEZ .bz-ag-table .ag-react-container{width:100%;}/*!sc*/ .bZwbEZ .bz-ag-table a{color:#2ca2d1;}/*!sc*/ .bZwbEZ .bz-ag-table__company-image{max-height:18px;margin-left:0.25rem;float:right;}/*!sc*/ .bZwbEZ .bz-ag-table__analyst-name{overflow:hidden;white-space:nowrap;width:100%;}/*!sc*/ .bZwbEZ .bz-ag-table__analyst-smart-score{color:white;background:#1c64f2;padding:2px 4px;width:35px;max-width:35px;line-height:20px;height:20px;max-height:20px;text-align:center;border-radius:9999px;margin-left:0.1rem;float:right;display:flex;align-items:center;justify-content:center;}/*!sc*/ .bZwbEZ .bz-ag-table__analyst-smart-score.green{background:#0e9f6e;}/*!sc*/ .bZwbEZ .bz-ag-table__analyst-smart-score.yellow{background:#e3a008;}/*!sc*/ .bZwbEZ .bz-ag-table__analyst-smart-score.orange{background:#ff8a4c;}/*!sc*/ .bZwbEZ .bz-ag-table__analyst-smart-score.red{background:#e02424;}/*!sc*/ .bZwbEZ .bz-ag-table .country-cell>span{display:flex;align-items:center;}/*!sc*/ .bZwbEZ div.company-name-cell{width:100%;display:inline-flex;justify-content:space-between;line-height:19px;}/*!sc*/ .bZwbEZ div.company-name-cell span{overflow:hidden;white-space:nowrap;text-overflow:ellipsis;}/*!sc*/ .bZwbEZ .server-side-calendar-container{display:flex;width:100%;overflow-x:auto;}/*!sc*/ .bZwbEZ .analyst-name-and-smart-score-cell{display:flex;align-items:center;justify-content:space-between;}/*!sc*/ .bZwbEZ .ratings-filters{display:flex;flex-direction:row;justify-content:space-between;align-items:flex-end;flex-wrap:wrap;width:100%;margin-bottom:1rem;position:relative;margin-bottom:1rem;}/*!sc*/ .bZwbEZ .ratings-filters h1{flex-shrink:0;margin-bottom:10px;}/*!sc*/ .bZwbEZ .ratings-filters .dates-filter .range-date-picker__picker-field{font-weight:500;}/*!sc*/ @media screen and (max-width: 500px){.bZwbEZ .ratings-filters .dates-filter{justify-content:space-between;flex-wrap:nowrap;}.bZwbEZ .ratings-filters .dates-filter .range-date-picker{padding-left:0;}.bZwbEZ .ratings-filters .dates-filter .range-date-picker__field-wrapper{width:153px;}.bZwbEZ .ratings-filters .dates-filter .range-date-picker__picker-field{font-size:10px;}.bZwbEZ .ratings-filters .dates-filter .bz3-search-bar-wrapper{width:auto;margin-left:5px;}}/*!sc*/ data-styled.g597[id="sc-dZzYrH"]{content:"bZwbEZ,"}/*!sc*/ .godhtp .table-cell-outcome{white-space:normal;}/*!sc*/ .godhtp .table-cell-get_alert{width:70px;}/*!sc*/ data-styled.g629[id="sc-bxcGCR"]{content:"godhtp,"}/*!sc*/ .ffPSdQ{margin-left:30px;}/*!sc*/ @media screen and (max-width: 1000px){.ffPSdQ{margin-bottom:10px;margin-left:0;margin-top:0;}}/*!sc*/ data-styled.g630[id="sc-ddqZcG"]{content:"ffPSdQ,"}/*!sc*/ .bZeEIF{margin-top:0;padding-top:10px;font-size:12px;line-height:21px;text-decoration:none;}/*!sc*/ data-styled.g708[id="sc-gjSWCP"]{content:"bZeEIF,"}/*!sc*/ .fpmJRV{transition:color 0.2s cubic-bezier(0.25, 0.46, 0.45, 0.94),color 0.2s ease;text-decoration:none;}/*!sc*/ data-styled.g709[id="sc-jIOndm"]{content:"fpmJRV,"}/*!sc*/ .kknTxh{display:flex;justify-content:center;align-items:center;width:40px;height:40px;border-radius:0.25rem;font-size:30px;color:#ffffff;-webkit-transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;}/*!sc*/ .kknTxh:hover{color:#3b5998;}/*!sc*/ .kknTxh svg{fill:#ffffff;}/*!sc*/ .kSqUML{display:flex;justify-content:center;align-items:center;width:40px;height:40px;border-radius:0.25rem;font-size:30px;color:#ffffff;-webkit-transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;}/*!sc*/ .kSqUML:hover{color:#e1306c;}/*!sc*/ .kSqUML svg{fill:#ffffff;}/*!sc*/ .gKRtMH{display:flex;justify-content:center;align-items:center;width:40px;height:40px;border-radius:0.25rem;font-size:30px;color:#ffffff;-webkit-transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;}/*!sc*/ .gKRtMH:hover{color:#0072b1;}/*!sc*/ .gKRtMH svg{fill:#ffffff;}/*!sc*/ .cOuPIH{display:flex;justify-content:center;align-items:center;width:40px;height:40px;border-radius:0.25rem;font-size:30px;color:#ffffff;-webkit-transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;}/*!sc*/ .cOuPIH:hover{color:#fe5000;}/*!sc*/ .cOuPIH svg{fill:#ffffff;}/*!sc*/ .cOwugh{display:flex;justify-content:center;align-items:center;width:40px;height:40px;border-radius:0.25rem;font-size:30px;color:#ffffff;-webkit-transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;}/*!sc*/ .cOwugh:hover{color:#000000;}/*!sc*/ .cOwugh svg{fill:#ffffff;}/*!sc*/ .gAbott{display:flex;justify-content:center;align-items:center;width:40px;height:40px;border-radius:0.25rem;font-size:30px;color:#ffffff;-webkit-transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;transition:color 200ms cubic-bezier(0.25, 0.46, 0.45, 0.94),color 200ms ease;}/*!sc*/ .gAbott:hover{color:red;}/*!sc*/ .gAbott svg{fill:#ffffff;}/*!sc*/ data-styled.g710[id="sc-ghbcbh"]{content:"kknTxh,kSqUML,gKRtMH,cOuPIH,cOwugh,gAbott,"}/*!sc*/ .byGBmO.button-wrapper{border-radius:6px;overflow:hidden;background-color:#ffffff;display:flex;align-items:center;justify-content:center;padding:5px;min-width:140px;-webkit-transition:all 200ms ease;transition:all 200ms ease;height:50px;box-sizing:border-box;}/*!sc*/ .byGBmO.button-wrapper:hover{background-color:#CEDDF2;}/*!sc*/ data-styled.g711[id="sc-jFWsBE"]{content:"byGBmO,"}/*!sc*/ .leyqvs.footer-row{display:grid;grid-auto-flow:column;grid-gap:20px;width:100%;padding-top:0.5rem;padding-bottom:2rem;padding-left:1rem;padding-right:1rem;margin-left:auto;margin-right:auto;}/*!sc*/ @media screen and (min-width: 480px){.leyqvs.footer-row{max-width:480px;}}/*!sc*/ @media screen and (min-width: 768px){.leyqvs.footer-row{padding-left:4rem;padding-right:4rem;max-width:100%;grid-gap:30px;}}/*!sc*/ @media screen and (max-width: 1000px){.leyqvs.footer-row{grid-auto-flow:row;grid-template-columns:repeat(auto-fill, minmax(200px, 1fr));}}/*!sc*/ data-styled.g713[id="sc-hwDNbq"]{content:"leyqvs,"}/*!sc*/ .gMllDn{display:flex;flex-direction:column;text-align:left;}/*!sc*/ .gMllDn h3{display:flex;color:#ffffff;font-size:18px;font-weight:600;margin:0;}/*!sc*/ @media screen and (min-width: 480px){.gMllDn h3{margin-top:0;}}/*!sc*/ @media screen and (min-width: 768px){.gMllDn h3{font-size:16px;margin-top:2rem;}}/*!sc*/ .gMllDn ul{list-style:none;padding:0;}/*!sc*/ .gMllDn ul li{font-size:16px;}/*!sc*/ @media screen and (min-width: 768px){.gMllDn ul li{font-size:14px;}}/*!sc*/ .gMllDn ul li >a{color:#CEDDF2;}/*!sc*/ .gMllDn ul li >a:hover{color:#ffffff;}/*!sc*/ data-styled.g714[id="sc-cXiSS"]{content:"gMllDn,"}/*!sc*/ .zcqvV{display:flex;align-items:center;margin:0 4px;padding-right:0px;width:192px;min-width:144px;}/*!sc*/ .zcqvV .benzinga-crypto-logo-wrapper{margin-bottom:-1px;}/*!sc*/ .zcqvV >a{display:inline-flex;}/*!sc*/ data-styled.g719[id="sc-jGeVcH"]{content:"zcqvV,"}/*!sc*/ .ilifZQ{align-items:center;display:flex;justify-content:space-between;}/*!sc*/ data-styled.g724[id="sc-iPOUNt"]{content:"ilifZQ,"}/*!sc*/ .eFsVII{color:#CEDDF2;font-weight:600;font-size:14px;line-height:20px;}/*!sc*/ data-styled.g725[id="sc-iBpinA"]{content:"eFsVII,"}/*!sc*/ .kQfrhl{color:#ffffff;font-size:12px;line-height:16px;}/*!sc*/ data-styled.g726[id="sc-cNGRH"]{content:"kQfrhl,"}/*!sc*/ .ibVicV{color:#99AECC;font-weight:700;display:flex;align-items:center;}/*!sc*/ .ibVicV .quote-icon{margin:0 4px;font-size:12px;}/*!sc*/ data-styled.g727[id="sc-ldJDQK"]{content:"ibVicV,"}/*!sc*/ .iZZowX{display:block;width:100%;max-width:145px;min-width:132px;padding:8px;background:linear-gradient(90deg, #f0525200 0%, #f052520d 100%);}/*!sc*/ .iZZowX .dark{color:#99AECC!important;}/*!sc*/ .iZZowX .light{color:#395173!important;}/*!sc*/ data-styled.g728[id="sc-bgmyod"]{content:"iZZowX,"}/*!sc*/ .iMBlzM{display:flex;flex-grow:1;height:52px;}/*!sc*/ data-styled.g729[id="sc-RMLOk"]{content:"iMBlzM,"}/*!sc*/ .jLtEqm{position:relative;overflow:hidden;white-space:nowrap;}/*!sc*/ .jLtEqm::before{animation:jBCTCY 5s ease-in-out infinite;content:'';position:absolute;top:0;width:100%;height:100%;background:linear-gradient(120deg, transparent, rgba(255, 255, 255, 0.2), transparent);}/*!sc*/ data-styled.g730[id="sc-dIGTRn"]{content:"jLtEqm,"}/*!sc*/ .ffjrNJ{line-height:48px;padding:0 10px;font-family:Manrope,Manrope-fallback,sans-serif;font-weight:bold;font-size:14px;color:#000000;height:100%;display:inline-flex;align-items:center;justify-content:center;}/*!sc*/ .ffjrNJ:hover{background-color:#e1effe;color:unset;}/*!sc*/ .ffjrNJ.trading-school{color:#298ccd!important;}/*!sc*/ @media screen and (min-width: 1292px){.ffjrNJ.trading-school svg{display:none;}}/*!sc*/ @media screen and (max-width: 800px){.ffjrNJ{color:white;width:100%;text-align:left;display:inline-flex;justify-content:start;}.ffjrNJ:hover{background-color:inherit;}}/*!sc*/ data-styled.g731[id="sc-duhhru"]{content:"ffjrNJ,"}/*!sc*/ .lmVuSP{line-height:2em;}/*!sc*/ .lmVuSP a{color:black;}/*!sc*/ .lmVuSP a:hover{color:#1a56db;}/*!sc*/ data-styled.g732[id="sc-kjxHLd"]{content:"lmVuSP,"}/*!sc*/ .fDLMAx{line-height:2em;}/*!sc*/ .fDLMAx a{display:block;padding:6px 12px;line-height:1.4rem;}/*!sc*/ .fDLMAx:hover{color:#1a79ff;}/*!sc*/ .fDLMAx.highlight{padding:0 5px;margin-bottom:5px;}/*!sc*/ .fDLMAx.highlight a{color:#ffffff;background-color:unset;font-weight:unset;text-align:center;}/*!sc*/ .fDLMAx.highlight:hover{color:unset;}/*!sc*/ data-styled.g733[id="sc-jUXVlk"]{content:"fDLMAx,"}/*!sc*/ .huBxHA{display:grid;gap:8px;grid-template-columns:repeat(2, minmax(0px, 1fr));}/*!sc*/ data-styled.g734[id="sc-goMudc"]{content:"huBxHA,"}/*!sc*/ .ddvSJk{border-bottom:1px solid #B8CBE6;color:#395173;font-weight:bold;margin-top:4px;margin-bottom:4px;margin-left:16px;margin-right:16px;padding-bottom:4px;}/*!sc*/ data-styled.g735[id="sc-WFjOp"]{content:"ddvSJk,"}/*!sc*/ .bCAaKz{display:none;position:absolute;width:max-content;top:48px;z-index:2000;background-color:#ffffff;box-shadow:0 4px 6px -1px rgba(0, 0, 0, 0.1),0 2px 4px -1px rgba(0, 0, 0, 0.06);}/*!sc*/ .bCAaKz:hover{display:flex;}/*!sc*/ .bCAaKz .subnav{right:0;}/*!sc*/ .bCAaKz .menu-wrapper a{width:100%;justify-content:left;}/*!sc*/ @media screen and (min-width: 910px){.bCAaKz{min-width:initial;}}/*!sc*/ @media screen and (min-width: 950px){.bCAaKz >div:nth-of-type(1){display:none;}}/*!sc*/ @media screen and (min-width: 1000px){.bCAaKz >div:nth-of-type(2){display:none;}}/*!sc*/ @media screen and (min-width: 1100px){.bCAaKz >div:nth-of-type(3){display:none;}}/*!sc*/ @media screen and (min-width: 1130px){.bCAaKz >div:nth-of-type(4){display:none;}}/*!sc*/ @media screen and (min-width: 1190px){.bCAaKz >div:nth-of-type(5){display:none;}}/*!sc*/ @media screen and (min-width: 1250px){.bCAaKz >div:nth-of-type(6){display:none;}}/*!sc*/ @media screen and (min-width: 1315px){.bCAaKz >div:nth-of-type(7){display:none;}}/*!sc*/ data-styled.g736[id="sc-jesuKm"]{content:"bCAaKz,"}/*!sc*/ .ideGoF.sub-group-wrapper{background-color:#ffffff;border-width:1px;border-top-width:1px;border-color:#CEDDF2;border-bottom-left-radius:2px;border-bottom-right-radius:2px;padding:8px 0;scrollbar-width:thin;max-height:calc(90vh - 100px);}/*!sc*/ .ideGoF.sub-group-wrapper ::-webkit-scrollbar{width:6px!important;}/*!sc*/ .ideGoF.sub-group-wrapper ::-webkit-scrollbar-track{background:#f1f1f1;}/*!sc*/ .ideGoF.sub-group-wrapper ::-webkit-scrollbar-thumb{background:#888;}/*!sc*/ .ideGoF.sub-group-wrapper ::-webkit-scrollbar-thumb:hover{background:#555;}/*!sc*/ data-styled.g737[id="sc-dMlkvz"]{content:"ideGoF,"}/*!sc*/ .blGfTM.secondary{position:relative;}/*!sc*/ .blGfTM.secondary .subnav{position:absolute;right:0;top:48px;}/*!sc*/ .blGfTM .subnav{display:none;position:absolute;z-index:2000;}/*!sc*/ .blGfTM .subnav .third-level-menu{display:none;position:absolute;left:100%;background:#ffffff;border:1px solid #CEDDF2;border-bottom-left-radius:2px;border-bottom-right-radius:2px;height:100%;z-index:999999;overflow:auto;top:0;height:auto;min-width:160px;}/*!sc*/ .blGfTM .subnav .more-nav-menu{position:absolute;top:50%;right:0;transform:translateY(-50%);}/*!sc*/ .blGfTM:hover .subnav{display:block;}/*!sc*/ .blGfTM .menu-items{padding:4px;}/*!sc*/ .blGfTM .menu-items .dropdown-menu-item{position:relative;}/*!sc*/ .blGfTM .menu-items .dropdown-menu-item:hover .third-level-menu{display:block;}/*!sc*/ @media screen and (max-width: 800px){.blGfTM .subnav{display:none!important;}}/*!sc*/ data-styled.g738[id="sc-jUFHcI"]{content:"blGfTM,"}/*!sc*/ .iInkzP{text-align:left;}/*!sc*/ .iInkzP.has-groups{width:480px;}/*!sc*/ .iInkzP.has-groups.money-app{max-width:480px;width:auto;min-width:180px;}/*!sc*/ data-styled.g739[id="sc-eCywNV"]{content:"iInkzP,"}/*!sc*/ .itwPjb{display:flex;align-items:center;justify-content:center;font-size:12px;font-weight:700;white-space:nowrap;}/*!sc*/ .itwPjb.others-btn{height:48px;color:#192940;text-transform:capitalize;padding:0 8px;}/*!sc*/ .itwPjb.others-btn:hover{color:#1a56db;}/*!sc*/ .itwPjb.research-btn{height:34px;color:white;text-transform:uppercase;border-radius:5px;letter-spacing:1px;padding:0 14px;}/*!sc*/ .itwPjb.research-btn:hover{opacity:100;color:white;}/*!sc*/ .itwPjb.invest-in-art-btn{height:34px;color:#000000;border-radius:5px;letter-spacing:1px;padding:0 10px;margin-right:8px;}/*!sc*/ .itwPjb.invest-in-art-btn:hover{background-color:#a4cafe;}/*!sc*/ data-styled.g740[id="sc-buPYkW"]{content:"itwPjb,"}/*!sc*/ .bfYCmN.menu-wrapper{background-color:#033251;position:relative;min-width:65px;}/*!sc*/ .bfYCmN.menu-wrapper:hover .global-menu-dropdown{display:block;}/*!sc*/ @media screen and (max-width: 800px){.bfYCmN.menu-wrapper{background-color:transparent;}}/*!sc*/ .bfYCmN.menu-wrapper .menu-button{align-items:center;color:white;cursor:pointer;display:inline-flex;font-size:12px;height:32px;padding:0px 12px;}/*!sc*/ .bfYCmN.menu-wrapper .menu-button .anticon-user{color:#1a79ff;margin-right:12px;}/*!sc*/ @media screen and (max-width: 800px){.bfYCmN.menu-wrapper .menu-button{padding:0px 6px;}.bfYCmN.menu-wrapper .menu-button .anticon-user{color:#a4cafe;font-size:18px;}.bfYCmN.menu-wrapper .menu-button .anticon-down{display:none;}}/*!sc*/ .bfYCmN.menu-wrapper .global-menu-dropdown{background-color:#033251;display:none;position:absolute;width:110px;width:max-content;z-index:100;}/*!sc*/ @media screen and (max-width: 800px){.bfYCmN.menu-wrapper .global-menu-dropdown{right:0px;}}/*!sc*/ .bfYCmN.menu-wrapper .global-menu-item{color:white;cursor:pointer;font-size:12px;padding:8px 12px;display:block;margin:0;}/*!sc*/ .bfYCmN.menu-wrapper .global-menu-item a{color:white;display:flex;align-items:center;}/*!sc*/ .bfYCmN.menu-wrapper .global-menu-item span{display:inline-block;vertical-align:middle;line-height:1;margin-right:10px;}/*!sc*/ .bfYCmN.menu-wrapper .global-menu-item img{width:30px;display:inline-block;vertical-align:middle;}/*!sc*/ .bfYCmN.menu-wrapper .global-text{margin-right:14px;}/*!sc*/ @media screen and (max-width: 800px){.bfYCmN.menu-wrapper .global-text{margin-right:0;}}/*!sc*/ @media screen and (max-width: 800px){.bfYCmN.menu-wrapper{width:3rem;text-align:center;}}/*!sc*/ data-styled.g741[id="sc-hsexvf"]{content:"bfYCmN,"}/*!sc*/ .kcwNjI.menu-wrapper{background-color:#033251;position:relative;width:140px;white-space:nowrap;}/*!sc*/ @media screen and (max-width: 800px){.kcwNjI.menu-wrapper{background-color:transparent;}}/*!sc*/ @media screen and (min-width: 800px){.kcwNjI.menu-wrapper:hover .account-menu-dropdown{display:block;box-shadow:0 1px 2px 0 rgba(0, 0, 0, 0.05);}}/*!sc*/ .kcwNjI.menu-wrapper .menu-button{align-items:center;color:white;cursor:pointer;display:inline-flex;font-size:12px;height:32px;padding:0px 12px;}/*!sc*/ .kcwNjI.menu-wrapper .menu-button .anticon-user{color:#1a79ff;margin-right:12px;}/*!sc*/ @media screen and (max-width: 800px){.kcwNjI.menu-wrapper .menu-button .anticon-user{color:#a4cafe;font-size:18px;margin-right:0;}.kcwNjI.menu-wrapper .menu-button .anticon-down{display:none;}}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-dropdown{background-color:#ffffff;border:1px solid #E1EBFA;display:none;position:absolute;width:140px;z-index:104;}/*!sc*/ @media screen and (max-width: 800px){.kcwNjI.menu-wrapper .account-menu-dropdown{right:0px;}}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-dropdown.open{display:block;}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-dropdown .checkbox-container label{display:flex;font-size:12px;}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-item{color:#000000;cursor:pointer;font-size:12px;font-weight:700;padding:8px 12px;}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-item a{color:#000000;display:inline-flex;}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-item.benzinga-plus a{color:#ff5a1f;}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-item.benzinga-pro a{color:#1A79FF;}/*!sc*/ .kcwNjI.menu-wrapper .account-menu-item.benzinga-edge a{color:#3f83f8;}/*!sc*/ .kcwNjI.menu-wrapper .divider{margin:0 auto;width:85%;border-color:#CEDDF2;}/*!sc*/ .kcwNjI.menu-wrapper .my-account-text{margin-right:14px;}/*!sc*/ @media screen and (max-width: 800px){.kcwNjI.menu-wrapper .my-account-text{display:none;}}/*!sc*/ @media screen and (max-width: 800px){.kcwNjI.menu-wrapper{width:3rem;}}/*!sc*/ data-styled.g742[id="sc-hIvhaM"]{content:"kcwNjI,"}/*!sc*/ .jWhawY{position:fixed;z-index:9999999;top:0;left:0;right:0;width:100%;transition:all linear 0.12s;}/*!sc*/ .jWhawY .raptive-header-banner{position:fixed;top:0;left:0;right:0;z-index:101;width:100%;transition:all linear 0.12s;}/*!sc*/ .jWhawY .raptive-header-banner .raptive-ad-wrapper{margin:0;min-height:0;}/*!sc*/ .jWhawY .mobile-header,.jWhawY .mobile-menu-wrapper,.jWhawY .mobile-quote-bar{background-color:#08244d;}/*!sc*/ .jWhawY .mobile-header{border-bottom:1px solid #36537e;margin-top:0;}/*!sc*/ .jWhawY .menu-icon-wrapper{display:flex;align-items:center;justify-content:center;cursor:pointer;flex-shrink:0;width:3rem;height:3rem;color:#CEDDF2;font-size:18px;}/*!sc*/ .jWhawY.fullscreen .account-menu{pointer-events:none;}/*!sc*/ .jWhawY .search-wrapper{background:linear-gradient(180deg, #082132 0%, #1d446a 100%);width:100%;z-index:30;}/*!sc*/ .jWhawY .search-wrapper.fixed{position:fixed;top:181px;}/*!sc*/ .jWhawY .search-wrapper.fullscreen{position:fixed;background:#242424e0;z-index:999;height:100vh;}/*!sc*/ .jWhawY .search-wrapper.fullscreen .searchbar-wrapper{padding:0;}/*!sc*/ .jWhawY .search-wrapper.fullscreen .searchbar-wrapper .search-input-container{border-bottom:1px solid #a4a4a4;padding:8px 12px;background-color:#1d446a;}/*!sc*/ .jWhawY .search-wrapper.fullscreen .searchbar-wrapper .search-input-wrapper{background-color:white;border-radius:4px;}/*!sc*/ .jWhawY .search-wrapper.fullscreen .search-dropdown{border-radius:unset;border:none;box-shadow:none;position:unset;}/*!sc*/ .jWhawY .search-wrapper.fullscreen .search-result-wrapper{border-radius:unset;}/*!sc*/ .jWhawY .search-wrapper .searchbar-wrapper{padding:8px 12px;background-color:transparent;font-weight:bold;line-height:15px;}/*!sc*/ .jWhawY .search-wrapper .searchbar-wrapper .search-icon{width:32px;}/*!sc*/ .jWhawY .search-wrapper .searchbar-wrapper input{font-size:14px;height:45px;}/*!sc*/ .jWhawY .search-wrapper .searchbar-wrapper .searchbar-container{background-color:white;border-radius:2px;}/*!sc*/ @media screen and (max-width: 800px){.jWhawY .search-wrapper .searchbar-wrapper input{font-size:16px;}}/*!sc*/ .jWhawY .mobile-menu-wrapper{z-index:999999;}/*!sc*/ .jWhawY .mobile-menu-wrapper .premium-button{color:white;line-height:40px;padding:4px 10px;position:fixed;height:min-content;bottom:0px;z-index:10000;background-color:#062b4c;}/*!sc*/ .jWhawY .mobile-menu-wrapper .premium-button div{background-color:#ff5a1f;border-radius:10px;padding:0px 10px;width:100%;border-radius:5px;margin:2px 0px;text-align:center;}/*!sc*/ .jWhawY .mobile-menu-wrapper .premium-button svg{font-size:20px;padding-right:5px;}/*!sc*/ .jWhawY .mobile-menu-wrapper .premium-button:hover div{background-color:#ff8a4c;border-bottom:3px solid #d03801;}/*!sc*/ .jWhawY .bz-pro-logo{height:60px;background:#062b4c;margin-bottom:60px;}/*!sc*/ .jWhawY .bz-pro-logo a{border-top:solid 1px #666;padding:1rem;width:100%;}/*!sc*/ .jWhawY .mobile-logo-wrapper{margin:0;padding:0;width:205px;margin-right:auto;}/*!sc*/ .jWhawY .mobile-logo-wrapper .benzinga-crypto-logo-wrapper{margin-top:5px;}/*!sc*/ .jWhawY .mobile-logo-wrapper .benzinga-logo{height:18.2px;width:134.35px;}/*!sc*/ .jWhawY .mobile-logo-wrapper .benzinga-logo.reactive-holiday-logo{height:30px;}/*!sc*/ data-styled.g746[id="sc-iTPigJ"]{content:"jWhawY,"}/*!sc*/ .dYbjnD{margin-top:242px;width:100%;}/*!sc*/ data-styled.g747[id="sc-bdoPik"]{content:"dYbjnD,"}/*!sc*/ .bpQUFE.top-bar-wrapper{background-color:#072232;height:32px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bar-layout-width{max-width:1400px;margin:0 auto;}/*!sc*/ .bpQUFE.top-bar-wrapper .top-bar-inner-wrapper{display:flex;justify-content:space-between;}/*!sc*/ .bpQUFE.top-bar-wrapper .top-bar-list{list-style:none;display:flex;margin:0;}/*!sc*/ .bpQUFE.top-bar-wrapper .auth-buttons{display:flex;height:32px;min-width:234px;}/*!sc*/ .bpQUFE.top-bar-wrapper .auth-link-button{color:#ffffff;cursor:pointer;line-height:32px;padding:0 12px;text-transform:uppercase;font-size:14px;font-weight:700;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-pro-btn{display:flex;align-items:center;justify-content:space-between;padding:0 12px;border-radius:3px;height:26px;color:white;font-weight:semi-bold;background-color:#0075cd;margin:3px 3px 0px 0px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item-label{color:white;font-size:12px;line-height:30px;margin:0 8px;white-space:nowrap;}/*!sc*/ .bpQUFE.top-bar-wrapper .contributor-link{align-items:center;color:white;display:inline-flex;font-size:12px;height:32px;margin:0 12px;}/*!sc*/ .bpQUFE.top-bar-wrapper .contributor-link a{color:white;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item{color:#ffffff;text-transform:uppercase;line-height:28px;font-weight:500;font-size:14px;margin:0;text-align:center;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item.ProLabel{border-top:none;text-transform:none;min-width:140px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item:nth-child(2){min-width:84px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item:nth-child(3){min-width:66px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item:nth-child(4){min-width:83px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item:nth-child(5){min-width:93px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item:nth-child(6){min-width:59px;}/*!sc*/ .bpQUFE.top-bar-wrapper .bz-top-bar-list-item:nth-child(7){min-width:86px;}/*!sc*/ data-styled.g751[id="sc-dnoZww"]{content:"bpQUFE,"}/*!sc*/ .fiWpzI.quote-bar-container{background:linear-gradient(180deg, #082132 0%, #1d446a 100%);}/*!sc*/ .fiWpzI.quote-bar-container .quote-bar-layout-width{max-width:1400px;margin:0 auto;height:52px;}/*!sc*/ .fiWpzI.quote-bar-container .quote-bar-wrapper,.fiWpzI.quote-bar-container .quotes-list{display:flex;flex-grow:1;}/*!sc*/ .fiWpzI.quote-bar-container .quote-list-container{flex-grow:1;overflow-x:auto;scrollbar-width:none;}/*!sc*/ .fiWpzI.quote-bar-container .quote-list-container ::-webkit-scrollbar{display:none;}/*!sc*/ .fiWpzI.quote-bar-container .search-wrapper{width:100%;max-width:288px;}/*!sc*/ .fiWpzI.quote-bar-container .search-wrapper .searchbar-wrapper{padding:8px 12px;background-color:transparent;font-weight:bold;font-size:16px;line-height:15px;}/*!sc*/ .fiWpzI.quote-bar-container .search-wrapper .searchbar-wrapper .search-icon{width:32px;}/*!sc*/ .fiWpzI.quote-bar-container .search-wrapper .searchbar-wrapper input{font-size:12px;}/*!sc*/ .fiWpzI.quote-bar-container .search-wrapper .searchbar-wrapper .searchbar-container{background-color:white;border-radius:2px;}/*!sc*/ @media (min-width: 1300px){.fiWpzI.quote-bar-container .search-wrapper .searchbar-wrapper{padding-right:0;}.fiWpzI.quote-bar-container .search-wrapper .searchbar-wrapper .search-icon{width:36px;}}/*!sc*/ .fiWpzI.quote-bar-container .search-wrapper .search-icon{height:36px;}/*!sc*/ data-styled.g752[id="sc-kqpPGb"]{content:"fiWpzI,"}/*!sc*/ .bJncSS.quote-switcher-wrapper{overflow-y:auto;height:52px;width:70px;scrollbar-width:none;flex:none;}/*!sc*/ .bJncSS.quote-switcher-wrapper ::-webkit-scrollbar{display:none;}/*!sc*/ .bJncSS.quote-switcher-wrapper .quote-switcher-container{display:flex;flex-direction:column;}/*!sc*/ data-styled.g753[id="sc-czPwHC"]{content:"bJncSS,"}/*!sc*/ .euzGLN.quote-switcher-button{max-width:73px;width:100%;border-left:1px solid #99AECC;background:linear-gradient(90deg, #99AECC1a 0%, #99AECC00 100%);text-align:left;color:#99AECC;font-size:12px;line-height:18px;padding:4px 9px;flex-grow:1;}/*!sc*/ .euzGLN.quote-switcher-button :focus{outline:none;}/*!sc*/ .bNBpVJ.quote-switcher-button{max-width:73px;width:100%;border-left:1px solid #E1EBFA;background:linear-gradient(90deg, #1c64f21a 0%, #1c64f200 100%);text-align:left;color:#ffffff;font-size:12px;line-height:18px;padding:4px 9px;flex-grow:1;}/*!sc*/ .bNBpVJ.quote-switcher-button :focus{outline:none;}/*!sc*/ data-styled.g754[id="sc-gvEBYa"]{content:"euzGLN,bNBpVJ,"}/*!sc*/ .bca-DLN{display:flex;overflow-x:scroll;scrollbar-width:none;justify-content:flex-start;}/*!sc*/ .bca-DLN ::-webkit-scrollbar{display:none;}/*!sc*/ .bca-DLN li{flex-shrink:0;}/*!sc*/ .bca-DLN li:nth-of-type(3),.bca-DLN li:nth-of-type(4),.bca-DLN li:nth-of-type(5),.bca-DLN li:nth-of-type(6),.bca-DLN li:nth-of-type(7),.bca-DLN li:nth-of-type(8),.bca-DLN li:nth-of-type(9),.bca-DLN li:nth-of-type(10),.bca-DLN li:nth-of-type(11),.bca-DLN li:nth-of-type(12){display:none;}/*!sc*/ @media screen and (min-width: 850px){.bca-DLN li:nth-of-type(3){display:initial;}}/*!sc*/ @media screen and (min-width: 900px){.bca-DLN li:nth-of-type(4){display:initial;}}/*!sc*/ @media screen and (min-width: 950px){.bca-DLN li:nth-of-type(5){display:initial;}}/*!sc*/ @media screen and (min-width: 1000px){.bca-DLN li:nth-of-type(6){display:initial;}}/*!sc*/ @media screen and (min-width: 1100px){.bca-DLN li:nth-of-type(7){display:initial;}}/*!sc*/ @media screen and (min-width: 1130px){.bca-DLN li:nth-of-type(8){display:initial;}}/*!sc*/ @media screen and (min-width: 1190px){.bca-DLN li:nth-of-type(9){display:initial;}}/*!sc*/ @media screen and (min-width: 1250px){.bca-DLN li:nth-of-type(10){display:initial;}}/*!sc*/ @media screen and (min-width: 1315px){.bca-DLN li:nth-of-type(11){display:initial;}}/*!sc*/ @media screen and (min-width: 1360px){.bca-DLN li:nth-of-type(12){display:initial;}}/*!sc*/ data-styled.g757[id="sc-bnRclF"]{content:"bca-DLN,"}/*!sc*/ .eWaiSj{display:block;position:unset;top:unset;width:unset;z-index:999;box-shadow:unset;}/*!sc*/ @media (max-width: 800px){.eWaiSj{display:none;}}/*!sc*/ .eWaiSj .breaking-news-banner{position:absolute;top:-50px;transition:all ease-in 0.5s;z-index:-1;}/*!sc*/ .eWaiSj .breaking-news-wrapper{position:relative;}/*!sc*/ .eWaiSj .breaking-news-wrapper--visible .breaking-news-banner{position:unset;top:0;}/*!sc*/ .eWaiSj .more-nav-tabs-icon-container{position:relative;display:flex;align-items:center;justify-content:center;margin-left:5px;margin-right:5px;cursor:pointer;}/*!sc*/ .eWaiSj .more-nav-tabs-icon-container:hover >div{display:flex;}/*!sc*/ @media screen and (min-width: 1315px){.eWaiSj .more-nav-tabs-icon-container{display:none!important;}}/*!sc*/ data-styled.g758[id="sc-iFEMmm"]{content:"eWaiSj,"}/*!sc*/ .gJOGKI{background-color:#ffffff;border-bottom:0px solid #B8CBE6;width:100%;padding:0;}/*!sc*/ data-styled.g759[id="sc-dnxBXz"]{content:"gJOGKI,"}/*!sc*/ .fdRSnI{height:48px;max-width:1400px;margin:0 auto;}/*!sc*/ data-styled.g760[id="sc-iPYwOE"]{content:"fdRSnI,"}/*!sc*/ .kgSstf{display:flex;position:relative;height:100%;justify-content:center;}/*!sc*/ data-styled.g763[id="sc-cxgeGX"]{content:"kgSstf,"}/*!sc*/ .jBQQBt{flex-grow:1;margin-left:20px;}/*!sc*/ data-styled.g764[id="sc-dTaEtF"]{content:"jBQQBt,"}/*!sc*/ .ilPLjY{display:inline-flex;align-items:center;justify-content:flex-end;height:48px;min-width:244px;}/*!sc*/ data-styled.g765[id="sc-dEARTM"]{content:"ilPLjY,"}/*!sc*/ .bpuEVa.header-container .navbar-placeholder{height:132px;}/*!sc*/ .bpuEVa.header-container.money-app .main-menu-bar{background-color:#192940;border:none;}/*!sc*/ .bpuEVa.header-container.money-app .main-menu-bar .main-menu-wrapper{max-width:1300px;}/*!sc*/ .bpuEVa.header-container.money-app .main-menu-bar .main-menu-wrapper .menu-wrapper:hover{background-color:#151f2e;}/*!sc*/ .bpuEVa.header-container.money-app .main-menu-bar .logo-wrapper{width:260px;}/*!sc*/ .bpuEVa.header-container.money-app .main-menu-bar .menu-item-link{color:#ceddf2;}/*!sc*/ .bpuEVa.header-container.money-app .main-menu-bar .menu-item-link:hover{background-color:transparent;}/*!sc*/ data-styled.g778[id="sc-dBYnXA"]{content:"bpuEVa,"}/*!sc*/ .hmEKVR{display:block;margin-bottom:0;}/*!sc*/ @media screen and (min-width: 800px){.hmEKVR{display:none;}}/*!sc*/ data-styled.g780[id="sc-grEoEK"]{content:"hmEKVR,"}/*!sc*/ @keyframes jBCTCY{0%{left:-100%;transition-property:left;}11.504424778761061%,100%{left:100%;transition-property:left;}}/*!sc*/ data-styled.g781[id="sc-keyframes-jBCTCY"]{content:"jBCTCY,"}/*!sc*/ .kzmRJW .bz-ag-table .ag-ltr .ag-cell{border-right:1px solid #aaa;border-bottom:1px solid #aaa;align-items:center;display:inline-flex;justify-content:space-between;}/*!sc*/ .kzmRJW .ag-cell .ag-cell-value span{width:100%;}/*!sc*/ .kzmRJW .ag-root-wrapper-body{height:100%;}/*!sc*/ .kzmRJW .bz-ag-table{background-color:#fff;border-left:solid 1px #ddd;border-right:solid 1px #ddd;border-bottom:solid 1px #ddd;border-radius:0px;margin:0.5rem 0;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-cell-text{font-size:12px;font-family:sans-serif;font-weight:700;}/*!sc*/ .kzmRJW .bz-ag-table__company-image{max-height:18px;margin-left:4px;float:right;}/*!sc*/ .kzmRJW .bz-ag-table .ag-root-wrapper{border:none;background:#fff;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header{background:none;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-cell-resize{display:none;}/*!sc*/ .kzmRJW .bz-ag-table .ag-row{height:28px;background:#fff;}/*!sc*/ .kzmRJW .bz-ag-table .ag-row:hover{background:rgba(64, 192, 243, 0.1);}/*!sc*/ .kzmRJW .bz-ag-table .ag-row:hover .gain-cell{background:#cef1ce;}/*!sc*/ .kzmRJW .bz-ag-table .ag-row:hover .lose-cell{background:#fdcece;}/*!sc*/ .kzmRJW .bz-ag-table__logo{height:17px;max-width:none;margin-left:10px;}/*!sc*/ .kzmRJW .bz-ag-table .ag-body-viewport::-webkit-scrollbar{width:16px;}/*!sc*/ .kzmRJW .bz-ag-table .ag-body-viewport::-webkit-scrollbar-track{background-color:#fff;}/*!sc*/ .kzmRJW .bz-ag-table .ag-body-viewport::-webkit-scrollbar-thumb{background-color:#babac0;border-radius:16px;border:5px solid #fff;min-height:50px;}/*!sc*/ .kzmRJW .bz-ag-table .ag-body-viewport::-webkit-scrollbar-thumb:hover{background-color:#a0a0a5;}/*!sc*/ .kzmRJW .bz-ag-table .ag-row-odd{background:#efefef;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-cell{font-size:13px;line-height:21px;font-weight:bold;color:#000;padding:4px 10px;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-cell:focus{outline:none;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-row{height:21px;}/*!sc*/ .kzmRJW .bz-ag-table .ag-row{font-size:10px;line-height:14px;border:0;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-icon.ag-header-label-icon.ag-filter-icon{display:none;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-cell-menu-button{opacity:1;}/*!sc*/ .kzmRJW .bz-ag-table .ag-icon-menu:before,.kzmRJW .bz-ag-table .ag-icon-filter:before{content:'';background:url('/next-assets/images/icons/table/filter.svg') no-repeat;width:10px;height:10px;display:block;}/*!sc*/ .kzmRJW .bz-ag-table .ag-header-cell-filtered .ag-header-icon .ag-icon-menu:before{background:url('/next-assets/images/icons/table/filter-filled.svg') no-repeat;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell{border:none;border-right:1px solid #aaa;border-bottom:1px solid #aaa;padding:4px 10px;line-height:16px;color:#333;font-weight:700;font-family:sans-serif;height:100%;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell:focus{outline:none;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell.ticker-cell{font-weight:bold;font-family:Manrope,Manrope-fallback,sans-serif;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell.insider-cell{overflow:visible;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell.wrap-cell{font-weight:bold;white-space:normal;overflow-wrap:break-word;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell.gain-cell{color:#009900;background:#f2faf2;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell.lose-cell{color:#cc0000;background:#f9e5e5;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell.importance-cell{padding:4px 4px;}/*!sc*/ .kzmRJW .bz-ag-table .ag-cell:last-child{border-right:0;}/*!sc*/ .kzmRJW .bz-ag-table--dark-blue .ag-header-icon{color:white;}/*!sc*/ .kzmRJW .bz-ag-table--dark-blue .ag-header-cell{border-left:1px solid #aaa;}/*!sc*/ .kzmRJW .bz-ag-table--dark-blue .ag-header-cell:first-child{border-left:none;}/*!sc*/ .kzmRJW .bz-ag-table--dark-blue .ag-header-viewport{background:#072232;}/*!sc*/ .kzmRJW .bz-ag-table--dark-blue .ag-header-container{background:#072232;border-bottom:3px solid #2ca2d1;}/*!sc*/ .kzmRJW .bz-ag-table--dark-blue .ag-header-cell-text{font-size:12px;color:#fff;font-family:sans-serif;font-weight:700;}/*!sc*/ .kzmRJW .bz-ag-table--dark-blue .ag-icon-menu:before,.kzmRJW .bz-ag-table--dark-blue .ag-icon-filter:before{content:'';background:url('/next-assets/images/icons/table/filter-filled-white.svg') no-repeat;}/*!sc*/ .kzmRJW .under-calendar-text{font-size:14px;}/*!sc*/ data-styled.g801[id="sc-lcMqGs"]{content:"kzmRJW,"}/*!sc*/ .jkpSxH{margin:1rem auto;}/*!sc*/ data-styled.g1347[id="sc-hHEtgg"]{content:"jkpSxH,"}/*!sc*/ .jueBjR h1,.jueBjR h2{margin-top:1rem;margin-bottom:0.5rem;}/*!sc*/ .jueBjR h1{font-size:36px;}/*!sc*/ .jueBjR h2{font-size:24px;}/*!sc*/ .jueBjR ul{list-style:disc;margin-left:2rem;margin-bottom:2rem;}/*!sc*/ .jueBjR.centered h1,.jueBjR.centered h2{text-align:center;text-transform:uppercase;padding-bottom:1rem;margin-top:2rem;margin-bottom:1rem;border-bottom:solid 1px #E1EBFA;}/*!sc*/ data-styled.g1387[id="sc-isHgOQ"]{content:"jueBjR,"}/*!sc*/ .kETrRm{font-size:24px;margin-bottom:10px;font-weight:700;}/*!sc*/ data-styled.g1393[id="sc-HiIYf"]{content:"kETrRm,"}/*!sc*/ .kEPWIN .newsfeed-card .post-title{font-size:18px;line-height:26px;-webkit-box-orient:vertical;-webkit-line-clamp:2;overflow:hidden;text-overflow:ellipsis;display:-webkit-box;}/*!sc*/ .kEPWIN .newsfeed-card .post-teaser{color:#7c7c7c;font-weight:400;font-size:12px;}/*!sc*/ .kEPWIN .newsfeed-card .post-card-image{position:relative;width:100px!important;height:100px!important;min-width:100px!important;min-height:100px!important;max-width:100px!important;max-height:100px!important;}/*!sc*/ .kEPWIN .feed-more-wrapper{align-items:center;display:flex;flex-direction:column;padding:16px;}/*!sc*/ .kEPWIN .feed-more-wrapper .load-more-button{color:#76a9fa;font-weight:700;font-size:12px;display:flex;flex-direction:column;align-items:center;}/*!sc*/ data-styled.g1394[id="sc-fnpAPw"]{content:"kEPWIN,"}/*!sc*/ .fAZYps .fda-calendar{min-height:500px;margin-bottom:2rem;margin-top:1rem;}/*!sc*/ data-styled.g1589[id="sc-bNIngB"]{content:"fAZYps,"}/*!sc*/ </style></head><body><div id="__next"><div class="sc-dBYnXA bpuEVa header-container "><div class="sc-grEoEK hmEKVR mobile-header-wrapper"><div class="sc-bdoPik dYbjnD"><div class="sc-iTPigJ jWhawY z-[9999999]" id="navigation-header"><div class="top-banner-fallback h-20 bg-[#0b131d] relative py-4"><div class="animate-pulse h-full relative rounded-full bg-slate-700/50 max-w-[1400px] mx-auto"></div></div><div class="left-0 right-0 top-0 z-[9999999]" id="mobile-main-block"><div class="mobile-header flex items-center justify-between relative" style="transition:all linear 0.3s;z-index:20"><div class="menu-icon-wrapper"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M0 80c0-8.8 7.2-16 16-16H432c8.8 0 16 7.2 16 16s-7.2 16-16 16H16C7.2 96 0 88.8 0 80zM0 240c0-8.8 7.2-16 16-16H432c8.8 0 16 7.2 16 16s-7.2 16-16 16H16c-8.8 0-16-7.2-16-16zM448 400c0 8.8-7.2 16-16 16H16c-8.8 0-16-7.2-16-16s7.2-16 16-16H432c8.8 0 16 7.2 16 16z" fill="currentColor"></path></svg></div></div><div class="sc-jGeVcH zcqvV logo-wrapper mobile-logo-wrapper"><a aria-label="Click to go home" href="/"><span class="sc-hTgaWy jNoPDg benzinga-logo light mobile"><svg height="100%" role="img" viewBox="0 0 471.1 63.8" width="100%" xmlns="http://www.w3.org/2000/svg"><path d="M67.7 63.8h45.2V51.9H81.4V37.3h26.1V25.4H81.4V11.9h31.7V0H67.7zm99.6-23.6L137.7 0h-20.4l6.4 8.1V64h13.6V22.1l30.6 41.7H181V0h-13.7zM47.1 31c6-1.1 11-6.7 11-14.6C58.1 7.9 51.9 0 39.6 0H0l6.2 7.9v56H41c12.3 0 18.7-7.7 18.7-17.3-.3-7.9-5.7-14.7-12.6-15.6zM19.8 12h17.1c4.6 0 7.5 2.7 7.5 6.7s-2.9 6.7-7.5 6.7H19.8V12zm17.7 40H19.8V37.3h17.7c5.2 0 8.1 3.3 8.1 7.3 0 4.6-3.1 7.3-8.1 7.4zm343.3-11.8h7.1v7.5c-3.7 3-8.3 4.7-13.1 4.8-11.4 0-19.4-8.7-19.4-20.4s8.1-20.4 19.4-20.4c5.9 0 11.4 3.1 14.6 8.1l10.8-6C395.6 6.5 387.5 0 374.7 0c-18.1 0-33.1 12.5-33.1 31.9s14.8 31.9 33.1 31.9c10 .2 19.5-4.1 26.1-11.5V28.7h-29.2l9.2 11.5zm-61.5 0L289.6 0h-20.3l6.3 8.1V64h13.7V22.1l30.6 41.7h13V0h-13.6zM446 0h-26.3l6.3 8.1-1.1 3.1L404.5 64h15.4l4-10.8h27.5l4 10.8h15.4L446 0zm-18.6 41.2l10-27.5 10 27.5h-20zM247.7 0h13.7v64.1h-13.7zm-10.9 11V0h-48.1v11.9h30.2l-30.2 41v10.9h48.6V51.9h-30.9z" fill="#FFFFFF"></path></svg></span></a></div><div class="flex h-12 items-center text-blue-300"><div class="sc-hsexvf bfYCmN global-menu menu-wrapper"><div aria-label="Global Menu" class="menu-button" role="button"><span class="global-text w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 513 342" title="USA"><path fill="#FFF" d="M0 0h513v342H0z"></path><path fill="#D80027" d="M0 0h513v38H0zm0 76h513v38H0zm0 76h513v38H0zm0 76h513v38H0zm0 76h513v38H0z"></path><path fill="#2E52B2" d="M0 0h256.5v190H0z"></path><path fill="#FFF" d="m47.8 141.9-4-12.8-4.3 12.8H26.3l10.7 7.7-4 12.8 10.8-7.9 10.7 7.9-4.2-12.8 10.9-7.7zm56.4 0-4.1-12.8-4.2 12.8H82.7l10.7 7.7-4.1 12.8 10.8-7.9 10.7 7.9-4-12.8 10.8-7.7zm56.4 0-4.2-12.8-4 12.8h-13.5l10.9 7.7-4.2 12.8 10.8-7.9 10.9 7.9-4.2-12.8 10.8-7.7zm56.3 0-4.1-12.8-4.2 12.8h-13.2l10.7 7.7-4 12.8 10.7-7.9 10.8 7.9-4.2-12.8 10.9-7.7zM100.1 78.3l-4.2 12.8H82.7L93.4 99l-4.1 12.6 10.8-7.8 10.7 7.8-4-12.6 10.8-7.9h-13.4zm-56.3 0-4.3 12.8H26.3L37 99l-4 12.6 10.8-7.8 10.7 7.8L50.3 99l10.9-7.9H47.8zm112.6 0-4 12.8h-13.5l10.9 7.9-4.2 12.6 10.8-7.8 10.9 7.8-4.2-12.6 10.8-7.9h-13.3zm56.4 0-4.2 12.8h-13.2l10.7 7.9-4 12.6 10.7-7.8 10.8 7.8-4.2-12.6 10.9-7.9h-13.4zm-169-50.6-4.3 12.6H26.3L37 48.2l-4 12.7L43.8 53l10.7 7.9-4.2-12.7 10.9-7.9H47.8zm56.3 0-4.2 12.6H82.7l10.7 7.9-4.1 12.7 10.8-7.9 10.7 7.9-4-12.7 10.8-7.9h-13.4zm56.3 0-4 12.6h-13.5l10.9 7.9-4.2 12.7 10.8-7.9 10.9 7.9-4.2-12.7 10.8-7.9h-13.3zm56.4 0-4.2 12.6h-13.2l10.7 7.9-4 12.7 10.7-7.9 10.8 7.9-4.2-12.7 10.9-7.9h-13.4z"></path></svg></span><span role="img" aria-label="down" class="anticon anticon-down"><svg viewBox="64 64 896 896" focusable="false" data-icon="down" width="1em" height="1em" fill="currentColor" aria-hidden="true"><path d="M884 256h-75c-5.1 0-9.9 2.5-12.9 6.6L512 654.2 227.9 262.6c-3-4.1-7.8-6.6-12.9-6.6h-75c-6.5 0-10.3 7.4-6.5 12.7l352.6 486.1c12.8 17.6 39 17.6 51.7 0l352.6-486.1c3.9-5.3.1-12.7-6.4-12.7z"></path></svg></span></div><div class="global-menu-dropdown"><div class="global-menu-item"><a href="https://es.benzinga.com" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="España"><path fill="#FFDA44" d="M0 85.331h512v341.337H0z"></path><path fill="#D80027" d="M0 85.331h512v113.775H0zm0 227.551h512v113.775H0z"></path></svg></span><span>España</span></a></div><div class="global-menu-item"><a href="https://in.benzinga.com" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="India"><path fill="#FFF" d="M0 85.337h512v341.326H0z"></path><path fill="#FF9811" d="M0 85.337h512v113.775H0z"></path><path fill="#6DA544" d="M0 312.888h512v113.775H0z"></path><circle cx="256" cy="256" r="43.896" fill="#0052B4"></circle><circle cx="256" cy="256" r="27.434" fill="#FFF"></circle><path fill="#0052B4" d="m256 222.146 8.464 19.195 20.855-2.268L272.927 256l12.392 16.927-20.855-2.268L256 289.854l-8.464-19.195-20.855 2.268L239.073 256l-12.392-16.927 20.855 2.268z"></path></svg></span><span>India</span></a></div><div class="global-menu-item"><a href="https://it.benzinga.com" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="Italia"><path fill="#FFF" d="M341.334 85.33H0v341.332h512V85.33z"></path><path fill="#6DA544" d="M0 85.333h170.663V426.67H0z"></path><path fill="#D80027" d="M341.337 85.333H512V426.67H341.337z"></path></svg></span><span>Italia</span></a></div><div class="global-menu-item"><a href="https://kr.benzinga.com/" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="대한민국"><path fill="#FFF" d="M0 85.331h512v341.337H0z"></path><path fill="#D80027" d="M318.33 255.994c0 15.583-27.906 54.539-62.33 54.539s-62.33-38.957-62.33-54.539c0-34.424 27.906-62.33 62.33-62.33s62.33 27.906 62.33 62.33"></path><path fill="#0052B4" d="M318.33 255.994c0 34.424-27.906 62.33-62.33 62.33s-62.33-27.906-62.33-62.33"></path><path d="m322.114 311.096 16.528-16.528 11.018 11.018-16.528 16.528zm-27.548 27.534 16.528-16.527 11.018 11.018-16.528 16.528zm60.604 5.502 16.527-16.528 11.018 11.018-16.527 16.528zm-27.549 27.557 16.528-16.528 11.018 11.018-16.528 16.528zm11.02-44.075 16.528-16.527 11.018 11.018-16.527 16.527zm-27.547 27.546 16.528-16.528 11.018 11.018-16.528 16.527zm44.083-154.264-44.073-44.073 11.018-11.018 44.073 44.073zm-44.078-11.015-16.528-16.527 11.017-11.018 16.528 16.528zm27.536 27.55-16.528-16.527 11.017-11.018 16.528 16.528zm5.5-60.606-16.528-16.528 11.018-11.018 16.528 16.528zm27.559 27.549-16.528-16.527 11.019-11.019 16.527 16.528zM140.31 327.61l44.073 44.074-11.018 11.018-44.074-44.073zm44.058 11.025 16.527 16.527-11.017 11.018-16.528-16.528zm-27.536-27.548 16.528 16.528-11.019 11.018-16.527-16.528zm16.531-16.523 44.073 44.073-11.018 11.019-44.073-44.074zm11.021-154.277-44.073 44.074-11.018-11.018 44.073-44.074zm16.511 16.536-44.073 44.074-11.018-11.018 44.073-44.074zm16.529 16.528-44.074 44.074-11.017-11.017 44.074-44.074z"></path></svg></span><span>대한민국</span></a></div><div class="global-menu-item"><a href="https://jp.benzinga.com/" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="日本"><path fill="#FFF" d="M0 85.331h512v341.337H0z"></path><circle cx="256" cy="255.994" r="96" fill="#D80027"></circle></svg></span><span>日本</span></a></div></div></div><div class="sc-hIvhaM kcwNjI account-menu menu-wrapper"><button class="menu-button"><span role="img" aria-label="user" class="anticon anticon-user"><svg viewBox="64 64 896 896" focusable="false" data-icon="user" width="1em" height="1em" fill="currentColor" aria-hidden="true"><path d="M858.5 763.6a374 374 0 00-80.6-119.5 375.63 375.63 0 00-119.5-80.6c-.4-.2-.8-.3-1.2-.5C719.5 518 760 444.7 760 362c0-137-111-248-248-248S264 225 264 362c0 82.7 40.5 156 102.8 201.1-.4.2-.8.3-1.2.5-44.8 18.9-85 46-119.5 80.6a375.63 375.63 0 00-80.6 119.5A371.7 371.7 0 00136 901.8a8 8 0 008 8.2h60c4.4 0 7.9-3.5 8-7.8 2-77.2 33-149.5 87.8-204.3 56.7-56.7 132-87.9 212.2-87.9s155.5 31.2 212.2 87.9C779 752.7 810 825 812 902.2c.1 4.4 3.6 7.8 8 7.8h60a8 8 0 008-8.2c-1-47.8-10.9-94.3-29.5-138.2zM512 534c-45.9 0-89.1-17.9-121.6-50.4S340 407.9 340 362c0-45.9 17.9-89.1 50.4-121.6S466.1 190 512 190s89.1 17.9 121.6 50.4S684 316.1 684 362c0 45.9-17.9 89.1-50.4 121.6S557.9 534 512 534z"></path></svg></span><span class="my-account-text">My Account</span><span role="img" aria-label="down" class="anticon anticon-down"><svg viewBox="64 64 896 896" focusable="false" data-icon="down" width="1em" height="1em" fill="currentColor" aria-hidden="true"><path d="M884 256h-75c-5.1 0-9.9 2.5-12.9 6.6L512 654.2 227.9 262.6c-3-4.1-7.8-6.6-12.9-6.6h-75c-6.5 0-10.3 7.4-6.5 12.7l352.6 486.1c12.8 17.6 39 17.6 51.7 0l352.6-486.1c3.9-5.3.1-12.7-6.4-12.7z"></path></svg></span></button><div class="account-menu-dropdown"><div class="account-menu-item benzinga-edge"><a href="https://www.benzinga.com/profile/portfolio">Benzinga Edge</a></div><div class="account-menu-item benzinga-plus"><a href="https://www.benzinga.com/research">Benzinga Research</a></div><div class="account-menu-item benzinga-pro"><a href="https://pro.benzinga.com">Benzinga Pro</a></div><hr class="divider"/><div class="account-menu-item"><button class="auth-link-button">Login</button></div></div></div></div></div></div><div class="mobile-quote-bar overflow-x-scroll" id="mobile-quote-bar"><div class="sc-RMLOk iMBlzM quote-list-wrapper"><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a></div></div><div class="search-wrapper transition" id="mobile-search-bar" style="transition:all linear 0.3s"><div class="sc-iftxFb IsyKQ searchbar-wrapper searchbar-default"><div class="sc-dUVpZY dHGnYo searchbar-container"><div class="sc-eXNUIU cyqgzj search-input-container"><div class="sc-cgyULZ jXkXBs search-input-wrapper" style="flex-direction:row"><div class="search-icon" role="presentation"><span role="img" aria-label="search" class="anticon anticon-search"><svg viewBox="64 64 896 896" focusable="false" data-icon="search" width="1em" height="1em" fill="currentColor" aria-hidden="true"><path d="M909.6 854.5L649.9 594.8C690.2 542.7 712 479 712 412c0-80.2-31.3-155.4-87.9-212.1-56.6-56.7-132-87.9-212.1-87.9s-155.5 31.3-212.1 87.9C143.2 256.5 112 331.8 112 412c0 80.1 31.3 155.5 87.9 212.1C256.5 680.8 331.8 712 412 712c67 0 130.6-21.8 182.7-62l259.7 259.6a8.2 8.2 0 0011.6 0l43.6-43.5a8.2 8.2 0 000-11.6zM570.4 570.4C528 612.7 471.8 636 412 636s-116-23.3-158.4-65.6C211.3 528 188 471.8 188 412s23.3-116.1 65.6-158.4C296 211.3 352.2 188 412 188s116.1 23.2 158.4 65.6S636 352.2 636 412s-23.3 116.1-65.6 158.4z"></path></svg></span></div><input aria-label="Search" class="search-input" placeholder="Search Tickers, Companies or News..." role="searchbox" tabindex="0" type="search" value=""/></div></div></div></div></div></div></div></div><div class="sc-iFEMmm eWaiSj desktop-menu-wrapper" id="navigation-header"><div class="top-banner-fallback h-20 bg-[#0b131d] relative py-4"><div class="animate-pulse h-full relative rounded-full bg-slate-700/50 max-w-[1400px] mx-auto"></div></div><div class="sc-dnoZww bpQUFE top-bar-wrapper"><div class="bar-layout-width"><div class="top-bar-inner-wrapper"><ul class="top-bar-list"><li class="bz-top-bar-list-item ProLabel"><a aria-label="Get Benzinga Pro" class="sc-dIGTRn jLtEqm shine-effect text-white bz-pro-btn" href="https://www.benzinga.com/pro/register?utm_source=homepage-blue-button">Get Benzinga Pro </a></li><li class="bz-top-bar-list-item"><a href="https://www.benzinga.com/apis"><div class="bz-top-bar-list-item-label">Data & APIs</div></a></li><li class="bz-top-bar-list-item"><a href="https://www.benzinga.com/events"><div class="bz-top-bar-list-item-label">Events</div></a></li><li class="bz-top-bar-list-item"><a href="https://www.benzinga.com/premarket"><div class="bz-top-bar-list-item-label">Premarket</div></a></li><li class="bz-top-bar-list-item"><a href="https://advertise.benzinga.com"><div class="bz-top-bar-list-item-label">Advertise</div></a></li></ul><div class="auth-buttons"><div class="contributor-link"><a href="https://contributor.benzinga.com/contributor-onboarding">Contribute</a></div><div class="sc-hsexvf bfYCmN global-menu menu-wrapper"><div aria-label="Global Menu" class="menu-button" role="button"><span class="global-text w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 513 342" title="USA"><path fill="#FFF" d="M0 0h513v342H0z"></path><path fill="#D80027" d="M0 0h513v38H0zm0 76h513v38H0zm0 76h513v38H0zm0 76h513v38H0zm0 76h513v38H0z"></path><path fill="#2E52B2" d="M0 0h256.5v190H0z"></path><path fill="#FFF" d="m47.8 141.9-4-12.8-4.3 12.8H26.3l10.7 7.7-4 12.8 10.8-7.9 10.7 7.9-4.2-12.8 10.9-7.7zm56.4 0-4.1-12.8-4.2 12.8H82.7l10.7 7.7-4.1 12.8 10.8-7.9 10.7 7.9-4-12.8 10.8-7.7zm56.4 0-4.2-12.8-4 12.8h-13.5l10.9 7.7-4.2 12.8 10.8-7.9 10.9 7.9-4.2-12.8 10.8-7.7zm56.3 0-4.1-12.8-4.2 12.8h-13.2l10.7 7.7-4 12.8 10.7-7.9 10.8 7.9-4.2-12.8 10.9-7.7zM100.1 78.3l-4.2 12.8H82.7L93.4 99l-4.1 12.6 10.8-7.8 10.7 7.8-4-12.6 10.8-7.9h-13.4zm-56.3 0-4.3 12.8H26.3L37 99l-4 12.6 10.8-7.8 10.7 7.8L50.3 99l10.9-7.9H47.8zm112.6 0-4 12.8h-13.5l10.9 7.9-4.2 12.6 10.8-7.8 10.9 7.8-4.2-12.6 10.8-7.9h-13.3zm56.4 0-4.2 12.8h-13.2l10.7 7.9-4 12.6 10.7-7.8 10.8 7.8-4.2-12.6 10.9-7.9h-13.4zm-169-50.6-4.3 12.6H26.3L37 48.2l-4 12.7L43.8 53l10.7 7.9-4.2-12.7 10.9-7.9H47.8zm56.3 0-4.2 12.6H82.7l10.7 7.9-4.1 12.7 10.8-7.9 10.7 7.9-4-12.7 10.8-7.9h-13.4zm56.3 0-4 12.6h-13.5l10.9 7.9-4.2 12.7 10.8-7.9 10.9 7.9-4.2-12.7 10.8-7.9h-13.3zm56.4 0-4.2 12.6h-13.2l10.7 7.9-4 12.7 10.7-7.9 10.8 7.9-4.2-12.7 10.9-7.9h-13.4z"></path></svg></span><span role="img" aria-label="down" class="anticon anticon-down"><svg viewBox="64 64 896 896" focusable="false" data-icon="down" width="1em" height="1em" fill="currentColor" aria-hidden="true"><path d="M884 256h-75c-5.1 0-9.9 2.5-12.9 6.6L512 654.2 227.9 262.6c-3-4.1-7.8-6.6-12.9-6.6h-75c-6.5 0-10.3 7.4-6.5 12.7l352.6 486.1c12.8 17.6 39 17.6 51.7 0l352.6-486.1c3.9-5.3.1-12.7-6.4-12.7z"></path></svg></span></div><div class="global-menu-dropdown"><div class="global-menu-item"><a href="https://es.benzinga.com" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="España"><path fill="#FFDA44" d="M0 85.331h512v341.337H0z"></path><path fill="#D80027" d="M0 85.331h512v113.775H0zm0 227.551h512v113.775H0z"></path></svg></span><span>España</span></a></div><div class="global-menu-item"><a href="https://in.benzinga.com" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="India"><path fill="#FFF" d="M0 85.337h512v341.326H0z"></path><path fill="#FF9811" d="M0 85.337h512v113.775H0z"></path><path fill="#6DA544" d="M0 312.888h512v113.775H0z"></path><circle cx="256" cy="256" r="43.896" fill="#0052B4"></circle><circle cx="256" cy="256" r="27.434" fill="#FFF"></circle><path fill="#0052B4" d="m256 222.146 8.464 19.195 20.855-2.268L272.927 256l12.392 16.927-20.855-2.268L256 289.854l-8.464-19.195-20.855 2.268L239.073 256l-12.392-16.927 20.855 2.268z"></path></svg></span><span>India</span></a></div><div class="global-menu-item"><a href="https://it.benzinga.com" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="Italia"><path fill="#FFF" d="M341.334 85.33H0v341.332h512V85.33z"></path><path fill="#6DA544" d="M0 85.333h170.663V426.67H0z"></path><path fill="#D80027" d="M341.337 85.333H512V426.67H341.337z"></path></svg></span><span>Italia</span></a></div><div class="global-menu-item"><a href="https://kr.benzinga.com/" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="대한민국"><path fill="#FFF" d="M0 85.331h512v341.337H0z"></path><path fill="#D80027" d="M318.33 255.994c0 15.583-27.906 54.539-62.33 54.539s-62.33-38.957-62.33-54.539c0-34.424 27.906-62.33 62.33-62.33s62.33 27.906 62.33 62.33"></path><path fill="#0052B4" d="M318.33 255.994c0 34.424-27.906 62.33-62.33 62.33s-62.33-27.906-62.33-62.33"></path><path d="m322.114 311.096 16.528-16.528 11.018 11.018-16.528 16.528zm-27.548 27.534 16.528-16.527 11.018 11.018-16.528 16.528zm60.604 5.502 16.527-16.528 11.018 11.018-16.527 16.528zm-27.549 27.557 16.528-16.528 11.018 11.018-16.528 16.528zm11.02-44.075 16.528-16.527 11.018 11.018-16.527 16.527zm-27.547 27.546 16.528-16.528 11.018 11.018-16.528 16.527zm44.083-154.264-44.073-44.073 11.018-11.018 44.073 44.073zm-44.078-11.015-16.528-16.527 11.017-11.018 16.528 16.528zm27.536 27.55-16.528-16.527 11.017-11.018 16.528 16.528zm5.5-60.606-16.528-16.528 11.018-11.018 16.528 16.528zm27.559 27.549-16.528-16.527 11.019-11.019 16.527 16.528zM140.31 327.61l44.073 44.074-11.018 11.018-44.074-44.073zm44.058 11.025 16.527 16.527-11.017 11.018-16.528-16.528zm-27.536-27.548 16.528 16.528-11.019 11.018-16.527-16.528zm16.531-16.523 44.073 44.073-11.018 11.019-44.073-44.074zm11.021-154.277-44.073 44.074-11.018-11.018 44.073-44.074zm16.511 16.536-44.073 44.074-11.018-11.018 44.073-44.074zm16.529 16.528-44.074 44.074-11.017-11.017 44.074-44.074z"></path></svg></span><span>대한민국</span></a></div><div class="global-menu-item"><a href="https://jp.benzinga.com/" rel="noreferrer" tabindex="0" target="_blank"><span class="w-[25px] h-[16px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 85.333 512 341.333" title="日本"><path fill="#FFF" d="M0 85.331h512v341.337H0z"></path><circle cx="256" cy="255.994" r="96" fill="#D80027"></circle></svg></span><span>日本</span></a></div></div></div><button class="auth-link-button">Login</button><button class="auth-link-button bg-orange-600">Register</button></div></div></div></div><div class="sc-dnxBXz gJOGKI main-menu-bar"><div class="sc-iPYwOE fdRSnI main-menu-wrapper"><div class="sc-cxgeGX kgSstf bar-content-layout"><div class="sc-jGeVcH zcqvV logo-wrapper mobile-logo-wrapper"><a aria-label="Click to go home" href="/"><span class="sc-hTgaWy jNoPDg benzinga-logo dark desktop"><svg height="100%" role="img" viewBox="0 0 471.1 63.8" width="100%" xmlns="http://www.w3.org/2000/svg"><path d="M67.7 63.8h45.2V51.9H81.4V37.3h26.1V25.4H81.4V11.9h31.7V0H67.7zm99.6-23.6L137.7 0h-20.4l6.4 8.1V64h13.6V22.1l30.6 41.7H181V0h-13.7zM47.1 31c6-1.1 11-6.7 11-14.6C58.1 7.9 51.9 0 39.6 0H0l6.2 7.9v56H41c12.3 0 18.7-7.7 18.7-17.3-.3-7.9-5.7-14.7-12.6-15.6zM19.8 12h17.1c4.6 0 7.5 2.7 7.5 6.7s-2.9 6.7-7.5 6.7H19.8V12zm17.7 40H19.8V37.3h17.7c5.2 0 8.1 3.3 8.1 7.3 0 4.6-3.1 7.3-8.1 7.4zm343.3-11.8h7.1v7.5c-3.7 3-8.3 4.7-13.1 4.8-11.4 0-19.4-8.7-19.4-20.4s8.1-20.4 19.4-20.4c5.9 0 11.4 3.1 14.6 8.1l10.8-6C395.6 6.5 387.5 0 374.7 0c-18.1 0-33.1 12.5-33.1 31.9s14.8 31.9 33.1 31.9c10 .2 19.5-4.1 26.1-11.5V28.7h-29.2l9.2 11.5zm-61.5 0L289.6 0h-20.3l6.3 8.1V64h13.7V22.1l30.6 41.7h13V0h-13.6zM446 0h-26.3l6.3 8.1-1.1 3.1L404.5 64h15.4l4-10.8h27.5l4 10.8h15.4L446 0zm-18.6 41.2l10-27.5 10 27.5h-20zM247.7 0h13.7v64.1h-13.7zm-10.9 11V0h-48.1v11.9h30.2l-30.2 41v10.9h48.6V51.9h-30.9z" fill="#093451"></path></svg></span></a></div><div class="sc-dTaEtF jBQQBt primary-menu-wrapper"><ul class="sc-bnRclF bca-DLN menu-item-container"><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/services" style="min-width:108px" title="Our Services">Our Services </a></div></li><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/news" style="min-width:57px" title="News">News </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/earnings" title="Earnings">Earnings</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/guidance" title="Guidance">Guidance</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/dividends" title="Dividends">Dividends</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/m-a" title="M&amp;A">M&A</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/buybacks" title="Buybacks">Buybacks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/legal" title="Legal">Legal</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/interview" title="Interviews">Interviews</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/management" title="Management">Management</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/offerings" title="Offerings">Offerings</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/ipos" title="IPOs">IPOs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/insider-trades" title="Insider Trades">Insider Trades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/fda-calendar" title="Biotech/FDA">Biotech/FDA</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/general/politics" title="Politics">Politics</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/healthcare" title="Healthcare">Healthcare</a></div></div></div></div></div></div></li><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/markets" style="min-width:75px" title="Markets">Markets </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/premarket" title="Pre-Market">Pre-Market</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/after-hours-center" title="After Hours">After Hours</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/movers" title="Movers">Movers</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/etfs" title="ETFs">ETFs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/forex" title="Forex">Forex</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/cannabis" title="Cannabis">Cannabis</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/commodities" title="Commodities">Commodities</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/binary-options" title="Binary Options">Binary Options</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/bonds" title="Bonds">Bonds</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/futures" title="Futures">Futures</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/author/cme-group" title="CME Group">CME Group</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/economic" title="Global Economics">Global Economics</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/mining" title="Mining">Mining</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/previews" title="Previews">Previews</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/small-cap" title="Small-Cap">Small-Cap</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/real-estate" title="Real Estate">Real Estate</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-penny-stocks" title="Penny Stocks">Penny Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/digital-securities" title="Digital Securities">Digital Securities</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/volatility" title="Volatility">Volatility</a></div></div></div></div></div></div></li><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/markets/options" style="min-width:75px" title="Options">Options </a></div></li><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/analyst-stock-ratings" style="min-width:73px" title="Ratings">Ratings </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-ratings/analyst-color" title="Analyst Color">Analyst Color</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings/downgrades" title="Downgrades">Downgrades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings/upgrades" title="Upgrades">Upgrades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings/initiations" title="Initiations">Initiations</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-ratings/price-target" title="Price Target">Price Target</a></div></div></div></div></div></div></li><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/trading-ideas" style="min-width:57px" title="Ideas">Ideas </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav has-groups"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="sc-goMudc huBxHA group-list"><div><div class="sc-WFjOp ddvSJk group-list-item-label">Trade Ideas</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/long-ideas" title="Long Ideas">Long Ideas</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/short-ideas" title="Short Ideas">Short Ideas</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/technicals" title="Technicals">Technicals</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/media" title="From The Press">From The Press</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/jim-cramer" title="Jim Cramer">Jim Cramer</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/rumors" title="Rumors">Rumors</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/stock-whisper-index" title="Whisper Index">Whisper Index</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/stock-of-the-day" title="Stock of the Day">Stock of the Day</a></div></div></div></div></div><div><div class="sc-WFjOp ddvSJk group-list-item-label">Best Stocks & ETFs</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-penny-stocks" title="Best Penny Stocks">Best Penny Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-sp-500-etfs" title="Best S&P 500 ETFs">Best S&P 500 ETFs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-swing-trade-stocks" title="Best Swing Trade Stocks">Best Swing Trade Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-blue-chip-stocks" title="Best Blue Chip Stocks">Best Blue Chip Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-high-volume-penny-stocks" title="Best High-Volume Penny Stocks">Best High-Volume Penny Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-small-cap-etfs" title="Best Small Cap ETFs">Best Small Cap ETFs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-stocks-to-day-trade" title="Best Stocks to Day Trade">Best Stocks to Day Trade</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-reits" title="Best Stocks to Day Trade">Best REITs</a></div></div></div></div></div></div></div></div></div></li><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/money" style="min-width:66px" title="Money">Money </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/investing" title="Investing">Investing</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/crypto" title="Cryptocurrency">Cryptocurrency</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/mortgages" title="Mortgage">Mortgage</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/insurance" title="Insurance">Insurance</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/yield-investments" title="Yield">Yield</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/personal-finance" title="Personal Finance">Personal Finance</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/forex" title="Forex">Forex</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/alternative-investments/startups" title="Startup Investing">Startup Investing</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/alternative-investments/real-estate" title="Real Estate Investing">Real Estate Investing</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-prop-trading-firms" title="Prop Trading">Prop Trading</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-credit-cards" title="Credit Cards">Credit Cards</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-stock-brokers-in-the-us" title="Stock Brokers">Stock Brokers</a></div></div></div></div></div></div></li><li><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/crypto" style="min-width:fit-content" title="Crypto">Crypto </a></div></li></ul></div><button aria-label="Click to open more navbar items" class="more-nav-tabs-icon-container"><div class="text-2xl text-black"><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M432 256a48 48 0 1 1 -96 0 48 48 0 1 1 96 0zm-160 0a48 48 0 1 1 -96 0 48 48 0 1 1 96 0zM64 304a48 48 0 1 1 0-96 48 48 0 1 1 0 96z" fill="currentColor"></path></svg></div><div class="sc-jesuKm bCAaKz more-menu-items-dropdown-container"><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/news" style="min-width:57px" title="News">News </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/earnings" title="Earnings">Earnings</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/guidance" title="Guidance">Guidance</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/dividends" title="Dividends">Dividends</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/m-a" title="M&amp;A">M&A</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/buybacks" title="Buybacks">Buybacks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/legal" title="Legal">Legal</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/interview" title="Interviews">Interviews</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/management" title="Management">Management</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/offerings" title="Offerings">Offerings</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/ipos" title="IPOs">IPOs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/insider-trades" title="Insider Trades">Insider Trades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/fda-calendar" title="Biotech/FDA">Biotech/FDA</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/general/politics" title="Politics">Politics</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/healthcare" title="Healthcare">Healthcare</a></div></div></div></div></div></div><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/markets" style="min-width:75px" title="Markets">Markets </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/premarket" title="Pre-Market">Pre-Market</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/after-hours-center" title="After Hours">After Hours</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/movers" title="Movers">Movers</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/etfs" title="ETFs">ETFs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/forex" title="Forex">Forex</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/cannabis" title="Cannabis">Cannabis</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/commodities" title="Commodities">Commodities</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/binary-options" title="Binary Options">Binary Options</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/bonds" title="Bonds">Bonds</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/futures" title="Futures">Futures</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/author/cme-group" title="CME Group">CME Group</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/economic" title="Global Economics">Global Economics</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/mining" title="Mining">Mining</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/previews" title="Previews">Previews</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/small-cap" title="Small-Cap">Small-Cap</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/real-estate" title="Real Estate">Real Estate</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-penny-stocks" title="Penny Stocks">Penny Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/digital-securities" title="Digital Securities">Digital Securities</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/volatility" title="Volatility">Volatility</a></div></div></div></div></div></div><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/markets/options" style="min-width:75px" title="Options">Options </a></div><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/analyst-stock-ratings" style="min-width:73px" title="Ratings">Ratings </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-ratings/analyst-color" title="Analyst Color">Analyst Color</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings/downgrades" title="Downgrades">Downgrades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings/upgrades" title="Upgrades">Upgrades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings/initiations" title="Initiations">Initiations</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-ratings/price-target" title="Price Target">Price Target</a></div></div></div></div></div></div><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/trading-ideas" style="min-width:57px" title="Ideas">Ideas </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav has-groups"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="sc-goMudc huBxHA group-list"><div><div class="sc-WFjOp ddvSJk group-list-item-label">Trade Ideas</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/long-ideas" title="Long Ideas">Long Ideas</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/short-ideas" title="Short Ideas">Short Ideas</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas/technicals" title="Technicals">Technicals</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/media" title="From The Press">From The Press</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/jim-cramer" title="Jim Cramer">Jim Cramer</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/news/rumors" title="Rumors">Rumors</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/stock-whisper-index" title="Whisper Index">Whisper Index</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/topic/stock-of-the-day" title="Stock of the Day">Stock of the Day</a></div></div></div></div></div><div><div class="sc-WFjOp ddvSJk group-list-item-label">Best Stocks & ETFs</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-penny-stocks" title="Best Penny Stocks">Best Penny Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-sp-500-etfs" title="Best S&P 500 ETFs">Best S&P 500 ETFs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-swing-trade-stocks" title="Best Swing Trade Stocks">Best Swing Trade Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-blue-chip-stocks" title="Best Blue Chip Stocks">Best Blue Chip Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-high-volume-penny-stocks" title="Best High-Volume Penny Stocks">Best High-Volume Penny Stocks</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-small-cap-etfs" title="Best Small Cap ETFs">Best Small Cap ETFs</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-stocks-to-day-trade" title="Best Stocks to Day Trade">Best Stocks to Day Trade</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-reits" title="Best Stocks to Day Trade">Best REITs</a></div></div></div></div></div></div></div></div></div><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/money" style="min-width:66px" title="Money">Money </a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/investing" title="Investing">Investing</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/crypto" title="Cryptocurrency">Cryptocurrency</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/mortgages" title="Mortgage">Mortgage</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/insurance" title="Insurance">Insurance</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/yield-investments" title="Yield">Yield</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/personal-finance" title="Personal Finance">Personal Finance</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/markets/forex" title="Forex">Forex</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/alternative-investments/startups" title="Startup Investing">Startup Investing</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/alternative-investments/real-estate" title="Real Estate Investing">Real Estate Investing</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-prop-trading-firms" title="Prop Trading">Prop Trading</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-credit-cards" title="Credit Cards">Credit Cards</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/money/best-stock-brokers-in-the-us" title="Stock Brokers">Stock Brokers</a></div></div></div></div></div></div><div class="sc-jUFHcI blGfTM menu-wrapper primary"><a class="sc-duhhru ffjrNJ menu-item-link initial" data-action="Navigation Main Menu Click" href="/crypto" style="min-width:fit-content" title="Crypto">Crypto </a></div></div></button><div class="sc-dEARTM ilPLjY secondary-menu-wrapper"><div class="sc-jUFHcI blGfTM menu-wrapper secondary"><a aria-label="This opens Research in a new tab" class="sc-buPYkW itwPjb others-btn primary-toolbar-button" href="https://www.benzinga.com/research" style="min-width:110px" target="_blank" title="Research"><div class="text-xl pr-2"><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 576 512" xmlns="http://www.w3.org/2000/svg"><path d="M96 32C60.7 32 32 60.7 32 96V384H96V96l384 0V384h64V96c0-35.3-28.7-64-64-64H96zM224 384v32H32c-17.7 0-32 14.3-32 32s14.3 32 32 32H544c17.7 0 32-14.3 32-32s-14.3-32-32-32H416V384c0-17.7-14.3-32-32-32H256c-17.7 0-32 14.3-32 32z" fill="currentColor"></path></svg></div>Research</a></div><div class="sc-jUFHcI blGfTM menu-wrapper secondary"><a aria-label="This opens My Stocks in a new tab" class="sc-buPYkW itwPjb others-btn primary-toolbar-button" href="https://www.benzinga.com/login?action=register&next=https://www.benzinga.com/profile/portfolio" style="min-width:105px" target="_blank" title="My Stocks"><div class="text-xl pr-1"><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 512 512" xmlns="http://www.w3.org/2000/svg"><path d="M500 89c13.8-11 16-31.2 5-45s-31.2-16-45-5L319.4 151.5 211.2 70.4c-11.7-8.8-27.8-8.5-39.2 .6L12 199c-13.8 11-16 31.2-5 45s31.2 16 45 5L192.6 136.5l108.2 81.1c11.7 8.8 27.8 8.5 39.2-.6L500 89zM160 256V448c0 17.7 14.3 32 32 32s32-14.3 32-32V256c0-17.7-14.3-32-32-32s-32 14.3-32 32zM32 352v96c0 17.7 14.3 32 32 32s32-14.3 32-32V352c0-17.7-14.3-32-32-32s-32 14.3-32 32zm288-64c-17.7 0-32 14.3-32 32V448c0 17.7 14.3 32 32 32s32-14.3 32-32V320c0-17.7-14.3-32-32-32zm96-32V448c0 17.7 14.3 32 32 32s32-14.3 32-32V256c0-17.7-14.3-32-32-32s-32 14.3-32 32z" fill="currentColor"></path></svg></div>My Stocks</a></div><div class="sc-jUFHcI blGfTM menu-wrapper secondary"><a aria-label="This opens Tools in a new tab" class="sc-buPYkW itwPjb others-btn primary-toolbar-button" href="https://www.benzinga.com/tools" style="min-width:100px" target="_blank" title="Tools"><div class="text-xl pr-1"><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 512 512" xmlns="http://www.w3.org/2000/svg"><path d="M352 320c88.4 0 160-71.6 160-160c0-15.3-2.2-30.1-6.2-44.2c-3.1-10.8-16.4-13.2-24.3-5.3l-76.8 76.8c-3 3-7.1 4.7-11.3 4.7H336c-8.8 0-16-7.2-16-16V118.6c0-4.2 1.7-8.3 4.7-11.3l76.8-76.8c7.9-7.9 5.4-21.2-5.3-24.3C382.1 2.2 367.3 0 352 0C263.6 0 192 71.6 192 160c0 19.1 3.4 37.5 9.5 54.5L19.9 396.1C7.2 408.8 0 426.1 0 444.1C0 481.6 30.4 512 67.9 512c18 0 35.3-7.2 48-19.9L297.5 310.5c17 6.2 35.4 9.5 54.5 9.5zM80 408a24 24 0 1 1 0 48 24 24 0 1 1 0-48z" fill="currentColor"></path></svg></div>Tools</a><div class="sc-eCywNV iInkzP sub-nav-wrapper subnav has-groups"><div class="sc-dMlkvz ideGoF sub-group-wrapper"><a aria-label="Free Benzinga Pro Trial" class="sc-dIGTRn jLtEqm shine-effect text-white block py-2 rounded-sm bg-bzblue-600 text-center mx-2 md:mx-4 my-2" href="https://pro.benzinga.com/register/?utm_source=tools-bz-pro-free-trial">Free Benzinga Pro Trial </a><div class="sc-goMudc huBxHA group-list"><div><div class="sc-WFjOp ddvSJk group-list-item-label">Calendars</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings" title="Analyst Ratings Calendar">Analyst Ratings Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/conference-calls" title="Conference Call Calendar">Conference Call Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/dividends" title="Dividend Calendar">Dividend Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/earnings" title="Earnings Calendar">Earnings Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/economic" title="Economic Calendar">Economic Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/fda-calendar" title="FDA Calendar">FDA Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/guidance" title="Guidance Calendar">Guidance Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/ipos" title="IPO Calendar">IPO Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/m-a" title="M&A Calendar">M&A Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/spac" title="SPAC Calendar">SPAC Calendar</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/stock-splits" title="Stock Split Calendar">Stock Split Calendar</a></div></div></div></div></div><div><div class="sc-WFjOp ddvSJk group-list-item-label">Trade Ideas</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/reports" title="Free Stock Reports">Free Stock Reports</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/sec/insider-trades/" title="Insider Trades">Insider Trades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/trading-ideas" title="Trade Idea Feed">Trade Idea Feed</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/analyst-stock-ratings" title="Analyst Ratings">Analyst Ratings</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/calendars/unusual-options-activity" title="Unusual Options Activity">Unusual Options Activity</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/research/tools/heatmap" title="Heatmaps">Heatmaps</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/free-newsletters" title="Free Newsletter">Free Newsletter</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/gov-trades" title="Government Trades">Government Trades</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/portfolio/perfect-stock-portfolio" title="Perfect Stock Portfolio">Perfect Stock Portfolio</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/portfolio/easy-income-portfolio" title="Easy Income Portfolio">Easy Income Portfolio</a></div></div></div></div></div><div><div class="sc-WFjOp ddvSJk group-list-item-label">Short Interest</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/short-interest/most-shorted" title="Most Shorted">Most Shorted</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/short-interest/largest-increase" title="Largest Increase">Largest Increase</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/short-interest/largest-decrease" title="Largest Decrease">Largest Decrease</a></div></div></div></div></div><div><div class="sc-WFjOp ddvSJk group-list-item-label">Calculators</div><div><div class="menu-items"><div class="sc-kjxHLd lmVuSP menu-item-wrapper"><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/margin-calculator" title="Margin Calculator">Margin Calculator</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/forex-profit-calculator" title="Forex Profit Calculator">Forex Profit Calculator</a></div><div class="sc-jUXVlk fDLMAx dropdown-menu-item"><a data-action="Navigation Sub-Menu Click" href="/research/tools/100x-options-profit-calculator" title="100x Options Profit Calculator">100x Options Profit Calculator</a></div></div></div></div></div></div></div></div></div></div></div></div></div><div class="sc-kqpPGb fiWpzI quote-bar-container"><div class="quote-bar-layout-width"><div class="quote-bar-wrapper"><div class="sc-czPwHC bJncSS quote-switcher-wrapper"><div class="quote-switcher-container"><button class="sc-gvEBYa euzGLN quote-switcher-button">Recent</button><button class="sc-gvEBYa bNBpVJ quote-switcher-button">Markets</button></div></div><div class="quote-list-container"><div class="sc-RMLOk iMBlzM quote-list-wrapper"><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a><a class="sc-bgmyod iZZowX quote-block " href="/quote/null"><h5 class="sc-iBpinA eFsVII quotebox-quote-name"></h5><div class="sc-iPOUNt ilifZQ quotebox-quote-data"><span class="sc-cNGRH kQfrhl quotebox-quote-price"></span><span class="sc-cNGRH sc-ldJDQK kQfrhl ibVicV quotebox-quote-change "><span></span></span></div></a></div></div><div class="search-wrapper"><div class="sc-iftxFb IsyKQ searchbar-wrapper searchbar-default"><div class="sc-dUVpZY dHGnYo searchbar-container"><div class="sc-eXNUIU cyqgzj search-input-container"><div class="sc-cgyULZ jXkXBs search-input-wrapper" style="flex-direction:row"><div class="search-icon" role="presentation"><span role="img" aria-label="search" class="anticon anticon-search"><svg viewBox="64 64 896 896" focusable="false" data-icon="search" width="1em" height="1em" fill="currentColor" aria-hidden="true"><path d="M909.6 854.5L649.9 594.8C690.2 542.7 712 479 712 412c0-80.2-31.3-155.4-87.9-212.1-56.6-56.7-132-87.9-212.1-87.9s-155.5 31.3-212.1 87.9C143.2 256.5 112 331.8 112 412c0 80.1 31.3 155.5 87.9 212.1C256.5 680.8 331.8 712 412 712c67 0 130.6-21.8 182.7-62l259.7 259.6a8.2 8.2 0 0011.6 0l43.6-43.5a8.2 8.2 0 000-11.6zM570.4 570.4C528 612.7 471.8 636 412 636s-116-23.3-158.4-65.6C211.3 528 188 471.8 188 412s23.3-116.1 65.6-158.4C296 211.3 352.2 188 412 188s116.1 23.2 158.4 65.6S636 352.2 636 412s-23.3 116.1-65.6 158.4z"></path></svg></span></div><input aria-label="Search" class="search-input" placeholder="Search Tickers, Companies or News..." role="searchbox" tabindex="0" type="search" value=""/></div></div></div></div></div></div></div></div></div></div><div class="sc-bNIngB fAZYps"><div class="sc-fqCdsd gcWRCu"><div class="sc-fccqSk kcYnRn layout-content-container lg:px-0 mx-auto px-4 layout-container max-w-7xl"><div class="sc-eFzpJt giQuHe layout-above"><div class="layout-container mx-auto"><div class="flex flex-col md:flex-row items-start md:items-center gap-2 md:gap-8"><h1 class="sc-jmONUi bpLYAM layout-title ">FDA Calendar</h1></div><p class="sc-hidnnO jbUZed section-description">Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates.</p><div class="fda-calendar"><div></div><div class="sc-bxcGCR godhtp"><div class="sc-dZzYrH bZwbEZ calendar-table"><div class="ratings-filters"><div class="sc-kOVexp fFxCoI top-tabs-wrapper"><div class="top-tabs"><button class="top-tabs__tab top-tabs__tab--active" id="tab-historical">Historical (243)</button><h2 class="top-tabs__tab" id="tab-exact-dates">Exact Dates</h2><h2 class="top-tabs__tab" id="tab-estimated-dates">Estimated Dates</h2><button class="top-tabs__tab" id="tab-pdufa">PDUFA</button></div></div><div class="sc-ddqZcG ffPSdQ"><div class="sc-bRoQge iVgNrI checkbox-container"><input id="core-checkbox-binary-events-only" style="font-weight:600" class="core-checkbox" type="checkbox"/><label for="core-checkbox-binary-events-only">Binary Events Only</label></div></div><div class="sc-ijWjlm bzMGnz"><div class="dates-filter"><div class="range-date-picker"><div class="range-date-picker__field-wrapper"><input class="range-date-picker__picker-field" placeholder="Select Date" value="02/01/2025 - 02/28/2025"/><div class="range-date-picker__icon"><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M152 24c0-13.3-10.7-24-24-24s-24 10.7-24 24V64H64C28.7 64 0 92.7 0 128v16 48V448c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V192 144 128c0-35.3-28.7-64-64-64H344V24c0-13.3-10.7-24-24-24s-24 10.7-24 24V64H152V24zM48 192H400V448c0 8.8-7.2 16-16 16H64c-8.8 0-16-7.2-16-16V192z" fill="currentColor"></path></svg></div></div></div><div class="sc-MHjuz dOEGLi bz3-search-bar-wrapper"><div class="bz3-search-field" style="background:white"><div class="bz3-search-field__tags-wrapper"><input class="bz3-search-field__input" placeholder="Filter by Tickers..." type="text" value=""/></div><button class="bz3-search-field__btn" type="button"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 512 512" xmlns="http://www.w3.org/2000/svg"><path d="M368 208A160 160 0 1 0 48 208a160 160 0 1 0 320 0zM337.1 371.1C301.7 399.2 256.8 416 208 416C93.1 416 0 322.9 0 208S93.1 0 208 0S416 93.1 416 208c0 48.8-16.8 93.7-44.9 129.1L505 471c9.4 9.4 9.4 24.6 0 33.9s-24.6 9.4-33.9 0L337.1 371.1z" fill="currentColor"></path></svg></div></button></div></div></div></div></div><div class="sc-lcMqGs kzmRJW"><div class="bz-ag-table ag-theme-alpine bz-ag-table--dark-blue" style="height:60vh;max-height:60vh"><div style="height:100%"></div></div><div></div><div class="under-calendar-text">Data brought to you by <a href="https://www.benzinga.com/apis/data/?utm_source=benzinga.com&utm_medium=web&utm_campaign=internal" rel="noreferrer" target="_blank">Benzinga APIs</a></div></div></div></div></div></div></div><div class="main-content-container layout-container mx-auto"><div class="layout-flex flex flex-col w-full items-start relative"><div class="layout-main flex flex-grow flex-col justify-between"><div><div class="mb-4"><div class="sc-fnpAPw kEPWIN"><div class="sc-kcknSm cLaOee mb-4"><h2 class="sc-HiIYf kETrRm news-feed-title">Recent FDA Approvals</h2></div><div class="newsfeed-card text-black"><div class="sc-kgTdLl conWOv post-card-wrapper"><div class="sc-eTGAKG fjcqMd post-card post-card-feed post-card-size-nano" title="What's Going On With Gene Therapy Company Bluebird Bio Stock Today?"><a class="post-card-article-link post-card-image image-wrapper" href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal"><span style="background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:absolute;top:0;left:0;bottom:0;right:0"><div role="img" class="sc-dffbf6d7-0 EuWGp"></div><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" class="sc-ecjqsm hkniJt post-thumb" decoding="async" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover;background-image:url("https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?width=100");background-position:0% 0%;background-size:cover;filter:blur(20px)"/><noscript><img alt="" sizes="(max-width: 800px) 120px, (min-width: 800px) 240px" src="https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260" srcSet="https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 16w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 32w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 48w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 64w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 96w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 128w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 256w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 384w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 640w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 750w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 828w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1080w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1200w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1920w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 2048w, https://cdn.benzinga.com/files/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg?optimize=medium&dpr=2&auto=webp&width=260 3840w" class="sc-ecjqsm hkniJt post-thumb" decoding="async" loading="lazy" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover"/></noscript></span></a><div class="post-card-text lg:w-auto flex flex-col space-y-2"><div class="post-card-text-wrapper"><a class="post-card-article-link" href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal"><span class="sc-kQUZUP iZczKq post-title"><div class="sc-llvwKJ sc-duVdMk hHJzBM cerdRw line-wrapper three-line post-card-title leading-normal text-2xl"><span>What's Going On With Gene Therapy Company Bluebird Bio Stock Today?</span></div></span></a><div class="post-card-article-link flex items-center"><div class="sc-cVuPSX davtfT"></div></div></div></div></div></div></div><div class="newsfeed-card text-black"><div class="sc-kgTdLl conWOv post-card-wrapper"><div class="sc-eTGAKG fjcqMd post-card post-card-feed post-card-size-nano" title="Health Insurance ETFs in Focus as RFK Jr Takes Over HHS"><a class="post-card-article-link post-card-image image-wrapper" href="https://www.benzinga.com/news/25/02/43769585/health-insurance-etfs-in-focus-as-rfk-jr-takes-over-hhs"><span style="background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:absolute;top:0;left:0;bottom:0;right:0"><div role="img" class="sc-dffbf6d7-0 bZSaNx"></div><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" class="sc-ecjqsm hkniJt post-thumb" decoding="async" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover;background-image:url("https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?width=100");background-position:0% 0%;background-size:cover;filter:blur(20px)"/><noscript><img alt="" sizes="(max-width: 800px) 120px, (min-width: 800px) 240px" src="https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260" srcSet="https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 16w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 32w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 48w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 64w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 96w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 128w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 256w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 384w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 640w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 750w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 828w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1080w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1200w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1920w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 2048w, https://cdn.benzinga.com/files/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 3840w" class="sc-ecjqsm hkniJt post-thumb" decoding="async" loading="lazy" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover"/></noscript></span></a><div class="post-card-text lg:w-auto flex flex-col space-y-2"><div class="post-card-text-wrapper"><a class="post-card-article-link" href="https://www.benzinga.com/news/25/02/43769585/health-insurance-etfs-in-focus-as-rfk-jr-takes-over-hhs"><span class="sc-kQUZUP iZczKq post-title"><div class="sc-llvwKJ sc-duVdMk hHJzBM cerdRw line-wrapper three-line post-card-title leading-normal text-2xl"><span>Health Insurance ETFs in Focus as RFK Jr Takes Over HHS</span></div></span></a><div class="post-card-article-link flex items-center"><div class="sc-cVuPSX davtfT"></div></div></div></div></div></div></div><div class="newsfeed-card text-black"><div class="sc-kgTdLl conWOv post-card-wrapper"><div class="sc-eTGAKG fjcqMd post-card post-card-feed post-card-size-nano" title="Evolus Announces FDA Approval Of Evolysse Form And Evolysse Smooth Injectable Hyaluronic Acid Gels; First Major Technological Breakthrough In Hyaluronic Acid Dermal Fillers In A Decade; U.S. Launch Planned In Q2 2025"><a class="post-card-article-link post-card-image image-wrapper" href="https://www.benzinga.com/general/biotech/25/02/43706404/evolus-announces-fda-approval-of-evolysse-form-and-evolysse-smooth-injectable-hyaluronic-acid-gel"><span style="background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" class="sc-ecjqsm hkniJt post-thumb" decoding="async" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover"/><noscript><img alt="" sizes="(max-width: 800px) 120px, (min-width: 800px) 240px" src="/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260" srcSet="/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 16w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 32w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 48w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 64w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 96w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 128w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 256w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 384w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 640w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 750w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 828w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 1080w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 1200w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 1920w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 2048w, /next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=260 3840w" class="sc-ecjqsm hkniJt post-thumb" decoding="async" loading="lazy" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover"/></noscript></span></a><div class="post-card-text lg:w-auto flex flex-col space-y-2"><div class="post-card-text-wrapper"><a class="post-card-article-link" href="https://www.benzinga.com/general/biotech/25/02/43706404/evolus-announces-fda-approval-of-evolysse-form-and-evolysse-smooth-injectable-hyaluronic-acid-gel"><span class="sc-kQUZUP iZczKq post-title"><div class="sc-llvwKJ sc-duVdMk hHJzBM cerdRw line-wrapper three-line post-card-title leading-normal text-2xl"><span>Evolus Announces FDA Approval Of Evolysse Form And Evolysse Smooth Injectable Hyaluronic Acid Gels; First Major Technological Breakthrough In Hyaluronic Acid Dermal Fillers In A Decade; U.S. Launch Planned In Q2 2025</span></div></span></a><div class="post-card-article-link flex items-center"><div class="sc-cVuPSX davtfT"></div></div></div></div></div></div></div><div class="newsfeed-card text-black"><div class="sc-kgTdLl conWOv post-card-wrapper"><div class="sc-eTGAKG fjcqMd post-card post-card-feed post-card-size-nano" title="Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines"><a class="post-card-article-link post-card-image image-wrapper" href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines"><span style="background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:absolute;top:0;left:0;bottom:0;right:0"><div role="img" class="sc-dffbf6d7-0 eZzlKy"></div><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" class="sc-ecjqsm hkniJt post-thumb" decoding="async" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover;background-image:url("https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=100");background-position:0% 0%;background-size:cover;filter:blur(20px)"/><noscript><img alt="" sizes="(max-width: 800px) 120px, (min-width: 800px) 240px" src="https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260" srcSet="https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 16w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 32w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 48w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 64w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 96w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 128w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 256w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 384w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 640w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 750w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 828w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1080w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1200w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1920w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 2048w, https://cdn.benzinga.com/files/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=260 3840w" class="sc-ecjqsm hkniJt post-thumb" decoding="async" loading="lazy" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover"/></noscript></span></a><div class="post-card-text lg:w-auto flex flex-col space-y-2"><div class="post-card-text-wrapper"><a class="post-card-article-link" href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines"><span class="sc-kQUZUP iZczKq post-title"><div class="sc-llvwKJ sc-duVdMk hHJzBM cerdRw line-wrapper three-line post-card-title leading-normal text-2xl"><span>Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines</span></div></span></a><div class="post-card-article-link flex items-center"><div class="sc-cVuPSX davtfT"></div></div></div></div></div></div></div><div class="newsfeed-card text-black"><div class="sc-kgTdLl conWOv post-card-wrapper"><div class="sc-eTGAKG fjcqMd post-card post-card-feed post-card-size-nano" title="Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead"><a class="post-card-article-link post-card-image image-wrapper" href="https://www.benzinga.com/25/02/43502578/amgen-impresses-with-q4-earnings-beat-analysts-see-growth-ahead"><span style="background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:absolute;top:0;left:0;bottom:0;right:0"><div role="img" class="sc-dffbf6d7-0 hnOMtb"></div><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" class="sc-ecjqsm hkniJt post-thumb" decoding="async" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover;background-image:url("https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?width=100");background-position:0% 0%;background-size:cover;filter:blur(20px)"/><noscript><img alt="" sizes="(max-width: 800px) 120px, (min-width: 800px) 240px" src="https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260" srcSet="https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 16w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 32w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 48w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 64w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 96w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 128w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 256w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 384w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 640w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 750w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 828w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1080w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1200w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 1920w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 2048w, https://cdn.benzinga.com/files/images/story/2025/02/05/Amgen-stock.jpeg?optimize=medium&dpr=2&auto=webp&width=260 3840w" class="sc-ecjqsm hkniJt post-thumb" decoding="async" loading="lazy" style="border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:cover"/></noscript></span></a><div class="post-card-text lg:w-auto flex flex-col space-y-2"><div class="post-card-text-wrapper"><a class="post-card-article-link" href="https://www.benzinga.com/25/02/43502578/amgen-impresses-with-q4-earnings-beat-analysts-see-growth-ahead"><span class="sc-kQUZUP iZczKq post-title"><div class="sc-llvwKJ sc-duVdMk hHJzBM cerdRw line-wrapper three-line post-card-title leading-normal text-2xl"><span>Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead</span></div></span></a><div class="post-card-article-link flex items-center"><div class="sc-cVuPSX davtfT"></div></div></div></div></div></div></div><div class="feed-more-wrapper"><button class="load-more-button" tabindex="0">Load More <div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 512 512" xmlns="http://www.w3.org/2000/svg"><path d="M233.4 406.6c12.5 12.5 32.8 12.5 45.3 0l192-192c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L256 338.7 86.6 169.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l192 192z" fill="currentColor"></path></svg></div></button></div></div></div><div class="sc-isHgOQ jueBjR"><div class="sc-dVraiA jRvBse money-blocks-wrapper"><div></div><div></div><h2 class="block core-block" id="what-is-an-f-d-a-calendar">What is an FDA Calendar?</h2><p class="block core-block">Biotech investing is risk-fraught, as stocks are at the mercy of several catalysts – most of which are make-or-break events, aka binary events. A prudent investment strategy is to make informed decisions, being in the know of when to expect these events, how these events will pan out and the potential stock reaction in the run-up to the event and post the event.</p><p class="block core-block">Benzinga’s FDA calendar is a meaningfully designed, user friendly, dynamically updated and simplistic investment tool that is a ‘must-have’ for those looking to make money from the volatility that is typic of trading in biotech stocks.</p><p class="block core-block">The calendar lists down all key catalysts that can materially impact stocks, including:</p><ul class="block core-block"><li>PDUFA dates, or in other words FDA decision dates</li><li>Filing schedules for regulatory applications such as new drug application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc</li><li>FDA decisions (approvals/complete response letter/delay)</li><li>According to special statuses for treatment options, including orphan drug designation, rare disease designation, accelerated approval, priority review etc.</li><li>FDA’s Advisory Committee, or Adcom, meetings</li><li>Review meetings with FDA (pre-investigational new drug application meetings, end-of-phase meetings, Type A, Type B and Type C meetings)</li><li>Decisions by overseas regulatory agencies</li><li>Clinical data readouts</li><li>Presentation of data at various scientific conferences.</li></ul><p class="block core-block">The calendar allows data screening, based on company names or tickers, events, date-wise or based on a date range. They are designed to serve as a ‘one-stop shop’ for data needs of investors, both existing and potential, to capitalize on the opportunities these catalysts throw up or cut the losses from an adverse development. </p><h2 class="block core-block" id="what-is-a-catalyst">What is a Catalyst?</h2><p class="block core-block">A catalyst is any event/development that has the potential to swing the stock, usually in an appreciable way, in either direction, depending on how it materializes. </p><h2 class="block core-block" id="biotech-stock-movers"><strong>Biotech Stock Movers</strong></h2><p class="block core-block">Regulatory actions and clinical readouts are stock-moving catalysts. The magnitude of the impact is usually disproportionate. Most clinical-stage biotechs, or companies which are yet to commercialize a product, do not generate revenues. The exceptions are those which may have out-licensed therapies-in-development to another company and as a result generate revenues in the form of licensing revenues. So, it will be years of investment (time money and efforts) into drug development, which usually takes about 10-15 years, on the promise of generating future returns.</p><p class="block core-block">A promising outcome in a particular stage of drug development is perceived by the market as an incremental step in bringing the company closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.</p><p class="block core-block">Similarly, an unfavorable or a partially successful outcome could suggest all the investment the company may have made in the investigational therapy could go down the drain. Quite appropriately, investors punish the stock by selling it in droves.</p><p class="block core-block">PDUFA and Adcom events are binary events that have two outcomes, triggering moves in stock depending on which outcome materializes.</p><div class="my-6"><div class="sc-fvoJAe fXDUkc stock-movers-container default"><div class="header-container"><div class="sc-iiqfCt kvSldG styled-line"></div><h2>Stock Movers</h2><div class="sc-iiqfCt kvSldG styled-line"></div></div><div class="stock-movers-table-container full-width-table flex" id="full-width-movers-table"><div><header class="sc-eAQwYs eyWkLM tab"><div style="margin-right:2px"><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 320 512" xmlns="http://www.w3.org/2000/svg"><path d="M182.6 137.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-9.2 9.2-11.9 22.9-6.9 34.9s16.6 19.8 29.6 19.8H288c12.9 0 24.6-7.8 29.6-19.8s2.2-25.7-6.9-34.9l-128-128z" fill="currentColor"></path></svg></div><h3>Gainers</h3></header><div class="sc-bWtsZH dczzGV stock-movers-table"><div class="stock-movers-table-wrapper overflow-x-auto"><table><thead class="whitespace-nowrap"><tr><th class="ticker" colSpan="1">Ticker</th><th colSpan="2">Company</th><th class="close" colSpan="1"><button class="w-full">Close<div class="header-sort-icons"><span class="header-sort-icon header-sort-icon__up ">▲</span><span class="header-sort-icon header-sort-icon__down ">▼</span></div></button></th><th class="change-percent">±%</th><th class="average-volume" colSpan="1"><button>Avg. Vol<div class="header-sort-icons"><span class="header-sort-icon header-sort-icon__up ">▲</span><span class="header-sort-icon header-sort-icon__down ">▼</span></div></button></th><th class="buy-stock-table-header w-[60px] text-right" colSpan="1">Buy Stock</th></tr></thead><tbody class="no-results"><tr><td><div class="h-full w-full text-center p-4">Loading...</div></td></tr></tbody></table></div><a class="benzinga-pro-link" data-label="Get Real Time Movers" href="https://www.benzinga.com/go/benzinga-pro/">Get in real-time</a></div></div><div><header class="sc-eAQwYs jQnOJj tab"><div style="margin-right:2px"><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 320 512" xmlns="http://www.w3.org/2000/svg"><path d="M137.4 374.6c12.5 12.5 32.8 12.5 45.3 0l128-128c9.2-9.2 11.9-22.9 6.9-34.9s-16.6-19.8-29.6-19.8L32 192c-12.9 0-24.6 7.8-29.6 19.8s-2.2 25.7 6.9 34.9l128 128z" fill="currentColor"></path></svg></div><h3>Loser</h3></header><div class="sc-bWtsZH dczzGV stock-movers-table"><div class="stock-movers-table-wrapper overflow-x-auto"><table><thead class="whitespace-nowrap"><tr><th class="ticker" colSpan="1">Ticker</th><th colSpan="2">Company</th><th class="close" colSpan="1"><button class="w-full">Close<div class="header-sort-icons"><span class="header-sort-icon header-sort-icon__up ">▲</span><span class="header-sort-icon header-sort-icon__down ">▼</span></div></button></th><th class="change-percent">±%</th><th class="average-volume" colSpan="1"><button>Avg. Vol<div class="header-sort-icons"><span class="header-sort-icon header-sort-icon__up ">▲</span><span class="header-sort-icon header-sort-icon__down ">▼</span></div></button></th><th class="buy-stock-table-header w-[60px] text-right" colSpan="1">Buy Stock</th></tr></thead><tbody class="no-results"><tr><td><div class="h-full w-full text-center p-4">Loading...</div></td></tr></tbody></table></div><a class="benzinga-pro-link" data-label="Get Real Time Movers" href="https://www.benzinga.com/go/benzinga-pro/">Get in real-time</a></div></div></div></div></div><div class="lazyload-wrapper "><div class="min-h-[300px] md:min-h-[186px] my-4"><div class="w-full min-h-[inherit]"><div class="w-full h-full min-h-[inherit] flex items-center justify-center mx-auto rounded-md border border-gray-300 p-4 shadow"><div class="flex flex-col md:flex-row animate-pulse w-full gap-4"><div class="icon-wrapper flex items-center justify-center mx-6"><svg aria-hidden="true" class="w-16 h-16 text-gray-400" fill="currentColor" viewBox="0 0 640 512" xmlns="http://www.w3.org/2000/svg"><path d="M480 80C480 35.82 515.8 0 560 0C604.2 0 640 35.82 640 80C640 124.2 604.2 160 560 160C515.8 160 480 124.2 480 80zM0 456.1C0 445.6 2.964 435.3 8.551 426.4L225.3 81.01C231.9 70.42 243.5 64 256 64C268.5 64 280.1 70.42 286.8 81.01L412.7 281.7L460.9 202.7C464.1 196.1 472.2 192 480 192C487.8 192 495 196.1 499.1 202.7L631.1 419.1C636.9 428.6 640 439.7 640 450.9C640 484.6 612.6 512 578.9 512H55.91C25.03 512 .0006 486.1 .0006 456.1L0 456.1z"></path></svg></div><div class="paragraphs-wrapper w-full"><div class="flex-1 space-y-6 py-1"><div class="h-3 rounded bg-gray-300"></div><div class="space-y-3"><div class="grid grid-cols-3 gap-4"><div class="col-span-2 h-2 rounded bg-gray-300"></div><div class="col-span-1 h-2 rounded bg-gray-300"></div></div><div class="h-2 rounded bg-gray-300"></div><div class="h-2 rounded bg-gray-300"></div><div class="h-2 rounded bg-gray-300"></div></div></div></div></div></div></div></div></div><h2 class="block core-block" id="frequently-asked-questions">Frequently Asked Questions</h2><div class="sc-hHEtgg jkpSxH block"><div class="sc-cAgXCv faGBSq faq-container"><div class="sc-fZcocS kEIiVN faq-block"><div class="sc-ldxRAc dUmRRP qa-container"><div class="qa-header"><div class="qa-letter-icon">Q</div><h3 class="font-bold question">What is an FDA PDUFA date?</h3></div><div class="qa-body"><div class="qa-letter-icon">A</div><div class="answer-container"><p><span style="font-weight: 400;">Prescription Drug User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an ‘approved’ decision, or a ‘complete response letter’ or a delay due to reasons specific to the company or extraneous to the company.</span></p> <p><span style="font-weight: 400;">PDUFA was passed in the U.S. in 1992, which allows the FDA to collect fees from the sponsor company to fund the review process.</span></p> <p><span style="font-weight: 400;">A CRL is issued by the FDA when it deems that the regulatory application is not complete in its current form. The deficiencies usually that lead to rejection could be the need for additional clinical studies to establish the efficacy and/or safety of the treatment option, problems with chemistry, manufacturing and controls, etc.</span></p> <p><span style="font-weight: 400;">A delay in the review period may stem from the FDA needs additional time to review any additional data/information that may have been tabled subsequent to the submission of the regulatory application or the FDA’s inability to complete site inspections where the drug ingredients are being made etc.</span></p> <p><span style="font-weight: 400;">The FDA may mention a specific date or a period (say Q1, Q2, Q3, Q4, first-half, second-half, the name of the month) as the timeline by which a decision will be given. If the FDA does not mention any timeline, the company may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn’t provide a timeline either, it is left to the investors to do the calculations.</span></p> </div></div></div><div class="sc-ldxRAc dUmRRP qa-container"><div class="qa-header"><div class="qa-letter-icon">Q</div><h3 class="font-bold question">How long does an FDA approval take? </h3></div><div class="qa-body"><div class="qa-letter-icon">A</div><div class="answer-container"><p><span style="font-weight: 400;">A regulatory application (NDA, sNDA, BLA, sBLA, etc.) is usually accepted for standard review or priority review. A standard review will mean the FDA has to hand out its verdict within 10 months of filing the application. The review window for a priority review gets shortened to six months.</span></p> <p><span style="font-weight: 400;">Once a company files for a regulatory application, the FDA takes up to 60 days to respond with an ‘accepted for review’ or ‘refuse-to-file’ decision.</span></p> </div></div></div><div class="sc-ldxRAc dUmRRP qa-container"><div class="qa-header"><div class="qa-letter-icon">Q</div><h3 class="font-bold question">How do you find FDA approvals?</h3></div><div class="qa-body"><div class="qa-letter-icon">A</div><div class="answer-container"><p><span style="font-weight: 400;">A Catalysts Calendar is one way of tracking all the </span><span style="font-weight: 400;">decisions in a single place. Usually, the FDA puts out a release and/or communicates to the company, which in turn will issue a press release.</span></p> </div></div></div></div></div></div></div></div></div></div><div class="layout-sidebar-sticky-box"><div class="sc-hSWyVn brajqy layout-sidebar flex-none justify-between"><div class="lazyload-wrapper "><div class="lazyload-placeholder"></div></div></div></div></div></div></div></div></div><div class="footer"><div class="footer-top-section"><div class="benzinga-links-section"><div class="logo-and-socials-wrapper"><span class="sc-hTgaWy jNoPDg benzinga-logo light presentation"><svg height="100%" role="img" viewBox="0 0 471.1 63.8" width="100%" xmlns="http://www.w3.org/2000/svg"><path d="M67.7 63.8h45.2V51.9H81.4V37.3h26.1V25.4H81.4V11.9h31.7V0H67.7zm99.6-23.6L137.7 0h-20.4l6.4 8.1V64h13.6V22.1l30.6 41.7H181V0h-13.7zM47.1 31c6-1.1 11-6.7 11-14.6C58.1 7.9 51.9 0 39.6 0H0l6.2 7.9v56H41c12.3 0 18.7-7.7 18.7-17.3-.3-7.9-5.7-14.7-12.6-15.6zM19.8 12h17.1c4.6 0 7.5 2.7 7.5 6.7s-2.9 6.7-7.5 6.7H19.8V12zm17.7 40H19.8V37.3h17.7c5.2 0 8.1 3.3 8.1 7.3 0 4.6-3.1 7.3-8.1 7.4zm343.3-11.8h7.1v7.5c-3.7 3-8.3 4.7-13.1 4.8-11.4 0-19.4-8.7-19.4-20.4s8.1-20.4 19.4-20.4c5.9 0 11.4 3.1 14.6 8.1l10.8-6C395.6 6.5 387.5 0 374.7 0c-18.1 0-33.1 12.5-33.1 31.9s14.8 31.9 33.1 31.9c10 .2 19.5-4.1 26.1-11.5V28.7h-29.2l9.2 11.5zm-61.5 0L289.6 0h-20.3l6.3 8.1V64h13.7V22.1l30.6 41.7h13V0h-13.6zM446 0h-26.3l6.3 8.1-1.1 3.1L404.5 64h15.4l4-10.8h27.5l4 10.8h15.4L446 0zm-18.6 41.2l10-27.5 10 27.5h-20zM247.7 0h13.7v64.1h-13.7zm-10.9 11V0h-48.1v11.9h30.2l-30.2 41v10.9h48.6V51.9h-30.9z" fill="#FFFFFF"></path></svg></span><div class="social-sites-list"><a aria-label="Click to check out Benzinga's facebook" class="sc-ghbcbh kknTxh facebook" color="#3b5998" href="https://web.facebook.com/Benzinga/?_rdc=1&_rdr" target="_blank"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64h98.2V334.2H109.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H255V480H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64z" fill="currentColor"></path></svg></div></a><a aria-label="Click to check out Benzinga's instagram" class="sc-ghbcbh kSqUML instagram" color="#e1306c" href="https://www.instagram.com/benzinga/?hl=en" target="_blank"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M224.1 141c-63.6 0-114.9 51.3-114.9 114.9s51.3 114.9 114.9 114.9S339 319.5 339 255.9 287.7 141 224.1 141zm0 189.6c-41.1 0-74.7-33.5-74.7-74.7s33.5-74.7 74.7-74.7 74.7 33.5 74.7 74.7-33.6 74.7-74.7 74.7zm146.4-194.3c0 14.9-12 26.8-26.8 26.8-14.9 0-26.8-12-26.8-26.8s12-26.8 26.8-26.8 26.8 12 26.8 26.8zm76.1 27.2c-1.7-35.9-9.9-67.7-36.2-93.9-26.2-26.2-58-34.4-93.9-36.2-37-2.1-147.9-2.1-184.9 0-35.8 1.7-67.6 9.9-93.9 36.1s-34.4 58-36.2 93.9c-2.1 37-2.1 147.9 0 184.9 1.7 35.9 9.9 67.7 36.2 93.9s58 34.4 93.9 36.2c37 2.1 147.9 2.1 184.9 0 35.9-1.7 67.7-9.9 93.9-36.2 26.2-26.2 34.4-58 36.2-93.9 2.1-37 2.1-147.8 0-184.8zM398.8 388c-7.8 19.6-22.9 34.7-42.6 42.6-29.5 11.7-99.5 9-132.1 9s-102.7 2.6-132.1-9c-19.6-7.8-34.7-22.9-42.6-42.6-11.7-29.5-9-99.5-9-132.1s-2.6-102.7 9-132.1c7.8-19.6 22.9-34.7 42.6-42.6 29.5-11.7 99.5-9 132.1-9s102.7-2.6 132.1 9c19.6 7.8 34.7 22.9 42.6 42.6 11.7 29.5 9 99.5 9 132.1s2.7 102.7-9 132.1z" fill="currentColor"></path></svg></div></a><a aria-label="Click to check out Benzinga's linkedin" class="sc-ghbcbh gKRtMH linkedin" color="#0072b1" href="https://www.linkedin.com/company/benzinga" target="_blank"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z" fill="currentColor"></path></svg></div></a><a aria-label="Click to check out Benzinga's soundcloud" class="sc-ghbcbh cOuPIH soundcloud" color="#fe5000" href="https://soundcloud.com/bztv" target="_blank"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 640 512" xmlns="http://www.w3.org/2000/svg"><path d="M111.4 256.3l5.8 65-5.8 68.3c-.3 2.5-2.2 4.4-4.4 4.4s-4.2-1.9-4.2-4.4l-5.6-68.3 5.6-65c0-2.2 1.9-4.2 4.2-4.2 2.2 0 4.1 2 4.4 4.2zm21.4-45.6c-2.8 0-4.7 2.2-5 5l-5 105.6 5 68.3c.3 2.8 2.2 5 5 5 2.5 0 4.7-2.2 4.7-5l5.8-68.3-5.8-105.6c0-2.8-2.2-5-4.7-5zm25.5-24.1c-3.1 0-5.3 2.2-5.6 5.3l-4.4 130 4.4 67.8c.3 3.1 2.5 5.3 5.6 5.3 2.8 0 5.3-2.2 5.3-5.3l5.3-67.8-5.3-130c0-3.1-2.5-5.3-5.3-5.3zM7.2 283.2c-1.4 0-2.2 1.1-2.5 2.5L0 321.3l4.7 35c.3 1.4 1.1 2.5 2.5 2.5s2.2-1.1 2.5-2.5l5.6-35-5.6-35.6c-.3-1.4-1.1-2.5-2.5-2.5zm23.6-21.9c-1.4 0-2.5 1.1-2.5 2.5l-6.4 57.5 6.4 56.1c0 1.7 1.1 2.8 2.5 2.8s2.5-1.1 2.8-2.5l7.2-56.4-7.2-57.5c-.3-1.4-1.4-2.5-2.8-2.5zm25.3-11.4c-1.7 0-3.1 1.4-3.3 3.3L47 321.3l5.8 65.8c.3 1.7 1.7 3.1 3.3 3.1 1.7 0 3.1-1.4 3.1-3.1l6.9-65.8-6.9-68.1c0-1.9-1.4-3.3-3.1-3.3zm25.3-2.2c-1.9 0-3.6 1.4-3.6 3.6l-5.8 70 5.8 67.8c0 2.2 1.7 3.6 3.6 3.6s3.6-1.4 3.9-3.6l6.4-67.8-6.4-70c-.3-2.2-2-3.6-3.9-3.6zm241.4-110.9c-1.1-.8-2.8-1.4-4.2-1.4-2.2 0-4.2.8-5.6 1.9-1.9 1.7-3.1 4.2-3.3 6.7v.8l-3.3 176.7 1.7 32.5 1.7 31.7c.3 4.7 4.2 8.6 8.9 8.6s8.6-3.9 8.6-8.6l3.9-64.2-3.9-177.5c-.4-3-2-5.8-4.5-7.2zm-26.7 15.3c-1.4-.8-2.8-1.4-4.4-1.4s-3.1.6-4.4 1.4c-2.2 1.4-3.6 3.9-3.6 6.7l-.3 1.7-2.8 160.8s0 .3 3.1 65.6v.3c0 1.7.6 3.3 1.7 4.7 1.7 1.9 3.9 3.1 6.4 3.1 2.2 0 4.2-1.1 5.6-2.5 1.7-1.4 2.5-3.3 2.5-5.6l.3-6.7 3.1-58.6-3.3-162.8c-.3-2.8-1.7-5.3-3.9-6.7zm-111.4 22.5c-3.1 0-5.8 2.8-5.8 6.1l-4.4 140.6 4.4 67.2c.3 3.3 2.8 5.8 5.8 5.8 3.3 0 5.8-2.5 6.1-5.8l5-67.2-5-140.6c-.2-3.3-2.7-6.1-6.1-6.1zm376.7 62.8c-10.8 0-21.1 2.2-30.6 6.1-6.4-70.8-65.8-126.4-138.3-126.4-17.8 0-35 3.3-50.3 9.4-6.1 2.2-7.8 4.4-7.8 9.2v249.7c0 5 3.9 8.6 8.6 9.2h218.3c43.3 0 78.6-35 78.6-78.3.1-43.6-35.2-78.9-78.5-78.9zm-296.7-60.3c-4.2 0-7.5 3.3-7.8 7.8l-3.3 136.7 3.3 65.6c.3 4.2 3.6 7.5 7.8 7.5 4.2 0 7.5-3.3 7.5-7.5l3.9-65.6-3.9-136.7c-.3-4.5-3.3-7.8-7.5-7.8zm-53.6-7.8c-3.3 0-6.4 3.1-6.4 6.7l-3.9 145.3 3.9 66.9c.3 3.6 3.1 6.4 6.4 6.4 3.6 0 6.4-2.8 6.7-6.4l4.4-66.9-4.4-145.3c-.3-3.6-3.1-6.7-6.7-6.7zm26.7 3.4c-3.9 0-6.9 3.1-6.9 6.9L227 321.3l3.9 66.4c.3 3.9 3.1 6.9 6.9 6.9s6.9-3.1 6.9-6.9l4.2-66.4-4.2-141.7c0-3.9-3-6.9-6.9-6.9z" fill="currentColor"></path></svg></div></a><a aria-label="Click to check out Benzinga's twitter" class="sc-ghbcbh cOwugh twitter" color="#000000" href="https://twitter.com/benzinga" target="_blank"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zm297.1 84L257.3 234.6 379.4 396H283.8L209 298.1 123.3 396H75.8l111-126.9L69.7 116h98l67.7 89.5L313.6 116h47.5zM323.3 367.6L153.4 142.9H125.1L296.9 367.6h26.3z" fill="currentColor"></path></svg></div></a><a aria-label="Click to check out Benzinga's youtube" class="sc-ghbcbh gAbott youtube" color="red" href="https://www.youtube.com/benzinga" target="_blank"><div><svg aria-hidden="true" class="leading-none" stroke="currentColor" stroke-width="1" style="height:1em;width:1em" viewBox="0 0 576 512" xmlns="http://www.w3.org/2000/svg"><path d="M549.655 124.083c-6.281-23.65-24.787-42.276-48.284-48.597C458.781 64 288 64 288 64S117.22 64 74.629 75.486c-23.497 6.322-42.003 24.947-48.284 48.597-11.412 42.867-11.412 132.305-11.412 132.305s0 89.438 11.412 132.305c6.281 23.65 24.787 41.5 48.284 47.821C117.22 448 288 448 288 448s170.78 0 213.371-11.486c23.497-6.321 42.003-24.171 48.284-47.821 11.412-42.867 11.412-132.305 11.412-132.305s0-89.438-11.412-132.305zm-317.51 213.508V175.185l142.739 81.205-142.739 81.201z" fill="currentColor"></path></svg></div></a></div></div><div class="app-store-wrapper"><a aria-label="Click to download the Benzinga app" class="sc-jFWsBE byGBmO google-play-store-button-wrapper button-wrapper" data-action="Download on Google Play Store Click" href="https://play.google.com/store/apps/details?id=com.benzinga.app&hl=en_NZ&gl=US"><svg clip-rule="evenodd" fill-rule="evenodd" height="39px" stroke-linejoin="round" stroke-miterlimit="2" viewBox="0 0 120 36" width="130px" xmlns="http://www.w3.org/2000/svg"><path d="M2863.6 530.6c-36.3 0-66.9-12.7-91.1-37.7-24-24.3-37.4-57.8-36.8-92 0-36.5 12.4-67.4 36.8-91.9 24.1-25 54.7-37.7 91-37.7 35.9 0 66.5 12.7 91.1 37.7 24.4 25.3 36.8 56.2 36.8 91.9-.4 36.6-12.8 67.5-36.8 91.9-24.1 25.2-54.7 37.8-91 37.8zm-1080.1 0c-35.5 0-66.3-12.5-91.5-37.2-25-24.6-37.7-55.7-37.7-92.4s12.7-67.8 37.7-92.4c24.7-24.7 55.5-37.2 91.5-37.2a127.533 127.533 0 0151.1 10.6c16.1 6.9 29.2 16.3 38.9 27.8l2.4 2.9-27.1 26.6-2.8-3.3c-15.3-18.2-35.8-27.1-62.9-27.1-24.2 0-45.3 8.6-62.7 25.6-17.5 17.1-26.4 39.5-26.4 66.6 0 27.1 8.9 49.5 26.4 66.6 17.4 17 38.5 25.6 62.7 25.6 25.8 0 47.5-8.6 64.4-25.6 10-10 16.2-24 18.4-41.7H1779v-37.4h124.2l.5 3.4c.9 6.3 1.8 12.8 1.8 18.8 0 34.5-10.4 62.4-31 83-23.4 24.4-54 36.8-91 36.8zm1436.1-5.3h-38.3L3064 337.6l1 33.8v153.8h-38.3V276.7h43.7l1.2 1.9 110.3 176.8-1-33.7v-145h38.7v248.6zm-643.8 0H2537V314.1h-67.3v-37.4H2643v37.4h-67.3v211.2h.1zm-137.7 0h-38.7V276.7h38.7v248.6zm-217.5 0h-38.7V314.1h-67.3v-37.4h173.3v37.4h-67.3v211.2zm-130.5-.4h-148.4V276.7h148.4v37.4h-109.6v68.2h98.9v37h-98.9v68.2h109.6v37.4zm710.8-57.7c17.3 17.3 38.3 26 62.7 26 25.1 0 45.6-8.5 62.7-26 17-17 25.6-39.3 25.6-66.2 0-26.9-8.6-49.3-25.5-66.2-17.3-17.3-38.4-26-62.7-26-25.1 0-45.6 8.5-62.6 26-17 17-25.6 39.3-25.6 66.2 0 26.9 8.5 49.3 25.4 66.2zM2732.1 872.4c-94.5 0-171.1 71.7-171.1 170.6 0 98 77.1 170.6 171.1 170.6 94.5 0 171.1-72.2 171.1-170.6 0-98.9-76.6-170.6-171.1-170.6zm0 273.6c-51.7 0-96.2-42.8-96.2-103.4 0-61.5 44.6-103.4 96.2-103.4 51.7 0 96.2 41.9 96.2 103.4.1 61-44.5 103.4-96.2 103.4zm-373.3-273.6c-94.5 0-171.1 71.7-171.1 170.6 0 98 77.1 170.6 171.1 170.6 94.5 0 171.1-72.2 171.1-170.6 0-98.9-76.7-170.6-171.1-170.6zm0 273.6c-51.7 0-96.2-42.8-96.2-103.4 0-61.5 44.6-103.4 96.2-103.4 51.7 0 96.2 41.9 96.2 103.4 0 61-44.5 103.4-96.2 103.4zm-444.2-221.5v72.2h173.3c-5.3 40.5-18.7 70.4-39.2 90.9-25.4 25.4-64.6 53-133.7 53-106.5 0-189.8-86-189.8-192.5s83.3-192.5 189.8-192.5c57.5 0 99.4 22.7 130.5 51.7l51.2-51.2c-43.2-41.4-100.7-73.1-181.3-73.1-146.1 0-268.7 119-268.7 264.7 0 146.1 122.5 264.7 268.7 264.7 78.9 0 138.1-25.8 184.9-74.4 47.7-47.7 62.8-115 62.8-169.3 0-16.9-1.3-32.1-4-45h-244.6c.1-.1.1.8.1.8zm1816.9 56.2C3717.2 942.4 3674 872 3585.4 872c-87.8 0-160.8 69.1-160.8 170.6 0 95.8 72.2 170.6 169.3 170.6 78 0 123.4-47.7 142.1-75.7l-57.9-38.8c-19.2 28.5-45.9 47.2-83.8 47.2-38.3 0-65.1-17.4-82.9-51.7l228.1-94.5c0 .1-8-19-8-19zm-232.6 57c-1.8-65.9 51.2-99.4 89.1-99.4 29.9 0 54.8 14.7 63.3 36.1l-152.4 63.3zM3313.6 1203h74.9V701.8h-74.9V1203zm-123-292.7h-2.7c-16.9-20.1-49-38.3-90-38.3-85.1 0-163.5 74.9-163.5 171.1 0 95.8 78 169.8 163.5 169.8 40.5 0 73.1-18.3 90-38.8h2.7v24.5c0 65.1-34.8 100.2-90.9 100.2-45.9 0-74.4-33-86-60.6l-65.1 27.2c18.7 45 68.6 100.7 151 100.7 87.8 0 162.2-51.7 162.2-177.8V882.2H3191v28.1h-.4zm-86 235.7c-51.7 0-94.9-43.2-94.9-102.9 0-60.2 43.2-103.8 94.9-103.8 51.2 0 90.9 44.1 90.9 103.8.5 59.7-39.6 102.9-90.9 102.9zm977.6-444.2h-179.1V1203h74.9v-189.8h104.3c82.9 0 164.4-60.1 164.4-155.5s-81.2-155.9-164.5-155.9zm2.2 241.4h-106.5v-172h106.5c56.1 0 87.8 46.3 87.8 86 0 39.3-32.1 86-87.8 86zm462.5-71.7c-54.4 0-110.5 24.1-133.7 76.6l66.4 27.6c14.3-27.6 40.5-37 68.2-37 38.8 0 78 23.2 78.9 64.6v5.3c-13.4-7.6-42.8-19.2-78-19.2-71.7 0-144.4 39.2-144.4 112.7 0 67.3 58.8 110.5 124.3 110.5 50.3 0 78-22.7 95.3-49h2.7v38.8h72.2v-192c0-89.4-66.4-138.9-151.9-138.9zm-9.4 274.5c-24.5 0-58.8-12-58.8-42.8 0-38.8 42.8-53.5 79.3-53.5 33 0 48.6 7.1 68.2 16.9-5.4 45-43.4 79-88.7 79.4zm424.7-263.8l-86 217.4h-2.7l-89.1-217.4h-80.6l133.7 303.9-76.2 168.9h78L5045 882.2h-82.8zM4288 1203h74.9V701.8H4288V1203zM418.4 302.1c-11.6 12.5-18.3 31.6-18.3 56.6v886.7c0 25 6.7 44.1 18.7 56.1l3.1 2.7 496.8-496.8v-11.1L421.5 299.4l-3.1 2.7z" fill="#0C2140" fill-rule="nonzero" transform="scale(.02208)"></path><path d="M1084 973.5L918.3 807.8v-11.6L1084 630.5l3.6 2.2 196 111.4c56.1 31.6 56.1 83.8 0 115.8l-196 111.4-3.6 2.2z" fill="#0C2140" fill-rule="nonzero" transform="scale(.02208)"></path><path d="M1087.6 971.3L918.3 802l-499.9 499.9c18.3 19.6 49 21.8 83.3 2.7l585.9-333.3M1087.6 632.7L501.7 299.9c-34.3-19.6-65.1-16.9-83.3 2.7L918.3 802l169.3-169.3z" fill="#0C2140" fill-rule="nonzero" transform="scale(.02208)"></path></svg></a><a aria-label="Click to download the Benzinga app" class="sc-jFWsBE byGBmO apple-app-store-button-wrapper button-wrapper" data-action="Download on Apple App Store Click" href="https://apps.apple.com/us/app/benzinga-stock-news-tracker/id688949481"><svg fill="#0c2140" height="43.3px" stroke-linejoin="round" stroke-miterlimit="2" viewBox="0 0 120 40" width="130px" xmlns="http://www.w3.org/2000/svg"><path d="M24.997 19.889a5.15 5.15 0 012.45-4.317 5.27 5.27 0 00-4.15-2.244c-1.746-.183-3.439 1.045-4.329 1.045-.907 0-2.277-1.027-3.753-.997a5.534 5.534 0 00-4.651 2.837c-2.011 3.482-.511 8.6 1.416 11.414.963 1.378 2.09 2.918 3.564 2.863 1.442-.06 1.981-.919 3.722-.919 1.725 0 2.231.919 3.734.885 1.548-.026 2.523-1.385 3.453-2.776a11.366 11.366 0 001.579-3.216 4.98 4.98 0 01-3.035-4.575zm-2.841-8.412a5.066 5.066 0 001.159-3.63 5.153 5.153 0 00-3.335 1.726 4.82 4.82 0 00-1.19 3.495 4.265 4.265 0 003.366-1.591zM42.302 27.14h-4.734l-1.136 3.356h-2.005l4.483-12.418h2.083l4.484 12.418h-2.039l-1.136-3.356zm-4.243-1.549h3.752l-1.85-5.447h-.052l-1.85 5.447zm17.1.379c0 2.813-1.506 4.621-3.778 4.621a3.076 3.076 0 01-2.849-1.584h-.043v4.484h-1.858V21.442h1.799v1.506h.034a3.216 3.216 0 012.883-1.6c2.298 0 3.812 1.816 3.812 4.622zm-1.91 0c0-1.833-.947-3.038-2.393-3.038-1.419 0-2.375 1.23-2.375 3.038 0 1.824.956 3.046 2.375 3.046 1.446 0 2.393-1.197 2.393-3.046zm11.876 0c0 2.813-1.507 4.621-3.779 4.621a3.076 3.076 0 01-2.849-1.584h-.043v4.484h-1.858V21.442h1.799v1.506h.034a3.216 3.216 0 012.883-1.6c2.297 0 3.813 1.816 3.813 4.622zm-1.911 0c0-1.833-.947-3.038-2.393-3.038-1.42 0-2.375 1.23-2.375 3.038 0 1.824.955 3.046 2.375 3.046 1.446 0 2.393-1.197 2.393-3.046zm8.495 1.066c.138 1.232 1.334 2.04 2.969 2.04 1.567 0 2.694-.808 2.694-1.919 0-.964-.68-1.541-2.289-1.936l-1.61-.388c-2.28-.551-3.339-1.617-3.339-3.348 0-2.142 1.867-3.614 4.518-3.614 2.625 0 4.424 1.472 4.484 3.614H77.26c-.112-1.239-1.136-1.987-2.634-1.987s-2.521.757-2.521 1.858c0 .878.654 1.395 2.255 1.79l1.368.336c2.548.603 3.605 1.626 3.605 3.443 0 2.323-1.849 3.778-4.793 3.778-2.753 0-4.613-1.421-4.733-3.667h1.902zM83.346 19.3v2.142h1.722v1.472h-1.722v4.991c0 .776.345 1.137 1.102 1.137.204-.004.408-.018.611-.043v1.463c-.34.063-.686.092-1.032.086-1.833 0-2.548-.689-2.548-2.445v-5.189h-1.316v-1.472h1.316V19.3h1.867zm2.718 6.67c0-2.849 1.678-4.639 4.294-4.639 2.625 0 4.295 1.79 4.295 4.639 0 2.856-1.661 4.638-4.295 4.638s-4.294-1.782-4.294-4.638zm6.695 0c0-1.954-.895-3.108-2.401-3.108s-2.401 1.162-2.401 3.108c0 1.962.895 3.106 2.401 3.106s2.401-1.144 2.401-3.106zm3.426-4.528h1.773v1.541h.043a2.164 2.164 0 012.177-1.635c.214-.001.428.022.637.069v1.738a2.62 2.62 0 00-.835-.112l-.076-.002a1.883 1.883 0 00-1.873 1.873 1.87 1.87 0 00.012.212v5.37h-1.858v-9.054zm13.198 6.395c-.25 1.643-1.85 2.771-3.898 2.771-2.634 0-4.269-1.764-4.269-4.595 0-2.84 1.644-4.682 4.191-4.682 2.505 0 4.08 1.721 4.08 4.466v.637h-6.395v.112l-.009.208a2.37 2.37 0 002.358 2.358l.087-.002a2.05 2.05 0 002.091-1.273h1.764zm-6.282-2.702h4.526l.004-.121a2.19 2.19 0 00-2.177-2.178l-.047.001a2.306 2.306 0 00-2.306 2.292v.006zM37.826 8.731l.189-.007a2.653 2.653 0 012.64 2.64 2.63 2.63 0 01-.021.332c0 1.906-1.03 3.002-2.808 3.002h-2.155V8.731h2.155zm-1.228 5.123h1.125l.112.003a1.884 1.884 0 001.875-1.876 1.79 1.79 0 00-.02-.273c.012-.085.018-.17.018-.256a1.89 1.89 0 00-1.881-1.881l-.104.003h-1.125v4.28zm5.083-1.41a2.143 2.143 0 012.123-2.336c1.17 0 2.133.963 2.133 2.133l-.009.203.01.207c0 1.171-.963 2.134-2.134 2.134s-2.133-.963-2.133-2.134l.01-.207zm3.333 0c0-.976-.439-1.547-1.208-1.547s-1.207.571-1.207 1.547c0 .984.434 1.551 1.207 1.551s1.208-.571 1.208-1.551zm6.559 2.254h-.922l-.93-3.317h-.071l-.926 3.317h-.913l-1.242-4.503h.902l.806 3.436h.067l.926-3.436h.852l.926 3.436h.07l.803-3.436h.889l-1.237 4.503zm2.281-4.503h.855v.715h.066a1.35 1.35 0 011.344-.802l.11-.004a1.472 1.472 0 011.449 1.679v2.915h-.889v-2.692c0-.724-.314-1.084-.972-1.084l-.048-.001a1.04 1.04 0 00-1.033 1.033.98.98 0 00.006.109v2.635h-.888v-4.503zm5.24-1.758h.889v6.261h-.889zm2.124 4.007a2.144 2.144 0 012.124-2.336c1.171 0 2.133.963 2.133 2.133l-.01.203a2.05 2.05 0 01.01.207c0 1.17-.963 2.134-2.133 2.134s-2.134-.964-2.134-2.134l.01-.207zm3.333 0c0-.976-.439-1.547-1.208-1.547s-1.207.571-1.207 1.547c0 .984.434 1.551 1.207 1.551s1.208-.571 1.208-1.551zm1.85.98c0-.81.603-1.278 1.675-1.344l1.219-.07v-.389c0-.475-.314-.744-.921-.744-.497 0-.84.182-.939.5h-.86c.091-.773.818-1.269 1.84-1.269 1.128 0 1.765.562 1.765 1.513v3.077h-.855v-.633h-.071a1.52 1.52 0 01-1.352.707 1.33 1.33 0 01-.141.007c-.744 0-1.357-.61-1.36-1.355zm2.894-.384v-.377l-1.099.07c-.62.042-.902.253-.902.65 0 .405.352.641.835.641a.97.97 0 00.107.005c.556 0 1.022-.435 1.059-.989zm2.053-.596c0-1.423.732-2.324 1.869-2.324a1.486 1.486 0 011.381.79h.067V8.437h.888v6.261h-.851v-.712h-.071a1.565 1.565 0 01-1.414.786c-1.145 0-1.869-.901-1.869-2.328zm.918 0c0 .955.45 1.53 1.203 1.53s1.212-.583 1.212-1.526-.468-1.53-1.212-1.53-1.203.579-1.203 1.526zm6.964 0l-.01-.203c0-1.17.963-2.133 2.134-2.133s2.133.963 2.133 2.133l-.01.203a2.05 2.05 0 01.01.207c0 1.171-.963 2.134-2.133 2.134s-2.134-.963-2.134-2.134l.01-.207zm3.333 0c0-.976-.438-1.547-1.208-1.547s-1.207.571-1.207 1.547c0 .984.435 1.551 1.207 1.551s1.208-.571 1.208-1.551zm2.106-2.249h.856v.715h.066a1.35 1.35 0 011.344-.802l.11-.004a1.47 1.47 0 011.464 1.464c0 .072-.005.144-.015.215v2.915h-.889v-2.692c0-.724-.314-1.084-.972-1.084l-.048-.001a1.04 1.04 0 00-1.033 1.033.98.98 0 00.006.109v2.635h-.889v-4.503zm8.846-1.121v1.141h.976v.749h-.976v2.315c0 .472.194.679.637.679.113-.001.226-.008.339-.021v.74c-.16.029-.322.044-.484.046-.988 0-1.381-.348-1.381-1.216v-2.543h-.715v-.749h.715V9.074h.889zm2.19-.637h.88v2.481h.071c.241-.53.792-.853 1.373-.806l.08-.002a1.49 1.49 0 011.484 1.483c0 .066-.005.132-.013.198v2.907h-.89V12.01c0-.719-.335-1.084-.963-1.084l-.086-.003a1.06 1.06 0 00-1.052 1.052l.004.093v2.63h-.888V8.437zm9.056 5.045a1.833 1.833 0 01-1.951 1.303h-.054a2.055 2.055 0 01-2.026-2.325 2.086 2.086 0 012.058-2.352c1.271 0 2.027.856 2.027 2.27v.31h-3.18v.05a1.1 1.1 0 00-.004.1c0 .653.537 1.19 1.19 1.19a1.09 1.09 0 001.085-.546h.855zm-3.126-1.451h2.275l.003-.081c0-.596-.491-1.086-1.087-1.086h-.025a1.16 1.16 0 00-1.166 1.152v.015z"></path></svg></a></div></div><div class="sc-hwDNbq leyqvs footer-row"><div class="sc-cXiSS gMllDn"><h3>Popular Channels</h3><ul><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/premarket-prep/" class="sc-jIOndm fpmJRV">PreMarket Playbook</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/pressreleases" class="sc-jIOndm fpmJRV">Press Releases</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/analyst-stock-ratings" class="sc-jIOndm fpmJRV">Analyst Ratings</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/news" class="sc-jIOndm fpmJRV">News</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/markets/options" class="sc-jIOndm fpmJRV">Options</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/etfs" class="sc-jIOndm fpmJRV">ETFs</a></li></ul></div><div class="sc-cXiSS gMllDn"><h3>Tools & Features</h3><ul><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://pro.benzinga.com/" class="sc-jIOndm fpmJRV">Real Time Feed</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/feeds/list" class="sc-jIOndm fpmJRV">Public RSS Feeds</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/contact" class="sc-jIOndm fpmJRV">Submit News Tips</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://pro.benzinga.com/blog/" class="sc-jIOndm fpmJRV">Blog</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/widgets" class="sc-jIOndm fpmJRV">Embeddable Finance Widgets & Tools</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/catalyst" class="sc-jIOndm fpmJRV">Benzinga Catalyst</a></li></ul></div><div class="sc-cXiSS gMllDn"><h3>Partners & Contributors</h3><ul><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://app.impact.com/campaign-promo-signup/Benzinga1659111587301.brand?execution=e1s1" class="sc-jIOndm fpmJRV">Affiliate Program</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://contributor.benzinga.com/contributor-onboarding" class="sc-jIOndm fpmJRV">Contributor Portal</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/apis/" class="sc-jIOndm fpmJRV">Licensing & Syndication</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/reach/" class="sc-jIOndm fpmJRV">Sponsored Content</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://advertise.benzinga.com/" class="sc-jIOndm fpmJRV">Advertise With Us</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/contact/" class="sc-jIOndm fpmJRV">Lead Generation & SEO</a></li></ul></div><div class="sc-cXiSS gMllDn"><h3>About Benzinga</h3><ul><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/about" class="sc-jIOndm fpmJRV">About Us</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://jobs.benzinga.com/" class="sc-jIOndm fpmJRV">Careers</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/inthenews" class="sc-jIOndm fpmJRV">In The News</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/events/" class="sc-jIOndm fpmJRV">Events</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/contact" class="sc-jIOndm fpmJRV">Contact Us</a></li></ul></div></div></div><div class="footer-bottom-section"><ul><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/terms-and-conditions" class="sc-jIOndm fpmJRV">Terms & Conditions </a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/page/privacy" class="sc-jIOndm fpmJRV"> Do Not Sell My Personal Data/Privacy Policy</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/disclaimer" class="sc-jIOndm fpmJRV">Disclaimer </a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="http://www.benzingastatus.com" class="sc-jIOndm fpmJRV">Service Status</a></li><li class="sc-gjSWCP bZeEIF footer-link"><a href="https://www.benzinga.com/sitemap" class="sc-jIOndm fpmJRV">Sitemap</a></li></ul><div class="copyright-section text-center w-full whitespace-nowrap mt-2">© 2025 Benzinga | All Rights Reserved</div></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"calendarDataSet":[{"commentary":"","companies":[{"cik":"1693011","id":"603cef7fb9e30d0001890185","name":"Inozyme Pharma Inc","securities":[{"exchange":"NASDAQ","symbol":"INZY"}]}],"created":1740146206,"date":"2025-02-21","drug":{"generic":false,"id":"60f8061e48f06700014e16b8","indication_symptom":["ABCC6 Deficiency"],"name":"INZ-701"},"event_type":"Data Presentation","id":"67b8861eb1c67f0001388a08","nic_number":"","notes":"","outcome":"Inozyme Pharma, Inc. announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company's Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43879886/inozyme-pharma-to-present-recently-announced-interim-data-for-inz-701-in-infants-and-young-childre","source_type":"Press Release","status":"","target_date":"","time":"08:56:46","updated":1740146284},{"commentary":"","companies":[{"cik":"","id":"6537b7a40d10db0001eb3939","name":"NKGen Biotech Inc","securities":[]}],"created":1740143583,"date":"2025-02-21","drug":{"generic":false,"id":"64f6d01badd8280001ff4e92","indication_symptom":["To Treat Alzheimer's Disease"],"name":"troculeucel (SNK01)"},"event_type":"Provided Update","id":"67b87bdfb156400001bf6584","nic_number":"","notes":"","outcome":"NKGen Biotech, Inc. announced the administration of troculeucel, an expanded autologous NK cell therapy, in an FTD patient under a single compassionate use, Investigational New Drug (\"IND\") cleared by the U.S. Food and Drug Administration (\"FDA\").","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43879052/nkgen-biotech-announces-administration-of-first-dose-of-troculeucel-to-frontotemporal-dementia-pat","source_type":"Press Release","status":"","target_date":"","time":"08:13:03","updated":1740143631},{"commentary":"","companies":[{"cik":"1727196","id":"603cef7eb9e30d000188fc93","name":"Scholar Rock Holding Corp","securities":[{"exchange":"NASDAQ","symbol":"SRRK"}]}],"created":1740143472,"date":"2025-02-21","drug":{"generic":false,"id":"606c60a46538960001890f39","indication_symptom":["Type 2 and Type 3 Spinal Muscular Atrophy (SMA)"],"name":"Apitegromab"},"event_type":"Additional data","id":"67b87b70b156400001bf6562","nic_number":"","notes":"","outcome":"Scholar Rock announced that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical \u0026 Scientific Conference being held March 16-19 in Dallas, Texas.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43879076/scholar-rock-to-present-additional-clinical-data-from-the-phase-3-sapphire-trial-at-the-2025-muscu","source_type":"Press Release","status":"Phase 3","target_date":"","time":"08:11:12","updated":1740143572},{"commentary":"","companies":[{"cik":"1348911","id":"603cef7eb9e30d000188f64d","name":"KalVista Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"KALV"}]}],"created":1740141222,"date":"2025-02-21","drug":{"generic":false,"id":"65522310a54dc20001b24526","indication_symptom":["Therapy for hereditary angioedema (HAE)."],"name":"sebetralstat"},"event_type":"Abstract","id":"67b872a6b1c67f00013888a4","nic_number":"","notes":"","outcome":"KalVista Pharmaceuticals, Inc. announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma \u0026 Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43878005/kalvista-pharmaceuticals-to-present-new-sebetralstat-data-at-the-american-academy-of-allergy-asthm","source_type":"Press Release","status":"","target_date":"","time":"07:33:42","updated":1740141265},{"commentary":"","companies":[{"cik":"200406","id":"603cef79b9e30d000188c04b","name":"Johnson \u0026 Johnson","securities":[{"exchange":"NYSE","symbol":"JNJ"}]}],"created":1740141143,"date":"2025-02-21","drug":{"generic":false,"id":"65f15d2e9acba600013a34e7","indication_symptom":["For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis"],"name":"Guselkumab"},"event_type":"Data","id":"67b87257b1c67f000138888e","nic_number":"","notes":"","outcome":"Johnson \u0026 Johnson announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC) at the 20th Congress of the European Crohn's and Colitis Organization (ECCO).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43878014/tremfya-guselkumab-subcutaneous-sc-induction-data-support-potential-to-be-the-first-and-only-in-it","source_type":"Press Release","status":"Phase 3","target_date":"","time":"07:32:23","updated":1740141198},{"commentary":"","companies":[{"cik":"1735438","id":"603cef7eb9e30d000188fcb8","name":"MeiraGTx Holdings PLC","securities":[{"exchange":"NASDAQ","symbol":"MGTX"}]}],"created":1740140913,"date":"2025-02-21","drug":{"generic":false,"id":"67b5d6d1dcc94e0001195706","indication_symptom":["For the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy"],"name":"rAAV8.hRKp.AIPL1"},"event_type":"Published Results","id":"67b87171b1c67f0001388860","nic_number":"","notes":"","outcome":"MeiraGTx Holdings plc announced the publication of results from the first-in-human interventional study to treat children with AIPL1-associated severe retinal dystrophy.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43877513/meiragtx-announces-the-lancet-publication-of-data-demonstrating-the-efficacy-of-raav8-hrkp-aipl1-f","source_type":"Press Release","status":"","target_date":"","time":"07:28:33","updated":1740141123},{"commentary":"","companies":[{"cik":"","id":"6527c12b7f1949000153cd6d","name":"Alvotech","securities":[]}],"created":1740140790,"date":"2025-02-21","drug":{"generic":false,"id":"661d203aed9ebb000171839e","indication_symptom":["For the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis"],"name":"SELARSDI"},"event_type":"Provided Update","id":"67b870f6b1c67f000138884e","nic_number":"","notes":"","outcome":"Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd and Alvotech announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43877004/teva-and-alvotech-announce-selarsdi-ustekinumab-aekn-injection-now-available-in-the-u-s","source_type":"Press Release","status":"","target_date":"","time":"07:26:30","updated":1740140859},{"commentary":"","companies":[{"cik":"","id":"62ac78209c3cd10001136787","name":"Kazia Therapeutics Limited","securities":[{"exchange":"NASDAQ","symbol":"KZIA"}]}],"created":1740129683,"date":"2025-02-20","drug":{"generic":false,"id":"62ac783fb9d3b000013dda48","indication_symptom":["Atypical rhabdoid / teratoid tumors (AT/RT)"," a rare and highly-aggressive childhood brain cancer"],"name":"Paxalisib"},"event_type":"Provided Update","id":"67b845932b94b70001fa2917","nic_number":"","notes":"","outcome":"Kazia Therapeutics Limited announced a research grant awarded from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson's disease (PD).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43847398/kazia-therapeutics-and-the-hebrew-university-of-jerusalem-receives-a-grant-from-the-michael-j-fox-","source_type":"Press Release","status":"","target_date":"","time":"04:21:23","updated":1740129729},{"commentary":"","companies":[{"cik":"1285819","id":"603cef7bb9e30d000188d970","name":"Omeros Corp","securities":[{"exchange":"NASDAQ","symbol":"OMER"}]}],"created":1740129594,"date":"2025-02-20","drug":{"generic":false,"id":"6045f55fe74cfd0001ed6961","indication_symptom":["Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)"],"name":"Narsoplimab"},"event_type":"Results","id":"67b8453a2b94b70001fa28b9","nic_number":"","notes":"","outcome":"Omeros Corporation announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43848477/omeros-announces-robust-results-for-narsoplimab-expanded-access-program-in-ta-tma","source_type":"Press Release","status":"","target_date":"","time":"04:19:54","updated":1740129645},{"commentary":"","companies":[{"cik":"882095","id":"603cef78b9e30d000188b89f","name":"Gilead Sciences Inc","securities":[{"exchange":"NASDAQ","symbol":"GILD"}]}],"created":1740129351,"date":"2025-02-20","drug":{"generic":false,"id":"64ec7d0031f02c000175ebc2","indication_symptom":["For the Treatment of Primary Biliary Cholangitis Including Pruritus"],"name":"seladelpar"},"event_type":"Marketing authorization","id":"67b844472b94b70001fa279f","nic_number":"","notes":"","outcome":"Gilead Sciences, Inc announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43867280/gileads-seladelpar-granted-conditional-european-marketing-authorization-for-the-treatment-of-prima","source_type":"Press Release","status":"","target_date":"","time":"04:15:51","updated":1740129561},{"commentary":"","companies":[{"cik":"1526119","id":"603cef7db9e30d000188ef9f","name":"Verastem Inc","securities":[{"exchange":"NASDAQ","symbol":"VSTM"}]}],"created":1740129259,"date":"2025-02-20","drug":{"generic":false,"id":"647048eaf3e2a000012587fb","indication_symptom":["Vutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC)."],"name":"RAMP 201"},"event_type":"Oral presentation","id":"67b843eb2b94b70001fa2752","nic_number":"","notes":"","outcome":"Verastem Oncology announced multiple oral and poster presentations, including an oral presentation of additional analyses from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial evaluating the investigational combination of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer, to be held on March 14-17 in Seattle, Washington.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43865665/verastem-oncology-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-an","source_type":"Press Release","status":"","target_date":"","time":"04:14:19","updated":1740129328},{"commentary":"","companies":[{"cik":"","id":"65200c923b3e38000193adc8","name":"ARS Pharmaceuticals Inc","securities":[]}],"created":1740129192,"date":"2025-02-20","drug":{"generic":false,"id":"66dfe71e6d02590001c90a27","indication_symptom":[" For Pediatric Patients with Type I Allergic Reactions"],"name":"neffy"},"event_type":"Provided Update","id":"67b843a82b94b70001fa26f2","nic_number":"","notes":"","outcome":"ARS Pharmaceuticals, Inc. announced that Cigna Healthcare, Navitus Health Systems and OptumRx, through their Group Purchasing Organization (GPO) Emisar, have added neffy® (epinephrine nasal spray) to their National Formularies.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43871199/ars-pharmaceuticals-announces-optumrx-cigna-healthcare-and-navitus-health-systems-add-neffy-epinep","source_type":"Press Release","status":"","target_date":"","time":"04:13:12","updated":1740129244},{"commentary":"","companies":[{"cik":"1680367","id":"603cef7fb9e30d0001890273","name":"Shattuck Labs Inc","securities":[{"exchange":"NASDAQ","symbol":"STTK"}]}],"created":1740060411,"date":"2025-02-20","drug":{"generic":false,"id":"66fa7e97c2ed5b00011d59d9","indication_symptom":["In inflammatory bowel disease"],"name":"SL-325"},"event_type":"Positive Data","id":"67b736fbdcc94e000119a387","nic_number":"","notes":"","outcome":"Shattuck Labs announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325 in non-human primates (NHP).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43847993/shattuck-labs-announces-positive-data-from-the-preclinical-glp-toxicology-study-of-sl-325-at-the-2","source_type":"Press Release","status":"","target_date":"","time":"09:06:51","updated":1740060487},{"commentary":"","companies":[{"cik":"1390478","id":"603cef7bb9e30d000188da03","name":"SELLAS Life Sciences Group Inc","securities":[{"exchange":"NASDAQ","symbol":"SLS"}]}],"created":1740060017,"date":"2025-02-20","drug":{"generic":false,"id":"651d470508e89000019cfd7a","indication_symptom":[" For Treatment of Acute Myeloid Leukemia"],"name":"SLS009"},"event_type":"Positive Data","id":"67b73571dcc94e000119a306","nic_number":"","notes":"","outcome":"SELLAS Life Sciences Group, announced data from Phase 2a trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43847362/sellas-announces-positive-data-from-phase-2a-trial-of-sls009-in-combination-with-zanubrutinib-in-d","source_type":"Press Release","status":"Phase 2a","target_date":"","time":"09:00:17","updated":1740060071},{"commentary":"","companies":[{"cik":"","id":"603cef79b9e30d000188c56c","name":"BioRestorative Therapies Inc","securities":[]}],"created":1740058599,"date":"2025-02-20","drug":{"generic":false,"id":"62019623e008470001d6fdb0","indication_symptom":["Chronic Lumbar Disc Disease"],"name":"BRTX-100"},"event_type":"Designation Grant","id":"67b72fe7b1c67f0001383566","nic_number":"","notes":"","outcome":"BioRestorative Therapies, announced that the U.S. Food and Drug Administration (\"FDA\") has granted Fast Track designation to the BRTX-100 program for the treatment chronic lumbar disc disease (\"cLDD\").","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43846927/biorestorative-receives-fda-fast-track-designation-for-brtx-100-chronic-lumbar-disc-disease-progra","source_type":"Press Release","status":"Fast Track Designation","target_date":"","time":"08:36:39","updated":1740058646},{"commentary":"","companies":[{"cik":"1531048","id":"603cef7eb9e30d00018900ab","name":"Inari Medical Inc","securities":[{"exchange":"NASDAQ","symbol":"NARI"}]},{"cik":"1401040","id":"603cef7ab9e30d000188d362","name":"DiaMedica Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"DMAC"}]}],"created":1740057424,"date":"2025-02-20","drug":{"generic":false,"id":"606b6881653896000188ff1c","indication_symptom":["Chronic Kidney Disease Stage II or III"],"name":"DM199"},"event_type":"Publication","id":"67b72b50b1c67f0001383481","nic_number":"","notes":"","outcome":"DiaMedica Therapeutics Inc announced the peer-reviewed publication entitled:Recombinant human tissue kallikrein-1 for treating acute ischemic stroke and preventing recurrence (Kasner, et al.) which is now available online and is scheduled for print publication in the February 2025 issue of Stroke.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43846390/diamedica-therapeutics-announces-publication-of-dm199s-mechanism-of-action-for-the-treatment-of-ac","source_type":"Press Release","status":"","target_date":"","time":"08:17:04","updated":1740057463},{"commentary":"","companies":[{"cik":"1426800","id":"603cef7cb9e30d000188eac8","name":"Assembly Biosciences Inc","securities":[{"exchange":"NASDAQ","symbol":"ASMB"}]}],"created":1740057263,"date":"2025-02-20","drug":{"generic":false,"id":"67b5d6d1dcc94e0001195708","indication_symptom":["For Recurrent Genital Herpes"],"name":"ABI-1179"},"event_type":"Positive Results","id":"67b72aafb1c67f0001383456","nic_number":"","notes":"","outcome":"Assembly Biosciences, Inc announced positive interim Phase 1a results in healthy participants from its ongoing Phase 1a/b study of ABI-1179, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate for recurrent genital herpes.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43845782/assembly-biosciences-reports-positive-interim-phase-1a-results-from-clinical-trial-evaluating-long","source_type":"Press Release","status":"Phase 1a","target_date":"","time":"08:14:23","updated":1740057384},{"commentary":"","companies":[{"cik":"725363","id":"603cef78b9e30d000188b722","name":"CEL-SCI Corp","securities":[{"exchange":"AMEX","symbol":"CVM"}]}],"created":1740057171,"date":"2025-02-20","drug":{"generic":false,"id":"60dc70dd74f1490001e1d7c0","indication_symptom":["Head and Neck Cancer"],"name":"Multikine"},"event_type":"Provided Update","id":"67b72a53b1c67f0001383434","nic_number":"","notes":"","outcome":"CEL-SCI Corporation announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte Interleukin, Injection) in newly diagnosed locally advanced head and neck cancer patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43845803/cel-sci-to-initiate-multikine-confirmatory-phase-3-cancer-trial","source_type":"Press Release","status":"","target_date":"","time":"08:12:51","updated":1740057247},{"commentary":"","companies":[{"cik":"725363","id":"603cef78b9e30d000188b722","name":"CEL-SCI Corp","securities":[{"exchange":"AMEX","symbol":"CVM"}]}],"created":1740057194,"date":"2025-02-20","drug":{"generic":false,"id":"60dc70dd74f1490001e1d7c0","indication_symptom":["Head and Neck Cancer"],"name":"Multikine"},"event_type":"Enrollment Update","id":"67b72a6ab1c67f000138343e","nic_number":"","notes":"","outcome":"CEL-SCI Corporation announced that Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor responses—Potential to set a new standard of care","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43845803/cel-sci-to-initiate-multikine-confirmatory-phase-3-cancer-trial","source_type":"Press Release","status":"","target_date":"2026-Q2","time":"08:13:14","updated":1740057246},{"commentary":"","companies":[{"cik":"1551152","id":"603cef7db9e30d000188f1b8","name":"AbbVie Inc","securities":[{"exchange":"NYSE","symbol":"ABBV"}]},{"cik":"1434265","id":"603cef7bb9e30d000188d89b","name":"Genmab A/S","securities":[{"exchange":"NASDAQ","symbol":"GMAB"},{"exchange":"OTC","symbol":"GNMSF"}]}],"created":1740057039,"date":"2025-02-20","drug":{"generic":false,"id":"667c84c55b3ba10001e4ab71","indication_symptom":["To Treat Patients with Relapsed or Refractory Follicular Lymphoma"],"name":"EPKINLY® (epcoritamab-bysp)"},"event_type":"Approved","id":"67b729cfb1c67f0001383421","nic_number":"","notes":"","outcome":"Genmab A/S that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY® (epcoritamab) for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL; Grades 1 to 3A) who have received two or more prior lines of therapy.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43845764/epkinly-epcoritamab-approved-by-japan-ministry-of-health-labour-and-welfare-for-additional-indicat","source_type":"Press Release","status":"Japanese Ministry of Health, Labour and Welfare (MHLW) Approval","target_date":"","time":"08:10:39","updated":1740057097},{"commentary":"","companies":[{"cik":"","id":"622a47f8cc9cd90001f8ede8","name":"Cognition Therapeutics, Inc.","securities":[{"exchange":"NASDAQ","symbol":"CGTX"}]}],"created":1740055216,"date":"2025-02-20","drug":{"generic":false,"id":"64a55e8f1d538a0001e7473b","indication_symptom":["Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex. "],"name":"CT1812"},"event_type":"Publication","id":"67b722b0b1c67f000138335e","nic_number":"","notes":"","outcome":"Cognition Therapeutics, announced that the American Chemical Society journal Organic Process Research \u0026 Development has published a manuscript describing the novel chemical process used to manufacture zervimesine (CT1812).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43844798/cognition-therapeutics-announces-publication-of-commercial-manufacturing-process-for-lead-alzheime","source_type":"Press Release","status":"","target_date":"","time":"07:40:16","updated":1740055279},{"commentary":"","companies":[{"cik":"1280776","id":"603cef7db9e30d000188f32f","name":"Immunic Inc","securities":[{"exchange":"NASDAQ","symbol":"IMUX"}]}],"created":1740055136,"date":"2025-02-20","drug":{"generic":false,"id":"6273bbb11c5f2e0001b8cf0d","indication_symptom":["Celiac disease"],"name":"IMU-856"},"event_type":"Provided Update","id":"67b72260b1c67f000138334d","nic_number":"","notes":"","outcome":"Immunic, Inc announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels in a post hoc analysis of patients from its phase 1b clinical trial in celiac disease.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43844817/immunics-oral-imu-856-demonstrated-dose-dependent-increase-of-glp-1-in-celiac-disease-patients-and","source_type":"Press Release","status":"","target_date":"","time":"07:38:56","updated":1740055201},{"commentary":"","companies":[{"cik":"882361","id":"603cef78b9e30d000188b93f","name":"Aptose Biosciences Inc","securities":[{"exchange":"TSE","symbol":"APS"},{"exchange":"NASDAQ","symbol":"APTO"}]}],"created":1740054930,"date":"2025-02-20","drug":{"generic":false,"id":"6482dc38fdfac50001750d1b","indication_symptom":["Tuspetinib is a potent inhibitor of FLT3"," SYK"," cKITMUT"," JAK"," and other kinases"],"name":"tuspetinib"},"event_type":"Approved","id":"67b72192b1c67f000138331e","nic_number":"","notes":"","outcome":"Aptose Biosciences Inc announced that the Cohort Safety Review Committee (CSRC) monitoring Aptose's Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has unanimously approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43844887/aptose-announces-positive-clinical-safety-review-committee-csrc-approval-to-dose-escalate-in-phase","source_type":"Press Release","status":"Cohort Safety Review Committee (CSRC)","target_date":"","time":"07:35:30","updated":1740055115},{"commentary":"","companies":[{"cik":"1539029","id":"603cef7eb9e30d000188f856","name":"Clearside Biomedical Inc","securities":[{"exchange":"NASDAQ","symbol":"CLSD"}]}],"created":1740053616,"date":"2025-02-20","drug":{"generic":false,"id":"6790e0bff0774b0001ecf9b0","indication_symptom":["Treatment for Uveitic Macular Edema in Australia and Singapore"],"name":"ARCATUS"},"event_type":"Provided Update","id":"67b71c70b1c67f00013831dd","nic_number":"","notes":"","outcome":"Clearside Biomedical, reported that Arctic Vision's New Drug Application (NDA) for ARCATUS® for the treatment of uveitic macular edema (UME) has been formally accepted for review by the Center for Drug Evaluation of China National Medical Products Administration.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43843966/clearside-biomedicals-asia-pacific-partner-arctic-vision-announced-acceptance-of-its-new-drug-appl","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"","time":"07:13:36","updated":1740054369},{"commentary":"","companies":[{"cik":"874015","id":"603cef79b9e30d000188c028","name":"Ionis Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"IONS"}]}],"created":1740053537,"date":"2025-02-20","drug":{"generic":false,"id":"6196ba6dca1b160001c07b9d","indication_symptom":["Hereditary angioedema (HAE)"],"name":"Donidalorsen (formerly IONIS-PKK-LRx)"},"event_type":"Additional data","id":"67b71c21b1c67f00013831c5","nic_number":"","notes":"","outcome":"Ionis Pharmaceuticals, Inc. announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43843754/new-positive-donidalorsen-data-to-be-presented-at-aaaaiwao-joint-congress-highlight-sustained-hae-","source_type":"Press Release","status":"Phase 3","target_date":"","time":"07:12:17","updated":1740053589},{"commentary":"","companies":[{"cik":"","id":"65804e1dde13e400018dc318","name":"Unicycive Therapeutics, Inc","securities":[]}],"created":1740053469,"date":"2025-02-20","drug":{"generic":false,"id":"65804de03d5b9b0001c0a24f","indication_symptom":["In Patients with Chronic Kidney Disease on Dialysis"],"name":"Oxylanthanum Carbonate"},"event_type":"Data Publication","id":"67b71bddb1c67f00013831b5","nic_number":"","notes":"","outcome":"Unicycive Therapeutics, announced the publication of preclinical data describing the benefits of combination treatment of oxylanthanum carbonate (OLC) and tenapanor on phosphate management in the American Society of Nephrology (ASN) journal, Kidney360.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43843748/unicycive-therapeutics-announces-the-publication-of-preclinical-data-on-synergies-between-oxylanth","source_type":"Press Release","status":"","target_date":"","time":"07:11:09","updated":1740053510},{"commentary":"","companies":[{"cik":"1585608","id":"603cef7db9e30d000188f588","name":"Jaguar Health Inc","securities":[{"exchange":"NASDAQ","symbol":"JAGX"}]}],"created":1739974184,"date":"2025-02-19","drug":{"generic":false,"id":"63054e00e4a8c5000194ce26","indication_symptom":["Microvillus inclusion disease (MVID) - Rare congenital diarrheal disorder"],"name":"Crofelemer"},"event_type":"Provided Update","id":"67b5e628dcc94e0001195ac9","nic_number":"","notes":"","outcome":"Jaguar Health, announced that the clinical protocol for Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for the indication of SBS-IF in adults has received regulatory clearance from health authorities in Italy and Germany, where the trial will be conducted.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43812310/jaguar-receives-regulatory-clearance-in-germany-and-italy-for-crofelemer-for-rare-disease-study-s","source_type":"Press Release","status":"Phase 2","target_date":"","time":"09:09:44","updated":1739974301},{"commentary":"","companies":[{"cik":"","id":"65d4b05afd3dd800013d8691","name":"enVVeno Medical Corporation","securities":[]},{"cik":"1661053","id":"603cef7eb9e30d000188fb40","name":"Hancock Jaffe Laboratories Inc","securities":[{"exchange":"NASDAQ","symbol":"HJLI"}]}],"created":1739973111,"date":"2025-02-19","drug":{"generic":false,"id":"60468aafe74cfd00012cae05","indication_symptom":["Chronic Venous Insufficiency (CVI)"],"name":"VenoValve"},"event_type":"Provided Update","id":"67b5e1f7dcc94e00011959f7","nic_number":"","notes":"","outcome":"enVVeno Medical announced that one-year follow-up data on 75 subjects from the VenoValve U.S. pivotal trial will be presented by Dr. Cassius Iyad Ochoa Chaar, Associate Professor Surgery, Yale School of Medicine, Division of Vascular and Endovascular Surgery, Principal Investigator, and lead enroller for the trial, at the 37th Annual Meeting of the American Venous Forum (VENOUS2025) being held February 16-19, 2025 in Atlanta, GA. The presentation is scheduled for today at 9:47 AM ET.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43811597/one-year-data-from-the-venovalve-r-u-s-pivotal-trial-highlighting-impact-on-patients-quality-of-l","source_type":"Press Release","status":"","target_date":"","time":"08:51:51","updated":1739973165},{"commentary":"","companies":[{"cik":"","id":"65310876c697190001dd8b9c","name":"IMUNON Inc","securities":[]}],"created":1739971594,"date":"2025-02-19","drug":{"generic":false,"id":"64c0cdbc9c212e0001522246","indication_symptom":["For ovarian cancer"],"name":"IMNN-001"},"event_type":"New Data","id":"67b5dc0adcc94e00011958bf","nic_number":"","notes":"","outcome":"IMUNON, Inc. announced new translational data from ongoing analyses of results from the Company's Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12) immunotherapy based on the company's proprietary TheraPlas® technology, for the treatment of newly diagnosed advanced ovarian cancer.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810387/imunon-announces-translational-data-from-phase-12-ovation-2-study-of-imnn-001-in-advanced-ovarian-","source_type":"Press Release","status":"Phase 2","target_date":"","time":"08:26:34","updated":1739971657},{"commentary":"","companies":[{"cik":"1802665","id":"603cef7fb9e30d00018901c6","name":"Harmony Biosciences Holdings Inc","securities":[{"exchange":"NASDAQ","symbol":"HRMY"}]}],"created":1739971504,"date":"2025-02-19","drug":{"generic":false,"id":"651d470208e89000019cfd58","indication_symptom":["For the treatment of excessive daytime sleepiness "],"name":"pitolisant"},"event_type":"Regulatory Update","id":"67b5dbb0dcc94e0001195896","nic_number":"","notes":"","outcome":"Harmony Biosciences Holdings, Inc announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43810390/harmony-biosciences-provides-update-on-the-status-of-the-supplemental-new-drug-application-for-pit","source_type":"Press Release","status":"Refusal to File (RTF)","target_date":"","time":"08:25:04","updated":1739971584},{"commentary":"","companies":[{"cik":"1408443","id":"603cef7eb9e30d000188fedb","name":"Milestone Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"MIST"}]}],"created":1739971441,"date":"2025-02-19","drug":{"generic":false,"id":"66040ef0cad84c00018292ad","indication_symptom":["For Treatment in Paroxysmal Supraventricular Tachycardia"],"name":"Etripamil"},"event_type":"Provided Update","id":"67b5db71dcc94e0001195877","nic_number":"","notes":"","outcome":"Milestone® Pharmaceuticals Inc. announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) on a new Method of Use patent for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810105/milestone-pharmaceuticals-notice-of-allowance-on-new-u-s-patent-for-etripamil","source_type":"Press Release","status":"","target_date":"","time":"08:24:01","updated":1739971481},{"commentary":"","companies":[{"cik":"","id":"655206cab3615100015df128","name":"Sagimet Biosciences Inc","securities":[]}],"created":1739971332,"date":"2025-02-19","drug":{"generic":false,"id":"65520a5f207b9d0001912b8d","indication_symptom":["For Liver Diseases"],"name":"denifanstat"},"event_type":"Presentation","id":"67b5db04dcc94e0001195862","nic_number":"","notes":"","outcome":"Sagimet Biosciences Inc. announced that an oral presentation on denifanstat's effect on triglycerides and LDL-cholesterol in advanced fibrosis patients will be delivered at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium being held February 23-26, 2025 in Banff, Canada.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810165/sagimet-biosciences-announces-oral-presentation-at-the-mash-pathogenesis-and-therapeutic-approache","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"08:22:12","updated":1739971413},{"commentary":"","companies":[{"cik":"","id":"6628d138ed9ebb000172cc47","name":"Alto Neuroscience Inc","securities":[]}],"created":1739971256,"date":"2025-02-19","drug":{"generic":false,"id":"675842ecaed0910001a272b2","indication_symptom":["adjunctive treatment in MDD"],"name":"ALTO-300"},"event_type":"Provided Update","id":"67b5dab8dcc94e0001195842","nic_number":"","notes":"","outcome":"Alto Neuroscience, Inc announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining to treatment of major depressive disorder (MDD) in patients with inadequate response to an antidepressant.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43810336/alto-neuroscience-announces-u-s-patent-granted-covering-alto-300-as-a-treatment-for-patients-with-","source_type":"Press Release","status":"","target_date":"","time":"08:20:56","updated":1739971297},{"commentary":"","companies":[{"cik":"1638097","id":"603cef7eb9e30d000188fbbb","name":"Entera Bio Ltd","securities":[{"exchange":"NASDAQ","symbol":"ENTX"}]}],"created":1739971178,"date":"2025-02-19","drug":{"generic":false,"id":"604a31833c2ff90001957721","indication_symptom":["Parathyroid hormone (1-34)"," or PTH for osteoporosis"],"name":"EB613"},"event_type":"Presentation","id":"67b5da6adcc94e0001195824","nic_number":"","notes":"","outcome":"Entera Bio Ltd. announced that the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Scientific Programme Committee has accepted both submitted abstracts related to EB613 for presentation at the WCO-IOF-ESCEO congress.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810123/effects-of-eb613-tablets-oral-pth-1-34-on-trabecular-and-cortical-bone-using-3d-dxa-post-hoc-resul","source_type":"Press Release","status":"","target_date":"","time":"08:19:38","updated":1739971219},{"commentary":"","companies":[{"cik":"","id":"6537b7a40d10db0001eb3939","name":"NKGen Biotech Inc","securities":[]}],"created":1739971062,"date":"2025-02-19","drug":{"generic":false,"id":"64f6d01badd8280001ff4e92","indication_symptom":["To Treat Alzheimer's Disease"],"name":"troculeucel (SNK01)"},"event_type":"Provided Update","id":"67b5d9f6dcc94e00011957f7","nic_number":"","notes":"","outcome":"NKGen Biotech, Inc. announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator (\"PI\") for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810122/nkgen-appoints-dr-anita-fletcher-as-national-principal-investigator-for-phase-2a-troculeucel-trial","source_type":"Press Release","status":"Phase 2a","target_date":"","time":"08:17:42","updated":1739971129},{"commentary":"","companies":[{"cik":"1566044","id":"603cef7eb9e30d000188fc00","name":"VYNE Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"VYNE"}]}],"created":1739970975,"date":"2025-02-19","drug":{"generic":false,"id":"6638c8f5ceb1f300011fd2a1","indication_symptom":["A Novel BD2-Selective BET Inhibitor"],"name":"VYN202"},"event_type":"Dosing Update","id":"67b5d99fdcc94e00011957e3","nic_number":"","notes":"","outcome":"VYNE Therapeutics Inc. announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810148/vyne-therapeutics-initiates-phase-1b-trial-of-vyn202-a-novel-bd2-selective-oral-bet-inhibitor-in-p","source_type":"Press Release","status":"Phase 1b","target_date":"","time":"08:16:15","updated":1739971026},{"commentary":"","companies":[{"cik":"","id":"60ddb25528baa50001aa9e5f","name":"Alzamend Neuro, Inc.","securities":[{"exchange":"NASDAQ","symbol":"ALZN"}]},{"cik":"1653087","id":"603cef7eb9e30d000188fe5c","name":"Alector Inc","securities":[{"exchange":"NASDAQ","symbol":"ALEC"}]}],"created":1739970839,"date":"2025-02-19","drug":{"generic":false,"id":"6516c5db9705270001e211c6","indication_symptom":["A Next-Generation Lithium Therapeutic Drug Candidate"," in Bipolar Disorder Patients"],"name":"AL001"},"event_type":"Provided Update","id":"67b5d917dcc94e00011957cd","nic_number":"","notes":"","outcome":"Alzamend Neuro, Inc. announced the completion of a groundbreaking head coil by Tesla Dynamic Coils BV (\"Tesla\").","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43810248/alzamend-neuro-announces-completion-of-a-novel-head-coil-by-tesla-for-measuring-brain-structure-li","source_type":"Press Release","status":"","target_date":"","time":"08:13:59","updated":1739970947},{"commentary":"","companies":[{"cik":"1135951","id":"603cef78b9e30d000188becd","name":"Dr Reddy's Laboratories Ltd","securities":[{"exchange":"NYSE","symbol":"RDY"}]},{"cik":"14272","id":"603cef78b9e30d000188b6a3","name":"Bristol-Myers Squibb Company","securities":[{"exchange":"NYSE","symbol":"BMY"},{"exchange":"OTC","symbol":"BMYMP"}]},{"cik":"1723128","id":"603cef7eb9e30d000188fc9d","name":"Amneal Pharmaceuticals Inc","securities":[{"exchange":"NYSE","symbol":"AMRX"}]}],"created":1739970632,"date":"2025-02-19","drug":{"generic":false,"id":"616f052d80db050001b8bfaf","indication_symptom":["Multiple myeloma and myelodysplastic syndrome"],"name":"Lenalidomide Capsules"},"event_type":"FDA Approval","id":"67b5d848dcc94e000119578e","nic_number":"","notes":"","outcome":"Amneal Pharmaceuticals announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for lenalidomide capsules in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43810207/amneal-launches-mesalamine-and-receives-u-s-fda-approval-for-lenalidomide","source_type":"Press Release","status":"Abbreviated New Drug Application (ANDA)","target_date":"","time":"08:10:32","updated":1739970777},{"commentary":"","companies":[{"cik":"1723128","id":"603cef7eb9e30d000188fc9d","name":"Amneal Pharmaceuticals Inc","securities":[{"exchange":"NYSE","symbol":"AMRX"}]}],"created":1739970537,"date":"2025-02-19","drug":{"generic":false,"id":"67b5d6d1dcc94e000119570a","indication_symptom":["For the treatment of moderately active ulcerative colitis in adults."],"name":"mesalamine 800"},"event_type":"Provided Update","id":"67b5d7e9dcc94e000119576f","nic_number":"","notes":"","outcome":"Amneal Pharmaceuticals, Inc. announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43810207/amneal-launches-mesalamine-and-receives-u-s-fda-approval-for-lenalidomide","source_type":"Press Release","status":"","target_date":"","time":"08:08:57","updated":1739970777},{"commentary":"","companies":[{"cik":"749660","id":"603cef79b9e30d000188bfaf","name":"icad Inc","securities":[{"exchange":"NASDAQ","symbol":"ICAD"}]}],"created":1739970227,"date":"2025-02-19","drug":{"generic":false,"id":"67af39ccb156400001be35a3","indication_symptom":["AI in Breast Imaging"],"name":"RPS 1002"},"event_type":"Oral presentation","id":"67b5d6b3dcc94e00011956f7","nic_number":"","notes":"","outcome":"iCAD, Inc. announced the Oral Presentations of RPS 1002 – Exploring the Role of AI in Breast Imaging","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810175/icad-to-showcase-five-ai-powered-research-presentations-advancing-breast-cancer-detection-risk-eva","source_type":"Press Release","status":"","target_date":"2025-02-27","time":"08:03:47","updated":1739970525},{"commentary":"","companies":[{"cik":"749660","id":"603cef79b9e30d000188bfaf","name":"icad Inc","securities":[{"exchange":"NASDAQ","symbol":"ICAD"}]}],"created":1739970446,"date":"2025-02-19","drug":{"generic":false,"id":"67b5d6d2dcc94e000119570c","indication_symptom":["Personalized Risk Prediction of Breast Cancer"],"name":"RPS 2202"},"event_type":"Oral presentation","id":"67b5d78edcc94e000119573d","nic_number":"","notes":"","outcome":"iCAD, Inc. announced the Oral Presentations of RPS 2202 – Personalized Risk Prediction of Breast Cancer","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810175/icad-to-showcase-five-ai-powered-research-presentations-advancing-breast-cancer-detection-risk-eva","source_type":"Press Release","status":"","target_date":"2025-02-27","time":"08:07:26","updated":1739970524},{"commentary":"","companies":[{"cik":"749660","id":"603cef79b9e30d000188bfaf","name":"icad Inc","securities":[{"exchange":"NASDAQ","symbol":"ICAD"}]}],"created":1739970176,"date":"2025-02-19","drug":{"generic":false,"id":"67af39ccb156400001be35a1","indication_symptom":["Artificial Intelligence in Breast Imaging"],"name":"RPS 705"},"event_type":"Oral presentation","id":"67b5d680dcc94e00011956e7","nic_number":"","notes":"","outcome":"iCAD, Inc. announced the Oral Presentations of RPS 705 – Artificial Intelligence in Breast Imaging","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43810175/icad-to-showcase-five-ai-powered-research-presentations-advancing-breast-cancer-detection-risk-eva","source_type":"Press Release","status":"","target_date":"2025-02-27","time":"08:02:56","updated":1739970524},{"commentary":"","companies":[{"cik":"1503802","id":"603cef7db9e30d000188f33d","name":"Karyopharm Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"KPTI"}]}],"created":1739968467,"date":"2025-02-19","drug":{"generic":false,"id":"618437c980db050001bc7968","indication_symptom":["Myelofibrosis"],"name":"Selinexor"},"event_type":"Clinical Update","id":"67b5cfd32b94b70001f99229","nic_number":"","notes":"","outcome":"Karyopharm Therapeutics Inc. provided an overview of its key clinical development programs.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43809479/karyopharm-reports-fourth-quarter-and-full-year-2024-financial-results-announces-update-to-phase-3","source_type":"Press Release","status":"","target_date":"","time":"07:34:27","updated":1739968546},{"commentary":"","companies":[{"cik":"","id":"6086fc4ceb87ad000173984b","name":"Chemomab Therapeutics, Ltd.","securities":[{"exchange":"NASDAQ","symbol":"CMMB"}]}],"created":1739967280,"date":"2025-02-19","drug":{"generic":false,"id":"61a8efd66788ac00012b6275","indication_symptom":["Primary Sclerosing Cholangitis"],"name":"CM-101 (PSC)"},"event_type":"FDA Meeting","id":"67b5cb302b94b70001f99150","nic_number":"","notes":"","outcome":"Chemomab Therapeutics announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43808690/chemomab-completes-successful-end-of-phase-2-meeting-and-aligns-with-fda-on-clear-and-efficient-pa","source_type":"Press Release","status":"Phase 2","target_date":"","time":"07:14:40","updated":1739967444},{"commentary":"","companies":[{"cik":"","id":"6086fc4ceb87ad000173984b","name":"Chemomab Therapeutics, Ltd.","securities":[{"exchange":"NASDAQ","symbol":"CMMB"}]}],"created":1739967326,"date":"2025-02-19","drug":{"generic":false,"id":"61a8efd66788ac00012b6275","indication_symptom":["Primary Sclerosing Cholangitis"],"name":"CM-101 (PSC)"},"event_type":"Provided Update","id":"67b5cb5e2b94b70001f9915d","nic_number":"","notes":"","outcome":"Chemomab Therapeutics announced that alignment with FDA on the design of a single Phase 3 registration study for its lead product candidate nebokitug (CM-101) for the treatment of primary sclerosing cholangitis (PSC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43808690/chemomab-completes-successful-end-of-phase-2-meeting-and-aligns-with-fda-on-clear-and-efficient-pa","source_type":"Press Release","status":"Phase 3","target_date":"","time":"07:15:26","updated":1739967443},{"commentary":"","companies":[{"cik":"1070081","id":"603cef7db9e30d000188f28a","name":"PTC Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"PTCT"}]}],"created":1739966802,"date":"2025-02-19","drug":{"generic":false,"id":"6091e85e2bc27400010a514a","indication_symptom":["Friedreich ataxia"],"name":"Vatiquinone (MOVE-FA)"},"event_type":"FDA Accepted","id":"67b5c9522b94b70001f990f3","nic_number":"","notes":"","outcome":"PTC Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43808727/ptc-therapeutics-announces-fda-acceptance-and-priority-review-for-vatiquinone-nda-for-the-treatmen","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"","time":"07:06:42","updated":1739966922},{"commentary":"","companies":[{"cik":"1070081","id":"603cef7db9e30d000188f28a","name":"PTC Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"PTCT"}]}],"created":1739966855,"date":"2025-02-19","drug":{"generic":false,"id":"6091e85e2bc27400010a514a","indication_symptom":["Friedreich ataxia"],"name":"Vatiquinone (MOVE-FA)"},"event_type":"PDUFA Date","id":"67b5c9872b94b70001f99103","nic_number":"","notes":"","outcome":"PTC Therapeutics, Inc. announced that PDUFA target action date of Aug. 19, 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43808727/ptc-therapeutics-announces-fda-acceptance-and-priority-review-for-vatiquinone-nda-for-the-treatmen","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"2025-08-19","time":"07:07:35","updated":1739966921},{"commentary":"","companies":[{"cik":"1129928","id":"603cef79b9e30d000188c10f","name":"Oncolytics Biotech Inc","securities":[{"exchange":"NASDAQ","symbol":"ONCY"}]}],"created":1739966627,"date":"2025-02-19","drug":{"generic":false,"id":"6616450e84104e0001863ddf","indication_symptom":["In Breast Cancer"],"name":"Pelareorep"},"event_type":"Provided Update","id":"67b5c8a32b94b70001f990d3","nic_number":"","notes":"","outcome":"Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43808761/oncolytics-biotech-advances-key-pancreatic-and-anal-cancer-trials-strengthening-pipeline-in-2025","source_type":"Press Release","status":"","target_date":"","time":"07:03:47","updated":1739966732},{"commentary":"","companies":[{"cik":"14272","id":"603cef78b9e30d000188b6a3","name":"Bristol-Myers Squibb Company","securities":[{"exchange":"NYSE","symbol":"BMY"},{"exchange":"OTC","symbol":"BMYMP"}]}],"created":1739966522,"date":"2025-02-19","drug":{"generic":false,"id":"604296e20a9fff00018dccb2","indication_symptom":["Resected esophageal or gastroesophageal junction (GEJ) cancer in the adjuvant setting"],"name":"Opdivo (nivolumab)"},"event_type":"Analysis","id":"67b5c83a2b94b70001f990a7","nic_number":"","notes":"","outcome":"Bristol Myers Squibb announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo® (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer (NSCLC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43808682/bristol-myers-squibb-announces-opdivo-plus-chemotherapy-as-the-first-and-only-neoadjuvant-only-imm","source_type":"Press Release","status":"Phase 3","target_date":"","time":"07:02:02","updated":1739966578},{"commentary":"","companies":[{"cik":"1129928","id":"603cef79b9e30d000188c10f","name":"Oncolytics Biotech Inc","securities":[{"exchange":"NASDAQ","symbol":"ONCY"}]}],"created":1739934878,"date":"2025-02-18","drug":{"generic":false,"id":"6616450e84104e0001863ddf","indication_symptom":["In Breast Cancer"],"name":"Pelareorep"},"event_type":"Provided Update","id":"67b54c9eb156400001bebb6d","nic_number":"","notes":"","outcome":"Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43797045/oncolytics-biotech-strengthens-its-pipeline-in-2025-with-key-pancreatic-and-anal-cancer-advances-i","source_type":"Press Release","status":"","target_date":"","time":"22:14:38","updated":1739934953},{"commentary":"","companies":[{"cik":"818686","id":"603cef79b9e30d000188c278","name":"Teva Pharmaceutical Industries Ltd","securities":[{"exchange":"NYSE","symbol":"TEVA"},{"exchange":"OTC","symbol":"TEVJF"}]}],"created":1739931471,"date":"2025-02-18","drug":{"generic":false,"id":"676171676003c10001981ffa","indication_symptom":["for the treatment of moderate-to-severe inflammatory bowel disease (IBD)."],"name":"duvakitug"},"event_type":"Provided Update","id":"67b53f4fdcc94e0001194bf4","nic_number":"","notes":"","outcome":"Teva Pharmaceutical announced that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R\u0026D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organization (ECCO).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43798285/teva-to-host-conference-call-on-february-24-2025-to-discuss-new-data-presented-for-duvakitug-anti-","source_type":"Press Release","status":"","target_date":"","time":"21:17:51","updated":1739931527},{"commentary":"","companies":[{"cik":"1356576","id":"603cef7db9e30d000188ec96","name":"Supernus Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"SUPN"}]}],"created":1739931358,"date":"2025-02-18","drug":{"generic":false,"id":"610b0e18b4035700018a096b","indication_symptom":["Resistant depression"],"name":"SPN-820"},"event_type":"Provided Update","id":"67b53ededcc94e0001194be2","nic_number":"","notes":"","outcome":"Supernus Pharmaceuticals announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD) did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score to Week 4 (SPN-820 [LS mean ± Standard Error]: -12.3 ± 0.96 vs. placebo: -11.9 ± 0.96; p = not significant).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43798052/supernus-announces-topline-results-from-phase-2b-study-in-adults-with-treatment-resistant-depressi","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"21:15:58","updated":1739931449},{"commentary":"","companies":[{"cik":"310158","id":"603cef78b9e30d000188b9a4","name":"Merck \u0026 Co Inc","securities":[{"exchange":"NYSE","symbol":"MRK"}]}],"created":1739931180,"date":"2025-02-18","drug":{"generic":false,"id":"6501af9d9ab00f00016a4d18","indication_symptom":["Treated Patients With Advanced Renal Cell Carcinoma (RCC)"],"name":"belzutifan"},"event_type":"Approved","id":"67b53e2cdcc94e0001194bcd","nic_number":"","notes":"","outcome":"Merck announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43776493/welireg-belzutifan-receives-first-european-commission-approval-for-two-indications","source_type":"Press Release","status":"European Commission Approval","target_date":"","time":"21:13:00","updated":1739931245},{"commentary":"","companies":[{"cik":"","id":"60632e1cdbb1f50001a50ddb","name":"Longeveron Inc.","securities":[]}],"created":1739930930,"date":"2025-02-18","drug":{"generic":false,"id":"64c0cdbd9c212e0001522252","indication_symptom":["Treatment of HLHS "],"name":"Lomecel-B™"},"event_type":"Approved","id":"67b53d32dcc94e0001194bb3","nic_number":"","notes":"","outcome":"Longeveron Inc announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization approved \"laromestrocel\" for the non-proprietary name of the Company's cellular therapy Lomecel-B™.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43782749/longeveron-announces-world-health-organization-approval-of-laromestrocel-as-international-non-prop","source_type":"Press Release","status":"International Nonproprietary Names (INN) Expert Committee","target_date":"","time":"21:08:50","updated":1739931041},{"commentary":"","companies":[{"cik":"1585608","id":"603cef7db9e30d000188f588","name":"Jaguar Health Inc","securities":[{"exchange":"NASDAQ","symbol":"JAGX"}]}],"created":1739887756,"date":"2025-02-18","drug":{"generic":false,"id":"630e082d98361b000144946f","indication_symptom":["Symptomatic Relief of Diarrhea from Cholera"],"name":"NP-300"},"event_type":"Provided Update","id":"67b4948cb1c67f0001379fdd","nic_number":"","notes":"","outcome":"Jaguar Health, announced that, on January 29, 2025, they extended their collaboration with Streeterville related to Napo's plans to develop its NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients and pursue a possible Tropical Disease Priority Review Voucher (\"TDPRV\") from the U.S. Food and Drug Administration (\"FDA\") for this indication.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776891/presenting-on-the-emerging-growth-conference-79-day-1-on-february-18-register-now","source_type":"Press Release","status":"","target_date":"","time":"09:09:16","updated":1739887803},{"commentary":"","companies":[{"cik":"1514183","id":"603cef7db9e30d000188ef8d","name":"SILO Pharma Inc","securities":[{"exchange":"OTC","symbol":"SILO"}]}],"created":1739884641,"date":"2025-02-18","drug":{"generic":false,"id":"659851cf8fadc3000117d386","indication_symptom":["Treatment for PTSD"],"name":"SPC-15"},"event_type":"Provided Update","id":"67b48861b156400001be7dde","nic_number":"","notes":"","outcome":"Silo Pharma, Inc. announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43781141/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-","source_type":"Press Release","status":"","target_date":"","time":"08:17:21","updated":1739886691},{"commentary":"","companies":[{"cik":"1515673","id":"603cef7db9e30d000188f3ae","name":"Ultragenyx Pharmaceutical Inc","securities":[{"exchange":"NASDAQ","symbol":"RARE"}]}],"created":1739884483,"date":"2025-02-18","drug":{"generic":false,"id":"666a8b3fe56ade0001156a70","indication_symptom":[" For Sanfilippo syndrome type A (MPS IIIA)"],"name":"UX111"},"event_type":"review","id":"67b487c3b156400001be7daa","nic_number":"","notes":"","outcome":"Ultragenyx Pharmaceutical announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43779022/ultragenyx-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-bla-f","source_type":"Press Release","status":"Biologics License Applications (BLA)","target_date":"","time":"08:14:43","updated":1739884623},{"commentary":"","companies":[{"cik":"1515673","id":"603cef7db9e30d000188f3ae","name":"Ultragenyx Pharmaceutical Inc","securities":[{"exchange":"NASDAQ","symbol":"RARE"}]}],"created":1739884565,"date":"2025-02-18","drug":{"generic":false,"id":"666a8b3fe56ade0001156a70","indication_symptom":[" For Sanfilippo syndrome type A (MPS IIIA)"],"name":"UX111"},"event_type":"PDUFA Date","id":"67b48815b156400001be7dc4","nic_number":"","notes":"","outcome":"Ultragenyx Pharmaceutical Inc announced that The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of August 18, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43779022/ultragenyx-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-bla-f","source_type":"Press Release","status":"Biologics License Applications (BLA)","target_date":"2025-08-18","time":"08:16:05","updated":1739884620},{"commentary":"","companies":[{"cik":"1623526","id":"603cef7eb9e30d000188ff32","name":"Stoke Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"STOK"}]}],"created":1739884399,"date":"2025-02-18","drug":{"generic":false,"id":"674ef635eee39a0001363d47","indication_symptom":[" For the treatment of Dravet syndrome with a confirmed mutation",""],"name":"zorevunersen"},"event_type":"Provided Update","id":"67b4876fb156400001be7d8e","nic_number":"","notes":"","outcome":"Biogen Inc announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43778917/biogen-and-stoke-therapeutics-enter-into-collaboration-to-develop-and-commercialize-zorevunersen-f","source_type":"Press Release","status":"","target_date":"","time":"08:13:19","updated":1739884465},{"commentary":"","companies":[{"cik":"","id":"67b486addcc94e0001190ccc","name":"Septerna Inc","securities":[{"exchange":"NASDAQ","symbol":"SEPN"}]}],"created":1739884169,"date":"2025-02-18","drug":{"generic":false,"id":"67b456a4b156400001be76e4","indication_symptom":[" PTH1R Agonist"],"name":"SEP-786"},"event_type":"Provided Update","id":"67b48689dcc94e0001190cc0","nic_number":"","notes":"","outcome":"Septerna, announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43778828/septerna-announces-discontinuation-of-sep-786-phase-1-clinical-trial-and-plans-to-advance-next-gen","source_type":"Press Release","status":"","target_date":"","time":"08:09:29","updated":1739884329},{"commentary":"","companies":[{"cik":"1651311","id":"603cef7eb9e30d000188f7ed","name":"Merus NV","securities":[{"exchange":"NASDAQ","symbol":"MRUS"}]}],"created":1739884088,"date":"2025-02-18","drug":{"generic":false,"id":"6642071fa3202c0001ae8c36","indication_symptom":["For the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)"],"name":"petosemtamab"},"event_type":"Designation Grant","id":"67b48638dcc94e0001190c9b","nic_number":"","notes":"","outcome":"Merus N.V announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to petosemtamab in combination with pembrolizumab for the first-line treatment of adult patients with recurrent or metastatic programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma (r/m HNSCC) with combined positive score (CPS) ≥ 1.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43778779/petosemtamab-granted-breakthrough-therapy-designation-by-the-u-s-fda-for-1l-pd-l1-positive-head-an","source_type":"Press Release","status":"Breakthrough Therapy Designation","target_date":"","time":"08:08:08","updated":1739884149},{"commentary":"","companies":[{"cik":"1062822","id":"603cef78b9e30d000188b91c","name":"Lexicon Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"LXRX"}]}],"created":1739884023,"date":"2025-02-18","drug":{"generic":false,"id":"6489b22c38ab3c0001934f60","indication_symptom":["INPEFA™ (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). "],"name":"sotagliflozin"},"event_type":"Publication","id":"67b485f7dcc94e0001190c6f","nic_number":"","notes":"","outcome":"Lexicon Pharmaceuticals, Inc announced The Lancet Diabetes \u0026 Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to reduce the risks of life-threatening cardiovascular outcomes.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43778780/published-data-in-the-lancet-diabetes-endocrinology-highlights-unique-efficacy-benefits-of-sotagli","source_type":"Press Release","status":"","target_date":"","time":"08:07:03","updated":1739884067},{"commentary":"","companies":[{"cik":"","id":"65200c923b3e38000193adc8","name":"ARS Pharmaceuticals Inc","securities":[]}],"created":1739882550,"date":"2025-02-18","drug":{"generic":false,"id":"66dfe71e6d02590001c90a27","indication_symptom":[" For Pediatric Patients with Type I Allergic Reactions"],"name":"neffy"},"event_type":"Presentation","id":"67b48036dcc94e0001190b59","nic_number":"","notes":"","outcome":"ARS Pharmaceuticals, Inc. announced today that nine presentations will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 28 to March 3, in San Diego, California.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43778782/ars-pharmaceuticals-to-showcase-innovation-and-present-data-on-neffy-epinephrine-nasal-spray-at-20","source_type":"Press Release","status":"","target_date":"","time":"07:42:30","updated":1739884011},{"commentary":"","companies":[{"cik":"1228627","id":"603cef7fb9e30d0001890310","name":"Ocuphire Pharma Inc","securities":[{"exchange":"NASDAQ","symbol":"OCUP"}]}],"created":1739882326,"date":"2025-02-18","drug":{"generic":false,"id":"6717a3e41e18f9000110b3e4","indication_symptom":["For LCA5"],"name":"OPGx-LCA5"},"event_type":"Dose Update","id":"67b47f56dcc94e0001190b05","nic_number":"","notes":"","outcome":"Opus Genetics, Inc. announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its investigational gene therapy for the treatment of Leber congenital amaurosis (LCA).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43778028/opus-genetics-announces-updates-on-opgx-lca5-clinical-program","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"07:38:46","updated":1739882398},{"commentary":"","companies":[{"cik":"1228627","id":"603cef7fb9e30d0001890310","name":"Ocuphire Pharma Inc","securities":[{"exchange":"NASDAQ","symbol":"OCUP"}]}],"created":1739882352,"date":"2025-02-18","drug":{"generic":false,"id":"6717a3e41e18f9000110b3e4","indication_symptom":["For LCA5"],"name":"OPGx-LCA5"},"event_type":"Initial Data","id":"67b47f70dcc94e0001190b11","nic_number":"","notes":"","outcome":"Opus plans to share initial data from the pediatric cohort by Q3 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43778028/opus-genetics-announces-updates-on-opgx-lca5-clinical-program","source_type":"Press Release","status":"","target_date":"2025-Q3","time":"07:39:12","updated":1739882397},{"commentary":"","companies":[{"cik":"1001316","id":"603cef78b9e30d000188b961","name":"TG Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"TGTX"}]}],"created":1739882246,"date":"2025-02-18","drug":{"generic":false,"id":"6493ecad08348c00019bdf5f","indication_symptom":[" For the management of autoimmune disorders"],"name":"BRIUMVI"},"event_type":"Presentation","id":"67b47f06dcc94e0001190af3","nic_number":"","notes":"","outcome":"TG Therapeutics, Inc. announced the schedule of presentations highlighting data from the ULTIMATE I \u0026 II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) to be presented at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 27 – March 1, 2025, in West Palm Beach, Florida.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43778015/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvi-ublituximab-in-multiple-scler","source_type":"Press Release","status":"Phase 3","target_date":"","time":"07:37:26","updated":1739882313},{"commentary":"","companies":[{"cik":"1087294","id":"603cef7ab9e30d000188d416","name":"Cumberland Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"CPIX"}]}],"created":1739882171,"date":"2025-02-18","drug":{"generic":false,"id":"651d470508e89000019cfd78","indication_symptom":["FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) "],"name":"Vibativ"},"event_type":"Approved","id":"67b47ebbdcc94e0001190ade","nic_number":"","notes":"","outcome":"Cumberland Pharmaceuticals Inc and SciClone Pharmaceuticals (Holdings) Limited announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ® (telavancin) injection in China.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43778030/vibativ-receives-marketing-approval-in-china","source_type":"Press Release","status":"","target_date":"","time":"07:36:11","updated":1739882234},{"commentary":"","companies":[{"cik":"1707502","id":"603cef7eb9e30d000188fc03","name":"Solid Biosciences Inc","securities":[{"exchange":"NASDAQ","symbol":"SLDB"}]}],"created":1739881704,"date":"2025-02-18","drug":{"generic":false,"id":"6553ed6282104a0001e65532","indication_symptom":["For Duchenne Muscular Dystrophy Gene Therapy"],"name":"SGT-003"},"event_type":"Positive Data","id":"67b47ce8dcc94e0001190aab","nic_number":"","notes":"","outcome":"Solid Biosciences announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776501/solid-biosciences-reports-positive-initial-clinical-data-from-next-generation-duchenne-gene-therap","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"07:28:24","updated":1739881761},{"commentary":"","companies":[{"cik":"","id":"67163c81d5a7650001307f36","name":"Elevai Biosciences Inc","securities":[{"exchange":"NASDAQ","symbol":"ELAB"}]}],"created":1739881564,"date":"2025-02-18","drug":{"generic":false,"id":"6717a3e51e18f9000110b3ea","indication_symptom":["In the treatment of obesity and muscle loss preservation."],"name":"EL-22"},"event_type":"Pre-IND Meeting","id":"67b47c5cdcc94e0001190a86","nic_number":"","notes":"","outcome":"Northstrive Biosciences, a subsidiary of PMGC Holdings Inc. announced the submission of a pre-IND meeting request to the FDA.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776940/northstrive-biosciences-inc-a-subsidiary-of-pmgc-holdings-inc-announces-successful-submission-of-p","source_type":"Press Release","status":"","target_date":"","time":"07:26:04","updated":1739881659},{"commentary":"","companies":[{"cik":"","id":"67163c81d5a7650001307f36","name":"Elevai Biosciences Inc","securities":[{"exchange":"NASDAQ","symbol":"ELAB"}]}],"created":1739881606,"date":"2025-02-18","drug":{"generic":false,"id":"6717a3e51e18f9000110b3ea","indication_symptom":["In the treatment of obesity and muscle loss preservation."],"name":"EL-22"},"event_type":"FDA Meeting","id":"67b47c86dcc94e0001190a93","nic_number":"","notes":"","outcome":"Northstrive anticipates having a Type B pre-IND meeting with the FDA in the second fiscal quarter of 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776940/northstrive-biosciences-inc-a-subsidiary-of-pmgc-holdings-inc-announces-successful-submission-of-p","source_type":"Press Release","status":"Type B Meeting","target_date":"2025-Q2","time":"07:26:46","updated":1739881658},{"commentary":"","companies":[{"cik":"1117480","id":"603cef7db9e30d000188f22e","name":"Chimerix Inc","securities":[{"exchange":"NASDAQ","symbol":"CMRX"}]}],"created":1739881441,"date":"2025-02-18","drug":{"generic":false,"id":"6756db23f5ad71000149f304","indication_symptom":["treatment for recurrent H3 K27M-mutant diffuse glioma "],"name":"dordaviprone"},"event_type":"FDA Accepted","id":"67b47be1dcc94e0001190a5d","nic_number":"","notes":"","outcome":"Chimerix announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776943/chimerix-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-dordaviprone-as-","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"","time":"07:24:01","updated":1739881545},{"commentary":"","companies":[{"cik":"1117480","id":"603cef7db9e30d000188f22e","name":"Chimerix Inc","securities":[{"exchange":"NASDAQ","symbol":"CMRX"}]}],"created":1739881481,"date":"2025-02-18","drug":{"generic":false,"id":"6756db23f5ad71000149f304","indication_symptom":["treatment for recurrent H3 K27M-mutant diffuse glioma "],"name":"dordaviprone"},"event_type":"PDUFA Date","id":"67b47c09dcc94e0001190a6a","nic_number":"","notes":"","outcome":"Chimerix announced that PDUFA Target Action Date of August 18, 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776943/chimerix-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-dordaviprone-as-","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"2025-08-18","time":"07:24:41","updated":1739881545},{"commentary":"","companies":[{"cik":"1815620","id":"603cef7ab9e30d000188cfac","name":"Opthea Ltd","securities":[{"exchange":"GREY","symbol":"CKDXF"},{"exchange":"NASDAQ","symbol":"OPT"}]}],"created":1739881333,"date":"2025-02-18","drug":{"generic":false,"id":"6655d2d63b127300013915c8","indication_symptom":["In Wet AMD"],"name":"sozinibercept"},"event_type":"Provided Update","id":"67b47b75dcc94e0001190a3b","nic_number":"","notes":"","outcome":"Opthea Limited announced that it has completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatment of wet AMD.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776880/opthea-completes-coast-final-week-52-patient-visit","source_type":"Press Release","status":"","target_date":"","time":"07:22:13","updated":1739881422},{"commentary":"","companies":[{"cik":"1815620","id":"603cef7ab9e30d000188cfac","name":"Opthea Ltd","securities":[{"exchange":"GREY","symbol":"CKDXF"},{"exchange":"NASDAQ","symbol":"OPT"}]}],"created":1739881356,"date":"2025-02-18","drug":{"generic":false,"id":"6655d2d63b127300013915c8","indication_symptom":["In Wet AMD"],"name":"sozinibercept"},"event_type":"Results","id":"67b47b8cdcc94e0001190a41","nic_number":"","notes":"","outcome":"Opthea Limited announced that The topline results from both trials are anticipated in early Q2 CY25 (COAST) and mid-CY25 (ShORe).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776880/opthea-completes-coast-final-week-52-patient-visit","source_type":"Press Release","status":"","target_date":"2025-Q2","time":"07:22:36","updated":1739881421},{"commentary":"","companies":[{"cik":"1759138","id":"603cef7eb9e30d000188ffed","name":"Cabaletta Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"CABA"}]}],"created":1739881026,"date":"2025-02-18","drug":{"generic":false,"id":"6548de99caf68a0001072ba8","indication_symptom":["For Treatment of Generalized Myasthenia Gravis"],"name":"CABA-201"},"event_type":"New Data","id":"67b47a42dcc94e00011909fe","nic_number":"","notes":"","outcome":"Cabaletta Bio, Inc. announced new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) across the RESET clinical development program.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43776901/cabaletta-bio-announces-updated-clinical-data-demonstrating-deepening-clinical-responses-across-mu","source_type":"Press Release","status":"","target_date":"","time":"07:17:06","updated":1739881200},{"commentary":"","companies":[{"cik":"1614744","id":"603cef7db9e30d000188eca2","name":"Purple Biotech Ltd","securities":[{"exchange":"NASDAQ","symbol":"PPBT"}]}],"created":1739880823,"date":"2025-02-18","drug":{"generic":false,"id":"60a65c3d674f65000188a2ae","indication_symptom":["Adults with Advanced Solid Tumors and Head and Neck Cancer"],"name":"NT219"},"event_type":"Provided Update","id":"67b47977dcc94e00011909de","nic_number":"","notes":"","outcome":"Purple Biotech Ltd. announced it is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).","outcome_brief":"","source_link":"https://www.globenewswire.com/news-release/2025/02/18/3027637/0/en/Purple-Biotech-Advances-NT219-into-Phase-2-Head-and-Neck-Cancer-Trial.html","source_type":"Other","status":"Phase 2","target_date":"","time":"07:13:43","updated":1739880967},{"commentary":"","companies":[{"cik":"","id":"6527c12b7f1949000153cd6d","name":"Alvotech","securities":[]},{"cik":"872589","id":"603cef78b9e30d000188ba95","name":"Regeneron Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"REGN"}]}],"created":1739878144,"date":"2025-02-18","drug":{"generic":false,"id":"612505bfb4035700018c2073","indication_symptom":["Wet age-related macular degeneration (wet AMD)"],"name":"EYLEA (aflibercept)"},"event_type":"FDA Accepted","id":"67b46f00dcc94e0001190727","nic_number":"","notes":"","outcome":"Alvotech announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43775568/alvotech-and-teva-announce-filing-acceptance-of-u-s-biologics-license-application-for-avt06-a-prop","source_type":"Press Release","status":"Biologics License Applications (BLA)","target_date":"","time":"06:29:04","updated":1739878275},{"commentary":"","companies":[{"cik":"","id":"6527c12b7f1949000153cd6d","name":"Alvotech","securities":[]},{"cik":"872589","id":"603cef78b9e30d000188ba95","name":"Regeneron Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"REGN"}]}],"created":1739878201,"date":"2025-02-18","drug":{"generic":false,"id":"612505bfb4035700018c2073","indication_symptom":["Wet age-related macular degeneration (wet AMD)"],"name":"EYLEA (aflibercept)"},"event_type":"Regulatory Update","id":"67b46f39b1c67f00013798cf","nic_number":"","notes":"","outcome":"Alvotech announced that The process to obtain regulatory approval is anticipated to be completed in the fourth quarter of 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43775568/alvotech-and-teva-announce-filing-acceptance-of-u-s-biologics-license-application-for-avt06-a-prop","source_type":"Press Release","status":"Biologics License Applications (BLA)","target_date":"2025-Q4","time":"06:30:01","updated":1739878274},{"commentary":"","companies":[{"cik":"872589","id":"603cef78b9e30d000188ba95","name":"Regeneron Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"REGN"}]},{"cik":"1121404","id":"603cef78b9e30d000188baf1","name":"Sanofi SA","securities":[{"exchange":"NASDAQ","symbol":"SNY"},{"exchange":"OTC","symbol":"SNYNF"}]}],"created":1739871336,"date":"2025-02-18","drug":{"generic":false,"id":"60408ace0216d50001d0a038","indication_symptom":["Moderate-to-severe asthma"],"name":"Dupixent (dupilumab)"},"event_type":"FDA Accepted","id":"67b45468b156400001be7642","nic_number":"","notes":"","outcome":"Regeneron Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults with bullous pemphigoid (BP).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43772719/press-release-dupixent-sbla-accepted-for-fda-priority-review-for-the-targeted-treatment-of-bullous","source_type":"Press Release","status":"supplemental Biologics License Applications (sBLA)","target_date":"","time":"04:35:36","updated":1739871394},{"commentary":"","companies":[{"cik":"","id":"659443f2b02d410001314f83","name":"GSK plc","securities":[]}],"created":1739871881,"date":"2025-02-17","drug":{"generic":false,"id":"67af39cdb156400001be35a5","indication_symptom":["Help Protect Against MenABCWY"],"name":"PENMENVY"},"event_type":"FDA Approval","id":"67b45689b156400001be76e1","nic_number":"","notes":"","outcome":"GSK plc announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).1,2","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43769819/gsk-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-gsk-plc-investors-with-substantia","source_type":"Press Release","status":"FDA Approved","target_date":"","time":"04:44:41","updated":1739872018},{"commentary":"","companies":[{"cik":"14272","id":"603cef78b9e30d000188b6a3","name":"Bristol-Myers Squibb Company","securities":[{"exchange":"NYSE","symbol":"BMY"},{"exchange":"OTC","symbol":"BMYMP"}]}],"created":1739871552,"date":"2025-02-17","drug":{"generic":false,"id":"6083004deb87ad0001ba1b2a","indication_symptom":["Moderate to severe plaque psoriasis"],"name":"Deucravacitinib"},"event_type":"Results","id":"67b45540b156400001be7677","nic_number":"","notes":"","outcome":"Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43758527/new-five-year-sotyktu-deucravacitinib-data-show-consistent-safety-and-durable-response-rates-in-mo","source_type":"Press Release","status":"","target_date":"","time":"04:39:12","updated":1739871672},{"commentary":"","companies":[{"cik":"1598599","id":"603cef7bb9e30d000188d70c","name":"Innate Pharma SA","securities":[{"exchange":"NASDAQ","symbol":"IPHA"},{"exchange":"OTC","symbol":"IPHYF"}]}],"created":1739871461,"date":"2025-02-17","drug":{"generic":false,"id":"6481b30f8dd1660001a0b25d","indication_symptom":["Treatment of patients with relapsed or refractory Sézary syndrome"],"name":"Lacutamab"},"event_type":"Designation Grant","id":"67b454e5b156400001be765a","nic_number":"","notes":"","outcome":"Innate Pharma Announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary Syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43762301/innate-pharma-announces-u-s-fda-granted-breakthrough-therapy-designation-to-lacutamab-for-relapsed","source_type":"Press Release","status":"Breakthrough Therapy Designation","target_date":"","time":"04:37:41","updated":1739871558},{"commentary":"","companies":[{"cik":"939767","id":"603cef78b9e30d000188b7de","name":"Exelixis Inc","securities":[{"exchange":"NASDAQ","symbol":"EXEL"}]},{"cik":"1395064","id":"603cef7bb9e30d000188d9a3","name":"Takeda Pharmaceutical Co Ltd","securities":[{"exchange":"NYSE","symbol":"TAK"},{"exchange":"OTC","symbol":"TKPHF"}]}],"created":1739871786,"date":"2025-02-15","drug":{"generic":false,"id":"6126ab10b6abe40001ef3ddc","indication_symptom":["Unresectable or Metastatic Renal Cell Carcinoma"],"name":"CABOMETYX (cabozantinib) + OPDIVO (nivolumab)"},"event_type":"Results","id":"67b4562ab156400001be76c8","nic_number":"","notes":"","outcome":"Exelixis, Inc announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx","source_type":"Press Release","status":"Phase 3","target_date":"","time":"04:43:06","updated":1739871847},{"commentary":"","companies":[{"cik":"901832","id":"603cef78b9e30d000188bd81","name":"AstraZeneca PLC","securities":[{"exchange":"NASDAQ","symbol":"AZN"},{"exchange":"OTC","symbol":"AZNCF"}]},{"cik":"1724521","id":"603cef7eb9e30d000188fc31","name":"Arcus Biosciences Inc","securities":[{"exchange":"NYSE","symbol":"RCUS"}]}],"created":1739871688,"date":"2025-02-15","drug":{"generic":false,"id":"66fd3beec2ed5b00011dd69a","indication_symptom":["In patients with ccRCC"],"name":"casdatifan"},"event_type":"New Data","id":"67b455c8b156400001be76a9","nic_number":"","notes":"","outcome":"Arcus Biosciences, Inc today presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43757118/new-data-demonstrated-best-in-class-potential-for-casdatifan-a-hif-2a-inhibitor-in-patients-with-m","source_type":"Press Release","status":"","target_date":"","time":"04:41:28","updated":1739871768},{"commentary":"","companies":[{"cik":"1768224","id":"603cef7db9e30d000188f1ed","name":"Arcturus Therapeutics Holdings Inc","securities":[{"exchange":"NASDAQ","symbol":"ARCT"}]}],"created":1739538750,"date":"2025-02-14","drug":{"generic":false,"id":"6164a138d5cb080001d22eb1","indication_symptom":["SARS-CoV-2 Delta Variant and Other Variants of Concern"],"name":"ARCT-154"},"event_type":"Marketing authorization","id":"67af413e2b94b70001f8f7cf","nic_number":"","notes":"","outcome":"Arcturus Therapeutics announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43727352/european-commission-approves-csl-and-arcturus-therapeutics-kostaive-the-first-self-amplifying-mrna","source_type":"Press Release","status":"","target_date":"","time":"08:12:30","updated":1739538867},{"commentary":"","companies":[{"cik":"1808898","id":"603cef7ab9e30d000188cf81","name":"Benitec Biopharma Inc","securities":[{"exchange":"NASDAQ","symbol":"BNTC"}]}],"created":1739538665,"date":"2025-02-14","drug":{"generic":false,"id":"613918e1b6abe40001f050d6","indication_symptom":["Oculopharyngeal Muscular Dystrophy (OPMD)"],"name":"BB-301"},"event_type":"Abstract","id":"67af40e92b94b70001f8f7b4","nic_number":"","notes":"","outcome":"Benitec Biopharma Inc. announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a Clinical Treatment Study ongoing in Subjects diagnosed with Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia. Interim clinical study updates for the first three Subjects will be discussed in an oral presentation at the Muscular Dystrophy Association Clinical and Scientific Conference on March 19, 2025 at 1:15 pm Central Time.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43727341/benitec-biopharma-announces-acceptance-of-late-breaking-oral-abstract-for-the-bb-301-phase-1b2a-cl","source_type":"Press Release","status":"Phase 1b/2a","target_date":"","time":"08:11:05","updated":1739538729},{"commentary":"","companies":[{"cik":"","id":"664c5fb857d42200014c0522","name":"OS Therapies Inc","securities":[]}],"created":1739537037,"date":"2025-02-14","drug":{"generic":false,"id":"66a0e0e1d989140001502fc2","indication_symptom":[" In patients with HER2-expressing solid tumors in breast cancer and other cancers"],"name":"OST-HER2"},"event_type":"Provided Update","id":"67af3a8db1c67f0001374513","nic_number":"","notes":"","outcome":"OS Therapies, Inc. announced that it has entered into agreements for the commercial manufacture of OST-HER2","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43726521/os-therapies-initiates-commercial-ready-manufacturing-of-ost-her2-to-support-anticipated-biologics","source_type":"Press Release","status":"","target_date":"","time":"07:43:57","updated":1739537090},{"commentary":"","companies":[{"cik":"","id":"67af39fcb156400001be35b5","name":"Medicus Pharma Ltd","securities":[{"exchange":"NASDAQ","symbol":"MDCX"}]}],"created":1739536820,"date":"2025-02-14","drug":{"generic":false,"id":"67af39cdb156400001be35a9","indication_symptom":["For the Treatment of Nodular Basal Cell Carcinoma"],"name":"SKNJCT-003"},"event_type":"Provided Update","id":"67af39b4b156400001be359e","nic_number":"","notes":"","outcome":"Medicus Pharma Ltd. announce that its phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43726369/medicus-pharma-provides-update-on-sknjct-003-phase-2-clinical-study-for-the-treatment-of-nodular-b","source_type":"Press Release","status":"Phase 2","target_date":"","time":"07:40:20","updated":1739537026},{"commentary":"","companies":[{"cik":"1187953","id":"603cef7cb9e30d000188e6e8","name":"Creative Medical Technology Holdings Inc","securities":[{"exchange":"OTC","symbol":"CELZ"}]}],"created":1739536069,"date":"2025-02-14","drug":{"generic":false,"id":"67abc343dcc94e0001182714","indication_symptom":["For the treatment of chronic lower back pain."],"name":"AlloStem"},"event_type":"Provided Update","id":"67af36c5b156400001be353d","nic_number":"","notes":"","outcome":"Creative Medical Technology Holdings, Inc. announced compelling mid-term follow-up data from its StemSpine® pilot study utilizing its AlloStem™ cells for the treatment of chronic lower back pain.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43725536/creative-medical-technology-holdings-announces-mid-term-follow-up-study-data-reporting-significant","source_type":"Press Release","status":"","target_date":"","time":"07:27:49","updated":1739536191},{"commentary":"","companies":[{"cik":"1512717","id":"603cef79b9e30d000188ca29","name":"Theratechnologies Inc","securities":[{"exchange":"TSE","symbol":"TH"},{"exchange":"NASDAQ","symbol":"THTX"}]}],"created":1739529858,"date":"2025-02-13","drug":{"generic":false,"id":"65afb1fded39a30001463e5e","indication_symptom":["For the reduction of excess abdominal fat in adults with HIV who have lipodystrophy."],"name":"Tesamorelin"},"event_type":"Provided Update","id":"67af1e82b1c67f00013742ec","nic_number":"","notes":"","outcome":"Theratechnologies Inc. announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV®.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43717960/theratechnologies-resumes-distribution-of-egrifta-sv","source_type":"Press Release","status":"","target_date":"","time":"05:44:18","updated":1739536077},{"commentary":"","companies":[{"cik":"1345099","id":"603cef7ab9e30d000188d03d","name":"Mesoblast Ltd","securities":[{"exchange":"OTC","symbol":"MEOBF"},{"exchange":"NASDAQ","symbol":"MESO"}]}],"created":1739529690,"date":"2025-02-13","drug":{"generic":false,"id":"650c1e618345120001a3d0eb","indication_symptom":[" For the treatment of severe and life-threatening inflammatory conditions. "],"name":"RYONCIL"},"event_type":"Provided Update","id":"67af1ddab1c67f00013742bc","nic_number":"","notes":"","outcome":"Mesoblast Limited announced that its recently approved product Ryoncil® (remestemcel-L) is being highlighted at the 2025 Transplantation \u0026 Cellular Therapy Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR), the industry's premier conference taking place this week in Honolulu, HI.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43717138/ryoncil-fda-approval-and-market-launch-highlighted-at-tandem-transplantation-meetings","source_type":"Press Release","status":"","target_date":"","time":"05:41:30","updated":1739529767},{"commentary":"","companies":[{"cik":"14272","id":"603cef78b9e30d000188b6a3","name":"Bristol-Myers Squibb Company","securities":[{"exchange":"NYSE","symbol":"BMY"},{"exchange":"OTC","symbol":"BMYMP"}]}],"created":1739484184,"date":"2025-02-13","drug":{"generic":false,"id":"67abc343dcc94e0001182716","indication_symptom":["For the adjuvant treatment of patients with completely resected stage III-IV melanoma"],"name":"Opdualag"},"event_type":"Endpoint Missed","id":"67ae6c182b94b70001f8f0df","nic_number":"","notes":"","outcome":"Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43712789/bristol-myers-squibb-provides-update-on-phase-3-relativity-098-trial","source_type":"Press Release","status":"Phase 3","target_date":"","time":"17:03:04","updated":1739484363},{"commentary":"","companies":[{"cik":"1737287","id":"603cef7eb9e30d000188fda5","name":"Allogene Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"ALLO"}]}],"created":1739483576,"date":"2025-02-13","drug":{"generic":false,"id":"66741da772eac3000118a58a","indication_symptom":["For Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse"],"name":"Cemacabtagene Ansegedleucel"},"event_type":"Data Publication","id":"67ae69b82b94b70001f8f08d","nic_number":"","notes":"","outcome":"Allogene Therapeutics, Inc. announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) as a Rapid Communication in the Journal of Clinical Oncology.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43713543/allogene-therapeutics-announces-publication-of-durable-response-data-from-phase-1-alphaalpha2-tria","source_type":"Press Release","status":"Phase 1","target_date":"","time":"16:52:56","updated":1739483646},{"commentary":"","companies":[{"cik":"","id":"60589bcc36622a00016516f8","name":"Virpax Pharmaceuticals, Inc.","securities":[]}],"created":1739480930,"date":"2025-02-13","drug":{"generic":false,"id":"6058bbe136622a0001789621","indication_symptom":["Liposomal (Hydro) Gel Technology for postoperative pain management"],"name":"Probudur"},"event_type":"Provided Update","id":"67ae5f622b94b70001f8ed12","nic_number":"","notes":"","outcome":"Virpax Pharmaceuticals, Inc announced the completion of the full study that followed the initial Probudur™ pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43711650/virpax-confirms-positive-results-with-us-army-with-probudur-for-combat-care-study","source_type":"Press Release","status":"","target_date":"","time":"16:08:50","updated":1739480973},{"commentary":"","companies":[{"cik":"1570562","id":"603cef7eb9e30d000188fc0d","name":"Evolus Inc","securities":[{"exchange":"NASDAQ","symbol":"EOLS"}]}],"created":1739480827,"date":"2025-02-13","drug":{"generic":false,"id":"664b3fa9b932e6000172873a","indication_symptom":["Evolus dermal filler",""],"name":"Evolysse™"},"event_type":"FDA Approval","id":"67ae5efb2b94b70001f8ecbd","nic_number":"","notes":"","outcome":"Evolus, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43706265/evolus-announces-fda-approval-of-evolysse-form-and-evolysse-smooth-injectable-hyaluronic-acid-gels","source_type":"Press Release","status":"FDA Approved","target_date":"","time":"16:07:07","updated":1739480880},{"commentary":"","companies":[{"cik":"1133818","id":"603cef7cb9e30d000188e0ea","name":"Bio-Path Holdings Inc","securities":[{"exchange":"NASDAQ","symbol":"BPTH"}]}],"created":1739456870,"date":"2025-02-13","drug":{"generic":false,"id":"66c48d64cf36400001781049","indication_symptom":["Treatment for Advanced Solid Tumors"],"name":"BP1001-A"},"event_type":"Provided Update","id":"67ae0166dcc94e0001187f0a","nic_number":"","notes":"","outcome":"Bio-Path Holdings, Inc provides an update from the Company's ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the Company's ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia (AML).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43690774/bio-path-holdings-provides-key-clinical-updates","source_type":"Press Release","status":"Phase 1/1b","target_date":"","time":"09:27:50","updated":1739457009},{"commentary":"","companies":[{"cik":"200406","id":"603cef79b9e30d000188c04b","name":"Johnson \u0026 Johnson","securities":[{"exchange":"NYSE","symbol":"JNJ"}]}],"created":1739456580,"date":"2025-02-13","drug":{"generic":false,"id":"64998c331d538a0001e65472","indication_symptom":["Treatment of alloimmunisedc pregnant individuals at high risk of severe HDFN"],"name":"Nipocalimab"},"event_type":"Data Publication","id":"67ae0044dcc94e0001187efa","nic_number":"","notes":"","outcome":"Johnson \u0026 Johnson announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigational neonatal Fc receptor (FcRn) blocker, in mAbs.a","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43691284/new-nipocalimab-data-published-in-mabs-journal-details-differentiated-molecular-design-clinical-pr","source_type":"Press Release","status":"","target_date":"","time":"09:23:00","updated":1739456629},{"commentary":"","companies":[{"cik":"","id":"613758f9b4035700018d2836","name":"RenovoRx, Inc.","securities":[{"exchange":"NASDAQ","symbol":"RNXT"}]}],"created":1739456192,"date":"2025-02-13","drug":{"generic":false,"id":"613758c4b4035700018d2824","indication_symptom":["Solid Tumors"],"name":"RenovoCath"},"event_type":"Preclinical Data","id":"67adfec0b1c67f000136f4a8","nic_number":"","notes":"","outcome":"RenovoRx, Inc abstract published promising pre-clinical datafrom the use of RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which aims to optimize local and targeted drug delivery in difficult-to-treat cancers.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43690828/renovorx-highlights-promising-pre-clinical-data-abstract-tamp-therapy-platform-offers-potential-to","source_type":"Press Release","status":"","target_date":"","time":"09:16:32","updated":1739456552},{"commentary":"","companies":[{"cik":"","id":"67adff52b1c67f000136f4ea","name":"Conduit Pharmaceuticals Inc.","securities":[{"exchange":"NASDAQ","symbol":"CDT"}]}],"created":1739456300,"date":"2025-02-13","drug":{"generic":false,"id":"67ade05edcc94e0001187b33","indication_symptom":["For Lupus Erythematosus model."],"name":"AZD1656"},"event_type":"Provided Update","id":"67adff2cb1c67f000136f4e3","nic_number":"","notes":"","outcome":"Conduit Pharmaceuticals Inc. announce an agreement with Charles River Laboratories Inc (\"Charles River\") to evaluate AZD1656 (and its derivatives) in a clinically relevant Systemic Lupus Erythematosus model.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43690749/conduit-pharmaceuticals-partners-with-charles-river-in-clinically-relevant-systemic-lupus-erythema","source_type":"Press Release","status":"","target_date":"","time":"09:18:20","updated":1739456478},{"commentary":"","companies":[{"cik":"1595248","id":"603cef7eb9e30d000188fb0d","name":"Genprex Inc","securities":[{"exchange":"NASDAQ","symbol":"GNPX"}]}],"created":1739456237,"date":"2025-02-13","drug":{"generic":false,"id":"6605e3c31d430a0001e539eb","indication_symptom":["For the NPRL2 tumor suppressor gene"],"name":"Oncoprex"},"event_type":"Provided Update","id":"67adfeedb1c67f000136f4bc","nic_number":"","notes":"","outcome":"Genprex, Inc announced that its research collaborators at a major cancer research center in Houston, Texas have published a new study in eLife titled, \"NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.\"","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43691635/genprex-collaborators-find-nprl2-gene-therapy-using-oncoprex-delivery-system-is-a-potential-treatm","source_type":"Press Release","status":"","target_date":"","time":"09:17:17","updated":1739456279},{"commentary":"","companies":[{"cik":"1528115","id":"603cef7fb9e30d0001890183","name":"Annexon Inc","securities":[{"exchange":"NASDAQ","symbol":"ANNX"}]}],"created":1739456118,"date":"2025-02-13","drug":{"generic":false,"id":"624eec13d52f390001cec18b","indication_symptom":["Geographic Atrophy"],"name":"ANX007"},"event_type":"Presentation","id":"67adfe76b1c67f000136f477","nic_number":"","notes":"","outcome":"Annexon, Inc. announced presentations on ANX007 in geographic atrophy (GA) at the Macula Society 48th Annual Meeting being held February 12-15 in Charlotte Harbor, Florida.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43692147/annexon-announces-presentations-highlighting-anx007-functional-and-structural-differentiation-in-g","source_type":"Press Release","status":"","target_date":"","time":"09:15:18","updated":1739456165},{"commentary":"","companies":[{"cik":"925741","id":"603cef78b9e30d000188bdc5","name":"BioCardia Inc","securities":[{"exchange":"NASDAQ","symbol":"BCDA"}]}],"created":1739455970,"date":"2025-02-13","drug":{"generic":false,"id":"67abc343dcc94e0001182718","indication_symptom":["For Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)"],"name":"BCDA-03"},"event_type":"Enrollment Update","id":"67adfde2b1c67f000136f427","nic_number":"","notes":"","outcome":"BioCardia, announced today completion of enrollment and dosing in the low dose cohort in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43692141/biocardia-reports-completion-of-low-dose-cohort-enrollment-for-cardiallo-phase-iii-clinical-trial-","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"09:12:50","updated":1739456083},{"commentary":"","companies":[{"cik":"","id":"6227734a26d793000121444e","name":"TC Biopharm (Holdings) PLC","securities":[{"exchange":"NASDAQ","symbol":"TCBP"}]}],"created":1739455909,"date":"2025-02-13","drug":{"generic":false,"id":"66d6ef99c2ed5b000119a615","indication_symptom":[" In patients with AML or MDS/AML"," with either refractory or relapsed disease."],"name":"TCB008"},"event_type":"Dose Update","id":"67adfda5b1c67f000136f408","nic_number":"","notes":"","outcome":"TC BioPharm announced that it has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43692157/tcbp-announces-successful-completion-of-cohort-a-in-the-achieve-clinical-trial","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"09:11:49","updated":1739455952},{"commentary":"","companies":[{"cik":"1433607","id":"603cef7cb9e30d000188e93d","name":"InspireMD Inc","securities":[{"exchange":"AMEX","symbol":"NSPR"}]}],"created":1739449537,"date":"2025-02-13","drug":{"generic":false,"id":"66e7db7dc2ed5b00011b9250","indication_symptom":["Prime Carotid Stent System"],"name":"CGuard"},"event_type":"Provided Update","id":"67ade4c1dcc94e0001187bc0","nic_number":"","notes":"","outcome":"InspireMD, Inc announced strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II pivotal study of InspireMD's CGuard Prime™ 80 cm carotid stent system for use in Transcarotid Artery Revascularization (TCAR) procedures.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43688508/inspiremd-and-namsa-to-partner-on-cguardians-ii-pivotal-clinical-trial-of-the-cguard-prime-80-cm-c","source_type":"Press Release","status":"","target_date":"","time":"07:25:37","updated":1739449593},{"commentary":"","companies":[{"cik":"1676047","id":"603cef7eb9e30d000188fad4","name":"Nutriband Inc","securities":[{"exchange":"OTC","symbol":"NTRB"}]}],"created":1739448403,"date":"2025-02-13","drug":{"generic":false,"id":"6603ecfbcad84c000182879e","indication_symptom":[" An abuse-deterrent fentanyl transdermal patch."],"name":"AVERSA"},"event_type":"Provided Update","id":"67ade053dcc94e0001187b30","nic_number":"","notes":"","outcome":"Nutriband Inc. announced that it has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa™ Fentanyl, that it has in place with its partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43688524/nutriband-and-kindeva-drug-delivery-formalize-exclusive-development-partnership-for-aversa-fentany","source_type":"Press Release","status":"","target_date":"","time":"07:06:43","updated":1739448485},{"commentary":"","companies":[{"cik":"863894","id":"603cef78b9e30d000188b803","name":"Veru Inc","securities":[{"exchange":"NASDAQ","symbol":"VERU"}]}],"created":1739446650,"date":"2025-02-13","drug":{"generic":false,"id":"609c403cf7862d0001172199","indication_symptom":["Metastatic Castration and AR Targeting Agent Resistant Prostate Cancer"],"name":"Sabizabulin (VERACITY)"},"event_type":"Provided Update","id":"67add97adcc94e0001187a18","nic_number":"","notes":"","outcome":"Veru Inc provided an update on progress of its clinical development programs.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43687694/veru-reports-fiscal-2025-first-quarter-financial-results-and-clinical-program-progress","source_type":"Press Release","status":"","target_date":"","time":"06:37:30","updated":1739446699},{"commentary":"","companies":[{"cik":"1439222","id":"603cef7db9e30d000188f2b2","name":"Agios Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"AGIO"}]}],"created":1739446515,"date":"2025-02-13","drug":{"generic":false,"id":"6494aff4943f950001b1e361","indication_symptom":["Sickle cell disease"],"name":"Mitapivat"},"event_type":"Primary Endpoint","id":"67add8f3b156400001bde8ff","nic_number":"","notes":"","outcome":"Agios Pharmaceuticals, announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to \u003c18 years with PK deficiency who are not regularly transfused achieved its primary endpoint of hemoglobin response.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43687696/agios-phase-3-activate-kids-study-of-mitapivat-in-children-with-pyruvate-kinase-pk-deficiency-not-","source_type":"Press Release","status":"Phase 3","target_date":"","time":"06:35:15","updated":1739446624},{"commentary":"","companies":[{"cik":"1676725","id":"603cef7eb9e30d000188ff08","name":"IDEAYA Biosciences Inc","securities":[{"exchange":"NASDAQ","symbol":"IDYA"}]}],"created":1739444805,"date":"2025-02-13","drug":{"generic":false,"id":"6078c2a94853ea0001eb188a","indication_symptom":["Solid Tumors"],"name":"IDE397"},"event_type":"Provided Update","id":"67add245b156400001bde867","nic_number":"","notes":"","outcome":"IDEAYA Biosciences, Inc. announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences, Inc. (Gilead) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion non-small cell lung cancer (NSCLC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43687015/ideaya-announces-further-gilead-sciences-clinical-study-collaboration-evaluating-combination-of-tr","source_type":"Press Release","status":"","target_date":"","time":"06:06:45","updated":1739444879},{"commentary":"","companies":[{"cik":"","id":"6537b7a40d10db0001eb3939","name":"NKGen Biotech Inc","securities":[]}],"created":1739366056,"date":"2025-02-12","drug":{"generic":false,"id":"64f6d01badd8280001ff4e92","indication_symptom":["To Treat Alzheimer's Disease"],"name":"troculeucel (SNK01)"},"event_type":"Designation Grant","id":"67ac9ea8b1c67f000136aa17","nic_number":"","notes":"","outcome":"NKGen Biotech, Inc. announced that the U.S. Food and Drug Administration (\"FDA\") has granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (\"AD\").","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43655034/nkgen-biotech-receives-u-s-fda-fast-track-designation-for-troculeucel-for-the-treatment-of-moderat","source_type":"Press Release","status":"Fast Track Designation","target_date":"","time":"08:14:16","updated":1739971128},{"commentary":"","companies":[{"cik":"1133818","id":"603cef7cb9e30d000188e0ea","name":"Bio-Path Holdings Inc","securities":[{"exchange":"NASDAQ","symbol":"BPTH"}]}],"created":1739394320,"date":"2025-02-12","drug":{"generic":false,"id":"6125022ab4035700018c1f19","indication_symptom":["Refractory/relapsed acute myeloid leukemia (AML) "],"name":"BP1002 (AML)"},"event_type":"Provided Update","id":"67ad0d10dcc94e0001186ded","nic_number":"","notes":"","outcome":"Bio-Path Holdings, Inc today provides an update from the Company's ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of refractory/relapsed acute myeloid leukemia (AML), including venetoclax-resistant patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43674377/bio-path-holdings-provides-update-from-phase-11b-clinical-trial-of-bp1002-for-treatment-of-refract","source_type":"Press Release","status":"Phase 1/1b","target_date":"","time":"16:05:20","updated":1739394395},{"commentary":"","companies":[{"cik":"1060736","id":"603cef78b9e30d000188bb1a","name":"Seagen Inc","securities":[{"exchange":"NASDAQ","symbol":"SGEN"}]},{"cik":"78003","id":"603cef79b9e30d000188c196","name":"Pfizer Inc","securities":[{"exchange":"NYSE","symbol":"PFE"}]}],"created":1739394058,"date":"2025-02-12","drug":{"generic":false,"id":"6489b0c438ab3c0001934f0c","indication_symptom":["Prescription medicine directed against the CD30 protein"],"name":"ADCETRIS"},"event_type":"FDA Approval","id":"67ad0c0adcc94e0001186db7","nic_number":"","notes":"","outcome":"Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor (CAR) T-cell therapy.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43666802/u-s-fda-approves-pfizers-adcetris-combination-regimen-for-the-treatment-of-relapsedrefractory-diff","source_type":"Press Release","status":"supplemental Biologics License Applications (sBLA)","target_date":"","time":"16:00:58","updated":1739394135},{"commentary":"","companies":[{"cik":"1098972","id":"603cef78b9e30d000188bd44","name":"Agenus Inc","securities":[{"exchange":"NASDAQ","symbol":"AGEN"}]}],"created":1739393960,"date":"2025-02-12","drug":{"generic":false,"id":"6076eb612290f10001c67d85","indication_symptom":["Multiple myeloma"],"name":"AgenT-797"},"event_type":"Oral presentation","id":"67ad0ba8dcc94e0001186d87","nic_number":"","notes":"","outcome":"MiNK Therapeutics, announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43668464/mink-therapeutics-to-present-updated-data-from-phase-2-study-testing-agent-797-in-gastric-cancer-a","source_type":"Press Release","status":"","target_date":"","time":"15:59:20","updated":1739394010},{"commentary":"","companies":[{"cik":"1668243","id":"603cef7eb9e30d000188fa66","name":"UroGen Pharma Ltd","securities":[{"exchange":"NASDAQ","symbol":"URGN"}]}],"created":1739366715,"date":"2025-02-12","drug":{"generic":false,"id":"6489b22c38ab3c0001934f62","indication_symptom":[" For primary chemoablative treatment of LG-UTUC in adults."],"name":"JELMYTO® (mitomycin)"},"event_type":"Results","id":"67aca13bb156400001bd99da","nic_number":"","notes":"","outcome":"UroGen Pharma Ltd. today highlights results from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial cancer (LG-UTUC) in adult patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43655007/data-from-a-long-term-follow-up-study-to-the-olympus-trial-that-shows-a-median-duration-of-respons","source_type":"Press Release","status":"","target_date":"","time":"08:25:15","updated":1739366758},{"commentary":"","companies":[{"cik":"","id":"6628d138ed9ebb000172cc47","name":"Alto Neuroscience Inc","securities":[]}],"created":1739366205,"date":"2025-02-12","drug":{"generic":false,"id":"675842ecaed0910001a272b2","indication_symptom":["adjunctive treatment in MDD"],"name":"ALTO-300"},"event_type":"Top-line results","id":"67ac9f3db156400001bd9975","nic_number":"","notes":"","outcome":"Alto Neuroscience, Inc announced that Topline results are expected in mid-2026","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43655236/alto-neuroscience-announces-favorable-outcome-from-interim-analysis-of-alto-300-phase-2b-major-dep","source_type":"Press Release","status":"","target_date":"2026-H1","time":"08:16:45","updated":1739366255},{"commentary":"","companies":[{"cik":"","id":"6628d138ed9ebb000172cc47","name":"Alto Neuroscience Inc","securities":[]}],"created":1739366167,"date":"2025-02-12","drug":{"generic":false,"id":"675842ecaed0910001a272b2","indication_symptom":["adjunctive treatment in MDD"],"name":"ALTO-300"},"event_type":"Provided Update","id":"67ac9f17b156400001bd9960","nic_number":"","notes":"","outcome":"Alto Neuroscience, Inc announced a favorable outcome from the planned interim analysis for the Phase 2b trial of ALTO-300 as an adjunctive treatment for patients with major depressive disorder (MDD).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43655236/alto-neuroscience-announces-favorable-outcome-from-interim-analysis-of-alto-300-phase-2b-major-dep","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"08:16:07","updated":1739366255},{"commentary":"","companies":[{"cik":"1055726","id":"603cef79b9e30d000188bfeb","name":"Inovio Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"INO"}]}],"created":1739365587,"date":"2025-02-12","drug":{"generic":false,"id":"64f86125add8280001ff7b2d","indication_symptom":["For the Treatment of Recurrent Respiratory Papillomatosis"],"name":"INO-3107"},"event_type":"Peer-reviewed data","id":"67ac9cd3b1c67f000136a9fa","nic_number":"","notes":"","outcome":"INOVIO announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Communications under the title DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43654992/clinical-and-immunological-results-from-phase-12-study-of-ino-3107-as-a-treatment-for-recurrent-re","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"08:06:27","updated":1739365672},{"commentary":"","companies":[{"cik":"1372299","id":"603cef7db9e30d000188f5da","name":"Ocugen Inc","securities":[{"exchange":"NASDAQ","symbol":"OCGN"}]}],"created":1739364473,"date":"2025-02-12","drug":{"generic":false,"id":"616f90633abe8b00016aad81","indication_symptom":["Dry Age-related Macular Degeneration (Dry AMD)"],"name":"OCU410"},"event_type":"Dose Update","id":"67ac9879b1c67f000136a935","nic_number":"","notes":"","outcome":"Ocugen, Inc. announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410—a novel multifunctional modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43654407/ocugen-inc-announces-dosing-completion-in-the-phase-2-armada-clinical-trial-for-ocu410-a-multifunc","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"07:47:53","updated":1739364526},{"commentary":"","companies":[{"cik":"1370053","id":"603cef7eb9e30d000188f7b0","name":"AnaptysBio Inc","securities":[{"exchange":"NASDAQ","symbol":"ANAB"}]}],"created":1739364378,"date":"2025-02-12","drug":{"generic":false,"id":"6192b70d3dfee90001535c80","indication_symptom":["Healthy Volunteer"],"name":"Rosnilimab (formerly ANB030)"},"event_type":"Data","id":"67ac981a2b94b70001f86b83","nic_number":"","notes":"","outcome":"AnaptysBio, Inc. announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis (RA).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43653924/anaptys-announces-rosnilimab-achieved-positive-results-in-ra-phase-2b-trial-and-highest-ever-repor","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"07:46:18","updated":1739364437},{"commentary":"","companies":[{"cik":"","id":"664c5fb857d42200014c0520","name":"Biodexa Pharmaceuticals PLC","securities":[]}],"created":1739364288,"date":"2025-02-12","drug":{"generic":false,"id":"6666eea6b531ba0001990fb5","indication_symptom":["In Familial Adenomatous Polyposis "],"name":"eRapa"},"event_type":"Designation Grant","id":"67ac97c02b94b70001f86b71","nic_number":"","notes":"","outcome":"Biodexa Pharmaceuticals PLC announced that it has received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43654085/following-positive-phase-2-results-and-orphan-drug-designation-biodexas-fap-drug-receives-fda-fas","source_type":"Press Release","status":"Fast Track Designation","target_date":"","time":"07:44:48","updated":1739364346},{"commentary":"","companies":[{"cik":"882361","id":"603cef78b9e30d000188b93f","name":"Aptose Biosciences Inc","securities":[{"exchange":"TSE","symbol":"APS"},{"exchange":"NASDAQ","symbol":"APTO"}]}],"created":1739362905,"date":"2025-02-12","drug":{"generic":false,"id":"6482dc38fdfac50001750d1b","indication_symptom":["Tuspetinib is a potent inhibitor of FLT3"," SYK"," cKITMUT"," JAK"," and other kinases"],"name":"tuspetinib"},"event_type":"Results","id":"67ac9259b156400001bd95df","nic_number":"","notes":"","outcome":"Aptose Biosciences Inc today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652730/aptoses-frontline-triple-drug-therapy-with-tuspetinib-achieves-notable-responses-in-newly-diagnose","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"07:21:45","updated":1739362971},{"commentary":"","companies":[{"cik":"1398733","id":"603cef7db9e30d000188ef63","name":"Aquestive Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"AQST"}]}],"created":1739362725,"date":"2025-02-12","drug":{"generic":false,"id":"65520424a54dc20001b23f87","indication_symptom":[" For epinephrine prodrug candidate product"],"name":"Anaphylm"},"event_type":"Presentation","id":"67ac91a5b156400001bd95ab","nic_number":"","notes":"","outcome":"Aquestive Therapeutics, Inc. announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652727/aquestive-therapeutics-to-present-new-findings-on-anaphylm-epinephrine-sublingual-film-at-the-2025","source_type":"Press Release","status":"","target_date":"","time":"07:18:45","updated":1739362768},{"commentary":"","companies":[{"cik":"","id":"603cef7bb9e30d000188dea8","name":"OKYO Pharma Ltd","securities":[]}],"created":1739362657,"date":"2025-02-12","drug":{"generic":false,"id":"637b2da09f15fd0001ad91d4","indication_symptom":["Treatment of Dry Eye Disease"],"name":"OK-101"},"event_type":"Provided Update","id":"67ac9161b156400001bd9590","nic_number":"","notes":"","outcome":"OKYO Pharma is pleased to announce that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) \"urcosimod\".","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652715/okyo-pharma-announces-ok-101-officially-assigned-usan-urcosimod","source_type":"Press Release","status":"","target_date":"","time":"07:17:37","updated":1739362711},{"commentary":"","companies":[{"cik":"882796","id":"603cef78b9e30d000188b665","name":"BioCryst Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"BCRX"}]}],"created":1739362586,"date":"2025-02-12","drug":{"generic":false,"id":"603e3ae4b3e2040001494e19","indication_symptom":["Hereditary angioedema (HAE)"],"name":"ORLADEYO (berotralstat)"},"event_type":"Provided Update","id":"67ac911ab156400001bd957e","nic_number":"","notes":"","outcome":"BioCryst Pharmaceuticals, Inc. announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652817/biocryst-launches-orladeyo-berotralstat-in-portugal","source_type":"Press Release","status":"","target_date":"","time":"07:16:26","updated":1739362643},{"commentary":"","companies":[{"cik":"1782999","id":"603cef7eb9e30d000188f711","name":"PureTech Health PLC","securities":[{"exchange":"NASDAQ","symbol":"PRTC"},{"exchange":"OTC","symbol":"PTCHF"}]}],"created":1739362365,"date":"2025-02-12","drug":{"generic":false,"id":"67abc344dcc94e000118271a","indication_symptom":[" lymphatic system"],"name":"Glyph"},"event_type":"Publication","id":"67ac903db156400001bd9524","nic_number":"","notes":"","outcome":"PureTech Health plc noted that its Founded Entity, Seaport Therapeutics announced the publication of new data showcasing the GlyphTM platform's unique ability to enhance drug transport through the lymphatic system for increased therapeutic exposure.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43652945/puretech-founded-entity-seaport-therapeutics-announces-the-publication-of-new-research-demonstrati","source_type":"Press Release","status":"","target_date":"","time":"07:12:45","updated":1739362551},{"commentary":"","companies":[{"cik":"1557746","id":"603cef7eb9e30d000188f7a0","name":"Aclaris Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"ACRS"}]}],"created":1739362276,"date":"2025-02-12","drug":{"generic":false,"id":"66e93a78a63e4e0001f2a640","indication_symptom":["For the Treatment of Moderate to Severe Atopic Dermatitis"],"name":"ATI-2138"},"event_type":"Provided Update","id":"67ac8fe4b156400001bd9509","nic_number":"","notes":"","outcome":"Aclaris Therapeutics, Inc. announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652361/new-publication-highlights-unique-properties-of-ati-2138-a-potent-and-selective-inhibitor-of-itk-a","source_type":"Press Release","status":"","target_date":"","time":"07:11:16","updated":1739362322},{"commentary":"","companies":[{"cik":"1711754","id":"603cef7eb9e30d000188fe71","name":"INmune Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"INMB"}]}],"created":1739362165,"date":"2025-02-12","drug":{"generic":false,"id":"60ec3b56e16dc10001cc4a60","indication_symptom":["High-Risk Myelodysplastic Syndrome (MDS)"],"name":"INKmune"},"event_type":"Dose Update","id":"67ac8f75b156400001bd94b9","nic_number":"","notes":"","outcome":"INmune Bio Inc. pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652740/inmune-bio-opens-phase-ii-in-high-dose-cohort-of-inkmune-trial-in-prostate-cancer","source_type":"Press Release","status":"Phase 1","target_date":"","time":"07:09:25","updated":1739362256},{"commentary":"","companies":[{"cik":"1593984","id":"603cef7db9e30d000188f434","name":"MediWound Ltd","securities":[{"exchange":"NASDAQ","symbol":"MDWD"}]}],"created":1739362094,"date":"2025-02-12","drug":{"generic":false,"id":"605ba9a036622a0001bfe2ef","indication_symptom":["Chronic Wounds"],"name":"EscharEx"},"event_type":"Provided Update","id":"67ac8f2eb156400001bd9479","nic_number":"","notes":"","outcome":"MediWound Ltd announced that Interim analysis planned after 65% of patients complete treatment, expected in mid-2026","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652725/mediwound-initiates-the-value-global-phase-iii-pivotal-trial-of-escharex-for-treatment-of-venous-l","source_type":"Press Release","status":"","target_date":"2026-H1","time":"07:08:14","updated":1739362153},{"commentary":"","companies":[{"cik":"1593984","id":"603cef7db9e30d000188f434","name":"MediWound Ltd","securities":[{"exchange":"NASDAQ","symbol":"MDWD"}]}],"created":1739362053,"date":"2025-02-12","drug":{"generic":false,"id":"605ba9a036622a0001bfe2ef","indication_symptom":["Chronic Wounds"],"name":"EscharEx"},"event_type":"Provided Update","id":"67ac8f05b156400001bd9465","nic_number":"","notes":"","outcome":"MediWound Ltd. announced the initiation of VALUE, a global, pivotal Phase III trial evaluating EscharEx® for the treatment of venous leg ulcers (VLUs).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43652725/mediwound-initiates-the-value-global-phase-iii-pivotal-trial-of-escharex-for-treatment-of-venous-l","source_type":"Press Release","status":"Phase 3","target_date":"","time":"07:07:33","updated":1739362146},{"commentary":"","companies":[{"cik":"1625297","id":"603cef7db9e30d000188f60c","name":"Indivior PLC","securities":[{"exchange":"OTC","symbol":"INVVY"},{"exchange":"OTC","symbol":"IZQVF"}]}],"created":1739348602,"date":"2025-02-12","drug":{"generic":false,"id":"6703c6f3a88f220001ad62e6","indication_symptom":[" For the treatment of moderate to severe opioid use disorder "],"name":"SUBLOCADE"},"event_type":"Provided Update","id":"67ac5a7adcc94e0001182ba2","nic_number":"","notes":"","outcome":"Indivior PLC provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE® (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43648323/indivior-statement-re-delayed-fda-approval-of-sublocade-label-changes","source_type":"Press Release","status":"","target_date":"","time":"03:23:22","updated":1739348663},{"commentary":"","companies":[{"cik":"1370053","id":"603cef7eb9e30d000188f7b0","name":"AnaptysBio Inc","securities":[{"exchange":"NASDAQ","symbol":"ANAB"}]}],"created":1739313485,"date":"2025-02-11","drug":{"generic":false,"id":"6192b70d3dfee90001535c80","indication_symptom":["Healthy Volunteer"],"name":"Rosnilimab (formerly ANB030)"},"event_type":"Provided Update","id":"67abd14ddcc94e0001182833","nic_number":"","notes":"","outcome":"AnaptysBio, Inc announced will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43643332/anaptys-to-announce-top-line-data-from-phase-2b-trial-of-rosnilimab-a-pd-1-depleter-and-agonist-in","source_type":"Press Release","status":"","target_date":"","time":"17:38:05","updated":1739313552},{"commentary":"","companies":[{"cik":"1773427","id":"603cef7eb9e30d000188ffaf","name":"SpringWorks Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"SWTX"}]}],"created":1739313232,"date":"2025-02-11","drug":{"generic":false,"id":"60c90ac2619f580001b5f756","indication_symptom":["Adult and pediatric patients with NF1-associated plexiform neurofibromas (NF1-PN)"],"name":"Mirdametinib"},"event_type":"FDA Approval","id":"67abd050dcc94e00011827fe","nic_number":"","notes":"","outcome":"SpringWorks Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks' MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43643302/springworks-therapeutics-announces-fda-approval-of-gomekli-mirdametinib-for-the-treatment-of-adult","source_type":"Press Release","status":"FDA Approved","target_date":"","time":"17:33:52","updated":1739313316},{"commentary":"","companies":[{"cik":"","id":"679790413729b60001c5d169","name":"Bicara Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"BCAX"}]}],"created":1739309884,"date":"2025-02-11","drug":{"generic":false,"id":"67972479dc32a800013296cf","indication_symptom":["squamous cancer of the anal canal (SCAC)."],"name":"ficerafusp alfa"},"event_type":"Enrollment Update","id":"67abc33cdcc94e0001182711","nic_number":"","notes":"","outcome":"Bicara Therapeutics Inc. announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43639818/bicara-therapeutics-announces-first-patients-enrolled-in-fortifi-hn01-a-pivotal-phase-23-clinical-","source_type":"Press Release","status":"Phase 2/3","target_date":"","time":"16:38:04","updated":1739309963},{"commentary":"","companies":[{"cik":"","id":"67abc165b156400001bd86b3","name":"Cosmos Health Inc","securities":[{"exchange":"NASDAQ","symbol":"COSM"}]}],"created":1739309587,"date":"2025-02-11","drug":{"generic":false,"id":"67ab5890dcc94e000117f269","indication_symptom":["Weight Management Solution"],"name":"CCX0722"},"event_type":"Clinical Trial","id":"67abc213b1c67f00013697f2","nic_number":"","notes":"","outcome":"Cosmos Health Inc. announced that Clinical trials expected to complete in late 2025 or early 2026","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43627268/cosmos-health-enters-final-development-phase-of-ccx0722-weight-management-solution-expected-produ","source_type":"Press Release","status":"","target_date":"","time":"16:33:07","updated":1739309758},{"commentary":"","companies":[{"cik":"","id":"67abc165b156400001bd86b3","name":"Cosmos Health Inc","securities":[{"exchange":"NASDAQ","symbol":"COSM"}]}],"created":1739309586,"date":"2025-02-11","drug":{"generic":false,"id":"67ab5890dcc94e000117f269","indication_symptom":["Weight Management Solution"],"name":"CCX0722"},"event_type":"Provided Update","id":"67abc212b1c67f00013697ea","nic_number":"","notes":"","outcome":"Cosmos Health Inc. announced that Product launch expected in the first or second quarter of 2026","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43627268/cosmos-health-enters-final-development-phase-of-ccx0722-weight-management-solution-expected-produ","source_type":"Press Release","status":"","target_date":"","time":"16:33:06","updated":1739309757},{"commentary":"","companies":[{"cik":"","id":"67abc165b156400001bd86b3","name":"Cosmos Health Inc","securities":[{"exchange":"NASDAQ","symbol":"COSM"}]}],"created":1739309335,"date":"2025-02-11","drug":{"generic":false,"id":"67ab5890dcc94e000117f269","indication_symptom":["Weight Management Solution"],"name":"CCX0722"},"event_type":"Provided Update","id":"67abc117b156400001bd8691","nic_number":"","notes":"","outcome":"Cosmos Health Inc. announced that it is entering the final stage of development for CCX0722, its innovative weight management solution.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43627268/cosmos-health-enters-final-development-phase-of-ccx0722-weight-management-solution-expected-produ","source_type":"Press Release","status":"","target_date":"","time":"16:28:55","updated":1739309757},{"commentary":"","companies":[{"cik":"1187953","id":"603cef7cb9e30d000188e6e8","name":"Creative Medical Technology Holdings Inc","securities":[{"exchange":"OTC","symbol":"CELZ"}]}],"created":1739283922,"date":"2025-02-11","drug":{"generic":false,"id":"63e3a07f691c6f0001d0ab60","indication_symptom":["Novel Cell Therapy for the Treatment of Type 1 Diabetes"],"name":"CELZ-201"},"event_type":"Follow-up data","id":"67ab5dd22b94b70001f829df","nic_number":"","notes":"","outcome":"Creative Medical Technology announced promising one-year follow-up data from the AlloStem ™ (CELZ-201) Type 2 Diabetes pilot study for late-stage patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43624700/creative-medical-technology-reports-positive-one-year-results-for-allostem-type-2-diabetes-program","source_type":"Press Release","status":"","target_date":"","time":"09:25:22","updated":1739283984},{"commentary":"","companies":[{"cik":"1743881","id":"603cef7eb9e30d000188ff2c","name":"BridgeBio Pharma Inc","securities":[{"exchange":"NASDAQ","symbol":"BBIO"}]}],"created":1739283849,"date":"2025-02-11","drug":{"generic":false,"id":"61c9b863a7cbdc00017384c7","indication_symptom":["Symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM)"],"name":"Acoramidis (ATTRibute-CM)"},"event_type":"Marketing authorization","id":"67ab5d892b94b70001f829c3","nic_number":"","notes":"","outcome":"BridgeBio Pharma, Inc. announced the European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name BEYONTTRA™, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43624472/beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-approved-by-the-european-commission","source_type":"Press Release","status":"","target_date":"","time":"09:24:09","updated":1739283906},{"commentary":"","companies":[{"cik":"","id":"659ce7728fadc30001181054","name":"Femasys Inc","securities":[]}],"created":1739282444,"date":"2025-02-11","drug":{"generic":false,"id":"67ab5897dcc94e000117f26b","indication_symptom":["For Female Infertility Treatment "],"name":"FemaSeed®"},"event_type":"Provided Update","id":"67ab580c2b94b70001f82742","nic_number":"","notes":"","outcome":"Femasys Inc., announces the receipt of the Medicines \u0026 Healthcare products Regulatory Agency (MHRA) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43623352/femasys-announces-uk-regulatory-approvals-for-femaseed-for-female-infertility-treatment-and-two-di","source_type":"Press Release","status":"UK MHRA Approval","target_date":"","time":"09:00:44","updated":1739282742},{"commentary":"","companies":[{"cik":"1680048","id":"603cef7eb9e30d000188fb23","name":"Mustang Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"MBIO"}]}],"created":1739281499,"date":"2025-02-11","drug":{"generic":false,"id":"672b3465057896000129c96d","indication_symptom":["To Treat Malignant Glioma"],"name":"MB-108"},"event_type":"Provided Update","id":"67ab545b2b94b70001f82577","nic_number":"","notes":"","outcome":"Moleculin Biotech, Inc. announced that Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the \"MIRACLE\" trial) in the first quarter of 2025,","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43622633/moleculin-receives-first-country-approval-in-europe-to-begin-recruiting-for-the-miracle-phase-3-rr","source_type":"Press Release","status":"","target_date":"2025-Q1","time":"08:44:59","updated":1739281552},{"commentary":"","companies":[{"cik":"1680048","id":"603cef7eb9e30d000188fb23","name":"Mustang Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"MBIO"}]}],"created":1739281446,"date":"2025-02-11","drug":{"generic":false,"id":"672b3465057896000129c96d","indication_symptom":["To Treat Malignant Glioma"],"name":"MB-108"},"event_type":"Regulatory Update","id":"67ab54262b94b70001f82568","nic_number":"","notes":"","outcome":"Moleculin Biotech, Inc., announced it has received first country regulatory approval in Europe to begin recruiting for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine (also known as \"Ara-C\" and for which the combination of Annamycin and Ara-C is referred to as \"AnnAraC\") for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML) (MB-108).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43622633/moleculin-receives-first-country-approval-in-europe-to-begin-recruiting-for-the-miracle-phase-3-rr","source_type":"Press Release","status":"Phase 3","target_date":"","time":"08:44:06","updated":1739281552},{"commentary":"","companies":[{"cik":"","id":"67ab52882b94b70001f823fa","name":"Kairos Pharma Ltd","securities":[{"exchange":"AMEX","symbol":"KAPA"}]}],"created":1739280997,"date":"2025-02-11","drug":{"generic":false,"id":"67a5efa2dcc94e00011758fc","indication_symptom":[" For castrate-resistant prostate cancer patients."],"name":"ENV105"},"event_type":"Provided Update","id":"67ab52652b94b70001f823f1","nic_number":"","notes":"","outcome":"Kairos Pharma Ltd announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43622200/kairos-pharma-adds-huntsman-cancer-institute-for-phase-2-env105-clinical-trial","source_type":"Press Release","status":"Phase 2","target_date":"","time":"08:36:37","updated":1739281134},{"commentary":"","companies":[{"cik":"876343","id":"603cef78b9e30d000188b671","name":"Lineage Cell Therapeutics Inc","securities":[{"exchange":"AMEX","symbol":"LCTX"}]}],"created":1739279370,"date":"2025-02-11","drug":{"generic":false,"id":"65804de03d5b9b0001c0a249","indication_symptom":["Treatment of Chronic and Subacute Spinal Cord Injury"],"name":"OPC1"},"event_type":"Study Initiation","id":"67ab4c0a2b94b70001f8234f","nic_number":"","notes":"","outcome":"Lineage Cell Therapeutics, Inc announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43620799/lineage-initiates-clinical-study-of-opc1-for-spinal-cord-injury","source_type":"Press Release","status":"","target_date":"","time":"08:09:30","updated":1739279551},{"commentary":"","companies":[{"cik":"1759138","id":"603cef7eb9e30d000188ffed","name":"Cabaletta Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"CABA"}]}],"created":1739279245,"date":"2025-02-11","drug":{"generic":false,"id":"6548de99caf68a0001072ba8","indication_symptom":["For Treatment of Generalized Myasthenia Gravis"],"name":"CABA-201"},"event_type":"Updated data","id":"67ab4b8d2b94b70001f8233b","nic_number":"","notes":"","outcome":"Cabaletta Bio, Inc. announced that updated clinical data on resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) will be featured in presentations at the 2025 American Association for the Advancement of Science Annual Meeting, which is being held at the Hynes Convention Center in Boston, MA from February 13-15, 2025, and the 5th International Conference on Lymphocyte Engineering, which is being held at the Holiday Inn Munich – City Center in Munich, Germany from February 20-22, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43620674/cabaletta-bio-announces-presentations-featuring-updated-clinical-data-on-rese-cel-at-upcoming-scie","source_type":"Press Release","status":"","target_date":"","time":"08:07:25","updated":1739279313},{"commentary":"","companies":[{"cik":"","id":"6113ec99b6abe40001edcd68","name":"IN8bio Inc.","securities":[{"exchange":"NASDAQ","symbol":"INAB"}]}],"created":1739279174,"date":"2025-02-11","drug":{"generic":false,"id":"6113ec43a3c6b90001e9ab65","indication_symptom":["Leukemia undergoing haploidentical stem cell transplant (HSCT)"],"name":"INB-100"},"event_type":"New Data","id":"67ab4b462b94b70001f82327","nic_number":"","notes":"","outcome":"IN8bio, Inc announced encouraging new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100, an allogeneic gamma-delta T cell therapy designed to help patients with complex leukemias, including AML.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43620714/in8bio-reports-updated-positive-results-from-phase-1-trial-of-inb-100-in-leukemia-patients","source_type":"Press Release","status":"Phase 1","target_date":"","time":"08:06:14","updated":1739279225},{"commentary":"","companies":[{"cik":"","id":"6565d6f32803140001e088f6","name":"Rallybio Corporation","securities":[]}],"created":1739278990,"date":"2025-02-11","drug":{"generic":false,"id":"6565d6a72803140001e088a2","indication_symptom":["For the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia"],"name":"RLYB212"},"event_type":"Dose Update","id":"67ab4a8e2b94b70001f822e5","nic_number":"","notes":"","outcome":"Rallybio Corporation announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43620705/rallybio-announces-initiation-of-dosing-in-rlyb212-phase-2-clinical-trial","source_type":"Press Release","status":"Phase 2","target_date":"","time":"08:03:10","updated":1739279153},{"commentary":"","companies":[{"cik":"","id":"6565d6f32803140001e088f6","name":"Rallybio Corporation","securities":[]}],"created":1739279028,"date":"2025-02-11","drug":{"generic":false,"id":"6565d6a72803140001e088a2","indication_symptom":["For the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia"],"name":"RLYB212"},"event_type":"Safety Data","id":"67ab4ab42b94b70001f822f4","nic_number":"","notes":"","outcome":"Rallybio Corporation announced that Pharmacokinetic (PK) and safety data from the second trimester are expected in the second quarter of 2025, with PK","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43620705/rallybio-announces-initiation-of-dosing-in-rlyb212-phase-2-clinical-trial","source_type":"Press Release","status":"","target_date":"2025-Q2","time":"08:03:48","updated":1739279153},{"commentary":"","companies":[{"cik":"","id":"6565d6f32803140001e088f6","name":"Rallybio Corporation","securities":[]}],"created":1739279067,"date":"2025-02-11","drug":{"generic":false,"id":"6565d6a72803140001e088a2","indication_symptom":["For the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia"],"name":"RLYB212"},"event_type":"Safety Data","id":"67ab4adb2b94b70001f822fe","nic_number":"","notes":"","outcome":"Rallybio Corporation announced that safety data at the time of delivery expected in the third quarter of 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43620705/rallybio-announces-initiation-of-dosing-in-rlyb212-phase-2-clinical-trial","source_type":"Press Release","status":"","target_date":"2025-Q3","time":"08:04:27","updated":1739279147},{"commentary":"","companies":[{"cik":"1514183","id":"603cef7db9e30d000188ef8d","name":"SILO Pharma Inc","securities":[{"exchange":"OTC","symbol":"SILO"}]}],"created":1739278058,"date":"2025-02-11","drug":{"generic":false,"id":"676171676003c10001981ff2","indication_symptom":["Targeting Chronic Pain and Fibromyalgia"],"name":"SP-26"},"event_type":"Provided Update","id":"67ab46eadcc94e000117ef63","nic_number":"","notes":"","outcome":"Silo Pharma, Inc. announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43620172/silo-pharma-announces-positive-initial-pharmacokinetic-safety-and-tolerability-study-of-sp-26-for-","source_type":"Press Release","status":"","target_date":"","time":"07:47:38","updated":1739278112},{"commentary":"","companies":[{"cik":"1595097","id":"603cef7db9e30d000188f5ef","name":"Corbus Pharmaceuticals Holdings Inc","securities":[{"exchange":"NASDAQ","symbol":"CRBP"}]}],"created":1739277181,"date":"2025-02-11","drug":{"generic":false,"id":"64b059e39c212e0001506c5e","indication_symptom":["Targets the expression of Nectin-4 on cancer cells "],"name":"CRB-701"},"event_type":"Abstract","id":"67ab437ddcc94e000117ed36","nic_number":"","notes":"","outcome":"Corbus Pharmaceuticals announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (\"Western study\") of CRB-701 (SYS6002) has been released.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43619811/corbus-pharmaceuticals-announces-clinical-data-for-crb-701-from-western-dose-escalation-study-to-b","source_type":"Press Release","status":"","target_date":"","time":"07:33:01","updated":1739277231},{"commentary":"","companies":[{"cik":"1689813","id":"603cef7eb9e30d000188fa68","name":"Biohaven Pharmaceutical Holding Co Ltd","securities":[{"exchange":"NYSE","symbol":"BHVN"}]}],"created":1739277097,"date":"2025-02-11","drug":{"generic":false,"id":"6115ad2fb6abe40001ee0734","indication_symptom":["Spinocerebellar Ataxia (SCA) "],"name":"Troriluzole (SCA)"},"event_type":"FDA review","id":"67ab4329dcc94e000117ecf1","nic_number":"","notes":"","outcome":"Biohaven Ltd. announced that the US Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for troriluzole for the treatment of adult patients with spinocerebellar ataxia (SCA) and has granted Priority Review.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43619822/biohaven-announces-fda-acceptance-and-priority-review-of-troriluzole-new-drug-application-for-the-","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"","time":"07:31:37","updated":1739277158},{"commentary":"","companies":[{"cik":"1438533","id":"603cef7db9e30d000188ebfc","name":"Travere Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"TVTX"}]}],"created":1739275946,"date":"2025-02-11","drug":{"generic":false,"id":"6494aff3943f950001b1e35b","indication_symptom":["Endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression"," generally a UPCR ≥1.5 g/g."],"name":"FILSPARI"},"event_type":"Provided Update","id":"67ab3eaadcc94e000117ea7e","nic_number":"","notes":"","outcome":"Travere Therapeutics, Inc. announced that The sNDA will be based on existing data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI and is expected to be submitted around the end of the first quarter of 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43618921/travere-therapeutics-to-submit-snda-for-filspari-sparsentan-in-fsgs","source_type":"Press Release","status":"","target_date":"2025-Q1","time":"07:12:26","updated":1739276006},{"commentary":"","companies":[{"cik":"1438533","id":"603cef7db9e30d000188ebfc","name":"Travere Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"TVTX"}]}],"created":1739275915,"date":"2025-02-11","drug":{"generic":false,"id":"6494aff3943f950001b1e35b","indication_symptom":["Endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression"," generally a UPCR ≥1.5 g/g."],"name":"FILSPARI"},"event_type":"FDA Meeting","id":"67ab3e8bdcc94e000117ea69","nic_number":"","notes":"","outcome":"Travere Therapeutics, Inc. announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration (FDA) and plans to submit a supplemental New Drug Application (sNDA) seeking traditional approval of FILSPARI for focal segmental glomerulosclerosis (FSGS).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43618921/travere-therapeutics-to-submit-snda-for-filspari-sparsentan-in-fsgs","source_type":"Press Release","status":"Type C Meeting","target_date":"","time":"07:11:55","updated":1739276006},{"commentary":"","companies":[{"cik":"872589","id":"603cef78b9e30d000188ba95","name":"Regeneron Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"REGN"}]}],"created":1739275772,"date":"2025-02-11","drug":{"generic":false,"id":"646dfefcf3e2a000012539cd","indication_symptom":["Designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing."],"name":"Linvoseltamab (BCMAxCD3)"},"event_type":"FDA review","id":"67ab3dfcdcc94e000117ea00","nic_number":"","notes":"","outcome":"Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43618899/linvoseltamab-bla-accepted-for-fda-review-for-the-treatment-of-relapsedrefractory-multiple-myeloma","source_type":"Press Release","status":"supplemental Biologics License Applications (sBLA)","target_date":"","time":"07:09:32","updated":1739275887},{"commentary":"","companies":[{"cik":"872589","id":"603cef78b9e30d000188ba95","name":"Regeneron Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"REGN"}]}],"created":1739275830,"date":"2025-02-11","drug":{"generic":false,"id":"646dfefcf3e2a000012539cd","indication_symptom":["Designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing."],"name":"Linvoseltamab (BCMAxCD3)"},"event_type":"PDUFA Date","id":"67ab3e36dcc94e000117ea1d","nic_number":"","notes":"","outcome":"Regeneron Pharmaceuticals announced that FDA decision expected by July 10, 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43618899/linvoseltamab-bla-accepted-for-fda-review-for-the-treatment-of-relapsedrefractory-multiple-myeloma","source_type":"Press Release","status":"supplemental Biologics License Applications (sBLA)","target_date":"2025-07-10","time":"07:10:30","updated":1739275887},{"commentary":"","companies":[{"cik":"1655759","id":"603cef7eb9e30d000188fd8b","name":"Arvinas Inc","securities":[{"exchange":"NASDAQ","symbol":"ARVN"}]}],"created":1739275714,"date":"2025-02-11","drug":{"generic":false,"id":"663b54cd4acd7300013dafa9","indication_symptom":["For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer."],"name":"Vepdegestrant"},"event_type":"Clinical Update","id":"67ab3dc2dcc94e000117e9c9","nic_number":"","notes":"","outcome":"Arvinas, Inc. provided a clinical update","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43618871/arvinas-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update","source_type":"Press Release","status":"","target_date":"","time":"07:08:34","updated":1739275760},{"commentary":"","companies":[{"cik":"","id":"67ab3d20dcc94e000117e986","name":"Third Harmonic Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"THRD"}]}],"created":1739275519,"date":"2025-02-11","drug":{"generic":false,"id":"67a5efa2dcc94e00011758fe","indication_symptom":["In chronic spontaneous urticaria"],"name":"THB335"},"event_type":"Results","id":"67ab3cffdcc94e000117e979","nic_number":"","notes":"","outcome":"Third Harmonic Bio, Inc. announced results from its Phase 1 single and multiple ascending dose (SAD/MAD) clinical trial of THB335 in healthy volunteers.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43618804/third-harmonic-bio-announces-phase-1-clinical-results-for-thb335-and-provides-corporate-strategic-","source_type":"Press Release","status":"Phase 1","target_date":"","time":"07:05:19","updated":1739275673},{"commentary":"","companies":[{"cik":"310158","id":"603cef78b9e30d000188b9a4","name":"Merck \u0026 Co Inc","securities":[{"exchange":"NYSE","symbol":"MRK"}]}],"created":1739275394,"date":"2025-02-11","drug":{"generic":false,"id":"63ff3c0b90259800010cd383","indication_symptom":["Evaluating neoadjuvant KEYTRUDA plus chemotherapy"],"name":"KEYNOTE-671"},"event_type":"Approved","id":"67ab3c82dcc94e000117e954","nic_number":"","notes":"","outcome":"Merck announced that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43618874/health-canada-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-adult-patients-with-rese","source_type":"Press Release","status":"Health Canada Approval","target_date":"","time":"07:03:14","updated":1739275483},{"commentary":"","companies":[{"cik":"1379006","id":"603cef7bb9e30d000188dbe6","name":"Nanoviricides Inc","securities":[{"exchange":"AMEX","symbol":"NNVC"}]}],"created":1739274558,"date":"2025-02-11","drug":{"generic":false,"id":"65536a7b7f07f10001c945eb","indication_symptom":["For MPox and Smallpox virus infections"],"name":"NV-387"},"event_type":"Provided Update","id":"67ab393edcc94e000117e7fb","nic_number":"","notes":"","outcome":"NanoViricides, Inc. declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu virus H5N1 likely cannot escape despite its ability to mutate rapidly with genomic changes.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43618143/nanoviricides-drug-can-fight-bird-flu-pandemic-h5n1-virus-cannot-escape","source_type":"Press Release","status":"","target_date":"","time":"06:49:18","updated":1739274597},{"commentary":"","companies":[{"cik":"","id":"655206ffb3615100015df138","name":"Lipella Pharmaceuticals Inc","securities":[]}],"created":1739274458,"date":"2025-02-11","drug":{"generic":false,"id":"655204e1207b9d0001912b70","indication_symptom":["For the treatment of oral Graft-versus-Host Disease (GvHD). "],"name":"LP-310"},"event_type":"Analysis","id":"67ab38dadcc94e000117e7b5","nic_number":"","notes":"","outcome":"Lipella Pharmaceuticals Inc. today shared topline analysis of its Phase 2a multicenter dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (\"OLP\").","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43617254/lipella-pharmaceuticals-reports-positive-topline-phase-2a-results-for-lp-310-in-the-treatment-of-o","source_type":"Press Release","status":"Phase 2a","target_date":"","time":"06:47:38","updated":1739274513},{"commentary":"","companies":[{"cik":"1724521","id":"603cef7eb9e30d000188fc31","name":"Arcus Biosciences Inc","securities":[{"exchange":"NYSE","symbol":"RCUS"}]}],"created":1739225639,"date":"2025-02-10","drug":{"generic":false,"id":"67a5efa3dcc94e0001175900","indication_symptom":["In patients that had received both prior TKI and anti-PD-1 therapy. "],"name":"ARC-20"},"event_type":"Presentation","id":"67aa7a27b156400001bd4275","nic_number":"","notes":"","outcome":"Arcus Biosciences, Inc announced that data from the ARC-20 study will be presented in a rapid oral session at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium taking place February 13 – 15, 2025, in San Francisco, CA.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43610058/arcus-biosciences-to-present-new-data-from-casdatifan-a-hif-2a-inhibitor-in-an-oral-presentation-a","source_type":"Press Release","status":"","target_date":"","time":"17:13:59","updated":1739225768},{"commentary":"","companies":[{"cik":"78003","id":"603cef79b9e30d000188c196","name":"Pfizer Inc","securities":[{"exchange":"NYSE","symbol":"PFE"}]}],"created":1739225388,"date":"2025-02-10","drug":{"generic":false,"id":"650c1e628345120001a3d0f3","indication_symptom":["For the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) "],"name":"EV-302"},"event_type":"Follow-up results","id":"67aa792cb156400001bd421f","nic_number":"","notes":"","outcome":"Pfizer Inc and Astellas Pharma Inc announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43610057/pfizer-and-astellas-padcev-enfortumab-vedotin-ejfv-plus-keytruda-pembrolizumab-shows-long-term-eff","source_type":"Press Release","status":"Phase 3","target_date":"","time":"17:09:48","updated":1739225614},{"commentary":"","companies":[{"cik":"","id":"61d3030630778300016a80ee","name":"Immix Biopharma, Inc.","securities":[{"exchange":"NASDAQ","symbol":"IMMX"}]}],"created":1739198132,"date":"2025-02-10","drug":{"generic":false,"id":"646b38d0f01bae000147b9e2","indication_symptom":["NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis."],"name":"NXC-201"},"event_type":"Designation Grant","id":"67aa0eb4dcc94e000117ab31","nic_number":"","notes":"","outcome":"Immix Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43593506/immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-nxc-201-s","source_type":"Press Release","status":"Regenerative Medicine Advanced Therapy (RMAT) Designation","target_date":"","time":"09:35:32","updated":1739198189},{"commentary":"","companies":[{"cik":"","id":"6227734a26d793000121444e","name":"TC Biopharm (Holdings) PLC","securities":[{"exchange":"NASDAQ","symbol":"TCBP"}]}],"created":1739197119,"date":"2025-02-10","drug":{"generic":false,"id":"66d6ef99c2ed5b000119a615","indication_symptom":[" In patients with AML or MDS/AML"," with either refractory or relapsed disease."],"name":"TCB008"},"event_type":"Dosing Update","id":"67aa0abfdcc94e000117a7cb","nic_number":"","notes":"","outcome":"TC BioPharm (Holdings) announced the first Cohort B patient in the ACHIEVE Phase 2B UK trial of TCB008 in Acute Myeloid Leukemia has completed the full dosing regimen.","outcome_brief":"","source_link":"https://www.benzinga.com/general/biotech/25/02/43592814/exclusive-nano-cap-tc-biopharm-concludes-initial-cohort-b-patient-dosing-in-mid-stage-leukemia-trial-data-readout-by-end-of-2025","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"09:18:39","updated":1739197191},{"commentary":"","companies":[{"cik":"1729944","id":"603cef7eb9e30d000188fdab","name":"IMAC Holdings Inc","securities":[{"exchange":"NASDAQ","symbol":"IMAC"}]}],"created":1739197008,"date":"2025-02-10","drug":{"generic":false,"id":"67a5efa3dcc94e0001175902","indication_symptom":["In Predicting Breast Cancer Therapy Response"],"name":"AKT–mTOR"},"event_type":"Publication","id":"67aa0a50dcc94e000117a7a8","nic_number":"","notes":"","outcome":"Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. announces the publication of a significant study in the British Journal of Cancer titled \"Functional activation of the AKT–mTOR signalling axis in a real-world metastatic breast cancer cohort\".","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43592798/ignite-proteomics-announces-publication-of-study-demonstrating-superiority-of-protein-activation-a","source_type":"Press Release","status":"","target_date":"","time":"09:16:48","updated":1739197102},{"commentary":"","companies":[{"cik":"1622229","id":"603cef7eb9e30d000188fc40","name":"Cogent Biosciences Inc","securities":[{"exchange":"NASDAQ","symbol":"COGT"}]}],"created":1739196937,"date":"2025-02-10","drug":{"generic":false,"id":"62a33cdc82e96e000155202b","indication_symptom":["Advanced Systemic Mastocytosis (AdvSM)"],"name":"Bezuclastinib"},"event_type":"Poster Presentation","id":"67aa0a09dcc94e000117a78e","nic_number":"","notes":"","outcome":"Cogent Biosciences, Inc announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma \u0026 Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43592799/cogent-biosciences-announces-bezuclastinib-poster-in-nonadvanced-systemic-mastocytosis-nonadvsm-at","source_type":"Press Release","status":"","target_date":"","time":"09:15:37","updated":1739196979},{"commentary":"","companies":[{"cik":"1799788","id":"603cef7fb9e30d000189013c","name":"Greenwich LifeSciences Inc","securities":[{"exchange":"NASDAQ","symbol":"GLSI"}]}],"created":1739196798,"date":"2025-02-10","drug":{"generic":false,"id":"618d7bc53dfee9000153070c","indication_symptom":["Breast cancer recurrences "],"name":"GLSI-100"},"event_type":"Provided Update","id":"67aa097edcc94e000117a77b","nic_number":"","notes":"","outcome":"Greenwich LifeSciences, announced the update on FLAMINGO-01 open label HLA data.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43587279/greenwich-lifesciences-provides-update-on-open-label-hla-data-from-flamingo-01","source_type":"Press Release","status":"","target_date":"","time":"09:13:18","updated":1739196881},{"commentary":"","companies":[{"cik":"906709","id":"603cef79b9e30d000188c07e","name":"Nektar Therapeutics","securities":[{"exchange":"NASDAQ","symbol":"NKTR"}]}],"created":1739196725,"date":"2025-02-10","drug":{"generic":false,"id":"6501af9c9ab00f00016a4d02","indication_symptom":[" For the treatment of atopic dermatitis."],"name":"Rezpegaldesleukin"},"event_type":"Designation Grant","id":"67aa0935dcc94e000117a75e","nic_number":"","notes":"","outcome":"Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43588402/nektar-therapeutics-receives-fast-track-designation-for-rezpegaldesleukin-for-the-treatment-of-mod","source_type":"Press Release","status":"Fast Track Designation","target_date":"","time":"09:12:05","updated":1739196775},{"commentary":"","companies":[{"cik":"1285819","id":"603cef7bb9e30d000188d970","name":"Omeros Corp","securities":[{"exchange":"NASDAQ","symbol":"OMER"}]}],"created":1739196642,"date":"2025-02-10","drug":{"generic":false,"id":"6045f55fe74cfd0001ed6961","indication_symptom":["Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)"],"name":"Narsoplimab"},"event_type":"Presentation","id":"67aa08e2dcc94e000117a741","nic_number":"","notes":"","outcome":"Omeros Corporation announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation \u0026 Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 12-15, 2025 in Honolulu, Hawaii.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43592291/omeros-corporation-announces-upcoming-presentations-detailing-outcomes-of-narsoplimab-treatment-fo","source_type":"Press Release","status":"","target_date":"","time":"09:10:42","updated":1739196680},{"commentary":"","companies":[{"cik":"","id":"61029fc2b403570001890faa","name":"Palisade Bio, Inc.","securities":[{"exchange":"NASDAQ","symbol":"PALI"}]}],"created":1739196181,"date":"2025-02-10","drug":{"generic":false,"id":"6616450f84104e0001863de5","indication_symptom":["For patients affected by UC."],"name":"PALI-2108"},"event_type":"Data Presentation","id":"67aa0715dcc94e000117a6d5","nic_number":"","notes":"","outcome":"Palisade Bio, Inc. announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43591737/palisade-bio-presents-positive-preclinical-data-of-pali-2108-for-the-treatment-of-ulcerative-colit","source_type":"Press Release","status":"","target_date":"","time":"09:03:01","updated":1739196224},{"commentary":"","companies":[{"cik":"882796","id":"603cef78b9e30d000188b665","name":"BioCryst Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"BCRX"}]}],"created":1739196040,"date":"2025-02-10","drug":{"generic":false,"id":"603e3ae4b3e2040001494e19","indication_symptom":["Hereditary angioedema (HAE)"],"name":"ORLADEYO (berotralstat)"},"event_type":"Abstract Presentation","id":"67aa0688dcc94e000117a6af","nic_number":"","notes":"","outcome":"BioCryst Pharmaceuticals, Inc. announced that the company will present five abstracts featuring new clinical and real-world outcomes with oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma \u0026 Immunology (AAAAI) / World Allergy Organization (WAO) joint congress.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43591350/biocryst-to-present-new-orladeyo-berotralstat-results-from-apex-p-pediatric-trial-at-2025-american","source_type":"Press Release","status":"","target_date":"","time":"09:00:40","updated":1739196127},{"commentary":"","companies":[{"cik":"949858","id":"603cef78b9e30d000188bb77","name":"Achieve Life Sciences Inc","securities":[{"exchange":"NASDAQ","symbol":"ACHV"}]}],"created":1739195927,"date":"2025-02-10","drug":{"generic":false,"id":"66571aaaf86556000186d475","indication_symptom":[" For smoking cessation and nicotine dependence",""],"name":"ORCA-OL"},"event_type":"NDA Filing","id":"67aa0617dcc94e000117a693","nic_number":"","notes":"","outcome":"Achieve Life Sciences, Inc announced that Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43591298/achieve-life-sciences-announces-positive-outcome-of-second-data-safety-monitoring-committee-review","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"2025-Q2","time":"08:58:47","updated":1739196024},{"commentary":"","companies":[{"cik":"949858","id":"603cef78b9e30d000188bb77","name":"Achieve Life Sciences Inc","securities":[{"exchange":"NASDAQ","symbol":"ACHV"}]}],"created":1739195875,"date":"2025-02-10","drug":{"generic":false,"id":"66571aaaf86556000186d475","indication_symptom":[" For smoking cessation and nicotine dependence",""],"name":"ORCA-OL"},"event_type":"Provided Update","id":"67aa05e3dcc94e000117a67b","nic_number":"","notes":"","outcome":"Achieve Life Sciences, Inc. announced that the Data Safety Monitoring Committee (DSMC) has recently completed its second independent review of the ongoing ORCA-OL trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43591298/achieve-life-sciences-announces-positive-outcome-of-second-data-safety-monitoring-committee-review","source_type":"Press Release","status":"Data Safety and Monitoring Board (DSMB) Review","target_date":"","time":"08:57:55","updated":1739196023},{"commentary":"","companies":[{"cik":"1055726","id":"603cef79b9e30d000188bfeb","name":"Inovio Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"INO"}]}],"created":1739193416,"date":"2025-02-10","drug":{"generic":false,"id":"64f86125add8280001ff7b2d","indication_symptom":["For the Treatment of Recurrent Respiratory Papillomatosis"],"name":"INO-3107"},"event_type":"Abstract","id":"67a9fc48b156400001bd08a6","nic_number":"","notes":"","outcome":"INOVIO announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43590435/immune-response-data-for-ino-3107-to-be-presented-as-a-poster-at-american-association-for-cancer-r","source_type":"Press Release","status":"","target_date":"","time":"08:16:56","updated":1739193453},{"commentary":"","companies":[{"cik":"","id":"62180a9d6f3eb90001e03887","name":"Jasper Therapeutics, Inc.","securities":[{"exchange":"NASDAQ","symbol":"JSPR"}]}],"created":1739193344,"date":"2025-02-10","drug":{"generic":false,"id":"651d470408e89000019cfd76","indication_symptom":["To address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU)"],"name":"Briquilimab"},"event_type":"Poster Presentation","id":"67a9fc00b156400001bd0895","nic_number":"","notes":"","outcome":"Jasper Therapeutics, announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43590284/jasper-therapeutics-announces-briquilimab-presentations-at-the-american-academy-of-allergy-asthma-","source_type":"Press Release","status":"","target_date":"","time":"08:15:44","updated":1739193390},{"commentary":"","companies":[{"cik":"","id":"656d94032803140001e13ceb","name":"Palvella Therapeutics, Inc","securities":[]}],"created":1739193217,"date":"2025-02-10","drug":{"generic":false,"id":"67811eeb9a903000017e3bae","indication_symptom":["In the Journal of Vascular Anomalies"],"name":"QTORIN™ rapamycin"},"event_type":"Provided Update","id":"67a9fb81b156400001bd087c","nic_number":"","notes":"","outcome":"Palvella Therapeutics, Inc announced that it will expand SELVA, the Company's Phase 3 clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), to include patients ages 3 to 5 years old.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43590177/palvella-therapeutics-to-expand-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel","source_type":"Press Release","status":"Phase 3","target_date":"","time":"08:13:37","updated":1739193324},{"commentary":"","companies":[{"cik":"","id":"653a514cc697190001de835b","name":"Ocean Biomedical Inc","securities":[]}],"created":1739193041,"date":"2025-02-10","drug":{"generic":false,"id":"67a5efa3dcc94e0001175904","indication_symptom":["For non-small cell lung cancer"],"name":"osimertinib"},"event_type":"Publication","id":"67a9fad1b156400001bd0860","nic_number":"","notes":"","outcome":"Ocean Biomedical announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43590161/ocean-biomedical-announces-breakthrough-findings-in-egfr-mutant-lung-cancer-and-plans-for-fda-alig","source_type":"Press Release","status":"","target_date":"","time":"08:10:41","updated":1739193178},{"commentary":"","companies":[{"cik":"","id":"67a9fa412b94b70001f7dd3d","name":"Radiopharm Theranostics","securities":[{"exchange":"NASDAQ","symbol":"RADX"}]}],"created":1739192859,"date":"2025-02-10","drug":{"generic":false,"id":"67a5efa3dcc94e0001175906","indication_symptom":["For for successful detection of brain metastases"],"name":"RAD 101"},"event_type":"Publication","id":"67a9fa1b2b94b70001f7dd35","nic_number":"","notes":"","outcome":"Radiopharm Theranostics announce the publication of a novel imaging approach demonstrating proof-of-concept for the use of RAD 101 for successful detection of brain metastases (both treatment-naïve and previously treated) from a variety of primary solid tumors.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43590166/new-clinical-trial-data-highlights-rad-101-18f-pivalate-successfully-detects-brain-metastases","source_type":"Press Release","status":"","target_date":"","time":"08:07:39","updated":1739193006},{"commentary":"","companies":[{"cik":"","id":"6148bacbf3823900010003f9","name":"Tempest Therapeutics, Inc.","securities":[{"exchange":"NASDAQ","symbol":"TPST"}]}],"created":1739192646,"date":"2025-02-10","drug":{"generic":false,"id":"6148ba898cd4c100016b5b4b","indication_symptom":["First-Line Regimen for Hepatocellular Carcinoma"],"name":"TPST-1120"},"event_type":"Designation Grant","id":"67a9f946b1c67f0001360eb4","nic_number":"","notes":"","outcome":"Tempest Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma (HCC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43590151/tempest-granted-fast-track-designation-from-the-u-s-food-and-drug-administration-for-amezalpat-to-","source_type":"Press Release","status":"Fast Track Designation","target_date":"","time":"08:04:06","updated":1739192702},{"commentary":"","companies":[{"cik":"1539029","id":"603cef7eb9e30d000188f856","name":"Clearside Biomedical Inc","securities":[{"exchange":"NASDAQ","symbol":"CLSD"}]}],"created":1739190074,"date":"2025-02-10","drug":{"generic":false,"id":"60c89d94619f580001b5e07d","indication_symptom":["Neovascular age-related macular degeneration (wet AMD)"],"name":"CLS-AX (axitinib injectable suspension"},"event_type":"Presentation","id":"67a9ef3ab156400001bd07cd","nic_number":"","notes":"","outcome":"Clearside Biomedical, announced today that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43588531/clearside-biomedical-announces-additional-data-from-the-cls-ax-odyssey-phase-2b-trial-presented-at","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"07:21:14","updated":1739190129},{"commentary":"","companies":[{"cik":"","id":"603cef79b9e30d000188c56c","name":"BioRestorative Therapies Inc","securities":[]}],"created":1739189926,"date":"2025-02-10","drug":{"generic":false,"id":"62019623e008470001d6fdb0","indication_symptom":["Chronic Lumbar Disc Disease"],"name":"BRTX-100"},"event_type":"Provided Update","id":"67a9eea6b156400001bd07ac","nic_number":"","notes":"","outcome":"BioRestorative Therapies, announced that its Vice President of Research and Development, Francisco Silva, presented 26–52 week blinded data from the first 15 patients (up from 10 reported previously) with chronic lumbar disc disease (\"cLDD\") enrolled in the ongoing Phase 2 clinical trial of BRTX-100 at the Orthopaedic Research Society (\"ORS\") annual meeting, taking place February 7-11, 2025 in Phoenix, AZ.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43588337/brtx-100-front-and-center-at-ors-2025","source_type":"Press Release","status":"","target_date":"","time":"07:18:46","updated":1739189987},{"commentary":"","companies":[{"cik":"1348911","id":"603cef7eb9e30d000188f64d","name":"KalVista Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"KALV"}]}],"created":1739189827,"date":"2025-02-10","drug":{"generic":false,"id":"65522310a54dc20001b24526","indication_symptom":["Therapy for hereditary angioedema (HAE)."],"name":"sebetralstat"},"event_type":"Data Presentation","id":"67a9ee43b156400001bd0797","nic_number":"","notes":"","outcome":"KalVista Pharmaceuticals, Inc announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma \u0026 Immunology (WSAAI) 2025 Annual Meeting taking place in Waimea, HI from February 9-13, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43588378/kalvista-pharmaceuticals-presents-new-sebetralstat-data-at-the-western-society-of-allergy-asthma-i","source_type":"Press Release","status":"","target_date":"","time":"07:17:07","updated":1739189904},{"commentary":"","companies":[{"cik":"1579428","id":"603cef7eb9e30d000188f7e1","name":"Axsome Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"AXSM"}]}],"created":1739189769,"date":"2025-02-10","drug":{"generic":false,"id":"65770ed9f754e50001dfb950","indication_symptom":["Patients with Major Depressive Disorder "],"name":"Auvelity"},"event_type":"Provided Update","id":"67a9ee09b156400001bd0787","nic_number":"","notes":"","outcome":"Axsome Therapeutics, Inc. announced that it has entered into a settlement agreement with Teva Pharmaceuticals, Inc.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43588347/axsome-therapeutics-announces-settlement-agreement-resolving-auvelity-dextromethorphan-hbr-bupropi","source_type":"Press Release","status":"","target_date":"","time":"07:16:09","updated":1739189808},{"commentary":"","companies":[{"cik":"1711754","id":"603cef7eb9e30d000188fe71","name":"INmune Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"INMB"}]}],"created":1739189637,"date":"2025-02-10","drug":{"generic":false,"id":"67a5efa3dcc94e0001175908","indication_symptom":["For Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)"],"name":"CORDStrom"},"event_type":"Provided Update","id":"67a9ed85b1c67f0001360d11","nic_number":"","notes":"","outcome":"INmune Bio, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43588338/inmune-bio-announces-plan-to-submit-fda-biologics-license-application-bla-seeking-approval-of-cord","source_type":"Press Release","status":"Biologics License Applications (BLA)","target_date":"","time":"07:13:57","updated":1739189755},{"commentary":"","companies":[{"cik":"14272","id":"603cef78b9e30d000188b6a3","name":"Bristol-Myers Squibb Company","securities":[{"exchange":"NYSE","symbol":"BMY"},{"exchange":"OTC","symbol":"BMYMP"}]}],"created":1739189541,"date":"2025-02-10","drug":{"generic":false,"id":"60c1ff910b7e3900011071a8","indication_symptom":["Second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL)"],"name":"Breyanzi (lisocabtagene maraleucel)"},"event_type":"Endpoint Met","id":"67a9ed25b1c67f0001360ced","nic_number":"","notes":"","outcome":"Bristol Myers Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi®(lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary endpoint in the marginal zone lymphoma (MZL) cohort.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43588330/bristol-myers-squibb-announces-positive-topline-results-for-breyanzi-lisocabtagene-maraleucel-in-a","source_type":"Press Release","status":"Phase 2","target_date":"","time":"07:12:21","updated":1739189610},{"commentary":"","companies":[{"cik":"1650648","id":"603cef7eb9e30d000188ffeb","name":"4D Molecular Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"FDMT"}]}],"created":1739182695,"date":"2025-02-08","drug":{"generic":false,"id":"644a571d9eebb200015e3aa6","indication_symptom":["Intravitreal vector"," R100"," and a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi."],"name":"4D-150"},"event_type":"Positive Data","id":"67a9d267b1c67f0001360b98","nic_number":"","notes":"","outcome":"4D Molecular Therapeutics announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population. Additional data were provided on the durability of aflibercept expression for up to two years.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43579183/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-d","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"05:18:15","updated":1739182748},{"commentary":"","companies":[{"cik":"872589","id":"603cef78b9e30d000188ba95","name":"Regeneron Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"REGN"}]}],"created":1739182609,"date":"2025-02-08","drug":{"generic":false,"id":"64998c341d538a0001e6547e","indication_symptom":["For the treatment of patients with wet age-related macular degeneration (wAMD)"," diabetic macular edema (DME) and diabetic retinopathy (DR)",""],"name":"Aflibercept"},"event_type":"Presentation","id":"67a9d211b1c67f0001360b83","nic_number":"","notes":"","outcome":"Regeneron Pharmaceuticals, Inc. announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43579472/eylea-hd-aflibercept-injection-8-mg-positive-phase-3-results-in-patients-with-macular-edema-follow","source_type":"Press Release","status":"Phase 3","target_date":"","time":"05:16:49","updated":1739182660},{"commentary":"","companies":[{"cik":"1746473","id":"603cef7fb9e30d0001890111","name":"Pliant Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"PLRX"}]}],"created":1738966548,"date":"2025-02-07","drug":{"generic":false,"id":"650c1e648345120001a3d104","indication_symptom":["Primary Sclerosing Cholangitis and Suspected Liver Fibrosis"],"name":"Bexotegrast"},"event_type":"Enrollment Update","id":"67a68614dcc94e0001179b7f","nic_number":"","notes":"","outcome":"Pliant Therapeutics, Inc announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43574512/pliant-therapeutics-provides-update-on-beacon-ipf-a-phase-2b3-trial-in-patients-with-idiopathic-pu","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"17:15:48","updated":1738966612},{"commentary":"","companies":[{"cik":"","id":"6063a3ebdbb1f50001cf73c9","name":"Eledon Pharmaceuticals, Inc.","securities":[]}],"created":1738963222,"date":"2025-02-07","drug":{"generic":false,"id":"671f7d9ad453ac0001621926","indication_symptom":["For Type 1 Diabetes "],"name":"tegoprubart"},"event_type":"Provided Update","id":"67a67916b156400001bcf481","nic_number":"","notes":"","outcome":"Eledon Pharmaceuticals, Inc. announced that tegoprubart, the company's investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a transplanted kidney from a genetically modified pig.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43562070/eledon-pharmaceuticals-announces-use-of-tegoprubart-as-key-component-of-immunosuppression-regimen-","source_type":"Press Release","status":"","target_date":"","time":"16:20:22","updated":1738963276},{"commentary":"","companies":[{"cik":"78003","id":"603cef79b9e30d000188c196","name":"Pfizer Inc","securities":[{"exchange":"NYSE","symbol":"PFE"}]}],"created":1738962895,"date":"2025-02-07","drug":{"generic":false,"id":"65f8219bcad84c000180aa7a","indication_symptom":["In the treatment of adult patients with complicated intra-abdominal infections (cIAI)"],"name":"EMBLAVEO"},"event_type":"Approved","id":"67a677cfb156400001bcf45a","nic_number":"","notes":"EMBLAVEO was jointly developed with Pfizer. AbbVie holds the rights to commercialize the therapy in the U.S. and Canada, with Pfizer responsible for commercialization in all other areas.","outcome":"AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43569835/u-s-fda-approves-emblaveo-aztreonam-and-avibactam-for-the-treatment-of-adults-with-complicated-int","source_type":"Press Release","status":"FDA Approved","target_date":"","time":"16:14:55","updated":1738963094},{"commentary":"","companies":[{"cik":"946644","id":"603cef78b9e30d000188bf67","name":"AIM ImmunoTech Inc","securities":[{"exchange":"AMEX","symbol":"AIM"}]}],"created":1738936373,"date":"2025-02-07","drug":{"generic":false,"id":"608811d2eb87ad000173bac0","indication_symptom":["COVID-19 and Other Respiratory Viral Diseases"],"name":"Ampligen"},"event_type":"Provided Update","id":"67a610352b94b70001f793a7","nic_number":"","notes":"","outcome":"AIM ImmunoTech Inc. announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company's antiviral priority development pipeline.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43559477/aim-immunotech-announces-a-planned-follow-up-clinical-study-evaluating-a-combination-treatment-of-","source_type":"Press Release","status":"","target_date":"","time":"08:52:53","updated":1738936413},{"commentary":"","companies":[{"cik":"1367644","id":"603cef7ab9e30d000188cf3a","name":"Emergent BioSolutions Inc","securities":[{"exchange":"NYSE","symbol":"EBS"}]}],"created":1738933665,"date":"2025-02-07","drug":{"generic":false,"id":"669e355dd9891400014fd655","indication_symptom":["Nasal Spray as manifested by respiratory and/or severe central nervous system depression."],"name":"NARCAN"},"event_type":"Provided Update","id":"67a605a1dcc94e0001175aa2","nic_number":"","notes":"","outcome":"Emergent BioSolutions announced today that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro football legend and NARCAN® Nasal Spray spokesperson, Emmitt Smith, as the city welcomes an anticipated 83,000 fans for the Big Game.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43558233/emergent-biosolutions-and-pro-football-legend-emmitt-smith-raise-awareness-of-ready-to-rescue-camp","source_type":"Press Release","status":"","target_date":"","time":"08:07:45","updated":1738933705},{"commentary":"","companies":[{"cik":"922247","id":"603cef79b9e30d000188c51e","name":"Cyclo Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"CYTH"}]}],"created":1738933574,"date":"2025-02-07","drug":{"generic":false,"id":"66d99e96c2ed5b00011a37a5","indication_symptom":["For the treatment of Niemann-Pick Disease Type C1 (NPC1)"],"name":"Trappsol® Cyclo™"},"event_type":"Top-line data","id":"67a60546dcc94e0001175a89","nic_number":"","notes":"","outcome":"Cyclo Therapeutics, Inc announced that Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43558210/cyclo-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-3-transportnpc-open-label","source_type":"Press Release","status":"","target_date":"2025-H1","time":"08:06:14","updated":1738933642},{"commentary":"","companies":[{"cik":"922247","id":"603cef79b9e30d000188c51e","name":"Cyclo Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"CYTH"}]}],"created":1738933523,"date":"2025-02-07","drug":{"generic":false,"id":"66d99e96c2ed5b00011a37a5","indication_symptom":["For the treatment of Niemann-Pick Disease Type C1 (NPC1)"],"name":"Trappsol® Cyclo™"},"event_type":"Data Presentation","id":"67a60513dcc94e0001175a7c","nic_number":"","notes":"","outcome":"Cyclo Therapeutics, Inc announced the presentation of data from its ongoing Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (\"NPC1\") at the 21st Annual WORLDSymposium™ in San Diego, CA.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43558210/cyclo-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-3-transportnpc-open-label","source_type":"Press Release","status":"Phase 3","target_date":"","time":"08:05:23","updated":1738933642},{"commentary":"","companies":[{"cik":"","id":"67a604842b94b70001f79175","name":"Maze Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"MAZE"}]}],"created":1738933324,"date":"2025-02-07","drug":{"generic":false,"id":"67a5efa4dcc94e000117590a","indication_symptom":["For APOL1 Kidney Disease"],"name":"MZE829"},"event_type":"Dose Update","id":"67a6044cdcc94e0001175a54","nic_number":"","notes":"","outcome":"Maze Therapeutics, Inc announced the first patient has been dosed in the company's Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease (AKD).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43558018/maze-therapeutics-doses-first-patient-in-phase-2-horizon-clinical-trial-evaluating-mze829-as-a-pot","source_type":"Press Release","status":"Phase 2","target_date":"","time":"08:02:04","updated":1738933473},{"commentary":"","companies":[{"cik":"1710340","id":"603cef7eb9e30d000188fd62","name":"Eton Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"ETON"}]}],"created":1738929410,"date":"2025-02-07","drug":{"generic":false,"id":"6411a3e700af890001092ecd","indication_symptom":["For the treatment of an endocrinology "],"name":"ET-600"},"event_type":"Provided Update","id":"67a5f502dcc94e0001175a01","nic_number":"","notes":"","outcome":"Eton Pharmaceuticals, Inc announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 12,214,010, covering its ET-600 product candidate's proprietary formulation of desmopressin oral solution.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43556329/eton-pharmaceuticals-expands-patent-portfolio-with-issuance-of-new-u-s-patent-for-et-600","source_type":"Press Release","status":"","target_date":"","time":"06:56:50","updated":1738929449},{"commentary":"","companies":[{"cik":"59478","id":"603cef78b9e30d000188b783","name":"Eli Lilly and Co","securities":[{"exchange":"NYSE","symbol":"LLY"}]}],"created":1738929338,"date":"2025-02-07","drug":{"generic":false,"id":"6785124cb19d2800017214b7","indication_symptom":["For Crohn's disease"],"name":"mirikizumab-mrkz"},"event_type":"Results","id":"67a5f4badcc94e00011759e4","nic_number":"","notes":"","outcome":"Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43556289/most-patients-on-lillys-omvoh-mirikizumab-mrkz-for-crohns-disease-achieved-sustained-clinical-remi","source_type":"Press Release","status":"","target_date":"","time":"06:55:38","updated":1738929391},{"commentary":"","companies":[{"cik":"","id":"655206ffb3615100015df138","name":"Lipella Pharmaceuticals Inc","securities":[]}],"created":1738928235,"date":"2025-02-06","drug":{"generic":false,"id":"655204e1207b9d0001912b70","indication_symptom":["For the treatment of oral Graft-versus-Host Disease (GvHD). "],"name":"LP-310"},"event_type":"Approved","id":"67a5f06bb1c67f000135bc5b","nic_number":"","notes":"","outcome":"Lipella Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43522207/lipella-pharmaceuticals-granted-fda-approval-for-expanded-access-program-for-lp-310-in-oral-lichen","source_type":"Press Release","status":"FDA Approved","target_date":"","time":"06:37:15","updated":1738928313},{"commentary":"","companies":[{"cik":"1684144","id":"603cef7db9e30d000188f399","name":"Zomedica Corp","securities":[{"exchange":"AMEX","symbol":"ZOM"}]}],"created":1738928028,"date":"2025-02-06","drug":{"generic":false,"id":"67a5efa4dcc94e000117590c","indication_symptom":["In Equine PPID Diagnosis"],"name":"TRUFORMA"},"event_type":"Groundbreaking update","id":"67a5ef9cdcc94e00011758f9","nic_number":"","notes":"","outcome":"Zomedica Corp. announced a groundbreaking update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA biosensor platform.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43522947/zomedica-launches-the-truforma-r-enhanced-endogenous-acth-assay-to-aid-in-equine-ppid-diagnosis","source_type":"Press Release","status":"","target_date":"","time":"06:33:48","updated":1738928189},{"commentary":"","companies":[{"cik":"310158","id":"603cef78b9e30d000188b9a4","name":"Merck \u0026 Co Inc","securities":[{"exchange":"NYSE","symbol":"MRK"}]}],"created":1738926898,"date":"2025-02-06","drug":{"generic":false,"id":"67a21b92dcc94e000116896a","indication_symptom":["For the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma"],"name":"LINE-010"},"event_type":"Clinical Trial","id":"67a5eb32b1c67f000135bbf0","nic_number":"","notes":"","outcome":"Merck announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43523295/merck-announces-phase-3-waveline-010-trial-initiation-evaluating-zilovertamab-vedotin-an-investiga","source_type":"Press Release","status":"Phase 3","target_date":"","time":"06:14:58","updated":1738926988},{"commentary":"","companies":[{"cik":"","id":"6164d697d8eaa700011dad59","name":"Immuneering Corporation","securities":[{"exchange":"NASDAQ","symbol":"IMRX"}]}],"created":1738926783,"date":"2025-02-06","drug":{"generic":false,"id":"6164d655d5cb080001d23979","indication_symptom":["Solid tumors"],"name":"IMM-1-104"},"event_type":"Provided Update","id":"67a5eabfb1c67f000135bbd1","nic_number":"","notes":"","outcome":"Immuneering Corporation announced a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo (cemiplimab).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43523598/immuneering-announces-clinical-supply-agreement-with-regeneron-pharmaceuticals-to-evaluate-imm-1-1","source_type":"Press Release","status":"","target_date":"","time":"06:13:03","updated":1738926835},{"commentary":"","companies":[{"cik":"911216","id":"603cef79b9e30d000188c149","name":"Palatin Technologies Inc","securities":[{"exchange":"AMEX","symbol":"PTN"}]}],"created":1738926540,"date":"2025-02-06","drug":{"generic":false,"id":"67a21b92dcc94e000116896c","indication_symptom":[" For the treatment of obesity. "],"name":"BMT-801"},"event_type":"Clinical Study","id":"67a5e9ccb1c67f000135bb80","nic_number":"","notes":"","outcome":"Palatin Technologies, Inc. announced the completion of its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP tirzepatide for the treatment of obesity. The last patient enrolled has completed their last visit.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43524706/palatin-completes-phase-2-obesity-study-with-mc4r-bremelanotide-plus-glp-1gip-tirzepatide","source_type":"Press Release","status":"Phase 2","target_date":"","time":"06:09:00","updated":1738926676},{"commentary":"","companies":[{"cik":"1501697","id":"603cef7eb9e30d000188fb97","name":"X4 Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"XFOR"}]}],"created":1738926479,"date":"2025-02-06","drug":{"generic":false,"id":"6576bcd5a2fb150001c8fb42","indication_symptom":["In people diagnosed with idiopathic"," cyclic"," or congenital neutropenia."],"name":"Mavorixafor"},"event_type":"Provided Update","id":"67a5e98fb1c67f000135bb70","nic_number":"","notes":"","outcome":"X4 Pharmaceuticals announced today a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat those with chronic neutropenia, while also optimizing its U.S. promotion of XOLREMDI® (mavorixafor), approved for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare immunodeficiency.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43524970/x4-pharmaceuticals-announces-strategic-restructuring-to-drive-value-and-maximize-opportunity-for-m","source_type":"Press Release","status":"","target_date":"","time":"06:07:59","updated":1738926517},{"commentary":"","companies":[{"cik":"1135951","id":"603cef78b9e30d000188becd","name":"Dr Reddy's Laboratories Ltd","securities":[{"exchange":"NYSE","symbol":"RDY"}]}],"created":1738926243,"date":"2025-02-06","drug":{"generic":false,"id":"67a21b93dcc94e000116896e","indication_symptom":["a biosimilar candidate to Darzalex® \u0026 Darzalex Faspro®"],"name":"HLX15"},"event_type":"Provided Update","id":"67a5e8a3b1c67f000135bb4b","nic_number":"","notes":"","outcome":"Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. announced that it has entered into a license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) related to the development and commercialization of HLX15, Henlius's investigational daratumumab biosimilar candidate to Darzalex® \u0026 Darzalex Faspro®.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43525424/dr-reddys-enters-into-collaboration-with-henlius-for-commercialization-of-hlx15-daratumumab-a-bios","source_type":"Press Release","status":"","target_date":"","time":"06:04:03","updated":1738926431},{"commentary":"","companies":[{"cik":"1401914","id":"603cef7db9e30d000188f45f","name":"Dare Bioscience Inc","securities":[{"exchange":"NASDAQ","symbol":"DARE"}]}],"created":1738925936,"date":"2025-02-06","drug":{"generic":false,"id":"67a21b93dcc94e0001168970","indication_symptom":["For HPV-related cervical diseases"],"name":"DARE-HPV"},"event_type":"Provided Update","id":"67a5e770b1c67f000135bb1c","nic_number":"","notes":"","outcome":"Daré Bioscience, announced that it received a Notice of Award of a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43525542/dar-bioscience-announces-funding-award-notice-from-the-national-institutes-of-health-nih-national-","source_type":"Press Release","status":"","target_date":"","time":"05:58:56","updated":1738926062},{"commentary":"","companies":[{"cik":"1430306","id":"603cef7cb9e30d000188e1dc","name":"Tonix Pharmaceuticals Holding Corp","securities":[{"exchange":"NASDAQ","symbol":"TNXP"}]}],"created":1738925867,"date":"2025-02-06","drug":{"generic":false,"id":"63d920ca3b88450001b81d00","indication_symptom":["Humanized monoclonal antibody "],"name":"TNX-1500"},"event_type":"Top-line results","id":"67a5e72bb1c67f000135bb06","nic_number":"","notes":"","outcome":"Tonix Pharmaceuticals announced positive topline results from its Phase 1, single ascending dose trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy participants.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43525535/tonix-pharmaceuticals-announces-positive-topline-results-from-phase-1-trial-for-tnx-1500-a-next-ge","source_type":"Press Release","status":"Phase 1","target_date":"","time":"05:57:47","updated":1738925916},{"commentary":"","companies":[{"cik":"","id":"6617e89740e824000148ad52","name":"TransCode Therapeutics Inc","securities":[]}],"created":1738925796,"date":"2025-02-06","drug":{"generic":false,"id":"661d203bed9ebb00017183ae","indication_symptom":["In Patients with Advanced Solid Tumors"],"name":"TTX-MC138"},"event_type":"Enrollment Update","id":"67a5e6e4b1c67f000135baee","nic_number":"","notes":"","outcome":"TransCode Therapeutics, Inc. announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43525644/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phas","source_type":"Press Release","status":"Phase 1","target_date":"","time":"05:56:36","updated":1738925839},{"commentary":"","companies":[{"cik":"1746466","id":"603cef7eb9e30d000188fdcf","name":"Equillium Inc","securities":[{"exchange":"NASDAQ","symbol":"EQ"}]}],"created":1738925726,"date":"2025-02-06","drug":{"generic":false,"id":"605241b936622a000156cdf9","indication_symptom":["Acute graft-versus-host disease (aGVHD)"],"name":"itolizumab"},"event_type":"Positive Results","id":"67a5e69eb1c67f000135bad8","nic_number":"","notes":"","outcome":"Equillium, Inc announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43525609/equillium-announces-positive-data-from-phase-2-study-evaluating-itolizumab-in-patients-with-modera","source_type":"Press Release","status":"Phase 2","target_date":"","time":"05:55:26","updated":1738925777},{"commentary":"","companies":[{"cik":"","id":"603cef7db9e30d000188f36c","name":"Allarity Therapeutics AS","securities":[{"exchange":"NASDAQ","symbol":"ALLR"}]}],"created":1738925561,"date":"2025-02-06","drug":{"generic":false,"id":"656f21fc258cdd000172e5c1","indication_symptom":[" For ovarian cancer (AOC)"],"name":"Stenoparib"},"event_type":"Provided Update","id":"67a5e5f9b1c67f000135baa3","nic_number":"","notes":"","outcome":"Allarity Therapeutics, Inc announced plans for the next step in advancing the clinical development of stenoparib toward FDA approval in advanced ovarian cancer.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43525545/allarity-therapeutics-announces-expansion-of-phase-2-clinical-trial-to-accelerate-development-of-s","source_type":"Press Release","status":"","target_date":"","time":"05:52:41","updated":1738925690},{"commentary":"","companies":[{"cik":"","id":"603cef7db9e30d000188f36c","name":"Allarity Therapeutics AS","securities":[{"exchange":"NASDAQ","symbol":"ALLR"}]}],"created":1738925640,"date":"2025-02-06","drug":{"generic":false,"id":"656f21fc258cdd000172e5c1","indication_symptom":[" For ovarian cancer (AOC)"],"name":"Stenoparib"},"event_type":"Enrollment Update","id":"67a5e648b1c67f000135bab9","nic_number":"","notes":"","outcome":"Allarity Therapeutics, Inc announced that Patient enrollment is expected to begin in the first half of 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43525545/allarity-therapeutics-announces-expansion-of-phase-2-clinical-trial-to-accelerate-development-of-s","source_type":"Press Release","status":"","target_date":"2025-H1","time":"05:54:00","updated":1738925690},{"commentary":"","companies":[{"cik":"1001233","id":"603cef78b9e30d000188baef","name":"Sangamo Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"SGMO"}]}],"created":1738925374,"date":"2025-02-06","drug":{"generic":false,"id":"6091f7842bc27400010a525a","indication_symptom":["FabryDisease"],"name":"ST-920"},"event_type":"Updated data","id":"67a5e53eb1c67f000135ba65","nic_number":"","notes":"","outcome":"Sangamo Therapeutics, Inc announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43526025/sangamo-therapeutics-announces-updated-phase-12-staar-study-data-in-fabry-disease-showing-sustaine","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"05:49:34","updated":1738925522},{"commentary":"","companies":[{"cik":"1001233","id":"603cef78b9e30d000188baef","name":"Sangamo Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"SGMO"}]}],"created":1738925457,"date":"2025-02-06","drug":{"generic":false,"id":"6091f7842bc27400010a525a","indication_symptom":["FabryDisease"],"name":"ST-920"},"event_type":"BLA Filing","id":"67a5e591b1c67f000135ba7d","nic_number":"","notes":"","outcome":"Sangamo Therapeutics, Inc announced that Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) anticipated in second half of 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43526025/sangamo-therapeutics-announces-updated-phase-12-staar-study-data-in-fabry-disease-showing-sustaine","source_type":"Press Release","status":"Biologics License Applications (BLA)","target_date":"2025-H2","time":"05:50:57","updated":1738925521},{"commentary":"","companies":[{"cik":"1001233","id":"603cef78b9e30d000188baef","name":"Sangamo Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"SGMO"}]}],"created":1738925415,"date":"2025-02-06","drug":{"generic":false,"id":"6091f7842bc27400010a525a","indication_symptom":["FabryDisease"],"name":"ST-920"},"event_type":"Data","id":"67a5e567b1c67f000135ba71","nic_number":"","notes":"","outcome":"Sangamo Therapeutics, Inc. announced Data to support Accelerated Approval pathway expected in first half of 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43526025/sangamo-therapeutics-announces-updated-phase-12-staar-study-data-in-fabry-disease-showing-sustaine","source_type":"Press Release","status":"","target_date":"2025-H1","time":"05:50:15","updated":1738925521},{"commentary":"","companies":[{"cik":"1631574","id":"603cef7eb9e30d000188f7df","name":"WAVE Life Sciences Ltd","securities":[{"exchange":"NASDAQ","symbol":"WVE"}]}],"created":1738925237,"date":"2025-02-06","drug":{"generic":false,"id":"67221b4b47411f0001bc18f4","indication_symptom":["For obesity."],"name":"WVE-007"},"event_type":"Clinical Data","id":"67a5e4b5b1c67f000135ba3e","nic_number":"","notes":"","outcome":"Wave Life Sciences Ltd Proof-of-concept clinical data from INLIGHT are expected in 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43526823/wave-life-sciences-announces-initiation-of-phase-1-inlight-clinical-trial-of-wve-007-in-obesity","source_type":"Press Release","status":"Proof-of-Concept Study","target_date":"2025-LATE","time":"05:47:17","updated":1738925294},{"commentary":"","companies":[{"cik":"1631574","id":"603cef7eb9e30d000188f7df","name":"WAVE Life Sciences Ltd","securities":[{"exchange":"NASDAQ","symbol":"WVE"}]}],"created":1738925183,"date":"2025-02-06","drug":{"generic":false,"id":"67221b4b47411f0001bc18f4","indication_symptom":["For obesity."],"name":"WVE-007"},"event_type":"Clinical trial application","id":"67a5e47fb1c67f000135ba32","nic_number":"","notes":"","outcome":"Wave Life Sciences Ltd announced clinical trial application (CTA) approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in obesity.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43526823/wave-life-sciences-announces-initiation-of-phase-1-inlight-clinical-trial-of-wve-007-in-obesity","source_type":"Press Release","status":"Phase 1","target_date":"","time":"05:46:23","updated":1738925294},{"commentary":"","companies":[{"cik":"1714899","id":"603cef7eb9e30d000188fbc4","name":"Denali Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"DNLI"}]}],"created":1738924956,"date":"2025-02-06","drug":{"generic":false,"id":"6489b22d38ab3c0001934f74","indication_symptom":["Gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX"," the deficient protein in hemophilia B. "],"name":"DNL310"},"event_type":"Analysis","id":"67a5e39cb1c67f000135ba20","nic_number":"","notes":"","outcome":"Denali Therapeutics Inc","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43535932/denali-therapeutics-announces-primary-analysis-and-long-term-follow-up-of-phase-12-study-in-hunter","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"05:42:36","updated":1738925010},{"commentary":"","companies":[{"cik":"","id":"6523e601b474e10001dc734d","name":"Hyperfine Inc","securities":[]}],"created":1738924756,"date":"2025-02-06","drug":{"generic":false,"id":"651d470408e89000019cfd6e","indication_symptom":[" Portable MR Imaging® System"],"name":"Swoop® System Sequences"},"event_type":"Presentation","id":"67a5e2d4b1c67f000135ba0e","nic_number":"","notes":"","outcome":"Hyperfine, Inc announced the presentation of two studies at the 2025 International Stroke Conference (ISC), which provide evidence supporting the value of AI-powered portable MRI in acute ischemic stroke triage and diagnosis.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43544670/hyperfine-reports-on-growing-evidence-for-the-use-of-swoop-system-images-in-stroke-diagnosis-prese","source_type":"Press Release","status":"","target_date":"","time":"05:39:16","updated":1738924808},{"commentary":"","companies":[{"cik":"1422143","id":"603cef7eb9e30d000188f7a9","name":"Kura Oncology Inc","securities":[{"exchange":"NASDAQ","symbol":"KURA"}]}],"created":1738928831,"date":"2025-02-05","drug":{"generic":false,"id":"63e4ec275f23fa0001076b13","indication_symptom":["Treatment of genetically defined AML patients with high unmet need"],"name":"Ziftomenib"},"event_type":"Positive Results","id":"67a5f2bfb1c67f000135bd0a","nic_number":"","notes":"","outcome":"Kura Oncology, Inc. announced positive topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly selective, once-daily, oral investigational menin inhibitor, in patients with relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43509177/kura-oncology-and-kyowa-kirin-announce-positive-ziftomenib-monotherapy-registrational-trial-and-po","source_type":"Press Release","status":"Phase 2","target_date":"","time":"06:47:11","updated":1738928914},{"commentary":"","companies":[{"cik":"1422143","id":"603cef7eb9e30d000188f7a9","name":"Kura Oncology Inc","securities":[{"exchange":"NASDAQ","symbol":"KURA"}]}],"created":1738928859,"date":"2025-02-05","drug":{"generic":false,"id":"63e4ec275f23fa0001076b13","indication_symptom":["Treatment of genetically defined AML patients with high unmet need"],"name":"Ziftomenib"},"event_type":"NDA Filing","id":"67a5f2dbb1c67f000135bd22","nic_number":"","notes":"","outcome":"Kura is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ziftomenib in the second quarter of 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43509177/kura-oncology-and-kyowa-kirin-announce-positive-ziftomenib-monotherapy-registrational-trial-and-po","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"2025-Q2","time":"06:47:39","updated":1738928913},{"commentary":"","companies":[{"cik":"","id":"623b775265a64100016d964a","name":"Rani Therapeutics Holdings, Inc.","securities":[{"exchange":"NASDAQ","symbol":"RANI"}]}],"created":1738928757,"date":"2025-02-05","drug":{"generic":false,"id":"6710fb124a361900010a7430","indication_symptom":["For the treatment of obesity"],"name":"RaniPill"},"event_type":"New Data","id":"67a5f275b1c67f000135bcc3","nic_number":"","notes":"","outcome":"Rani Therapeutics Holdings, announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor (GLP-1) agonist semaglutide administered via the RaniPill® capsule.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43509393/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide","source_type":"Press Release","status":"","target_date":"","time":"06:45:57","updated":1738928809},{"commentary":"","companies":[{"cik":"1607678","id":"603cef7db9e30d000188f53a","name":"Viking Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"VKTX"}]}],"created":1738928683,"date":"2025-02-05","drug":{"generic":false,"id":"61dc8dd72925770001ed8dff","indication_symptom":["Metabolic disorders"],"name":"VK2735"},"event_type":"Clinical Update","id":"67a5f22bb1c67f000135bcb1","nic_number":"","notes":"","outcome":"Viking Therapeutics, Inc. provided clinical Updates","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43509453/viking-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corpor","source_type":"Press Release","status":"","target_date":"","time":"06:44:43","updated":1738928728},{"commentary":"","companies":[{"cik":"1651311","id":"603cef7eb9e30d000188f7ed","name":"Merus NV","securities":[{"exchange":"NASDAQ","symbol":"MRUS"}]}],"created":1738928469,"date":"2025-02-05","drug":{"generic":false,"id":"6089e158d46fa80001f6eb45","indication_symptom":["Advanced pancreas cancer and other solid tumors harboring NRG1 fusions"],"name":"Zenocutuzumab"},"event_type":"Published Results","id":"67a5f155b1c67f000135bc85","nic_number":"","notes":"","outcome":"Merus N.V. announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43513460/new-england-journal-of-medicine-publishes-efficacy-of-zenocutuzumab-in-nrg1-fusion-positive-cancer","source_type":"Press Release","status":"Phase 2","target_date":"","time":"06:41:09","updated":1738928517},{"commentary":"","companies":[{"cik":"","id":"6154826373a5f300019b73de","name":"Recursion","securities":[{"exchange":"NASDAQ","symbol":"RXRX"}]}],"created":1738928396,"date":"2025-02-05","drug":{"generic":false,"id":"623487d002807e000111c3e8","indication_symptom":["Cerebral Cavernous Malformation (CCM)"],"name":"REC-994"},"event_type":"Data","id":"67a5f10cb1c67f000135bc73","nic_number":"","notes":"","outcome":"Recursion reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43514580/recursion-presents-phase-2-data-for-rec-994-in-ccm-in-late-breaking-oral-presentation-at-the-inter","source_type":"Press Release","status":"Phase 2","target_date":"","time":"06:39:56","updated":1738928439},{"commentary":"","companies":[{"cik":"1521036","id":"603cef7db9e30d000188f52a","name":"Lantheus Holdings Inc","securities":[{"exchange":"NASDAQ","symbol":"LNTH"}]}],"created":1738762499,"date":"2025-02-05","drug":{"generic":false,"id":"60af9702c878010001d5bafd","indication_symptom":["Metastasis or recurrence of prostate cancer"],"name":"PYLARIFY (piflufolastat F 18)"},"event_type":"Presentation","id":"67a36903b156400001bc31f3","nic_number":"","notes":"","outcome":"Lantheus Holdings, announced piflufolastat F 18 data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 13-15, 2025, in San Francisco, CA.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43493644/lantheus-announces-presentations-featuring-pylarify-piflufolastat-f-18-data-at-the-asco-gu-meeting","source_type":"Press Release","status":"","target_date":"","time":"08:34:59","updated":1738762555},{"commentary":"","companies":[{"cik":"1472091","id":"603cef7eb9e30d000188f79c","name":"PDS Biotechnology Corp","securities":[{"exchange":"NASDAQ","symbol":"PDSB"}]}],"created":1738761033,"date":"2025-02-05","drug":{"generic":false,"id":"64c0cdbe9c212e0001522256","indication_symptom":["Evaluating the safety and efficacy of PDS0101 in combination with Merck's anti-PD-1 therapy"," KEYTRUDA® (pembrolizumab) versus KEYTRUDA® monotherapy."],"name":"VERSATILE-003"},"event_type":"Provided Update","id":"67a36349b156400001bc3165","nic_number":"","notes":"","outcome":"PDS Biotechnology today reaffirmed the Company's guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune® HPV plus pembrolizumab for first-line treatment of recurrent and/or metastatic (R/M) HPV16-positive head and neck squamous cell cancer (HNSCC) in the first quarter of this year.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43492592/pds-biotech-reaffirms-guidance-for-first-quarter-initiation-of-versatile-003-phase-3-clinical-tria","source_type":"Press Release","status":"Phase 3","target_date":"","time":"08:10:33","updated":1738761076},{"commentary":"","companies":[{"cik":"946644","id":"603cef78b9e30d000188bf67","name":"AIM ImmunoTech Inc","securities":[{"exchange":"AMEX","symbol":"AIM"}]}],"created":1738760946,"date":"2025-02-05","drug":{"generic":false,"id":"608811d2eb87ad000173bac0","indication_symptom":["COVID-19 and Other Respiratory Viral Diseases"],"name":"Ampligen"},"event_type":"Approved","id":"67a362f2b156400001bc3147","nic_number":"","notes":"","outcome":"AIM ImmunoTech Inc. announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (\"DURIPANC\").","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43492529/erasmus-medical-center-safety-committee-grants-approval-to-proceed-with-phase-2-study-of-ampligen-","source_type":"Press Release","status":"Phase 1b/2","target_date":"","time":"08:09:06","updated":1738761018},{"commentary":"","companies":[{"cik":"1649094","id":"603cef7fb9e30d0001890127","name":"Vaxcyte Inc","securities":[{"exchange":"NASDAQ","symbol":"PCVX"}]}],"created":1738760872,"date":"2025-02-05","drug":{"generic":false,"id":"64c0cdbe9c212e000152225a","indication_symptom":["For the Prevention of Invasive Pneumococcal Disease "],"name":"VAX-31"},"event_type":"Dosing Update","id":"67a362a8b156400001bc3135","nic_number":"","notes":"","outcome":"Vaxcyte, Inc. announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 in healthy infants.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43492565/vaxcyte-advances-to-second-stage-of-ongoing-phase-2-study-evaluating-vax-31-for-the-prevention-of-","source_type":"Press Release","status":"Phase 2","target_date":"","time":"08:07:52","updated":1738760918},{"commentary":"","companies":[{"cik":"","id":"652d39c20d10db0001ea2496","name":"Acrivon Therapeutics Inc","securities":[]}],"created":1738760800,"date":"2025-02-05","drug":{"generic":false,"id":"64b059e39c212e0001506c58","indication_symptom":["For patients with ovarian"," endometrial"," or bladder cancer"],"name":"ACR-368"},"event_type":"Designation Grant","id":"67a36260b156400001bc311d","nic_number":"","notes":"","outcome":"Acrivon Therapeutics, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43492554/acrivon-therapeutics-announces-fda-has-granted-breakthrough-device-designation-for-acr-368-oncosig","source_type":"Press Release","status":"Breakthrough Device Designation","target_date":"","time":"08:06:40","updated":1738760852},{"commentary":"","companies":[{"cik":"1515673","id":"603cef7db9e30d000188f3ae","name":"Ultragenyx Pharmaceutical Inc","securities":[{"exchange":"NASDAQ","symbol":"RARE"}]}],"created":1738760715,"date":"2025-02-05","drug":{"generic":false,"id":"666a8b3fe56ade0001156a70","indication_symptom":[" For Sanfilippo syndrome type A (MPS IIIA)"],"name":"UX111"},"event_type":"New Data","id":"67a3620bb156400001bc310d","nic_number":"","notes":"","outcome":"Ultragenyx Pharmaceutical announced new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a statistically significant improvement in the Bayley-IIIi raw scores for the subdomains of cognition, receptive communication and expressive communication in patients with Sanfilippo syndrome type A (MPS IIIA) compared to natural history data from untreated patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43492531/ultragenyx-announces-new-data-demonstrating-that-treatment-with-ux111-aav-gene-therapy-significant","source_type":"Press Release","status":"","target_date":"","time":"08:05:15","updated":1738760760},{"commentary":"","companies":[{"cik":"1477845","id":"603cef7eb9e30d000188ff6d","name":"Annovis Bio Inc","securities":[{"exchange":"AMEX","symbol":"ANVS"}]}],"created":1738760657,"date":"2025-02-05","drug":{"generic":false,"id":"61f035661d739c00019ac15a","indication_symptom":["Parkinson's Disease (PD)"],"name":"Buntanetap"},"event_type":"Pivotal Study","id":"67a361d1b156400001bc30f6","nic_number":"","notes":"","outcome":"Annovis Bio Inc. announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43492519/annovis-announces-first-patients-entered-into-pivotal-phase-3-study-of-buntanetap-for-early-alzhei","source_type":"Press Release","status":"Phase 3","target_date":"","time":"08:04:17","updated":1738760701},{"commentary":"","companies":[{"cik":"","id":"61ba5a74d64b280001d578c7","name":"Ensysce Biosciences, Inc.","securities":[{"exchange":"NASDAQ","symbol":"ENSC"}]}],"created":1738760603,"date":"2025-02-05","drug":{"generic":false,"id":"61ba5a43d64b280001d578c1","indication_symptom":["Opioid overdose"],"name":"PF614-MPAR"},"event_type":"Enrollment Update","id":"67a3619bb156400001bc30d9","nic_number":"","notes":"","outcome":"Ensysce Biosciences, announced continued subject enrollment and successful dosing augmenting the progress of its second clinical trial to evaluate PF614-MPAR for overdose protection.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/ac43492729/ensysce-biosciences-reports-continued-positive-progress-in-groundbreaking-trial-on-pf614-mpar-com","source_type":"Press Release","status":"","target_date":"","time":"08:03:23","updated":1738760642},{"commentary":"","companies":[{"cik":"","id":"656745222803140001e0b455","name":"Pasithea Therapeutics Corp","securities":[]}],"created":1738758045,"date":"2025-02-05","drug":{"generic":false,"id":"656733737f07f10001caf23b","indication_symptom":["Allosteric inhibitor of MEK 1/2"],"name":"PAS-004"},"event_type":"Recommendation","id":"67a3579db1c67f0001353733","nic_number":"","notes":"","outcome":"Pasithea Therapeutics Corp. announced that the external Safety Review Committee recommended that the Company's Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to cohort 5, 22mg capsule, without modification.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43490337/pasithea-therapeutics-announces-positive-safety-review-committee-src-recommendation-from-its-ongoi","source_type":"Press Release","status":"Phase 1","target_date":"","time":"07:20:45","updated":1738758095},{"commentary":"","companies":[{"cik":"1720580","id":"603cef7fb9e30d000189010e","name":"Adicet Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"ACET"}]}],"created":1738757976,"date":"2025-02-05","drug":{"generic":false,"id":"6048da983c2ff90001a1268b","indication_symptom":["B cell non-Hodgkin's lymphoma (NHL)"],"name":"ADI-001"},"event_type":"Designation Grant","id":"67a35758b1c67f000135371a","nic_number":"","notes":"","outcome":"Adicet Bio, Inc announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43490747/adicet-bio-receives-fda-fast-track-designation-for-adi-001-for-the-treatment-of-refractory-systemi","source_type":"Press Release","status":"Fast Track Designation","target_date":"","time":"07:19:36","updated":1738758020},{"commentary":"","companies":[{"cik":"","id":"673350f491a4760001b2eb81","name":"Zenas BioPharma Inc","securities":[{"exchange":"NASDAQ","symbol":"ZBIO"}]}],"created":1738757894,"date":"2025-02-05","drug":{"generic":false,"id":"672b343a86a8560001f8f2fb","indication_symptom":[" Immunoglobulin G4-Related Disease (IgG4-RD)"],"name":"Obexelimab"},"event_type":"Clinical Update","id":"67a35706b1c67f0001353707","nic_number":"","notes":"","outcome":"Zenas BioPharma, Inc announced its 2024 accomplishments, outlined its key business objectives for 2025 and announced preliminary unaudited cash balance as of year-end 2024.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43490556/zenas-biopharma-announces-key-2024-accomplishments-and-2025-business-objectives-to-support-the-glo","source_type":"Press Release","status":"","target_date":"","time":"07:18:14","updated":1738757933},{"commentary":"","companies":[{"cik":"1720893","id":"603cef7eb9e30d000188fc2b","name":"BioXcel Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"BTAI"}]}],"created":1738757294,"date":"2025-02-05","drug":{"generic":false,"id":"604a18e23c2ff9000155d560","indication_symptom":["Schizophrenia and bipolar disorders"],"name":"BXCL501 (SERENITY)"},"event_type":"Provided Update","id":"67a354aeb156400001bc2fc3","nic_number":"","notes":"","outcome":"BioXcel Therapeutics, today provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well as its recent steps to enhance operational and financial flexibility and strengthen its Board leadership.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43490353/bioxcel-therapeutics-provides-clinical-and-business-update","source_type":"Press Release","status":"","target_date":"","time":"07:08:14","updated":1738757332},{"commentary":"","companies":[{"cik":"1314102","id":"603cef78b9e30d000188ba55","name":"EyePoint Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"EYPT"}]}],"created":1738757179,"date":"2025-02-05","drug":{"generic":false,"id":"6630e50eefec610001c22f85","indication_symptom":["In patients with non-proliferative diabetic retinopathy (NPDR)."],"name":"DURAVYU"},"event_type":"Provided Update","id":"67a3543bb156400001bc2f94","nic_number":"","notes":"","outcome":"EyePoint Pharmaceuticals, Inc Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43490361/eyepoint-announces-positive-six-month-results-for-the-phase-2-verona-clinical-trial-of-duravyu-for","source_type":"Press Release","status":"Phase 3","target_date":"2025-LATE","time":"07:06:19","updated":1738757276},{"commentary":"","companies":[{"cik":"1314102","id":"603cef78b9e30d000188ba55","name":"EyePoint Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"EYPT"}]}],"created":1738757127,"date":"2025-02-05","drug":{"generic":false,"id":"6630e50eefec610001c22f85","indication_symptom":["In patients with non-proliferative diabetic retinopathy (NPDR)."],"name":"DURAVYU"},"event_type":"Positive Results","id":"67a35407b156400001bc2f8a","nic_number":"","notes":"","outcome":"EyePoint Pharmaceuticals, Inc announced positive six-month results for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU™ (vorolanib intravitreal insert), an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor (TKI) formulated in proprietary bioerodible Durasert E™.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43490361/eyepoint-announces-positive-six-month-results-for-the-phase-2-verona-clinical-trial-of-duravyu-for","source_type":"Press Release","status":"Phase 2","target_date":"","time":"07:05:27","updated":1738757275},{"commentary":"","companies":[{"cik":"1649989","id":"603cef7eb9e30d000188f85c","name":"Outlook Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"OTLK"}]}],"created":1738678020,"date":"2025-02-04","drug":{"generic":false,"id":"60648df5fdf9b90001501e29","indication_symptom":["Wet age-related macular degeneration (wet AMD)"],"name":"ONS-5010 / LYTENAVA (Bevacizumab-vikg)"},"event_type":"Provided Update","id":"67a21f04dcc94e0001168a90","nic_number":"","notes":"","outcome":"Outlook Therapeutics, Inc. announced that Jennifer Kissner, Ph.D., SVP Clinical Development of Outlook Therapeutics participated in a Virtual Investor \"What This Means\" segment.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43462671/outlook-therapeutics-participates-in-virtual-investor-what-this-means-segment","source_type":"Press Release","status":"","target_date":"","time":"09:07:00","updated":1738678087},{"commentary":"","companies":[{"cik":"1356576","id":"603cef7db9e30d000188ec96","name":"Supernus Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"SUPN"}]}],"created":1738677948,"date":"2025-02-04","drug":{"generic":false,"id":"610b0d54b4035700018a0961","indication_symptom":["Continuous treatment of motor fluctuations in Parkinson's disease (PD)"],"name":"SPN-830 (apomorphine infusion pump)"},"event_type":"Provided Update","id":"67a21ebcdcc94e0001168a69","nic_number":"","notes":"","outcome":"Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43462326/supernus-announces-fda-approval-of-onapgo-apomorphine-hydrochloride-for-parkinsons-disease","source_type":"Press Release","status":"","target_date":"2025-Q2","time":"09:05:48","updated":1738677997},{"commentary":"","companies":[{"cik":"1356576","id":"603cef7db9e30d000188ec96","name":"Supernus Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"SUPN"}]}],"created":1738677854,"date":"2025-02-04","drug":{"generic":false,"id":"610b0d54b4035700018a0961","indication_symptom":["Continuous treatment of motor fluctuations in Parkinson's disease (PD)"],"name":"SPN-830 (apomorphine infusion pump)"},"event_type":"FDA Approval","id":"67a21e5edcc94e0001168a38","nic_number":"","notes":"","outcome":"Supernus Pharmaceuticals, announced that that the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43462326/supernus-announces-fda-approval-of-onapgo-apomorphine-hydrochloride-for-parkinsons-disease","source_type":"Press Release","status":"FDA Approved","target_date":"","time":"09:04:14","updated":1738677997},{"commentary":"","companies":[{"cik":"","id":"653a5131c697190001de8357","name":"PaxMedica Inc","securities":[]}],"created":1738677783,"date":"2025-02-04","drug":{"generic":false,"id":"6501af9d9ab00f00016a4d0c","indication_symptom":["For Trypanosoma brucei rhodesiense"],"name":"FemaSeed"},"event_type":"Provided Update","id":"67a21e17dcc94e0001168a19","nic_number":"","notes":"","outcome":"Femasys Inc. announces the receipt of the Israeli Medical Device Division of the Ministry of Health's (AMAR) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43462358/femasys-announces-israeli-regulatory-approvals-for-femaseed-for-female-infertility-treatment-and-t","source_type":"Press Release","status":"Israeli Ministry of Health Approval","target_date":"","time":"09:03:03","updated":1738677839},{"commentary":"","companies":[{"cik":"1027838","id":"603cef7eb9e30d000188f863","name":"Tactile Systems Technology Inc","securities":[{"exchange":"NASDAQ","symbol":"TCMD"}]}],"created":1738677682,"date":"2025-02-04","drug":{"generic":false,"id":"66e7db7dc2ed5b00011b924c","indication_symptom":["Pneumatic compression platform"],"name":"Nimbl"},"event_type":"Provided Update","id":"67a21db2dcc94e0001168a08","nic_number":"","notes":"","outcome":"Tactile Systems Technology announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43459986/tactile-medical-expands-launch-of-nimbl-to-include-patients-with-lower-extremity-lymphedema","source_type":"Press Release","status":"","target_date":"","time":"09:01:22","updated":1738677728},{"commentary":"","companies":[{"cik":"","id":"65266f4cb6b19d00018a76c0","name":"MAIA Biotechnology Inc","securities":[]}],"created":1738677496,"date":"2025-02-04","drug":{"generic":false,"id":"669f98e8d9891400015004aa","indication_symptom":["In patients with advanced non-small cell lung cancer (NSCLC) "],"name":"THIO-101"},"event_type":"Positive Data","id":"67a21cf8dcc94e00011689f0","nic_number":"","notes":"","outcome":"MAIA Biotechnology, Inc announced positive updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43462032/maia-biotechnology-announces-positive-efficacy-updates-for-phase-2-thio-101-trial-in-advanced-non-","source_type":"Press Release","status":"Phase 2","target_date":"","time":"08:58:16","updated":1738677540},{"commentary":"","companies":[{"cik":"","id":"606b65f2653896000188fe31","name":"IceCure Medical Ltd","securities":[]}],"created":1738677412,"date":"2025-02-04","drug":{"generic":false,"id":"606b657c653896000188fe0f","indication_symptom":["T1 invasive breast cancer and/or patients not suitable for surgical alternatives for the treatment of breast cancer"],"name":"ProSense Cryoablation System"},"event_type":"Marketing authorization","id":"67a21ca4dcc94e00011689d7","nic_number":"","notes":"","outcome":"IceCure Medical Ltd. announced that FDA's decision on ProSense® market authorization for early-stage breast cancer expected Q1 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43461266/icecures-prosense-in-the-spotlight-at-society-of-interventional-oncology-sio-annual-meeting-award-","source_type":"Press Release","status":"","target_date":"2025-Q1","time":"08:56:52","updated":1738677477},{"commentary":"","companies":[{"cik":"","id":"606b65f2653896000188fe31","name":"IceCure Medical Ltd","securities":[]}],"created":1738677363,"date":"2025-02-04","drug":{"generic":false,"id":"606b657c653896000188fe0f","indication_symptom":["T1 invasive breast cancer and/or patients not suitable for surgical alternatives for the treatment of breast cancer"],"name":"ProSense Cryoablation System"},"event_type":"Provided Update","id":"67a21c73dcc94e00011689cc","nic_number":"","notes":"","outcome":"IceCure Medical Ltd. announced its participation as one of the sponsors of the Breast Cryoablation Mini Masterclass held during the 2025 Society of Interventional Oncology (SIO) Annual Meeting in Las Vegas, which took place January 29 to February 3, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43461266/icecures-prosense-in-the-spotlight-at-society-of-interventional-oncology-sio-annual-meeting-award-","source_type":"Press Release","status":"","target_date":"","time":"08:56:03","updated":1738677476},{"commentary":"","companies":[{"cik":"883975","id":"603cef79b9e30d000188c1ef","name":"Microbot Medical Inc","securities":[{"exchange":"NASDAQ","symbol":"MBOT"}]}],"created":1738677252,"date":"2025-02-04","drug":{"generic":false,"id":"66b9fbd3157a570001811ce9","indication_symptom":["Device Study"],"name":"LIBERTY® Endovascular Robotic Surgical System"},"event_type":"Late Breaking Presentation","id":"67a21c04dcc94e00011689a8","nic_number":"","notes":"","outcome":"Microbot Medical Inc. announced the acceptance of a late-breaking abstract that will be presented at the upcoming Society of Interventional Radiology (SIR) annual meeting, being held in Nashville, TN on March 29 - April 2, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43461234/microbot-medical-announces-late-breaking-abstract-acceptance-at-the-society-of-interventional-radi","source_type":"Press Release","status":"","target_date":"2025-04-02","time":"08:54:12","updated":1738677314},{"commentary":"","companies":[{"cik":"1555280","id":"603cef7db9e30d000188f121","name":"Zoetis Inc","securities":[{"exchange":"NYSE","symbol":"ZTS"}]}],"created":1738677071,"date":"2025-02-04","drug":{"generic":false,"id":"67a21b92dcc94e0001168968","indication_symptom":["For Canine Osteoarthritis (OA) Pain"],"name":"Librela"},"event_type":"Provided Update","id":"67a21b4fdcc94e0001168944","nic_number":"","notes":"","outcome":"Zoetis Inc announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S. Food and Drug Administration (FDA).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43460129/zoetis-announces-u-s-label-update-for-librela-bedinvetmab-injection-a-treatment-to-control-canine-","source_type":"Press Release","status":"","target_date":"","time":"08:51:11","updated":1738677229},{"commentary":"","companies":[{"cik":"","id":"66be054ac55fed00014b5b0f","name":"Glucotrack Inc","securities":[{"exchange":"NASDAQ","symbol":"GCTK"}]}],"created":1738675680,"date":"2025-02-04","drug":{"generic":false,"id":"67a20a50b1c67f000134efa3","indication_symptom":["Vein-Based Continuous Glucose Monitor"],"name":"Subclavian"},"event_type":"Provided Update","id":"67a215e0dcc94e000116881b","nic_number":"","notes":"","outcome":"Glucotrack, Inc. announced the successful completion of its first in human clinical study, marking a significant milestone in continuous glucose monitoring.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43460168/glucotrack-announces-successful-completion-of-its-first-human-clinical-study-of-continuous-blood-g","source_type":"Press Release","status":"","target_date":"","time":"08:28:00","updated":1738675767},{"commentary":"","companies":[{"cik":"","id":"6284da526a002e00012f5d86","name":"IO Biotech","securities":[{"exchange":"NASDAQ","symbol":"IOBT"}]}],"created":1738675201,"date":"2025-02-04","drug":{"generic":false,"id":"67a20a50b1c67f000134efa7","indication_symptom":["Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate"],"name":"IO112"},"event_type":"NDA Filing","id":"67a21401dcc94e00011687bd","nic_number":"","notes":"","outcome":"IO Biotech announced that Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 –","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43460283/io-biotech-announces-publication-of-preclinical-data-investigating-immune-modulatory-effects-of-io","source_type":"Press Release","status":"New Drug Application (NDA)","target_date":"","time":"08:20:01","updated":1738675274},{"commentary":"","companies":[{"cik":"","id":"6284da526a002e00012f5d86","name":"IO Biotech","securities":[{"exchange":"NASDAQ","symbol":"IOBT"}]}],"created":1738675087,"date":"2025-02-04","drug":{"generic":false,"id":"67a20a50b1c67f000134efa7","indication_symptom":["Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate"],"name":"IO112"},"event_type":"Publication","id":"67a2138fdcc94e0001168789","nic_number":"","notes":"","outcome":"IO Biotech announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1 (Arg1), in the Journal for ImmunoTherapy of Cancer.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43460283/io-biotech-announces-publication-of-preclinical-data-investigating-immune-modulatory-effects-of-io","source_type":"Press Release","status":"","target_date":"","time":"08:18:07","updated":1738675274},{"commentary":"","companies":[{"cik":"","id":"6544b88f5cf4640001b2a7b4","name":"Mineralys Therapeutics Inc","securities":[]}],"created":1738674987,"date":"2025-02-04","drug":{"generic":false,"id":"6544b85ccba3b6000149a432","indication_symptom":["For the treatment of uncontrolled and resistant hypertension "],"name":"lorundrostat"},"event_type":"Enrollment Update","id":"67a2132bdcc94e0001168766","nic_number":"","notes":"","outcome":"Mineralys Therapeutics, Inc announced that it has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subjects with CKD and albuminuria, despite receiving stable treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) and an SGLT2 inhibitor..","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43460033/mineralys-therapeutics-completes-enrollment-in-explore-ckd-phase-2-trial-of-lorundrostat-for-the-t","source_type":"Press Release","status":"Phase 2","target_date":"","time":"08:16:27","updated":1738675056},{"commentary":"","companies":[{"cik":"1509261","id":"603cef7db9e30d000188effd","name":"Rezolute Inc","securities":[{"exchange":"NASDAQ","symbol":"RZLT"}]}],"created":1738674785,"date":"2025-02-04","drug":{"generic":false,"id":"67a20a50b1c67f000134efa9","indication_symptom":["For Hypoglycemia Due to Congenital Hyperinsulinism"],"name":"Ersodetug"},"event_type":"Enrollment Update","id":"67a21261dcc94e0001168714","nic_number":"","notes":"","outcome":"Rezolute, Inc. announced that sunRIZE enrollment completion expected in Q2 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43459940/rezolute-provides-update-on-its-phase-3-sunrize-study-of-ersodetug-for-the-treatment-of-hypoglycem","source_type":"Press Release","status":"","target_date":"2025-Q2","time":"08:13:05","updated":1738674946},{"commentary":"","companies":[{"cik":"1509261","id":"603cef7db9e30d000188effd","name":"Rezolute Inc","securities":[{"exchange":"NASDAQ","symbol":"RZLT"}]}],"created":1738674665,"date":"2025-02-04","drug":{"generic":false,"id":"67a20a50b1c67f000134efa9","indication_symptom":["For Hypoglycemia Due to Congenital Hyperinsulinism"],"name":"Ersodetug"},"event_type":"Provided Update","id":"67a211e9dcc94e00011686e6","nic_number":"","notes":"","outcome":"Rezolute, Inc. announced outcomes from an independent Data Monitoring Committee (DMC) review of the open label arm (OLA) portion of the sunRIZE Phase 3 study of ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism (HI) and provided additional study updates including guidance on its upcoming interim analysis (IA) by the DMC.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43459940/rezolute-provides-update-on-its-phase-3-sunrize-study-of-ersodetug-for-the-treatment-of-hypoglycem","source_type":"Press Release","status":"Phase 3","target_date":"","time":"08:11:05","updated":1738674945},{"commentary":"","companies":[{"cik":"","id":"6731f7bfb3805500018f1d41","name":"Pyxis Oncology Inc","securities":[{"exchange":"NASDAQ","symbol":"PYXS"}]}],"created":1738672827,"date":"2025-02-04","drug":{"generic":false,"id":"672b343b86a8560001f8f305","indication_symptom":["In multiple types of solid tumors"],"name":"PYX-201"},"event_type":"Provided Update","id":"67a20abbdcc94e0001168526","nic_number":"","notes":"","outcome":"Pyxis Oncology, Inc. announced significant progress in its clinical program for PYX-201, a first-in-concept antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix (ECM), which is highly expressed in various tumor types.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43459095/pyxis-oncology-initiates-new-pyx-201-combination-trial-and-initiates-cohort-expansions-of-ongoing-","source_type":"Press Release","status":"","target_date":"","time":"07:40:27","updated":1738672865},{"commentary":"","companies":[{"cik":"1087294","id":"603cef7ab9e30d000188d416","name":"Cumberland Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"CPIX"}]}],"created":1738672702,"date":"2025-02-04","drug":{"generic":false,"id":"67a20a51b1c67f000134efab","indication_symptom":[" In Duchenne Muscular Dystrophy Heart Disease"],"name":"ifetroban"},"event_type":"Top-line results","id":"67a20a3eb1c67f000134ef9f","nic_number":"","notes":"","outcome":"Cumberland Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43459112/cumberland-pharmaceuticals-announces-breakthrough-results-from-the-phase-2-fight-dmd-trial-in-duch","source_type":"Press Release","status":"Phase 2","target_date":"","time":"07:38:22","updated":1738672804},{"commentary":"","companies":[{"cik":"1082554","id":"603cef79b9e30d000188c311","name":"United Therapeutics Corp","securities":[{"exchange":"NASDAQ","symbol":"UTHR"}]}],"created":1738670707,"date":"2025-02-04","drug":{"generic":false,"id":"60424146e74cfd0001f68f97","indication_symptom":["Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)"],"name":"Tyvaso (Treprostinil)"},"event_type":"Enrollment Update","id":"67a202732b94b70001f6afb4","nic_number":"","notes":"","outcome":"United Therapeutics Corporation announced full enrollment of the TETON 1 study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of idiopathic pulmonary fibrosis (IPF).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43458111/united-therapeutics-corporation-announces-full-enrollment-of-the-teton-1-study-of-inhaled-treprost","source_type":"Press Release","status":"","target_date":"","time":"07:05:07","updated":1738670763},{"commentary":"","companies":[{"cik":"1553846","id":"603cef7db9e30d000188ee31","name":"Redhill Biopharma Ltd","securities":[{"exchange":"NASDAQ","symbol":"RDHL"}]}],"created":1738670631,"date":"2025-02-04","drug":{"generic":false,"id":"6070a5f46d58b1000154842d","indication_symptom":["Severe COVID-19 pneumonia"],"name":"Opaganib"},"event_type":"Study Initiation","id":"67a202272b94b70001f6af9e","nic_number":"","notes":"","outcome":"RedHill Biopharma Ltd announced the initiation of a Phase 2 clinical study to evaluate the efficacy of opaganib[3] in combination with darolutamide[4] in men with metastatic castrate-resistant prostate cancer (mCRPC).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/n43458150/redhill-announces-initiation-of-phase-2-study-of-opaganib-and-darolutamide-in-advanced-prostate-ca","source_type":"Press Release","status":"Phase 2","target_date":"","time":"07:03:51","updated":1738670673},{"commentary":"","companies":[{"cik":"","id":"618c515280db050001bdf6f3","name":"NeuroPace, Inc.","securities":[{"exchange":"NASDAQ","symbol":"NPCE"}]}],"created":1738616824,"date":"2025-02-03","drug":{"generic":false,"id":"618c511f80db050001bdf6e4","indication_symptom":["Drug-resistant idiopathic generalized epilepsy"],"name":"RNS System"},"event_type":"Oral presentation","id":"67a12ff82b94b70001f6a26b","nic_number":"","notes":"","outcome":"NeuroPace, Inc announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43448629/neuropace-announces-upcoming-oral-presentation-of-data-from-the-post-approval-study-of-the-rns-sys","source_type":"Press Release","status":"","target_date":"","time":"16:07:04","updated":1738616880},{"commentary":"","companies":[{"cik":"","id":"62b3773a118ebc0001427b67","name":"Alpha Tau Medical Ltd.","securities":[{"exchange":"NASDAQ","symbol":"DRTS"}]}],"created":1738589851,"date":"2025-02-03","drug":{"generic":false,"id":"62b3771c9c3cd100011418ce","indication_symptom":["Prostate cancer"],"name":"Alpha DaRT"},"event_type":"FDA Approval","id":"67a0c69b2b94b70001f66509","nic_number":"","notes":"","outcome":"Alpha Tau Medical Ltd announced an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43432752/alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-pilot-trial-of-alpha-dart-to-thirty-p","source_type":"Press Release","status":"Investigational Device Exemption (IDE) Application","target_date":"","time":"08:37:31","updated":1738589912},{"commentary":"","companies":[{"cik":"1615219","id":"603cef7eb9e30d000188f64e","name":"Salarius Pharmaceuticals Inc","securities":[{"exchange":"NASDAQ","symbol":"SLRX"}]}],"created":1738589210,"date":"2025-02-03","drug":{"generic":false,"id":"679be6ef3c7fb90001b8462a","indication_symptom":["For Hematologic Cancers"],"name":"azacitidine"},"event_type":"Enrollment Update","id":"67a0c41a2b94b70001f6646e","nic_number":"","notes":"","outcome":"Salarius Pharmaceuticals, Inc. announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43431719/salarius-pharmaceuticals-announces-patient-enrollment-to-resume-in-investigator-initiated-phase-12","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"08:26:50","updated":1738589303},{"commentary":"","companies":[{"cik":"","id":"67a0c3bfb156400001bb88e6","name":"Jupiter Neurosciences Inc","securities":[{"exchange":"NASDAQ","symbol":"JUNS"}]}],"created":1738589090,"date":"2025-02-03","drug":{"generic":false,"id":"679be6f03c7fb90001b8462c","indication_symptom":["For Parkinson's disease."],"name":"JOTROL"},"event_type":"Provided Update","id":"67a0c3a2b156400001bb88cb","nic_number":"","notes":"","outcome":"Jupiter Neurosciences, Inc. announced it has entered into an agreement with Catalent Pharma Solutions, LLC (\"Catalent\") for the production of JOTROL™ softgel capsules to support Jupiter's upcoming Phase 2a clinical trial in Parkinson's disease.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43431716/jupiter-neurosciences-announces-jotrol-manufacturing-agreement-with-catalent-to-support-phase-2a-p","source_type":"Press Release","status":"","target_date":"","time":"08:24:50","updated":1738589200},{"commentary":"","companies":[{"cik":"1774163","id":"603cef7eb9e30d000188fde5","name":"Innovent Biologics Inc","securities":[{"exchange":"OTC","symbol":"IVBIY"},{"exchange":"GREY","symbol":"IVBXF"}]}],"created":1738589028,"date":"2025-02-03","drug":{"generic":false,"id":"621eb25e6dd755000147016e","indication_symptom":["ROS1-Positive Non-Small Cell Lung Cancer"],"name":"Taletrectinib"},"event_type":"Provided Update","id":"67a0c364b156400001bb88ab","nic_number":"","notes":"","outcome":"Nuvation Bio Inc announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no comparable or satisfactory alternative therapy options are available.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43431770/nuvation-bio-announces-expanded-access-program-in-the-u-s-for-taletrectinib-in-advanced-ros1-posit","source_type":"Press Release","status":"","target_date":"","time":"08:23:48","updated":1738589067},{"commentary":"","companies":[{"cik":"200406","id":"603cef79b9e30d000188c04b","name":"Johnson \u0026 Johnson","securities":[{"exchange":"NYSE","symbol":"JNJ"}]}],"created":1738586033,"date":"2025-02-03","drug":{"generic":false,"id":"679be6f03c7fb90001b8462e","indication_symptom":["For Advanced EGFR-Mutated Non-Small Cell Lung Cancer"],"name":"RYBREVANT®(amivantamab)"},"event_type":"Positive Opinion","id":"67a0b7b1b1c67f000134a348","nic_number":"","notes":"","outcome":"Halozyme Therapeutics, Inc. nnounced that Janssen-Cilag International NV, a Johnson \u0026 Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy.","outcome_brief":"","source_link":"https://www.jnj.com/media-center/press-releases/chmp-recommends-subcutaneous-rybrevant-amivantamab-for-the-treatment-of-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer","source_type":"Press Release","status":"European Medicines Agency (EMA)","target_date":"","time":"07:33:53","updated":1738586286},{"commentary":"","companies":[{"cik":"924717","id":"603cef79b9e30d000188c221","name":"Surmodics Inc","securities":[{"exchange":"NASDAQ","symbol":"SRDX"}]}],"created":1738585490,"date":"2025-02-03","drug":{"generic":false,"id":"64870f0818fb560001fa21d2","indication_symptom":["Intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature in vessels 3.5 mm to 6 mm in diameter."],"name":"Pounce™ LP Thrombectomy System"},"event_type":"Provided Update","id":"67a0b592dcc94e000116366b","nic_number":"","notes":"","outcome":"Surmodics, Inc. announced the successful early clinical use of its Pounce™ XL Thrombectomy System.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43430030/surmodics-announces-successful-early-clinical-use-of-pounce-xl-thrombectomy-system-suitable-for-no","source_type":"Press Release","status":"","target_date":"","time":"07:24:50","updated":1738585536},{"commentary":"","companies":[{"cik":"1728117","id":"603cef7eb9e30d000188fe47","name":"Gossamer Bio Inc","securities":[{"exchange":"NASDAQ","symbol":"GOSS"}]}],"created":1738585418,"date":"2025-02-03","drug":{"generic":false,"id":"6465f79be0e71d0001be3490","indication_symptom":["Treatment of Pulmonary Arterial Hypertension "],"name":"seralutinib"},"event_type":"Oral presentation","id":"67a0b54adcc94e0001163657","nic_number":"","notes":"","outcome":"Gossamer Bio, Inc presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February 1st in Rio de Janeiro, Brazil.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43430082/gossamer-bio-presented-clinical-and-preclinical-data-at-the-pulmonary-vascular-research-institute-","source_type":"Press Release","status":"","target_date":"","time":"07:23:38","updated":1738585461},{"commentary":"","companies":[{"cik":"","id":"617b25093abe8b00016c722e","name":"HCW Biologics Inc.","securities":[{"exchange":"NASDAQ","symbol":"HCWB"}]}],"created":1738585174,"date":"2025-02-03","drug":{"generic":false,"id":"67a0b139dcc94e00011634df","indication_symptom":["For alopecia areata"],"name":"HCW9302"},"event_type":"FDA Clearance","id":"67a0b456dcc94e000116361d","nic_number":"","notes":"","outcome":"HCW Biologics Inc announced that it has received clearance of its Investigational New Drug Application (\"IND\") from the U.S. Food and Drug Administration (\"FDA\") to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative FDA approved treatments.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43430431/hcw-biologics-granted-fda-clearance-to-evaluate-one-of-the-companys-lead-product-candidates-in-a-f","source_type":"Press Release","status":"Investigational New Drug (IND)","target_date":"","time":"07:19:34","updated":1738585281},{"commentary":"","companies":[{"cik":"","id":"61ae6de166e2a30001a148a9","name":"GH Research PLC","securities":[{"exchange":"NASDAQ","symbol":"GHRS"}]}],"created":1738585064,"date":"2025-02-03","drug":{"generic":false,"id":"61ae6db1f9b5b4000145fcb1","indication_symptom":["Resistant Depression"],"name":"GH001"},"event_type":"Endpoint Met","id":"67a0b3e8dcc94e000116360a","nic_number":"","notes":"","outcome":"GH Research PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-201).","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43430039/gh-research-announces-primary-endpoint-met-in-phase-2b-trial-with-gh001-in-trd-demonstrating-15-5-","source_type":"Press Release","status":"Phase 2b","target_date":"","time":"07:17:44","updated":1738585116},{"commentary":"","companies":[{"cik":"","id":"66c32eaf157a57000181eb86","name":"Apogee Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"APGE"}]}],"created":1738584930,"date":"2025-02-03","drug":{"generic":false,"id":"671a2cf81e18f90001113c5d","indication_symptom":["For the Treatment for Atopic Dermatitis and Other Inflammatory Diseases"],"name":"APG777"},"event_type":"Results","id":"67a0b362dcc94e00011635dc","nic_number":"","notes":"","outcome":"Apogee Therapeutics, Inc announced that Part A 16-week proof-of-concept data anticipated in mid-2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43429994/apogee-therapeutics-announces-first-patient-dosed-in-part-b-of-phase-2-apex-trial-of-apg777-in-pat","source_type":"Press Release","status":"Proof-of-Concept Study","target_date":"2025-H1","time":"07:15:30","updated":1738585035},{"commentary":"","companies":[{"cik":"","id":"66c32eaf157a57000181eb86","name":"Apogee Therapeutics Inc","securities":[{"exchange":"NASDAQ","symbol":"APGE"}]}],"created":1738584922,"date":"2025-02-03","drug":{"generic":false,"id":"671a2cf81e18f90001113c5d","indication_symptom":["For the Treatment for Atopic Dermatitis and Other Inflammatory Diseases"],"name":"APG777"},"event_type":"Dose Update","id":"67a0b35adcc94e00011635d8","nic_number":"","notes":"","outcome":"Apogee Therapeutics, Inc. announced the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 in patients with moderate-to-severe AD, as well as enrollment completion in the Part A portion of the trial.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43429994/apogee-therapeutics-announces-first-patient-dosed-in-part-b-of-phase-2-apex-trial-of-apg777-in-pat","source_type":"Press Release","status":"Phase 2","target_date":"","time":"07:15:22","updated":1738585035},{"commentary":"","companies":[{"cik":"1393434","id":"603cef7db9e30d000188f519","name":"Ocular Therapeutix Inc","securities":[{"exchange":"NASDAQ","symbol":"OCUL"}]}],"created":1738584785,"date":"2025-02-03","drug":{"generic":false,"id":"6501af9b9ab00f00016a4cfe","indication_symptom":[" For the treatment of wet AMD"],"name":"OTX-TKI"},"event_type":"Presentation Update","id":"67a0b2d1dcc94e00011635a5","nic_number":"","notes":"","outcome":"Ocular Therapeutix, Inc. announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43430014/ocular-therapeutix-announces-upcoming-presentations-at-the-angiogenesis-exudation-and-degeneration","source_type":"Press Release","status":"","target_date":"2025-02-08","time":"07:13:05","updated":1738584897},{"commentary":"","companies":[{"cik":"","id":"65789984f754e50001e0048a","name":"Invivyd, Inc.","securities":[]}],"created":1738584703,"date":"2025-02-03","drug":{"generic":false,"id":"66d83b34a88f220001a8f0ef","indication_symptom":["Next Generation Monoclonal Antibody Candidate for COVID-19"," Building on the Success of PEMGARDA™"],"name":"VYD2311"},"event_type":"Positive Data","id":"67a0b27fdcc94e0001163585","nic_number":"","notes":"","outcome":"Invivyd, Inc. announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd's novel monoclonal antibody (mAb) candidate designed to be a superior alternative to COVID-19 vaccination for the broad population as frontline protection in a convenient form, as well as to provide a novel, potent, long-acting option for the treatment of COVID-19.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43429989/invivyd-announces-positive-phase-12-clinical-data-for-vyd2311-a-monoclonal-antibody-designed-to-be","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"07:11:43","updated":1738584742},{"commentary":"","companies":[{"cik":"","id":"627c249172b50e0001b7659b","name":"Entrada Therapeutics, Inc.","securities":[{"exchange":"NASDAQ","symbol":"TRDA"}]}],"created":1738584548,"date":"2025-02-03","drug":{"generic":false,"id":"679be6f03c7fb90001b84630","indication_symptom":["For Duchenne Muscular Dystrophy"],"name":"ELEVATE-44-201"},"event_type":"Authorization","id":"67a0b1e4dcc94e000116353a","nic_number":"","notes":"","outcome":"Entrada Therapeutics announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43429995/entrada-therapeutics-receives-authorization-in-the-united-kingdom-to-initiate-elevate-44-201-a-pha","source_type":"Press Release","status":"Phase 1/2","target_date":"","time":"07:09:08","updated":1738584691},{"commentary":"","companies":[{"cik":"","id":"627c249172b50e0001b7659b","name":"Entrada Therapeutics, Inc.","securities":[{"exchange":"NASDAQ","symbol":"TRDA"}]}],"created":1738584618,"date":"2025-02-03","drug":{"generic":false,"id":"679be6f03c7fb90001b84630","indication_symptom":["For Duchenne Muscular Dystrophy"],"name":"ELEVATE-44-201"},"event_type":"Provided Update","id":"67a0b22adcc94e000116355e","nic_number":"","notes":"","outcome":"Entrada Therapeutics, Inc. announced that Company on track to initiate ELEVATE-44-201 in Q2 2025 –","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43429995/entrada-therapeutics-receives-authorization-in-the-united-kingdom-to-initiate-elevate-44-201-a-pha","source_type":"Press Release","status":"","target_date":"2025-Q2","time":"07:10:18","updated":1738584690},{"commentary":"","companies":[{"cik":"1082554","id":"603cef79b9e30d000188c311","name":"United Therapeutics Corp","securities":[{"exchange":"NASDAQ","symbol":"UTHR"}]}],"created":1738584447,"date":"2025-02-03","drug":{"generic":false,"id":"679be6f03c7fb90001b84632","indication_symptom":[" Xenotransplantation"],"name":"UKidney"},"event_type":"Provided Update","id":"67a0b17fdcc94e0001163502","nic_number":"","notes":"","outcome":"United Therapeutics Corporation announced that First xenotransplant is expected to occur around mid-year 2025","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43430028/united-therapeutics-corporation-announces-fda-clearance-of-its-investigational-new-drug-applicatio","source_type":"Press Release","status":"","target_date":"2025-H1","time":"07:07:27","updated":1738584516},{"commentary":"","companies":[{"cik":"1082554","id":"603cef79b9e30d000188c311","name":"United Therapeutics Corp","securities":[{"exchange":"NASDAQ","symbol":"UTHR"}]}],"created":1738584361,"date":"2025-02-03","drug":{"generic":false,"id":"679be6f03c7fb90001b84632","indication_symptom":[" Xenotransplantation"],"name":"UKidney"},"event_type":"FDA Clearance","id":"67a0b129dcc94e00011634dc","nic_number":"","notes":"","outcome":"United Therapeutics Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) to initiate a clinical study of the company's investigational UKidney™ derived from a 10 gene-edited source pig.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43430028/united-therapeutics-corporation-announces-fda-clearance-of-its-investigational-new-drug-applicatio","source_type":"Press Release","status":"Investigational New Drug (IND)","target_date":"","time":"07:06:01","updated":1738584516},{"commentary":"","companies":[{"cik":"78003","id":"603cef79b9e30d000188c196","name":"Pfizer Inc","securities":[{"exchange":"NYSE","symbol":"PFE"}]}],"created":1738584191,"date":"2025-02-03","drug":{"generic":false,"id":"6797247adc32a800013296d7","indication_symptom":["In Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer"],"name":"BRAFTOVI"},"event_type":"Top-line results","id":"67a0b07fb1c67f000134a2bf","nic_number":"","notes":"","outcome":"Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/b43429693/pfizers-braftovi-combination-regimen-significantly-improved-progression-free-survival-and-overall-","source_type":"Press Release","status":"Phase 3","target_date":"","time":"07:03:11","updated":1738584231},{"commentary":"","companies":[{"cik":"1372299","id":"603cef7db9e30d000188f5da","name":"Ocugen Inc","securities":[{"exchange":"NASDAQ","symbol":"OCGN"}]}],"created":1738584109,"date":"2025-02-03","drug":{"generic":false,"id":"6048a8633c2ff900010c858b","indication_symptom":["Retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA)."],"name":"OCU400 (AAV5-hNR2E3)"},"event_type":"Positive Opinion","id":"67a0b02db1c67f000134a2a5","nic_number":"","notes":"","outcome":"Ocugen, Inc announced that the European Commission has provided a positive opinion from the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) for OCU400 Advanced Therapy Medicinal Product (ATMP) classification.","outcome_brief":"","source_link":"https://www.benzinga.com/pressreleases/25/02/g43429554/ocugen-announces-positive-opinion-of-european-medicines-agencys-committee-for-advanced-therapies-f","source_type":"Press Release","status":"European Commission","target_date":"","time":"07:01:49","updated":1738584156}],"includeAGGridStyles":true,"initialDateRange":{"date_from":"2025-02-01","date_to":"2025-02-28"},"initialTab":null,"metaProps":{"author":"Benzinga","canonical":"https://www.benzinga.com/fda-calendar","dateCreated":"2025-02-20T21:27:13.709Z","description":"Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates.","dimensions":{"authorName":"Benzinga","contentType":"tool"},"image":"https://cdn.benzinga.com/files/imagecache/bz2_opengraph_meta_image_400x300/sites/all/themes/bz2/images/bz-icon.png","pageType":"website","structuredData":{"keywords":["\"category: Calendar\""]},"title":"FDA Calendar and Recent FDA News"},"page":{"id":105610,"title":"FDA Calendar","post_type":"page","robots":"","intro":null,"slug":"fda-biotech","template":"page","canonical_link":"https://www.benzinga.com/fda-biotech","image":null,"taxonomies":[{"term_taxonomy_id":2,"term_id":2,"taxonomy":"verticals","description":"","parent":0,"count":3344,"term":{"term_id":2,"name":"Investing","slug":"investing"}},{"term_taxonomy_id":728,"term_id":728,"taxonomy":"page-type","description":"","parent":0,"count":19,"term":{"term_id":728,"name":"Calendar","slug":"calendar"}}],"parent":[],"meta":{"title":"FDA Calendar","description":"","image":null,"author":"Luke Jacobi","authorSlug":"luke","postId":105610,"publishedDate":"2021-04-17T14:34:23.000000Z","modifiedDate":"2024-10-04T12:22:21.000000Z","verifiedUserSlug":null,"verifiedBy":null,"editedUserSlug":null,"editedBy":null,"hrefLanguage":"en"},"breadcrumbs":[{"id":105610,"href":"/fda-biotech","name":"FDA Calendar"}],"blocks":[{"blockName":"acf/news-feed","attrs":{"name":"acf/news-feed","data":{"primary_header":false,"header_see_more_text":"","header_see_more_link":"","title":"Recent FDA Approvals","description_visible":true,"thumbnail_hidden":false,"see_all_text":"","see_all_link":"","feed_type":"topic","topics":["FDA Approvals"],"channels":[],"news_custom_urls":"","news_primary_channel":"","posts_limit":"5","top_posts":null,"news":null,"style":"default","load_more":true,"show_newsletter_block":false,"hide_tickers":false,"newsletter_title":null,"newsletter_form_id":null,"newsletter_description":null,"newsletter_style":null,"newsletter_utm_label":null,"newsletter_show_position":null,"news_feed_mode":"stories","excluded_authors":""},"align":"","mode":"preview"},"innerBlocks":[],"innerHTML":"","type":"default"},{"blockName":"acf/news-feed","attrs":{"name":"acf/news-feed","data":{"primary_header":false,"header_see_more_text":"","header_see_more_link":"","title":"Recent FDA News","description_visible":true,"thumbnail_hidden":false,"see_all_text":"","see_all_link":"","feed_type":"topic","topics":[""],"channels":["FDA"],"news_custom_urls":"","news_primary_channel":"","posts_limit":"5","top_posts":null,"news":null,"style":"default","load_more":true,"show_newsletter_block":false,"hide_tickers":false,"newsletter_title":null,"newsletter_form_id":null,"newsletter_description":null,"newsletter_style":null,"newsletter_utm_label":null,"newsletter_show_position":null,"news_feed_mode":"stories","excluded_authors":""},"align":"","mode":"edit"},"innerBlocks":[],"innerHTML":"","type":"default"},{"blockName":"core/heading","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003ch2\u003eWhat is an FDA Calendar?\u003c/h2\u003e\n","tag":"h2","id":"what-is-an-f-d-a-calendar","html":"What is an FDA Calendar?","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eBiotech investing is risk-fraught, as stocks are at the mercy of several catalysts – most of which are make-or-break events, aka binary events. A prudent investment strategy is to make informed decisions, being in the know of when to expect these events, how these events will pan out and the potential stock reaction in the run-up to the event and post the event.\u003c/p\u003e\n","html":"Biotech investing is risk-fraught, as stocks are at the mercy of several catalysts – most of which are make-or-break events, aka binary events. A prudent investment strategy is to make informed decisions, being in the know of when to expect these events, how these events will pan out and the potential stock reaction in the run-up to the event and post the event.","tag":"p","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eBenzinga’s FDA calendar is a meaningfully designed, user friendly, dynamically updated and simplistic investment tool that is a ‘must-have’ for those looking to make money from the volatility that is typic of trading in biotech stocks.\u003c/p\u003e\n","html":"Benzinga’s FDA calendar is a meaningfully designed, user friendly, dynamically updated and simplistic investment tool that is a ‘must-have’ for those looking to make money from the volatility that is typic of trading in biotech stocks.","tag":"p","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eThe calendar lists down all key catalysts that can materially impact stocks, including:\u003c/p\u003e\n","html":"The calendar lists down all key catalysts that can materially impact stocks, including:","tag":"p","type":"default"},{"blockName":"core/list","attrs":{"data":[]},"innerBlocks":[{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003ePDUFA dates, or in other words FDA decision dates\u003c/li\u003e\n","innerContent":["\n\u003cli\u003ePDUFA dates, or in other words FDA decision dates\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003eFiling schedules for regulatory applications such as new drug application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc\u003c/li\u003e\n","innerContent":["\n\u003cli\u003eFiling schedules for regulatory applications such as new drug application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003eFDA decisions (approvals/complete response letter/delay)\u003c/li\u003e\n","innerContent":["\n\u003cli\u003eFDA decisions (approvals/complete response letter/delay)\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003eAccording to special statuses for treatment options, including orphan drug designation, rare disease designation, accelerated approval, priority review etc.\u003c/li\u003e\n","innerContent":["\n\u003cli\u003eAccording to special statuses for treatment options, including orphan drug designation, rare disease designation, accelerated approval, priority review etc.\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003eFDA’s Advisory Committee, or Adcom, meetings\u003c/li\u003e\n","innerContent":["\n\u003cli\u003eFDA’s Advisory Committee, or Adcom, meetings\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003eReview meetings with FDA (pre-investigational new drug application meetings, end-of-phase meetings, Type A, Type B and Type C meetings)\u003c/li\u003e\n","innerContent":["\n\u003cli\u003eReview meetings with FDA (pre-investigational new drug application meetings, end-of-phase meetings, Type A, Type B and Type C meetings)\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003eDecisions by overseas regulatory agencies\u003c/li\u003e\n","innerContent":["\n\u003cli\u003eDecisions by overseas regulatory agencies\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003eClinical data readouts\u003c/li\u003e\n","innerContent":["\n\u003cli\u003eClinical data readouts\u003c/li\u003e\n"]},{"blockName":"core/list-item","attrs":[],"innerBlocks":[],"innerHTML":"\n\u003cli\u003ePresentation of data at various scientific conferences.\u003c/li\u003e\n","innerContent":["\n\u003cli\u003ePresentation of data at various scientific conferences.\u003c/li\u003e\n"]}],"innerHTML":"\u003cul\u003e\u003cli\u003ePDUFA dates, or in other words FDA decision dates\u003c/li\u003e\u003cli\u003eFiling schedules for regulatory applications such as new drug application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc\u003c/li\u003e\u003cli\u003eFDA decisions (approvals/complete response letter/delay)\u003c/li\u003e\u003cli\u003eAccording to special statuses for treatment options, including orphan drug designation, rare disease designation, accelerated approval, priority review etc.\u003c/li\u003e\u003cli\u003eFDA’s Advisory Committee, or Adcom, meetings\u003c/li\u003e\u003cli\u003eReview meetings with FDA (pre-investigational new drug application meetings, end-of-phase meetings, Type A, Type B and Type C meetings)\u003c/li\u003e\u003cli\u003eDecisions by overseas regulatory agencies\u003c/li\u003e\u003cli\u003eClinical data readouts\u003c/li\u003e\u003cli\u003ePresentation of data at various scientific conferences.\u003c/li\u003e\u003c/ul\u003e","tag":"ul","html":"\u003cli\u003ePDUFA dates, or in other words FDA decision dates\u003c/li\u003e\u003cli\u003eFiling schedules for regulatory applications such as new drug application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc\u003c/li\u003e\u003cli\u003eFDA decisions (approvals/complete response letter/delay)\u003c/li\u003e\u003cli\u003eAccording to special statuses for treatment options, including orphan drug designation, rare disease designation, accelerated approval, priority review etc.\u003c/li\u003e\u003cli\u003eFDA’s Advisory Committee, or Adcom, meetings\u003c/li\u003e\u003cli\u003eReview meetings with FDA (pre-investigational new drug application meetings, end-of-phase meetings, Type A, Type B and Type C meetings)\u003c/li\u003e\u003cli\u003eDecisions by overseas regulatory agencies\u003c/li\u003e\u003cli\u003eClinical data readouts\u003c/li\u003e\u003cli\u003ePresentation of data at various scientific conferences.\u003c/li\u003e","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eThe calendar allows data screening, based on company names or tickers, events, date-wise or based on a date range. They are designed to serve as a ‘one-stop shop’ for data needs of investors, both existing and potential, to capitalize on the opportunities these catalysts throw up or cut the losses from an adverse development.\u0026nbsp;\u003c/p\u003e\n","html":"The calendar allows data screening, based on company names or tickers, events, date-wise or based on a date range. They are designed to serve as a ‘one-stop shop’ for data needs of investors, both existing and potential, to capitalize on the opportunities these catalysts throw up or cut the losses from an adverse development.\u0026nbsp;","tag":"p","type":"default"},{"blockName":"core/heading","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003ch2\u003eWhat is a Catalyst?\u003c/h2\u003e\n","tag":"h2","id":"what-is-a-catalyst","html":"What is a Catalyst?","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eA catalyst is any event/development that has the potential to swing the stock, usually in an appreciable way, in either direction, depending on how it materializes.\u0026nbsp;\u003c/p\u003e\n","html":"A catalyst is any event/development that has the potential to swing the stock, usually in an appreciable way, in either direction, depending on how it materializes.\u0026nbsp;","tag":"p","type":"default"},{"blockName":"core/heading","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003ch2\u003e\u003cstrong\u003eBiotech Stock Movers\u003c/strong\u003e\u003c/h2\u003e\n","tag":"h2","id":"biotech-stock-movers","html":"\u003cstrong\u003eBiotech Stock Movers\u003c/strong\u003e","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eRegulatory actions and clinical readouts are stock-moving catalysts. The magnitude of the impact is usually disproportionate. Most clinical-stage biotechs, or companies which are yet to commercialize a product, do not generate revenues. The exceptions are those which may have out-licensed therapies-in-development to another company and as a result generate revenues in the form of licensing revenues. So, it will be years of investment (time money and efforts) into drug development, which usually takes about 10-15 years, on the promise of generating future returns.\u003c/p\u003e\n","html":"Regulatory actions and clinical readouts are stock-moving catalysts. The magnitude of the impact is usually disproportionate. Most clinical-stage biotechs, or companies which are yet to commercialize a product, do not generate revenues. The exceptions are those which may have out-licensed therapies-in-development to another company and as a result generate revenues in the form of licensing revenues. So, it will be years of investment (time money and efforts) into drug development, which usually takes about 10-15 years, on the promise of generating future returns.","tag":"p","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eA promising outcome in a particular stage of drug development is perceived by the market as an incremental step in bringing the company closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.\u003c/p\u003e\n","html":"A promising outcome in a particular stage of drug development is perceived by the market as an incremental step in bringing the company closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.","tag":"p","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003eSimilarly, an unfavorable or a partially successful outcome could suggest all the investment the company may have made in the investigational therapy could go down the drain. Quite appropriately, investors punish the stock by selling it in droves.\u003c/p\u003e\n","html":"Similarly, an unfavorable or a partially successful outcome could suggest all the investment the company may have made in the investigational therapy could go down the drain. Quite appropriately, investors punish the stock by selling it in droves.","tag":"p","type":"default"},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003ePDUFA and Adcom events are binary events that have two outcomes, triggering moves in stock depending on which outcome materializes.\u003c/p\u003e\n","html":"PDUFA and Adcom events are binary events that have two outcomes, triggering moves in stock depending on which outcome materializes.","tag":"p","type":"default"},{"blockName":"acf/stock-movers","attrs":{"name":"acf/stock-movers","data":{"stock_movers_list_type":"default","session":"REGULAR","stock_movers_list_title":"","max_results":"20","less_than":"","greater_than":"","market_cap_less_than":"","market_cap_greater_than":"","filter_categories":true,"category_type":"Industry","industry":{"term_id":68,"name":"Biotechnology","slug":"biotechnology","term_group":0,"term_taxonomy_id":68,"taxonomy":"industry","description":"Companies in the biotechnology industry engage in the design and development of instruments for use in the medical industry. This field is among one of the newest -- and therefore most volatile -- of the healthcare sector. However, the field is also very multidisciplinary, with medicine, biology, chemistry, computer hardware, computer software and electronics often coalescing in order to create new products. This provides much-needed diversification to the industry and makes it even more attractive for investors looking to create balanced portfolios all the while being able to trade in a volatile space.","parent":0,"count":506,"filter":"raw","term_order":"0"},"from_date":"","to_date":"","include_partner":true,"go_link":"https://www.benzinga.com/go/sofi-active-invest","partner_text":"Go to SoFi","query":{"session":"REGULAR","maxResults":"20","screenerQuery":{"industry_in":"Biotechnology"}},"display":""},"align":"","mode":"preview"},"innerBlocks":[],"innerHTML":"","type":"default"},{"blockName":"acf/cta-placeholder","attrs":{"name":"acf/cta-placeholder","data":{"cta_placeholder_type":"primary","cta_data":null,"has_placements":true,"placeholder_type":"primary","widget":null},"align":"","mode":"edit"},"innerBlocks":[],"innerHTML":"","type":"default"},{"blockName":"core/heading","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003ch2\u003eFrequently Asked Questions\u003c/h2\u003e\n","tag":"h2","id":"frequently-asked-questions","html":"Frequently Asked Questions","type":"default"},{"blockName":"acf/faq","attrs":{"name":"acf/faq","data":{"questions":[{"question_text":"What is an FDA PDUFA date?","answer_text":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003ePrescription Drug User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an ‘approved’ decision, or a ‘complete response letter’ or a delay due to reasons specific to the company or extraneous to the company.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003ePDUFA was passed in the U.S. in 1992, which allows the FDA to collect fees from the sponsor company to fund the review process.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA CRL is issued by the FDA when it deems that the regulatory application is not complete in its current form. The deficiencies usually that lead to rejection could be the need for additional clinical studies to establish the efficacy and/or safety of the treatment option, problems with chemistry, manufacturing and controls, etc.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA delay in the review period may stem from the FDA needs additional time to review any additional data/information that may have been tabled subsequent to the submission of the regulatory application or the FDA’s inability to complete site inspections where the drug ingredients are being made etc.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThe FDA may mention a specific date or a period (say Q1, Q2, Q3, Q4, first-half, second-half, the name of the month) as the timeline by which a decision will be given. If the FDA does not mention any timeline, the company may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn’t provide a timeline either, it is left to the investors to do the calculations.\u003c/span\u003e\u003c/p\u003e\n","answer_link":"https://www.benzinga.com/?post_type=page\u0026p=105610","author":"","created_at":"2021-04-17","style":"default"},{"question_text":"How long does an FDA approval take? ","answer_text":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA regulatory application (NDA, sNDA, BLA, sBLA, etc.) is usually accepted for standard review or priority review. A standard review will mean the FDA has to hand out its verdict within 10 months of filing the application. The review window for a priority review gets shortened to six months.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eOnce a company files for a regulatory application, the FDA takes up to 60 days to respond with an ‘accepted for review’ or ‘refuse-to-file’ decision.\u003c/span\u003e\u003c/p\u003e\n","answer_link":"https://www.benzinga.com/?post_type=page\u0026p=105610","author":"","created_at":"2021-04-17","style":"default"},{"question_text":"How do you find FDA approvals?","answer_text":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA Catalysts Calendar is one way of tracking all the \u003c/span\u003e\u003cspan style=\"font-weight: 400;\"\u003edecisions in a single place. Usually, the FDA puts out a release and/or communicates to the company, which in turn will issue a press release.\u003c/span\u003e\u003c/p\u003e\n","answer_link":"https://www.benzinga.com/?post_type=page\u0026p=105610","author":"","created_at":"2021-04-17","style":"default"}],"tailwind_layout":false},"align":"","mode":"edit"},"innerBlocks":[],"innerHTML":"","faq":[{"answer_link":"https://www.benzinga.com/?post_type=page\u0026p=105610","author":"","created_at":"2021-04-17","style":"default","question":"What is an FDA PDUFA date?","answer":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003ePrescription Drug User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an ‘approved’ decision, or a ‘complete response letter’ or a delay due to reasons specific to the company or extraneous to the company.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003ePDUFA was passed in the U.S. in 1992, which allows the FDA to collect fees from the sponsor company to fund the review process.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA CRL is issued by the FDA when it deems that the regulatory application is not complete in its current form. The deficiencies usually that lead to rejection could be the need for additional clinical studies to establish the efficacy and/or safety of the treatment option, problems with chemistry, manufacturing and controls, etc.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA delay in the review period may stem from the FDA needs additional time to review any additional data/information that may have been tabled subsequent to the submission of the regulatory application or the FDA’s inability to complete site inspections where the drug ingredients are being made etc.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThe FDA may mention a specific date or a period (say Q1, Q2, Q3, Q4, first-half, second-half, the name of the month) as the timeline by which a decision will be given. If the FDA does not mention any timeline, the company may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn’t provide a timeline either, it is left to the investors to do the calculations.\u003c/span\u003e\u003c/p\u003e\n"},{"answer_link":"https://www.benzinga.com/?post_type=page\u0026p=105610","author":"","created_at":"2021-04-17","style":"default","question":"How long does an FDA approval take? ","answer":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA regulatory application (NDA, sNDA, BLA, sBLA, etc.) is usually accepted for standard review or priority review. A standard review will mean the FDA has to hand out its verdict within 10 months of filing the application. The review window for a priority review gets shortened to six months.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eOnce a company files for a regulatory application, the FDA takes up to 60 days to respond with an ‘accepted for review’ or ‘refuse-to-file’ decision.\u003c/span\u003e\u003c/p\u003e\n"},{"answer_link":"https://www.benzinga.com/?post_type=page\u0026p=105610","author":"","created_at":"2021-04-17","style":"default","question":"How do you find FDA approvals?","answer":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA Catalysts Calendar is one way of tracking all the \u003c/span\u003e\u003cspan style=\"font-weight: 400;\"\u003edecisions in a single place. Usually, the FDA puts out a release and/or communicates to the company, which in turn will issue a press release.\u003c/span\u003e\u003c/p\u003e\n"}],"type":"default"}],"campaigns":{"primary":{"has_targeting":true,"placements":[{"id":37540,"type":"campaign","devices":"all-devices","geo_target":"NON-US","multiplier":"2"},{"id":53620,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"2"},{"id":300597,"type":"campaign","devices":"all-devices","geo_target":"geo_300599","multiplier":"1","country":["AU","ES","SE","PH","GR","NO","PL","DK","EE","EC","CO","JP","VN","ID","IL","SA","TR","UA","BY","BA","AL","ME","HT","CU","NI","PR","IR","IQ","LB","SY","LY","TN","YE","AF","ER","ML","SO","SD","GU","MP","MM","ZW","SS","SL","LR","GW","CF","CD"],"states":[],"country_exclude":false,"state_exclude":false},{"id":347102,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"3"},{"id":260960,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"1"},{"id":351534,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"1"},{"id":351539,"type":"campaign","devices":"all-devices","geo_target":"geo_318061","multiplier":"3","country":["GB","ZA","AU"],"states":[],"country_exclude":false,"state_exclude":false}],"campaigns":{"37540":{"position":"horizontal","cta_title":"Featured Broker: Interactive Brokers","cta_text":"Open an Account","cta_description":"Interactive Brokers gives you access to market data 24 hours a day, 6 days a week. \r\n","link_type":"internal","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","placement_slug":"interactive-brokers-cta","bzgo_link_id":23282,"bzpartner_id":72108,"url":"https://www.benzinga.com/go/interactive-brokers","go_link_dofollow":0,"partner":"Interactive Brokers","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `IBKR Market Data` ::Partner:: `Interactive Brokers` ::Title:: `Featured Broker: Interactive Brokers`","href":"https://www.benzinga.com/go/interactive-brokers","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2021/09/15084546/ibkr-stacked.jpg","product_id":null},"53620":{"position":"horizontal","cta_title":"Lower Your Cost! ","cta_description":"Open an IBKR account with no added spreads, markups, account minimums, or inactivity fees.","cta_text":"Get Started","link_type":"internal","placement_country":"","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","placement_slug":"interactive-brokers-lowest-cost-best-execution-cta","bzgo_link_id":23282,"bzpartner_id":72108,"url":"https://www.benzinga.com/go/interactive-brokers","go_link_dofollow":0,"partner":"Interactive Brokers","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `IBKR Low Cost A` ::Partner:: `Interactive Brokers` ::Title:: `Lower Your Cost!`","href":"https://www.benzinga.com/go/interactive-brokers","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2021/09/15084546/ibkr-stacked.jpg","product_id":null},"260960":{"cta_title":"Get Up to $9,000 in FREE Stocks","cta_description":"Open and fund a new TradeUP account to win up to $9,000 worth of free stocks! Trade stocks, ETFs, options and more.","cta_text":"Learn More","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","link_type":"internal","placement_slug":"tradeup","bzgo_link_id":260866,"bzpartner_id":260869,"url":"https://www.benzinga.com/go/tradeup-2","go_link_dofollow":0,"partner":"TradeUP","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `TradeUP` ::Partner:: `TradeUP` ::Title:: `Get Up to $9,000 in FREE Stocks`","href":"https://www.benzinga.com/go/tradeup-2","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2020/02/14174413/tradeuplogo.png","product_id":260870},"300597":{"cta_title":"Trade CFDs and Get Rewarded","cta_description":"Gain an extra 50% on your deposit or up to 100% when you make your first-time deposit to a Perpetual Account.","cta_text":"","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","link_type":"internal","placement_slug":"vantage-markets","bzgo_link_id":115505,"bzpartner_id":149404,"url":"https://www.benzinga.com/go/vantage-markets","go_link_dofollow":0,"partner":"Vantage Markets","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `Vantage Markets` ::Partner:: `Vantage Markets` ::Title:: `Trade CFDs and Get Rewarded`","href":"https://www.benzinga.com/go/vantage-markets","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2021/05/11143557/vantage-markets.jpeg","product_id":115503},"347102":{"cta_title":"Get Zero-Commission Stock Investing and Up to $1,000 in Stock","cta_description":"Receive up to $1,000 in stock when you fund a new active invest account with SoFi. Trade stocks, funds, alternative investments, options, and fractional shares with as little as $5.","cta_text":"Get Started","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE\r\nBrokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). \r\nProbability of Member receiving $1,000 is a probability of 0.028%","link_type":"internal","placement_slug":"sofi-investing-campaign","bzgo_link_id":73452,"bzpartner_id":72314,"url":"https://www.benzinga.com/go/sofi-active-invest","go_link_dofollow":0,"partner":"SoFi","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `SoFi Investing Campaign` ::Partner:: `SoFi` ::Title:: `Get Zero-Commission Stock Investing and Up to $1,000 in Stock`","href":"https://www.benzinga.com/go/sofi-active-invest","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/01/07044413/SoFi-Logo.png","product_id":null},"351534":{"cta_title":"Earn a Fixed 7.0% APY on Your Savings","cta_description":"Invest in bonds with as little as $10 with no fees or penaltiies, and earn a fixed 7.0% APY. Interest is compounded daily. No minimum balances or maturity dates. ","cta_text":"","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","link_type":"internal","placement_slug":"worthy-bonds","bzgo_link_id":351536,"bzpartner_id":168971,"url":"https://www.benzinga.com/go/worthy-bonds","go_link_dofollow":0,"partner":"Worthy","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `Worthy Bonds` ::Partner:: `Worthy` ::Title:: `Earn a Fixed 7.0% APY on Your Savings`","href":"https://www.benzinga.com/go/worthy-bonds","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/02/16113227/Worthy-Bonds.png","product_id":null},"351539":{"cta_title":"Start Trading CFDs and Forex for Free Today","cta_description":"Instant Access to 2400+ Global Markets. 24 Hour Trading on Key US Equities. Automated Trading with MetaTrader. Cutting-Edge Data with TradingView. Get a Free Demo Account Today.","cta_text":"Get Started","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":true,"disclosure":"CFDs are complex instruments and come with a high risk of losing money rapidly\r\ndue to leverage. Between 74-89 % of retail investor accounts lose money when\r\ntrading CFDs. You should consider whether you understand how CFDs work and\r\nwhether you can afford to take the high risk of losing your money.","link_type":"internal","custom_floating_popup":{"title":"Try Spread Betting, CFDs and Forex for Free","description":"Instant Access to 2400+ Global Markets. 24 Hour Trading on Key US Equities. Automate Your Trading with MetaTrader.","button_text":"Get Started"},"placement_slug":"pepperstone-investing-ac","bzgo_link_id":70012,"bzpartner_id":72319,"url":"https://www.benzinga.com/go/pepperstone-forex","go_link_dofollow":0,"partner":"Pepperstone","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `Pepperstone Investing AC` ::Partner:: `Pepperstone` ::Title:: `Start Trading CFDs and Forex for Free Today`","href":"https://www.benzinga.com/go/pepperstone-forex","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/02/16183901/Pepperstone-Logo.jpg","product_id":null}},"placeholder_type":"primary"},"secondary":{"has_targeting":true,"placements":[{"id":37540,"type":"campaign","devices":"all-devices","geo_target":"NON-US","multiplier":"2"},{"id":53620,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"2"},{"id":300597,"type":"campaign","devices":"all-devices","geo_target":"geo_300599","multiplier":"1","country":["AU","ES","SE","PH","GR","NO","PL","DK","EE","EC","CO","JP","VN","ID","IL","SA","TR","UA","BY","BA","AL","ME","HT","CU","NI","PR","IR","IQ","LB","SY","LY","TN","YE","AF","ER","ML","SO","SD","GU","MP","MM","ZW","SS","SL","LR","GW","CF","CD"],"states":[],"country_exclude":false,"state_exclude":false},{"id":347102,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"3"},{"id":260960,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"1"},{"id":351534,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"1"},{"id":351539,"type":"campaign","devices":"all-devices","geo_target":"geo_318061","multiplier":"3","country":["GB","ZA","AU"],"states":[],"country_exclude":false,"state_exclude":false}],"campaigns":{"37540":{"position":"horizontal","cta_title":"Featured Broker: Interactive Brokers","cta_text":"Open an Account","cta_description":"Interactive Brokers gives you access to market data 24 hours a day, 6 days a week. \r\n","link_type":"internal","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","placement_slug":"interactive-brokers-cta","bzgo_link_id":23282,"bzpartner_id":72108,"url":"https://www.benzinga.com/go/interactive-brokers","go_link_dofollow":0,"partner":"Interactive Brokers","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `IBKR Market Data` ::Partner:: `Interactive Brokers` ::Title:: `Featured Broker: Interactive Brokers`","href":"https://www.benzinga.com/go/interactive-brokers","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2021/09/15084546/ibkr-stacked.jpg","product_id":null},"53620":{"position":"horizontal","cta_title":"Lower Your Cost! ","cta_description":"Open an IBKR account with no added spreads, markups, account minimums, or inactivity fees.","cta_text":"Get Started","link_type":"internal","placement_country":"","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","placement_slug":"interactive-brokers-lowest-cost-best-execution-cta","bzgo_link_id":23282,"bzpartner_id":72108,"url":"https://www.benzinga.com/go/interactive-brokers","go_link_dofollow":0,"partner":"Interactive Brokers","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `IBKR Low Cost A` ::Partner:: `Interactive Brokers` ::Title:: `Lower Your Cost!`","href":"https://www.benzinga.com/go/interactive-brokers","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2021/09/15084546/ibkr-stacked.jpg","product_id":null},"260960":{"cta_title":"Get Up to $9,000 in FREE Stocks","cta_description":"Open and fund a new TradeUP account to win up to $9,000 worth of free stocks! Trade stocks, ETFs, options and more.","cta_text":"Learn More","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","link_type":"internal","placement_slug":"tradeup","bzgo_link_id":260866,"bzpartner_id":260869,"url":"https://www.benzinga.com/go/tradeup-2","go_link_dofollow":0,"partner":"TradeUP","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `TradeUP` ::Partner:: `TradeUP` ::Title:: `Get Up to $9,000 in FREE Stocks`","href":"https://www.benzinga.com/go/tradeup-2","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2020/02/14174413/tradeuplogo.png","product_id":260870},"300597":{"cta_title":"Trade CFDs and Get Rewarded","cta_description":"Gain an extra 50% on your deposit or up to 100% when you make your first-time deposit to a Perpetual Account.","cta_text":"","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","link_type":"internal","placement_slug":"vantage-markets","bzgo_link_id":115505,"bzpartner_id":149404,"url":"https://www.benzinga.com/go/vantage-markets","go_link_dofollow":0,"partner":"Vantage Markets","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `Vantage Markets` ::Partner:: `Vantage Markets` ::Title:: `Trade CFDs and Get Rewarded`","href":"https://www.benzinga.com/go/vantage-markets","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2021/05/11143557/vantage-markets.jpeg","product_id":115503},"347102":{"cta_title":"Get Zero-Commission Stock Investing and Up to $1,000 in Stock","cta_description":"Receive up to $1,000 in stock when you fund a new active invest account with SoFi. Trade stocks, funds, alternative investments, options, and fractional shares with as little as $5.","cta_text":"Get Started","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE\r\nBrokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). \r\nProbability of Member receiving $1,000 is a probability of 0.028%","link_type":"internal","placement_slug":"sofi-investing-campaign","bzgo_link_id":73452,"bzpartner_id":72314,"url":"https://www.benzinga.com/go/sofi-active-invest","go_link_dofollow":0,"partner":"SoFi","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `SoFi Investing Campaign` ::Partner:: `SoFi` ::Title:: `Get Zero-Commission Stock Investing and Up to $1,000 in Stock`","href":"https://www.benzinga.com/go/sofi-active-invest","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/01/07044413/SoFi-Logo.png","product_id":null},"351534":{"cta_title":"Earn a Fixed 7.0% APY on Your Savings","cta_description":"Invest in bonds with as little as $10 with no fees or penaltiies, and earn a fixed 7.0% APY. Interest is compounded daily. No minimum balances or maturity dates. ","cta_text":"","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","link_type":"internal","placement_slug":"worthy-bonds","bzgo_link_id":351536,"bzpartner_id":168971,"url":"https://www.benzinga.com/go/worthy-bonds","go_link_dofollow":0,"partner":"Worthy","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `Worthy Bonds` ::Partner:: `Worthy` ::Title:: `Earn a Fixed 7.0% APY on Your Savings`","href":"https://www.benzinga.com/go/worthy-bonds","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/02/16113227/Worthy-Bonds.png","product_id":null},"351539":{"cta_title":"Start Trading CFDs and Forex for Free Today","cta_description":"Instant Access to 2400+ Global Markets. 24 Hour Trading on Key US Equities. Automated Trading with MetaTrader. Cutting-Edge Data with TradingView. Get a Free Demo Account Today.","cta_text":"Get Started","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":true,"disclosure":"CFDs are complex instruments and come with a high risk of losing money rapidly\r\ndue to leverage. Between 74-89 % of retail investor accounts lose money when\r\ntrading CFDs. You should consider whether you understand how CFDs work and\r\nwhether you can afford to take the high risk of losing your money.","link_type":"internal","custom_floating_popup":{"title":"Try Spread Betting, CFDs and Forex for Free","description":"Instant Access to 2400+ Global Markets. 24 Hour Trading on Key US Equities. Automate Your Trading with MetaTrader.","button_text":"Get Started"},"placement_slug":"pepperstone-investing-ac","bzgo_link_id":70012,"bzpartner_id":72319,"url":"https://www.benzinga.com/go/pepperstone-forex","go_link_dofollow":0,"partner":"Pepperstone","utm_action":"::AdvancedCampaign:: `Investing Default Advanced Campaign` ::Campaign:: `Pepperstone Investing AC` ::Partner:: `Pepperstone` ::Title:: `Start Trading CFDs and Forex for Free Today`","href":"https://www.benzinga.com/go/pepperstone-forex","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/02/16183901/Pepperstone-Logo.jpg","product_id":null}},"placeholder_type":"secondary"},"floating":{"has_targeting":true,"placements":[{"id":347102,"type":"campaign","devices":"all-devices","geo_target":""},{"id":235669,"type":"campaign","devices":"all-devices","geo_target":""}],"campaigns":{"235669":{"cta_title":"Free Futures Trading Simulator! ","cta_description":"Get started with NinjaTrader's award winning futures trading platforn and SIM trade with free real-time market data, charting and 100+ indicators. ","cta_text":"Get Started","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"","link_type":"internal","placement_slug":null,"bzgo_link_id":198750,"bzpartner_id":71908,"url":"https://www.benzinga.com/go/ninjatrader","go_link_dofollow":0,"partner":"NinjaTrader","utm_action":"::Campaign:: `NinjaTrader` ::Partner:: `NinjaTrader` ::Title:: `Free Futures Trading Simulator!`","href":"https://www.benzinga.com/go/ninjatrader","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2023/03/02122721/NinjaTrader_Wordmark_color_RGB-340x43-1.png","product_id":31525},"347102":{"cta_title":"Get Zero-Commission Stock Investing and Up to $1,000 in Stock","cta_description":"Receive up to $1,000 in stock when you fund a new active invest account with SoFi. Trade stocks, funds, alternative investments, options, and fractional shares with as little as $5.","cta_text":"Get Started","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE\r\nBrokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). \r\nProbability of Member receiving $1,000 is a probability of 0.028%","link_type":"internal","placement_slug":null,"bzgo_link_id":73452,"bzpartner_id":72314,"url":"https://www.benzinga.com/go/sofi-active-invest","go_link_dofollow":0,"partner":"SoFi","utm_action":"::Campaign:: `SoFi Investing Campaign` ::Partner:: `SoFi` ::Title:: `Get Zero-Commission Stock Investing and Up to $1,000 in Stock`","href":"https://www.benzinga.com/go/sofi-active-invest","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/01/07044413/SoFi-Logo.png","product_id":null}},"display_y_position":400},"popup":{"has_targeting":true,"placements":[{"id":302664,"type":"campaign","devices":"all-devices","geo_target":"US","multiplier":"1"},{"id":302664,"type":"campaign","devices":"all-devices","geo_target":"NON-US","multiplier":"1"}],"campaigns":{"302664":{"cta_title":"Trade CFDs on the Most Popular Stocks","cta_description":"with advanced trading tools to control profits and losses.","cta_text":"get started","cta_btn_type":"button","cta_btn_position":"below_image","impression_tag":"","customize_modal_popup":false,"customize_floating_popup":false,"disclosure":"82% of retail CFD accounts lose money.","link_type":"internal","placement_slug":"plus500-stocks-non-us","bzgo_link_id":340235,"bzpartner_id":72092,"url":"https://www.benzinga.com/go/plus500-advanced-campaign","go_link_dofollow":0,"partner":"Plus500","utm_action":"::AdvancedCampaign:: `Plus500 Guaranteed SOV Advanced Campaign (Investing)` ::Campaign:: `Plus500 Stocks - Non US` ::Partner:: `Plus500` ::Title:: `Trade CFDs on the Most Popular Stocks`","href":"https://www.benzinga.com/go/plus500-advanced-campaign","image_url":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2018/12/16153923/plus500_source-5c5b58f746e0fb0001ca8550.png","product_id":27392}},"delay":10000},"compare_partners":{"widget":{"ID":69793,"post_author":"5911","post_date":"2020-05-19 14:49:49","post_date_gmt":"2020-05-19 18:49:49","post_content":"\u003c!-- wp:paragraph {\"align\":\"left\"} --\u003e\n\u003cp class=\"has-text-align-left\"\u003e\u003cstrong\u003e\u003ca href=\"https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh\"\u003eClaim Exclusive Offers\u003c/a\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c!-- /wp:paragraph --\u003e\n\n\u003c!-- wp:acf/compare-products {\"name\":\"acf/compare-products\",\"data\":{\"compare_products\":[\"218220\",\"27392\",\"63970\",\"772\",\"91816\"],\"_compare_products\":\"block_compare_products\",\"show_product_names\":\"0\",\"_show_product_names\":\"show_product_names\",\"default_open_description\":\"0\",\"_default_open_description\":\"default_open_description\",\"disable_block\":\"0\",\"_disable_block\":\"field_disable_block\"},\"align\":\"\",\"mode\":\"edit\"} /--\u003e\n\n\u003c!-- wp:paragraph --\u003e\n\u003cp\u003e\u003c/p\u003e\n\u003c!-- /wp:paragraph --\u003e","post_title":"Compare Investing Brokers (USE THIS ONE)","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"compare-brokers","to_ping":"","pinged":"","post_modified":"2024-11-04 07:44:48","post_modified_gmt":"2024-11-04 12:44:48","post_content_filtered":"","post_parent":0,"guid":"https://www.benzinga.com/?post_type=widget\u0026#038;p=69793","menu_order":0,"post_type":"widget","post_mime_type":"","comment_count":"0","filter":"raw"},"blocks":[{"blockName":"core/paragraph","attrs":{"align":"left","data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp class=\"has-text-align-left\"\u003e\u003cstrong\u003e\u003ca href=\"https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh\"\u003eClaim Exclusive Offers\u003c/a\u003e\u003c/strong\u003e\u003c/p\u003e\n","html":"\u003cstrong\u003e\u003ca href=\"https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh\"\u003eClaim Exclusive Offers\u003c/a\u003e\u003c/strong\u003e","tag":"p"},{"blockName":"acf/compare-products","attrs":{"name":"acf/compare-products","data":{"b_id":"vStaAf","compare_products":[218220,27392,63970,772,91816],"style":"","show_product_names":false,"opened":false},"align":"","mode":"edit"},"innerBlocks":[],"innerHTML":"","products":[{"id":218220,"image":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2017/07/15102926/ib-logo-stacked-1200x627-1-768x401.png","square_image":null,"best_for":"Active and Global Traders","teaser":"","filters":[],"name":"IBKR Stocks","link":"https://www.benzinga.com/go/ibkr-stocks","rating":5,"review":"https://www.benzinga.com/money/interactive-brokers-review","insurance_types_of_plans":"","hide_securely_through":false,"trust":"Securely through Interactive Brokers’ website","current_promotion":null,"disclosure":"","button_text":"get started","sponsored_for":false,"product_badge_image":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2022/12/14143408/Best-Day-Trading-Software-Interactive-Brokers.png","go_link_id":218219,"company_id":107,"company_name":"Interactive Brokers","tune_offer_id":"","go_link_dofollow":0,"details":{"desc":"\u003cspan style=\"font-weight: 400;\"\u003eInteractive Brokers is a comprehensive trading platform that gives you access to a massive range of securities at affordable prices. You can buy assets from all around the world from the comfort of your home or office with access to over 150 global markets. Options, futures, forex and fund trading are also available, and most traders won’t pay a commission on any purchase or sale. \u003c/span\u003e\r\n\r\n\u003cspan style=\"font-weight: 400;\"\u003eIBKR is geared primarily toward experienced traders and investors but now with the availability of free trades with IBKR Lite, casual traders can also acclimate to IBKR’s offerings.\u003c/span\u003e","pros":["IB SmartRouting provides significant price improvement vs. industry","Fractional trading allows investing regardless of share price","Industry's lowest margin rates","Earn more by lending your fuly-paid shares"],"cons":["Beginner investors might prefer a broker that offers a bit more hand-holding and educational resources"],"best_for":["Access to international markets","Active traders","Detailed mobile app that makes trading simple","Wide range of available account types and tradeable assets"],"custom_sec":[]},"phone":"","data":{}},{"id":27392,"image":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2018/12/16153923/plus500_source-5c5b58f746e0fb0001ca8550-768x294.png","square_image":null,"best_for":"Stock CFDs","teaser":"","filters":[],"name":"Plus500 Yield","link":"https://www.benzinga.com/go/plus500-cc-link-a","rating":4,"review":"https://www.benzinga.com/money/plus500-review","insurance_types_of_plans":"","hide_securely_through":false,"trust":"securely through Plus500 Yield's website","current_promotion":"","disclosure":"\u003cp\u003e82% of retail accounts lose money\u003c/p\u003e\n","button_text":"get started","sponsored_for":[25661],"product_badge_image":false,"go_link_id":250291,"company_id":27390,"company_name":"Plus500","tune_offer_id":"","go_link_dofollow":0,"details":{"desc":"\u003cspan style=\"font-weight: 400;\"\u003e\u003cstrong\u003e82% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.\u003c/strong\u003e\u003c/span\u003e\r\n\r\n\u003cspan style=\"font-weight: 400;\"\u003ePlus500 is an online CFD broker focusing on contracts for difference (CFDs). CFDs are similar to binary options in the U.S. where traders take all-or-nothing speculation on the prices of certain securities like indices, commodities or currencies. While not legal to trade in the U.S., CFDs are legal in many jurisdictions across the globe and Plus500 offers a wide array of tradable markets using these instruments. \u003c/span\u003e\r\n\r\n\u003cspan style=\"font-weight: 400;\"\u003ePlus500 doesn’t charge commission and only profits off the spread, which is the difference between the buy and sell price of a specific security. But Plus500 is not a broker for beginners — the education materials are sparse and CFDs are risky derivatives capable of sapping out all of an investor’s capital. Only trade these instruments if you understand how they operate and the risks involved with buying them.\u003c/span\u003e","pros":["Great mobile app","Low spreads and commissions","Unlimited demo account"],"cons":["Only derivatives are available","Not open to U.S. residents"],"best_for":["Traders looking for a smooth mobile experience"],"custom_sec":[]},"phone":"","data":{}},{"id":63970,"image":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2023/06/01170410/public-logo.png","square_image":null,"best_for":"Trading Ideas","teaser":"","filters":[],"name":"public.com","link":"https://www.benzinga.com/go/public","rating":4.5,"review":"https://www.benzinga.com/money/public-com-review","insurance_types_of_plans":"","hide_securely_through":false,"trust":"securely through public.com's website","current_promotion":"","disclosure":"","button_text":"get started","sponsored_for":false,"product_badge_image":false,"go_link_id":64439,"company_id":63967,"company_name":"public.com","tune_offer_id":"","go_link_dofollow":0,"details":{"desc":"\u003cspan style=\"font-weight: 400;\"\u003ePublic is the only investing platform that lets you trade stocks, ETFs, crypto, bonds, options and alternative assets—like fine art and collectibles—all in one place. Public also provides access to custom company metrics, live shows about the markets, and insights from a community of millions of investors, creators, and analysts.\u003c/span\u003e\r\n\r\n\u003cspan style=\"font-weight: 400;\"\u003eToday, Public provides more ways to create a diversified portfolio than nearly any other online broker. Members can engage in sophisticated investing strategies and access a wealth of investing insights—from company-specific analysis to live audio shows and town hall-style Q\u0026amp;As. In addition, Public offers a premium membership tier with unique company KPIs, detailed performance metrics, and institutional-grade research. \u003c/span\u003e\r\n\r\n\u0026nbsp;","pros":["Commission-free stock and ETF trading","Fractional share investing","Advanced data, tools, and insights with Public Premium"],"cons":["You can't transfer crypto to another wallet","No mutual funds or precious metals","At this time, only offers individual brokerage accounts and not IRAs"],"best_for":["Stock and ETF investors","Crypto investors","Investors looking to diversify with alternative assets or bonds and options"],"custom_sec":[]},"phone":"","data":{}},{"id":772,"image":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2017/08/30201651/robinhood.png","square_image":null,"best_for":"Beginners","teaser":"","filters":[],"name":"Robinhood","link":"https://www.benzinga.com/go/robinhood","rating":4.5,"review":"https://www.benzinga.com/money/robinhood-review","insurance_types_of_plans":"","hide_securely_through":false,"trust":"securely through Robinhood's website","current_promotion":"Refer friends and get FREE stock","disclosure":"","button_text":"get started","sponsored_for":false,"product_badge_image":false,"go_link_id":11199,"company_id":773,"company_name":"Robinhood","tune_offer_id":"","go_link_dofollow":0,"details":{"desc":"\u003cp style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eRobinhood is a popular trading platform known for its commission-free trades and user-friendly mobile app. Ideal for novice investors, Robinhood makes it easy to buy and sell stocks, ETFs and cryptocurrencies. The platform offers a straightforward, no-frills experience, making it accessible for users new to investing. With features like fractional shares and a sleek interface, Robinhood lowers the barriers to entry for investing, allowing users to start with just a few dollars. It lacks the advanced tools and research options that more experienced investors might seek. Overall, Robinhood is a great choice for beginners seeking a simple way to invest.\u003c/span\u003e\u003c/p\u003e","pros":["User-friendly mobile app","Instant double","Cash management","Access to cryptocurrencies"],"cons":["Limited research tools","No mutual funds available","Basic customer support options"],"best_for":["Beginners looking for simplicity","Mobile-first investors","Commission-free trades"],"custom_sec":[]},"phone":"","data":{}},{"id":91816,"image":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2020/11/07101028/IMG_5065-768x135.png","square_image":null,"best_for":"Global Broker for Short Selling","teaser":"","filters":[],"name":"TradeZero","link":"https://www.benzinga.com/go/tradezero","rating":4.5,"review":"https://www.benzinga.com/money/tradezero-review","insurance_types_of_plans":"","hide_securely_through":false,"trust":"securely through TradeZero's website","current_promotion":"","disclosure":"","button_text":"get started","sponsored_for":false,"product_badge_image":"https://cdnwp-s3.benzinga.com/wp-content/uploads/2020/11/14143059/Best-Brokerage-for-Short-Selling-TradeZero.png","go_link_id":38233,"company_id":91824,"company_name":"TradeZero","tune_offer_id":"","go_link_dofollow":0,"details":{"desc":"\u003cspan style=\"font-weight: 400;\"\u003eTradeZero is an online broker and free stock trading platform that provides everything you need to successfully share and trade, including round-the-clock customer support. TradeZero provides four different trading state-of-the-art software programs with its services, a locator for sourcing shares for shorting, commission-free trades, and real-time streaming, to name a few of the features promoted on their website. The software is a unique and (potentially) affordable option for anyone interested in stock trading.\u003c/span\u003e","pros":["24/7 live customer support","Uses ZeroWeb technology, a powerful level 2 online platform with direct market access","Mobile app allows users to access stocks and trade in real-time while on the go"],"cons":["Enforces Pattern Day Trading restrictions (accounts need to maintain a daily equity balance of at least $25k)","Mobile app could offer more features"],"best_for":["Traders seeking high transparency and mobility in a stock trading program","Those attracted to commission-free trades","Those seeking a free version of a high-quality trading program"],"custom_sec":[]},"phone":"","data":{}}]},{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003e\u003c/p\u003e\n","html":"","tag":"p"}]}},"cornerstone":[],"header":null,"content_header":null,"in_content":null,"in_article_content":null,"sidebar":null,"unmonetized_interstitial":null,"sidebar_placement":null,"left_sidebar":null,"global_footer":{"id":160497,"title":"Advertise With Us","type":"footer","blocks":[{"blockName":"core/paragraph","attrs":{"data":[]},"innerBlocks":[],"innerHTML":"\n\u003cp\u003e\u003cstrong\u003eWant to advertise with us? \u003ca href=\"https://www.benzinga.com/money/advertise-with-us/\" target=\"_blank\" rel=\"noreferrer noopener\"\u003eSend us a message\u003c/a\u003e. \u003c/strong\u003e\u003c/p\u003e\n","html":"\u003cstrong\u003eWant to advertise with us? \u003ca href=\"https://www.benzinga.com/money/advertise-with-us/\" target=\"_blank\" rel=\"noreferrer noopener\"\u003eSend us a message\u003c/a\u003e. \u003c/strong\u003e","tag":"p"}]},"content_footer":{"id":57895,"title":"Investing Article Footer","type":"footer","blocks":[]},"footer":null,"layout":{"settings":{"cache_max_age":0,"display_y_position":0,"show_author_credentials":false,"floating_cta_hide":false,"footer_hide":false,"hide_article_footer":false,"hide_article_header":false,"hide_navigation_bar":false,"hide_menu_bar_items":false,"simple_article_title":false,"hide_quotes_searchbar":false,"hide_sidebar_placement":false,"hide_sidebar":false,"hide_site_footer":false,"ignore_compare_products_popup":false,"is_root_path":false,"no_direct_partnership":false,"popup_delay":0,"popup_hide":false,"post_alternative_title":"","post_exclusive_partner":"","post_update_frequency":"","post_verified_by_user":null,"banner_text":"","banner_link":"","menu_location":"page"}},"surrogate_keys":"campaign:37540 campaign:53620 campaign:300597 campaign:347102 campaign:260960 campaign:351534 campaign:351539 campaign:37540 campaign:53620 campaign:300597 campaign:347102 campaign:260960 campaign:351534 campaign:351539 campaign:302664 campaign:302664 verticals:investing page-type:calendar post-id:105610","author":{"wordpress_id":101,"slug":"luke","avatar":"//secure.gravatar.com/avatar/a7a3e4487e9cc2c28d57bae0a878c1f2?d=mm","display_name":"Luke Jacobi"}},"pageTargeting":{"BZ_CHANNEL":["FDA"],"BZ_PTYPE":"channel"},"recentFDAApprovals":[{"id":43880289,"author":"Nabaparna Bhattacharya","created":"Fri, 21 Feb 2025 09:53:37 -0400","updated":"Fri, 21 Feb 2025 09:53:37 -0400","title":"What's Going On With Gene Therapy Company Bluebird Bio Stock Today?","teaser":"","body":"","url":"https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal","image":[{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg"},{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/21/Partnership--Two-Business-People-Shaking.jpeg"}],"channels":[{"name":"Equities"},{"name":"M\u0026A"},{"name":"News"},{"name":"Top Stories"},{"name":"Markets"},{"name":"Movers"},{"name":"General"}],"stocks":[{"name":"BLUE"},{"name":"CG"}],"tags":[{"name":"Briefs"},{"name":"Stories That Matter"},{"name":"why it's moving"}]},{"id":43769585,"author":"Chandrima Sanyal","created":"Mon, 17 Feb 2025 16:15:00 -0400","updated":"Mon, 17 Feb 2025 16:17:49 -0400","title":"Health Insurance ETFs in Focus as RFK Jr Takes Over HHS","teaser":"","body":"","url":"https://www.benzinga.com/news/25/02/43769585/health-insurance-etfs-in-focus-as-rfk-jr-takes-over-hhs","image":[{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg"},{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/17/Trump-Has-Asked-Me-To-Do-3-Things--Says-.jpeg"}],"channels":[{"name":"News"}],"stocks":[{"name":"ELV"},{"name":"IHF"},{"name":"MRNA"},{"name":"PFE"},{"name":"UNH"},{"name":"XLV"}],"tags":[{"name":"Robert Kennedy Jr."},{"name":"Stories That Matter"}]},{"id":43706404,"author":"Benzinga Newsdesk","created":"Thu, 13 Feb 2025 14:31:22 -0400","updated":"Thu, 13 Feb 2025 14:31:23 -0400","title":"Evolus Announces FDA Approval Of Evolysse Form And Evolysse Smooth Injectable Hyaluronic Acid Gels; First Major Technological Breakthrough In Hyaluronic Acid Dermal Fillers In A Decade; U.S. Launch Planned In Q2 2025","teaser":"","body":"","url":"https://www.benzinga.com/general/biotech/25/02/43706404/evolus-announces-fda-approval-of-evolysse-form-and-evolysse-smooth-injectable-hyaluronic-acid-gel","image":[],"channels":[{"name":"Biotech"},{"name":"News"},{"name":"FDA"},{"name":"General"}],"stocks":[{"name":"EOLS"}],"tags":[]},{"id":43525518,"author":"Vandana Singh","created":"Thu, 06 Feb 2025 08:59:59 -0400","updated":"Thu, 06 Feb 2025 08:59:59 -0400","title":"Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines","teaser":"","body":"","url":"https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines","image":[{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg"},{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/06/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg"}],"channels":[{"name":"Biotech"},{"name":"Earnings"},{"name":"Large Cap"},{"name":"News"},{"name":"Guidance"},{"name":"Health Care"},{"name":"Top Stories"},{"name":"Trading Ideas"},{"name":"General"}],"stocks":[{"name":"LLY"}],"tags":[{"name":"Briefs"},{"name":"Stories That Matter"},{"name":"why it's moving"}]},{"id":43502578,"author":"Vandana Singh","created":"Wed, 05 Feb 2025 13:21:53 -0400","updated":"Wed, 05 Feb 2025 13:21:54 -0400","title":"Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead","teaser":"","body":"","url":"https://www.benzinga.com/25/02/43502578/amgen-impresses-with-q4-earnings-beat-analysts-see-growth-ahead","image":[{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/05/Amgen-stock.jpeg"},{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/05/Amgen-stock.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/05/Amgen-stock.jpeg"}],"channels":[{"name":"Analyst Color"},{"name":"Biotech"},{"name":"Earnings"},{"name":"Large Cap"},{"name":"News"},{"name":"Guidance"},{"name":"Health Care"},{"name":"Top Stories"},{"name":"Analyst Ratings"},{"name":"Movers"},{"name":"Trading Ideas"},{"name":"General"}],"stocks":[{"name":"AMGN"}],"tags":[{"name":"Briefs"},{"name":"Expert Ideas"},{"name":"Stories That Matter"},{"name":"why it's moving"}]}]},"__N_SSP":true},"page":"/fda-calendar","query":{},"buildId":"0BHLnDvbhzltU4ONkiCGh","isFallback":false,"isExperimentalCompile":false,"gssp":true,"scriptLoader":[]}</script></body></html>